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NEW THERAPEUTIC OPTION AND INSIGHTS INTO THE IMPACT OF 
SYMPTOM SEVERITY ON QUALITY OF LIFE IN WOMEN WITH INTERSTITIAL 
CYSTITIS 
 
Samar R. El Khoudary, Ph.D. 
University of Pittsburgh, 2008
 
Background: Interstitial Cystitis (IC) is a poorly understood condition of urinary bladder 
characterized by pelvic pain, urinary frequency, urgency and nocturia in the absence of other 
obvious pathology. The public health significance of IC is related to its profound impact on 
patients’ physical and emotional Quality of Life (QOL). The actual prevalence rate is unknown, 
and estimates range widely from 67/100,000 to 575/100,000. The majority of IC cases are 
females in the midlife age. This research addressed 1) the extent to which socio-demographic 
and clinical factors affect both symptom severity and QOL in IC patients, 2) the impact of 
symptom severity on QOL and 3) the efficacy of a combination of oral and intravesical Pentosan 
Polysulfate Sodium (PPS) as a new therapeutic option for IC. Methods: Forty one women with 
IC (age 20-71 years) were studied. Demographic, reproductive and clinical characteristics as well 
as QOL measures were evaluated in a cross-sectional design to assess the first two aims. To 
examine the third aim, participants were randomized to receive either a combination of oral plus 
intravesical PPS (treatment group) or oral PPS plus intravesical placebo (placebo group) in a 
clinical trial design. The main outcomes were the changes in subjective and objective measures 
of symptom severity, QOL and sexual functions. Results: Unmarried patients reported more 
severe symptoms compared to married patients. Being unemployed, obese, currently unmarried 
 iv 
and never pregnant were associated with a decrement in at least one QOL domain. Moreover, 
symptom severity was associated with worse QOL on 4 domains, (p<0.05).  On the other hand, 
the results from the clinical trial showed a greater significant reduction in symptom severity 
among the treatment group compared to the placebo group (46% reduction vs. 24% reduction 
respectively, p=0.04) and significant improvement in all QOL domains in the treatment group 
compared to the baseline (p<0.05). Conclusion: Being unmarried and symptom severity are 
important factors that may disturb the QOL in IC patients. Moreover, the use of intravesical PPS 
simultaneously with oral PPS is an effective therapeutic option. The findings of this research will 
open a new option for IC patients to reduce their devastating symptoms and to improve their 
quality of life. 
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1.0  INTRODUCTION 
1.1 RATIONALE AND SIGNIFICANCE OF PUBLIC HEALTH  
Interstitial Cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It affects 
the internal bladder wall and eventually disables its function. When a subject complains of 
urinary urgency, frequency, and/or pelvic/perineal pain in the absence of any identifiable cause, 
such as bacterial infection or carcinoma, a diagnosis of IC is likely. 1 Despite the long-standing 
recognition of interstitial cystitis, there are still no definitive answers to vital issues, such as the 
etiology, prevalence, diagnostic definition and therapy. 
It was thought that IC was a very rare event; however, ongoing prevalence studies 
demonstrate the otherwise. Until 1999 in the United States (US) the prevalence rate ranged from 
37 to 67 per 100,000. 2, 3 Since then, the prevalence of IC has been estimated at 575 to 12,600 per 
100,000. 4 Such a dramatic increase in prevalence has also been observed in Europe, as the 
estimated prevalence rate currently ranges from 300 to 680 per 100,000 5, 6 compared to 10.6 per 
100,000 in 1975.7 The explanations for this huge gap in estimating IC prevalence rate can be 
related to the absence of single diagnostic criterion and to the use of different methods in 
estimating the rate. An increasing awareness about IC among both patients and health workers 
might be another explanation that could lead to higher prevalence estimates.  Moreover, earlier 
studies were based on already established diagnosed IC cases rather than evaluating the 
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prevalence of symptoms of IC in a general population, which may have underestimated the true 
prevalence rate, as both mild and early cases may not have been included in the earlier 
estimations. 
IC affects women and men of any age or race, including children and the elderly. The 
majority of IC patients are white, 8, 9 female, 10 and premenopausal with a median age at 
diagnosis of 42-46 years. 3 Although IC can affect both men and women, it has been 
predominantly seen in women (historical female to male ratio is 9:1). 11 A recent study reports, 
however, that men currently account for higher proportion of IC patients (current female to male 
ratio is 5:1) compared to earlier estimates. 12 Whether this new estimate is correct, is still unclear. 
Well-designed epidemiological studies are necessary to determine the epidemiology of IC, which 
affects a wide variety of individuals and impairs their health related quality of life, as well as the 
magnitude of the problem. 
Importantly, IC might have a significant influence on the national economy. For instance, 
the average cost of treating an IC patient is over $7,500 a year, based on the INGENIX (Eden 
Prairie, Minnesota) claims-based dataset, the economic impact in the United States is estimated 
at approximately $3 billion per year. 13  
The impact of IC on patients’ Health Related Quality of Life (HRQL) is much more 
pervasive. It impairs physical, social, and emotional functions and well-being of the patients. It is 
a serious health problem that leaves many patients unable to cope with basic daily functions. 
Patient suffers 5 to 7 years on average and often visits as many as 8 physicians before the correct 
diagnosis is made. 2 IC patients often need to void more than 60 times a day, and experience 
severe pelvic pain and dyspareunia (pain with sexual activity), which can isolate them from 
social life, family relationships, work and can lead severe disability and depression. 14-16 IC 
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patients are 3 to 4 times more likely to report thoughts of suicide, and 5 times more likely to be 
treated for emotional problems as the general population. 2 Approximately, 30% of the patients 
reported that employment is impossible due to the severity of IC symptoms. 17, 18 Furthermore, an 
average of 50% of the patients are unable to work full time, and those who do work earn 
approximately $3.41 or less per hour. 19  
Several limitations were identified in earlier studies that assessed the impact of IC on 
patient’s quality of life. Most of the findings originate from studies using specific questions 
rather than standardized instruments to assess HRQL. 2, 4, 6, 18, 20 In fact, there are few reports 
available that use universally validated instruments, 17, 21, 22  such as the SF-36 survey instrument. 
The limited existing studies indicate that IC patients reported a poorer HRQL than controls 
across all SF-36 domains (physical functioning, role limitations related to physical problems, 
bodily pain, general health perceptions, vitality, social functioning, role limitations due to 
emotional problems, and general mental health). 22 Moreover, women with IC experienced 
greater decrements in HRQL compared to those with hypertension, but not compared to those 
with rheumatoid arthritis. 21 
A first step towards improving the lives of IC patients is to learn more about how IC 
affects HRQL. It is crucial to determine the factors that are associated with the severity of 
symptoms and the impairments in HRQL in IC patients. Identifying these factors will enable us 
to investigate if symptom severity has significant independent effect on the HRQL in IC patients 
after adjusting for such factors.  Moreover, it is of great interest to examine which domain of 
HRQL is most affected by the severity of symptoms. Also, it is important to identify which 
specific symptom (pain, urgency, urinary frequency, and/or nocturia) affects HRQL the greatest. 
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Answering all these questions will help to modify treatment options to focus on the main 
impaired domain of HRQL and the most devastating symptom.  
Two studies have attempted to answer some of the above questions. Unfortunately, 
several limitations exist. 17, 22 Investigators in both studies used non validated, self-reported 
measures  to classify the severity of pain, urgency and urinary frequency symptoms as mild, 
moderate, and severe without the use of any objective verification of disease severity. This, in 
fact, may be introduced misclassification bias and uncertainty into the classification of symptom 
severity. Currently there are two important standardized and validated instruments: O’Leary-Sant 
Interstitial Cystitis Symptom and Problem Index, and Pelvic Pain and Urgency/ Frequency 
Patient Symptom Scale (PUF) that have been created to either evaluate the development of 
established IC 23 or as a screening test of IC. 24 Both instruments can be used to classify the 
severity of IC symptoms in a more objective manner. Another limitation to be addressed; both 
studies did not identify the important covariates that may confound the association between 
symptom severity and HRQL. Furthermore, only the distributions of answers to selected items 
on the SF-36 questionnaire were reported in one of the two studies. 17 Given the above 
limitations, further studies are needed to more definitively evaluate the association between 
symptom severity and HRQL. 
A second step in improving lives of IC patients is to determine the best treatment for the 
relief of IC symptoms. Several possible etiologies have been suggested for IC; for each 
etiological theory there are different treatment options tailored to the postulated mechanism of 
action. Because there is no single confirmed etiology of IC, treatment is currently prescribed on 
the basis of a patient’s symptomatology. A total of 183 different therapeutic regimens currently 
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exist for IC; including cystoscopy and hydrodistension, amitriptyline, phenazopyridine, special 
diet and intravesical heparin. 25  
The bladder permeability theory is one of the most widely studied as a possible etiology 
of IC. In brief, it states that the epithelial lining of the bladder (the glycosaminoglycan or GAG 
layer) is deficient in IC patients, thus urine components can penetrate and irritate the bladder. 26 
Using substances with the same chemical nature of the GAG layer can replace the defective 
glycosaminoglycan in the bladder epithelium, and relieve symptoms. Pentosan Polysulfate 
Sodium (PPS) (Elmiron®) is one of the main treatment options based on bladder permeability 
theory. PPS remains the only oral therapy for IC approved by the Food and Drug Administration 
(FDA). 27, 28 Its efficacy and safety as an oral treatment for IC have been documented in several 
randomized double blind clinical trials. 27-33 However, one important drawback of PPS as an oral 
treatment is the low amount of active drug reaching the bladder (only 1-3% of the oral dose is 
excreted in the urine) resulting in a long lag time before clinical improvement is expected. 
Approximately 3 to 6 months is usually required before symptoms improve. 34 If the oral therapy 
is not sufficient to improve symptoms, intravesical therapy (the direct instillation of medication 
into the bladder using a catheter inserted through the urethra) is an alternative. It is one of the 
mainstays for the treatment of interstitial cystitis. The main advantages of intravesical therapy 
over oral therapy include high concentration of the drug in the bladder, short dwell time in the 
bladder, lack of significant side effects and non-interference with renal or liver metabolism. 35 
Currently, dimethyl sulfoxide (Rimso-50TM) is the only intravesical therapy approved by FDA.  
Because the efficacy of PPS as an oral therapy (response rate ranges from 27-42%) 36 is 
well-documented, 28-33 and the only important pitfall is related to its pharmacokinetic properties 
(only 3% of the oral dose reaches the bladder), researchers are now considering the use of PPS as 
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an intravesical therapy to overcome this drawback and to achieve higher efficacy. To the best of 
our knowledge, only one small randomized blind clinical trial assessed the efficacy of 
intravesical PPS compared to placebo. 37 This trial was conducted in the Netherlands and 
included 20 IC patients (10 patients per arm). Participants were randomized to receive either 
intravesical PPS (300 mg in 50 ml of 0.9% sodium chloride) applied twice a week for 3 months 
or a placebo. Significant symptomatic relief was reported in 4 of those who received the 
intravesical PPS compared to 2 of those receiving placebo. Furthermore, a significant increase in 
bladder capacity was reported among patients treated with PPS compared to placebo. However, 
one important limitation was that the intravesical instillation of PPS was done by a specialist 
only one time; after the first treatment, the patients had to perform self-catheterization. This self-
catheterization might affect the validity and the repeatability of results, since patients may not 
perform all required instillations properly due to a lack of supervision.  
In a small study in the US, Davis et al. 38 evaluated the effect of direct bladder application 
of PPS on the symptoms of IC among 31 female IC patients. The O’Leary-Sant’s IC Symptom 
Problem Questionnaire, Parsons’ Patient Symptom Scale (PUF), and the IC Network pain index 
were used to assess the efficacy of intravesical PPS. After receiving 5 instillations of PPS over a 
period of 21 months, participants reported 39.43% reduction in average pain score and 15% or 
more reduction in all the other three assessment scale scores.  
Although the substantial effect of IC on HRQL is well recognized, very few clinical trials 
that assessed the efficacy of oral PPS considered quality of life one of its endpoints. All the 
studies focused on symptoms as primary endpoint. The present study is the first, randomized 
double blind clinical trial in the US that tests the efficacy of intravesical instillation of PPS in the 
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bladder, and uses HRQL as well as symptom severity as main outcomes. The following section 
specifies the main aims of the current study. 
1.2 SPECIFIC AIMS  
The following specific aims were addressed in this study: 
1) To determine to what extent socio-demographic, lifestyle, reproductive and clinical factors are 
associated with symptom severity and impairment in HRQL in women diagnosed with IC. 
We hypothesize that age, education, smoking history, menopausal status, and co-morbid 
conditions will be associated with symptom severity, and that the same factors, with the 
exception of smoking history, will also be associated with impairment in HRQL in women 
diagnosed with IC. 
 
2) To determine if symptom severity is correlated with impairment in all HRQL domains after 
adjusting for confounders that will be identified from assessing the Specific Aim 1 of this study. 
We hypothesize that symptom severity will be associated with impairment in physical function, 
social function and mental health domains of HRQL and that these associations will not be 
significantly altered after adjusting for lifestyle and socio-demographic factors. 
 
3) To determine which symptom (pain, urinary frequency, nocturia and/or urgency) is most 
likely to impair IC patients’ HRQL represented by Physical Component Summary (PCS) and 
Mental Component Summary (MCS) of the SF-36 instrument.  
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We hypothesize that there will be variability in the effect of each symptom on PCS and MCS 
scales, and that pain will be the symptom most likely to impair both summary components. 
 
4) To determine if the intravesical instillation of PPS plus the administration of oral PPS will 
reduce symptom severity more than oral PPS plus intravesical placebo at the following 
endpoints: week 6, week 12, and/or week 18 of the trial.  
We hypothesize that the use of both intravesical PPS and oral PPS for the first 6 weeks of the 
trial will improve IC symptoms significantly more than the use of oral PPS and intravesical 
placebo. 
 
5) To determine which symptom (pain, urgency, nocturia and/or urinary frequency) is most 
likely to be improved as a result of administering either intravesical PPS plus oral PPS or 
intravesical placebo plus oral PPS at the following endpoints: week 6, week 12, and/or week 18 
of the trial.   
We hypothesize that pain will be the most improved symptom as a result of administering either 
intravesical PPS plus oral PPS or intravesical placebo plus oral PPS at each endpoint. 
 
6) To determine if the proportion of responders (defined by those who reported any improvement 
through patient global assessment instrument) is significantly more among those who received 
both intravesical PPS and oral PPS (treatment group) in comparison to those who received 
intravesical placebo and oral PPS (placebo group) by the end of the study (at week 18). 
We hypothesize that the proportion of responders will be significantly more among the 
treatment group compared to the placebo group at week 18 of the study. 
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7) To test if the intravesical instillation of PPS plus the administration of oral PPS will improve 
IC patients’ HRQL represented by Physical Component Summary (PCS) and Mental Component 
Summary (MCS) of the SF-36 more than intravesical placebo plus oral PPS at week 4 and/or at 
the end of the trial (at week 18). 
We hypothesize that the use of both intravesical PPS and oral PPS will improve HRQL in IC 
patients significantly more than the use of intravesical placebo plus oral PPS at both endpoints. 
 
8) To determine which domain of HRQL is most likely to be improved as a result of 
administering either intravesical PPS plus oral PPS or intravesical placebo plus oral PPS at week 
4 and/or at the end of the trial (at week 18).  
We hypothesize that the use of either intravesical PPS plus oral PPS or intravesical placebo plus 
oral PPS will not have the same improvement effect on all HRQL domains at both endpoints, 
and that administering intravesical PPS plus oral PPS will significantly improve all HRQL 
domains by the end of the trial.  
 
9) To determine if the administration of both intravesical PPS and oral PPS will improve sexual 
function more than intravesical placebo and oral PPS at week 4 and/or at the end of the trial (at 
week 18).  
We hypothesize that the use of both intravesical PPS and oral PPS will improve sexual function 
of IC patients more than the use of intravesical placebo and oral PPS at both endpoints.  
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2.0  GENERAL BACKGROUND AND LITERATURE REVIEW 
2.1 HISTORICAL BACKGROUND 
Interstitial Cystitis (IC), or as it is called today, Painful Bladder Syndrome (PBS), has been a 
relatively poorly recognized condition. Its etiology has remained obscure at least partly because 
of the lack of research on the disorder as well as a precise definition and diagnosis of the disease.  
Historically, IC has been known since 1836. 39 At that time, IC was described as a 
spontaneous rupture of the urinary bladder secondary to ulceration. Later, Skene defined the term 
IC as the end stage of a disease that attacks the bladder. 40 In 1907, Nitze described IC as a 
condition of the bladder in which the frequency of micturation, pain, and mucosal ulceration are 
the most important features. 41 The concerns about IC have received much attention since 
Hunner associated IC with a rare type of bladder ulcer known as Hunner’s ulcer and defined as a 
reddened area of the bladder wall that can be found on cystoscopy. 42 Unfortunately, this 
discovery led people to think that the disease might be focal and not a pancystitis (cystitis 
involving the entire thickness of the wall of the urinary bladder) even when in fact it is, and it 
also led physicians to look for an ulcer at cystoscopy to confirm the diagnosis of IC. 43 Later, 
new descriptive terms appeared and it became clear that Hunner ulceration is not the only feature 
of the disease.  
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2.2 CLINICAL PRESENTATION OF IC 
2.2.1 Definition and Classification 
Given the fact that there is no single theory that exhaustively explains the etiology of IC, several 
definitions were suggested. IC is defined as a chronic disease or syndrome characterized by the 
symptoms of urinary frequency, urgency, or pelvic pain in any combination in the absence of 
another well defined cause (Urinary tract infection or bladder cancer). 44 Pathoanatomically, IC is 
defined by an elevation of mast cell count in the detrusor muscle to more than 28 mast cell/mm2. 
45, 46, 47 Holm-Bentzen et al., define IC to include all the following: 1) chronic cystitis symptoms, 
including suprapubic pain, for at least one year, 2) sterile and cytological normal urine, 3) most 
often, but not necessarily, either an abnormal cystoscopy before distension or a petechial 
bleeding after distension, 4) an elevated mast cell count in the detrusor muscle. 48 
Based on cystoscopic findings, IC can be classified into two different types; either 
ulcerative (classic) or non-ulcerative (early).  The classic type is characterized by the presence of 
granulation tissue; usually about 94% of classic cases have granulation. 49 On the other hand, the 
so-called strawberry-like hemorrhages (known as glomerulations) are seen in the early type. 49 In 
fact, the early type is the most common; approximately 90% of IC patients are classified as non-
ulcerative cases. 9 Studies showed that patients with the classic type have a smaller bladder 
capacity (less than 450 ml) compared to patients with the early type. Another difference between 
the two types is the concentration of mononuclear cells (present in the mucosa) that represent the 
degree of inflammation. Patients with the classic type have higher mononuclear concentration 
compared to early type patients. 49 
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2.2.2 Symptoms 
The most prevalent symptoms of IC are urinary frequency, urgency, suprapubic and pelvic or 
perineal pain. The pain can occur in the lower abdomen, inguinal area, labia, vaginal-perineal 
region, lower back or medial aspect of the thighs, and its severity is not affected by filling or 
emptying the bladder. 44 The urgency is one of the most devastating symptoms.  In some severe 
cases a patient may need to urinate over 60 times a day and to void up to 20 times during the 
night. 45 
Interestingly, most women report an increase of pelvic pain one week prior to menses; 
some women experience dysmenorrhea. Sexual intimacy was found to be associated with IC 
pain; the pain occurs before, during and/or after sexual intercourse in both women and men. 
Symptoms may also be exacerbated by specific foods, beverages, physical or emotional stress.44 
2.2.3 Etiology 
The etiology of IC is still not clear. Several theories have been postulated; however, none of 
them can stand alone. In 1986, Messing reviewed all the existing theories about the pathology 
and etiology of IC. These theories included infection, toxic agents in the urine, genetic or 
endocrinologic deficiencies, lymphatic or vascular obstruction, neurogenic, autoimmune causes 
and psychiatric causes. 50 In fact, there is a general agreement that IC etiology is multifactorial 
and that we are dealing with a syndrome, not just a single disease. 51 Major theories are presented 
in the following sections.  
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2.2.3.1 Epithelial Dysfunction Theory (Leaky Bladder Theory) 
The mucous surface coat lining the urothelium, with its content of glycosaminoglycan (GAG), is 
thought of as playing an important protective role for the bladder wall. 26 There are seven major 
classes of GAG (called mucopolysaccharides): chondroitin 4- and 6-sulfate, dermatan sulfate, 
keratan sulfate, heparan sulfate, hyalouronic acid and heparin. In 1983, Parsons was the first who 
drew attention to the role of GAG layer in the development of IC. He hypothesized that IC 
patients do not have the GAG layer, or have a defective one and, therefore, they need to be 
treated using synthetic GAG. 52 Later, both Lilly and Parsons suggested that the GAG layer acts 
as an epithelial permeability barrier between the bladder wall and the urine. 53 They showed that 
the GAG layer prevents the small molecule urea from leaking across bladder wall, and this 
protective effect can be impaired by instilling a quaternary amine (protamine) into the bladder, 
and can be restored by instilling a sulfate polysaccharide (heparin) into the bladder.  
In fact, GAG contains negatively charged, sulfated polysaccharide groups with 
hydrophilic property. This provides the hydrated surface layer (GAG) with the ability to prevent 
urinary solutes from damaging the bladder cells. Thus, if GAG is damaged, bladder cells will 
become subject to harmful solutes. One potentially damaging urinary solute is potassium which 
is found in high levels (40 to 140 mEq/L) in normal urine. Potassium in this concentration does 
not transfer through a healthy bladder. However, if there is a dysfunction in the bladder 
epithelium, potassium will diffuse into the bladder muscles. As a result, depolarization of nerve 
and muscle can take place, which can lead to an injury, and then, induce IC symptoms of 
urgency and pain. 54 
In 1994, Chelsky et al. published a paper that conflicted with the GAG theory (epithelial 
leak). They tested the bladder permeability through measuring the transvesical migration of the 
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radioisotope technetium99m-diethylenetriaminepentaacetic acid (99mTc-DTPA) into the systemic 
circulation in 10 IC patients and 9 controls. The result of the study showed that there is a 
considerable variability in the absorption of 99mTc-DTPA in both IC patients and normal people. 
However, the differences between the two groups were not statistically significant. 55 This study 
suggests that the permeability spectrum of the bladder of normal people is not different from that 
in IC patients.   
Although the previous study did not support the GAG theory, it may have lacked 
statistical power to detect a true difference because of its small sample size. Moreover, we 
cannot ignore all the clinical studies that reported synthetic polysaccharides as a successful 
treatment of IC. 28-30, 56 All these studies support the GAG theory, and suggest that the 
abnormality of GAG layer could be an important etiology of IC in a subset of patients, and that 
more than 50% of IC patients will get benefits from using synthetic polysaccharides.  
In summary, it is important to mention that this theory has not been completely proven; 
therefore, it remains an area of active research. We still need to identify the reasons that lead to 
the changes in the permeability of the urothelium, and how these changes correlate with bladder 
permeability. 
2.2.3.2 Mast Cell Theory and Neurogenic Inflammation 
Mast cells are inflammatory cells that secrete a variety of mediators (histamine, prostaglandins, 
leukotrienes, cytokines, and chemotactic factors) relevant to IC symptoms. These mediators are 
either synthesized de novo or released from the intracellular granules, when the mast cells are 
activated (degranulated). The main triggers of mast cells degranulation are antigen binding to 
IgE on mast cell surface, cholinergic agonists, hormones, stress, and trauma. 57   
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When mast cells are activated, they release inflammatory mediators (such as histamine) 
which in turn induce IC symptoms (pain, hyperemia, and fibrosis). Several studies support this 
theory. Simmons et al. are the first to outline the role of mast cells as a cause of IC. 58 They 
found mast cells in the wall of the normal bladder secreting histamine, and they reported 
improvement in IC symptoms among IC patients who received antihistamines (tripelennamine) 
three times a day. In 1982, Larsen et al. reported that mast cells had a potential role in the 
pathogeneses of IC. 59 Kastrup et al. suggested using mast cell count; in particular, in the detrusor 
muscle of the bladder as a diagnostic criterion. 60 They reported mast cell count significantly 
higher in detrusor muscle of IC patients compared to control subjects.  
In a more intensive study, Holm-Bentzen and his colleagues attempted to relate 
symptoms and findings of cystoscopy and cystometry in 115 IC patients with or without mast 
cell count in the detrusor muscle (detrusor mastocytosis). 61 They divided patients into two main 
groups; those with mast cell count greater than 28, and those with less than 28 mast cells/mm2. 
Patients with mast cell count greater than 28 had hematuria, more damaged bladder, redness, 
scarring, increased visualization of bladder mucosa at cystoscopy before hydrodistension and 
reduction in bladder capacity compared to those with mast cell count less than 28 per square 
millimeter.  On the other hand, petechial bleeding was found to be similar in both groups, and the 
patients with a mast cell count less than 28 had a vulnerable mucosa after bladder distension.  
Because the two groups largely overlapped, the investigators of this study suggested that mast 
cell count alone cannot be considered as the only factor which induces the symptoms in IC 
patients.  
Hanno et al. agreed with Holm-Bentzen et al. that mast cell count in the detrusor muscle 
cannot be used to confirm IC diagnosis. They evaluated the mast cell count in 55 patients with IC 
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and 21 patients who had voiding dysfunction due to a cause other than IC. 1 The mean detrusor 
mast cell count was not statistically different between the two groups. Thus, although detrusor 
mast cells could be an important mediator of the disease, it cannot be used alone as an exhaustive 
diagnostic criterion. 
As was mentioned previously, hormones have been implicated as triggers to mast cells 
activations. Spanos et al. in their animal study reported that estradiol was responsible for the 
activation of the mast cells in the bladder. 62 This could be an explanation of the higher 
prevalence of the disease among females. In fact, human mast cells contain estrogen receptors, 
which may also explain why IC symptoms get worse during ovulation. 63  
There is an association between the existence of mast cells in IC patients and the 
occurrence of neurogenic inflammation. Some studies have reported that many mast cells 
degranulated near sensory nerve fibers. 64-67 This suggests that IC could be a neurogenic 
inflammation that starts when sensory nerves are stimulated and release neuropathies (Substance 
P) which promote inflammation by several mechanisms including the activation of mast cells. 64 
Once the mast cells are activated, they release their mediators which induce pain, and stimulate 
the sensory nerve fibers again, creating a vicious cycle. 
Overall, it is not known whether mast cells play a causative or a secondary role. If they 
are causative agents, then they will produce the symptoms of IC by degranulation. Another 
possibility is that they are activated by other factors such as epithelial leak, in which case mast 
cells can be considered playing a secondary role. Thus, we can tell that they play an important 
role in IC, but we cannot say for sure that they are the only causative factor. 36 
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2.2.3.3 Autoimmune Theory 
Since the 1970s, researchers have been suggesting that autoimmune reactions might explain 
many facets of IC. Silk compared the sera of 20 IC patients and those of other groups: 10 normal 
volunteers, 15 patients with acute and chronic bacterial cystitis and 10 patients with known 
thyroid, adrenal and gastric antibodies. 68 He found bladder antibodies in IC patients, but not in 
any other group in the study. Oravisto et al. agreed with Silk, and reported the presence of 
antinuclear antibodies in 85% of their IC patients. 69  
There are two different kinds of autoimmune diseases: organ-specific and non-organ-
specific. According to several autoimmune studies, it seems that IC is a non-organ specific 
autoimmune condition. Although the researchers found bladder antibodies, they failed to report 
bladder-specific auto-antibodies. Jokinen et al. studied the sera of 33 IC patients and found that 
28 out of them had antinuclear antibodies, 70 but could not detect any bladder-specific auto-
antibody among IC patients. Furthermore, Anderson and his colleagues in their study where IC 
patients were examined in comparison with controls who matched on age, sex, but with different 
urological problem, reported the presence of non-organ-specific antibodies in 65% of the IC 
patients and 22% of the controls. 71 They also found that 40% of the patients and 22% of the 
controls had antinuclear antibodies while 75% of the patients and 40% of the controls had 
bladder-specific antibodies. Finding bladder-specific antibodies among the controls indicates that 
these antibodies are not specific to IC patients. As a result, Anderson and his colleagues 
concluded that the immunological characteristics of IC are most likely to be secondary to 
inflammation rather than causative factors.  
      In fact, there are more studies which support this theory. Evidences show the pres-
ence of autoimmune components can be summarized as follows: 72 
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• IC has been reported in association with other autoimmune diseases such as Sjögren’s, 
rheumatoid arthritis, lupus, and Hashimoto’s thyroiditis.  
• Plasma cells and antibody deposits are found in the bladder.  
• Using cortisone treatment led to remission of some symptoms of IC which are similar to 
those in the systemic autoimmune diseases, lupus and scleroderma. 
• Mouse immunization with autologous bladder antigens results in IC-like bladder changes.  
In conclusion, the exact role of autoimmunity in IC remains nebulous. For a clearer 
understanding of its function, more detailed animal studies are to be conducted. 
2.2.3.4 Inflammation Theory 
There is an argument that IC is an inflammatory disease, because several inflammatory 
mediators e.g., interleukin-6 (IL-6), IL-2, kallikrein, and neutophil chemotactic factors, are 
increased in IC patient’s urine. 73-77 Still, the primary causative agent that starts the sequence of 
the inflammation process is not yet known. Different possible causative factors have been 
suggested such as; neurogenic inflammation, dysfunction of the bladder epithelium that leads to 
the diffusion of different irritating materials, allergy or hypersensitivity to urine components, 
microbial agent and autoimmune infection. 78 However, there are no specific studies that show 
which is the real causative factor. This theory needs more research to clarify it. 
2.2.3.5 Microbiological Theory  
The earlier literature attempts to incriminate microbiological agents such as bacteria, virus, and 
fungi as possible causes of IC with no success. 48 Hunner was among the first researchers who 
suggested that IC might be caused by a bacterial agent. 79  
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In 1945, Powell argued that lymphatic obstruction might have an important role; however 
he could not present any strong evidence to support the idea. 47 In 1970, Hanash and Pool 
examined the urine of 30 IC patients in order to detect the presence of any bacteria or fungi, but 
failed to find anything. 80  
In contrast, Wilkins et al. were able to isolate Fastidious bacteria, Gardnerella vaginales 
and Lactobacillus species from catheter specimens and/or bladder biopsies of IC patients. 81 They 
stated that the presence of these organisms might lead to acute cystitis if no treatment was 
provided.   
Unfortunately, however, the use of more developed, highly sensitive and faster technique 
like: ribosomal RNA gene sequence and polymerase chain reaction (PCR) could not yet offer 
any reliable evidence that can allow researchers to confirm the theory. 82, 83  
Later, though, unlike the prior studies that could not prove the validity of the theory, a 
recent pilot double blind, placebo-control trial found it helpful to use antibiotics to treat IC. 84 
The results could however, be biased by the fact that antibiotics have anti-inflammatory effects 
(it has been proposed that IC is an inflammatory disease). Therefore the improvement that was 
observed could be due to the anti-inflammatory effect of antibiotics, not because of IC caused by 
microbes. 85  
Although the general direction of research in this area does not support the 
microbiological theory, researchers are still interested in pursuing and conducting more studies 
to understand the role of microbes in this complex disease. 
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2.2.3.6 Toxic Urine Component Theory 
Another suggested etiological factor for IC is the presence of toxic substances in the urine. 
Several studies have investigated the urine of IC patients for toxicity. Some investigators 
exposed rabbit bladder to the urine of IC patients or controls and they were able to report the 
development of IC signs in the rabbit bladder that was exposed to the urine of IC patients, but 
not to the controls’ urine. 86 Another study showed that the urine of IC patients were able to 
inhibit the proliferation of human epithelial cells in primary culture. 87  
2.2.3.7 Psychological Theory 
A psychological etiology of IC has been mentioned. IC often is misdiagnosed as a psychiatric 
disorder, and its treatment with psychotropic medication is not uncommon.19  
The major psychological factor, stress, has been considered to play a role in autoimmune 
and neuroinflammatory syndromes in which the nervous system interacts with the immune 
system. 88, 89 Stress is also known to worsen syndromes involving mast cells such as interstitial 
cystitis. 57 The possible role of stress as an etiological factor of IC is thought to be related to its 
ability to activate mast cells. In vivo animal studies have shown that immobilization stress 
activates over 70% of bladder mast cells within a short period. 90, 91 It has been suggested that the 
activation of bladder nerve endings under stress may lead to release of Substance P (SP) and 
neuropeptide (neurotensin) which then activate local mast cells to secrete vasoactive, 
proinflammatory and nociceptive mediators. 90, 92 The effect of these, in turn, could explain most 
of the clinical symptoms of IC.  
On the other hand, the chronic pain, frequency, urgency and sleep deprivation associated 
with interstitial cystitis may contribute to psychological stress and secondary depression. 
Suicidal ideation is three to four times more common in patients with interstitial cystitis than in 
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the general population. 93 More than one half of symptomatic patients with interstitial cystitis 
have depression. 94 Thus, it is not clear if psychological factors play a primary, a secondary, or 
both primary and secondary roles in the initiation of IC. More research is needed in this area. 
2.2.4 Diagnosis 
There is no single definitive test that can confirm the diagnosis of IC. One of the difficulties in 
the diagnosis of IC has been the multitude of symptoms and the lack of a clear etiology and 
pathogenesis of the disease. In fact, patients may see as many as 8 physicians and suffer from 
symptoms for 5 to 7 years before an accurate diagnosis of IC is made. 44 Thus, the current 
diagnosis usually depends on patient symptomatology, urologic evaluation including cystoscopy, 
and the exclusion of other recognizable bladder diseases.  
2.2.4.1 The National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) 
Diagnostic Criteria 
In 1987, the National Institute of Diabetes, Digestive, and Kidney diseases (NIDDK) developed 
a set of criteria for accrual of patients in IC studies sponsored by NIH. Thus, homogeneity and 
similarity between one site and another can be ensured. A list of NIDDK guidelines is shown in 
Table 2-1. An IC case can be confirmed if it meets the following inclusion criteria: painful 
bladder or urinary urgency, and glomerulations (glumerulus is a small tuft or cluster, as of food 
vessels or nerve fibers) or Hunner’s ulcer on cystoscopic examination. 45  
 
 
 
                                                                                                                                                             46 
        Table  2-1: The Original NIDDK Criteria for Inclusion in IC Studies-1987*  
 
THE ORIGINAL NIDDK CRITERIA FOR INCLUSION IN IC STUDIES 
Automatic Exclusion: 
• Age <18 years 
• Benign or malignant bladder tumors 
• Radiation cystitis 
• Bacterial cystitis 
• Vaginitis 
• Cyclophosphamide cystitis 
• Symptomatic urethral diverticulum 
• Uterine, cervical, vaginal, or urethral cancer 
• Active herpes 
• Bladder or lower urethral calculi 
• Waking frequency less than five times in 12 hr 
• Nocturia less than two times 
• Symptoms relieved by antibiotics, urinary antiseptics, urinary analgesics 
• Duration less than 12 months 
• Involuntary bladder contractions (urodynamics) 
• Capacity greater than 400 cc, absence of sensory urgency 
 
Automatic Inclusions: 
• Hunner’s ulcer 
 
Positive Factors: A 
• Pain on bladder filling, relieving by emptying 
• Pain (suprapubic, pelvic, urethral, vaginal, or perineal) 
• Glomerulations on endoscopy 
• Decreased compliance on cystometrogram 
           *  Reprinted with permission from Nigro DA, Wein AJ. Interstitial cystitis: clinical and endoscopic features. In: Sant GR., ed.  
               Interstitial Cystitis, Philadelphia: Lippincott-Raven; 1997:137-142. Copyright©1997 http://lww.com 
           A  Two required for inclusion in study population 
 
Several felt that these criteria were too restrictive in clinical setting. Thus, later in 1988, 
the NIDDK criteria were revised. A list of the revised NIDDK guidelines is shown in Table 2-2. 
Current research studies must follow these guidelines in identifying IC cases to be included in 
the study. Although these criteria help a lot in establishing the homogeneity and similarity in the 
study population among study centers, some IC cases may be excluded from studies on IC, as 
these criteria do not represent less common symptoms and signs. 95 Interestingly, strict 
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application of the NIDDK criteria would have misdiagnosed more than 60 percent of patients 
who were diagnosed by researchers as definitely having or likely to have interstitial cystitis. 96    
 
       Table  2-2: The Revised NIDDK Criteria for Inclusion in IC Studies-1988 * 
 
THE REVISED NIDDK CRITERIA FOR INCLUSION IN IC STUDIES  
 
The presence of any one of the following criteria will exclude the diagnosis of 
IC for study purpose: 
• Bladder capacity > 350 ml on awake cystometry using either gas or liquid as 
a filling medium 
• Absence of an intense urge to void with the bladder filled to 100 ml of gas or 
150 ml of water during cystometry using a fill rate of 30-100 ml/min 
• The demonstration of phasic involuntary bladder contractions on cystometry 
using the filling rate described above 
• Duration of symptoms less than 9 months 
• Absence of nocturia 
• Symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics, or 
antispasmodics 
• A frequency of urination , while awake, less than 8 times per day 
• A diagnosis of bacterial cystitis or prostatitis within 3 month period 
• Bladder or lower urethral calculi 
• Active genital herpes 
• Uterine, cervical, vaginal, or urethral cancer 
• Urethral diverticulum 
• Cyclophosphamide or any type of chemical cystitis 
• Tuberculosis cystitis 
• Radiation cystitis 
• Benign or malignant bladder tumors 
• Vaginitis 
• Age less than 18 years  
 
To be diagnosed as having IC, patients must have either glomerulations in 
cystoscopic examination or classic Hunner’s ulcer, and either pain associated 
with the bladder or urinary urgency. An examination for glomerulations should 
be undertaken after distension of the bladder under anesthesia to 80 to 100 cm 
water pressure for 1 to 2 min. The bladder may be distended up to two times 
before evaluation. The glomerulations must be diffused (present in at least 
three quadrants of the bladder) and there must be at least ten glomerulations 
per quadrant. The glomerulations must not be located along the path of the 
cystoscope (to avoid artifact from instrumentation contact). 
* Reprinted with permission from Nigro DA, Wein AJ. Interstitial cystitis: clinical and endoscopic features. In: Sant GR., ed.  
   Interstitial Cystitis, Philadelphia: Lippincott-Raven; 1997:137-142. Copyright©1997 http://lww.com
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2.2.4.2 Traditional Diagnostic Criteria 
Currently, IC diagnosis is still based on presenting signs and symptoms after a differential 
diagnosis. Bladder or urinary tract infection, bladder cancer, sexually transmitted diseases, 
urethral diverticula, and uterovaginal prolapse should be excluded to confirm that the diagnosis 
is IC. A strong history of urinary urgency, frequency and pelvic pain, a physical examination to 
detect suprapubic tenderness, anterior vaginal wall tenderness, Levator muscle spasm, and 
possible rectal spasm also must be documented. The urine analysis should be normal with a 
sterile urine culture and negative cytology. Because IC patients may void more than 60 times a 
day, each patient should be asked to perform a voiding log to show the number of voids per day 
as a part of the overall method of IC diagnosis. Table 2-3 summarizes the current traditional 
diagnostic criteria. 44 
 
    Table  2-3: Current Traditional Diagnostic Criteria*  
 
CURRENT TRADITIONAL DIAGNOSTIC CRITERIA 
 
Differential diagnosis of IC 
• Bladder or urinary tract infection 
• Bladder cancer 
• Sexually transmitted diseases 
• Urethral diverticula 
• Uterovaginal prolapse 
Patient history 
• Urinary urgency, and frequency 
• Pelvic pain 
Physical examination 
• Possible suprapubic tenderness 
• Possible anterior vaginal wall/ bladder base tenderness 
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• Levator muscle spasm 
• Possible rectal spasm 
Clean urine analysis  
Sterile urine culture 
Negative cytology 
Voiding log more than 8 voids in 24 hours 
Table 2-3 Cont’d
      *  Reprinted with permission from J Reprod Med., 2004; 49 (3 Suppl): 235-42, Parsons CL. Diagnosing chronic pelvic pain of bladder      
           origin. Copyright©2004 J Reprod Med, Inc. 
 
2.2.4.3 Additional Diagnostic Tools 
2.2.4.3.1 Cystoscopy With Hydrodistension 
The purpose of using cystoscopy with hydrodistension is to detect glomerulations and/or 
Hunner’s ulcer in some patients with IC. The main procedure is to fill the bladder under 
anesthesia with water to a relatively high pressure. This will be followed by emptying the 
bladder and finally inspecting it. 44 Although using cystoscopy after hydrodistension is one of the 
recommendations of NIDDK as an important procedure to diagnose IC, it cannot be used alone 
as only, 11.3% of IC patients will have Hunner’s ulcers. 9 Moreover, most patients have no 
visible lesions upon routine inspection of the bladder. Furthermore, glomerulations are not 
specific to IC. They can be seen in various types of inflammatory bladder disease (such as after 
treatment with intravesical chemotherapy and radiation), also with infectious (tuberculosis, 
fungus), toxic (Cyclophosphamide, formalin) and neoplastic disorders of the bladder. They may 
also simply be a result of stretching the bladder several hundred cubic centimeters beyond its 
usual capacity. 97 Cystoscopy with hydrodistension can be used to assess the capacity of the 
bladder. Small capacity supports IC diagnosis and is inversely proportionate to the presence of 
Hunner’s ulcer. 44 
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2.2.4.3.2 Urodynamic Testing 
Urodynamic is the study of how the body stores and releases urine. It shows how the bladder and 
sphincter muscles work and thus helps in explaining symptoms like frequent urination, sudden 
and strong urge, and painful urination. Most urodynamic tests focus on the bladder's ability to 
empty steadily and completely. Through these tests a physician can determine if a patient has any 
difficulty starting the urine stream, if the stream is interrupted, and if any urine remains in the 
bladder after micturation.98 
Several urodynamic tests are currently available. In the following section, we will describe those 
used in the present study to evaluate the change due to the intervention therapy. 
Uroflowmetry 
Uroflowmetry is the simplest urodynamic test because it is noninvasive and performed through 
very simple and non-expensive equipment, the uroflowmeter, which creates a graph that provides 
several important measures as follows: 99 
• Flow rate defined as the volume of the fluid expelled via the urethra per unit time and 
expressed in milliliters per second (ml/s). 
• Maximum flow rate defined as the maximum measured value of the flow rate. 
• Average flow rate defined as the voided volume divided by flow time. 
• Time to maximum flow defined as the elapsed time from onset of flow to maximum flow. 
• Flow time defined as the total time of measurable flow. 
• Voided volume defined as the total volume expelled via urethra. 
Using this test, the physician is able to keep track of changes in the flow rate from second 
to second; the peak flow rate and how many seconds it took to get there. Because urine flow is 
highly dependent on the volume voided (flow rates are highest and most predictable in the 
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volume range between 200ml and 400ml), it is not easy to specify fixed norms. One way to 
overcome this is to define the lowest acceptable maximum urine flow rates for minimum voided 
volumes. For example, the lowest acceptable maximum urine flow rate for a female aged 
between 46 and 65 with a minimum voiding volume 200 ml is 15 ml/s, and for female aged 66-
80 is 10 ml/s when the same voided volume is used. 99 If the results are abnormal this will 
indicate that bladder muscle (detrusor) is weak or the urine flow is obstructed. 98   
Simple Cystometry (Measurement of Bladder Pressure) 
Importantly, uroflowmetry provides limited information about the storage phase of micturation, 
and thus it cannot show if the abnormal flow is related to weakness in bladder muscle or to an 
obstruction. On the other hand, cystometry overcomes this limitation. 99 The cystometrogram 
(CMG) measures how much the bladder can hold, how much pressure builds up inside the 
bladder as it stores urine, and how full it is when a patient feels the urge to urinate. 98 The 
principal aim of CMG is to define detrusor function and urethral function during both filling and 
voiding processes. In this way, a physician will be able to provide a possible diagnosis during 
cystometry. For instance, during the filling process, if the detrusor function is normal while the 
urethra is incompetent, the possible diagnosis is incontinence. On the other hand, during voiding, 
if detrusor is underactive while the urethra is normal, a low flow rate will be observed, and the 
patient strained to void. 99  
Normal cystometry is defined as the ability to fill the bladder (using distending medium 
such as sterile water, saline, carbon dioxide, or urine) to a normal maximum cystometric capacity 
in the absence of any involuntary detrusor contractions or voluntary uninhibited contractions. 
The normal maximum cystometric capacities will differ depending on the medium used to 
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distend the bladder. For example, if the distending medium is carbon dioxide, detrusor instability 
may occur. 100 
The first step in CMG is to empty the patient bladder. This will be followed by filling the 
bladder with the distending medium using a smaller pressure-measuring catheter called 
cystometer with a desired filling rate. There are three categories of filling rate: slow-fill 
cystometry (up to 10 ml/min), medium-fill cystometry (between 10 ml/min and 100 ml/min) and 
fast-fill cystometry (greater than 100 ml/min). The rate of bladder filling has considerable effect 
on the results of the test. The faster the bladder is filled, the lower the bladder compliance is 
(bladder compliance: a relation between bladder volume and bladder pressure). As the patient’s 
bladder is filled, he or she will state when he or she feels the first need to urinate. This is 
recorded and the process continues. The physician normally asks the patient to wait until he or 
she feels so full as to want to get off the freeway and use the restroom at a gas station rather than 
endure until he or she gets back home. This will also be recorded. The filling process will 
continue until the patient can stand no more due to pain or extreme discomfort. This will be the 
maximum cystometric capacity. During cystometry the patient may be asked to cough so that 
involuntary bladder contractions can be identified. 98, 100 
Post Void Residual (PVR) 
PVR is defined as the volume of urine left in the bladder at the end of micturation. 99 It is usually 
measured by either a thin catheter that is gently glided into the urethra or by ultrasound 
equipment that creates a picture of the bladder and determines the amount of PVR.  
Many define normal residuals as less than 30 ml, whereas others choose a cutoff of 50 
ml. It is important to mention that residuals must be evaluated in relation to the volume voided. 
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For example, the residual of 30 ml after the void of 45 ml is not normal. However, the same 
residual might be reasonable after a patient voids 500 ml of urine. 101 
2.2.4.3.3 O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index 
(ICPI) 
This index is designed to identify the most prominent voiding and pain symptoms in patients 
with IC and the extent of the perceived problem (Appendix B). It has been validated by 
examining 45 newly diagnosed IC patients and 67 women recruited from healthy volunteers at a 
gynecology clinic. 23 The results showed high internal consistency for both symptom and 
problem indices (Cronbach’s alpha >0.85) as well as high reliability (test-retest reliabilities 
exceeded 0.9). The validity, reliability and responsiveness of the scores have been reported again 
more recently. 102 The results were consistent with the previous study. 
2.2.4.3.4 Pelvic Pain and Urgency/ Frequency Patient Symptom Scale (PUF)  
The PUF includes 8 questions that measure the presence and the severity of IC symptoms and the 
degree to which patients are bothered by the symptoms (Appendix C). The questions assess the 
urgency and the frequency of voiding during waking and sleeping hours, the presence of pain or 
urinary urgency during or after sexual intercourse, the presence of pain in the pelvic area, and the 
degree to which these symptoms are bothersome. 
The maximum total score is 35 while the minimum recorded score among healthy 
participants is < 2. A total score of 10+ points clearly indicates a very high probability that the 
patient has IC. 44 A total score of 10 to 14 indicates a 74% chance to have IC, 15 to 19 indicates a 
76% chance to have IC, and 20 or higher indicates a 91% chance to have IC. 24 
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2.2.4.3.5 Potassium Sensitivity Test (PST) 
The PST was developed to identify patients who respond with pain following the instillation of 
potassium chloride into the bladder. In fact, this test is based on leaky bladder theory. The 
abnormal permeability of the bladder surface’s barrier (GAG) allows potassium to leak and to be 
absorbed into the bladder wall. This in turn will stimulate nerves, and cause pain and 
inflammation in the bladder wall. A positive PST (pain following the instillation of potassium 
chloride into the bladder) indicates that a patient with chronic pelvic pain has a bladder 
component, and could be an IC case. However, because PST has been shown to give positive 
results in other bladder diseases such as radiation cystitis or acute bacterial cystitis, these 
diseases must be ruled out. Furthermore, a negative result of PST does not indicate that IC 
diagnosis is ruled out. This false negative result can occur when a patient was recently treated 
with intravesical dimethyl sulfoxide or heparin therapy or hydrodistension. 24 
The main procedure includes a very slow instillation of 40 ml of room temperature sterile 
water into the bladder through a thin catheter over 2-3 minutes to establish the baseline of pain 
perception and urgency using 0-5 point scale (5 indicates severe pain and severe urgency). Water 
retained in the bladder for 5 minutes and then emptied through the catheter. About 40 ml of 
potassium chloride then is to be instilled, whereby re-evaluation of pain and urgency will be 
achieved. Potassium chloride can be retained in the bladder for 5 minutes if there is no severe 
response. A positive PST is indicated for any pain score greater than or equal to 2. If no response 
takes place, then the catheter is removed and the patient is asked to urinate and re-evaluate the 
level of pain and urgency. PST validity was tested previously. Of 1500 PSTs performed on 
individuals with IC, approximately 80% were positive. 24  
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2.2.4.3.6 Urinary Biomarkers 
There is no single and specific diagnosis of IC. Moreover, the currently used criteria have been 
developed for clinical research and may be too restrictive. It is important, therefore, to find an 
objective marker for IC to facilitate the diagnosis. It has been indicated that certain objective 
biomarkers could be more specific than either symptomatic or cystoscopic criteria for IC. 103-106 
Besides, some of these biomarkers give rise to new theories of possible etiologies for IC. 107 
Several biomarkers have been discovered in urine, serum, or tissue from IC patients. 105 
Anti-proliferative factor (APF), heparin binding epidermal growth factor (HB-EGF), epidermal 
growth factor (EGF), and interleukin 6 (IL-6) were found to be highly significantly different 
between patients and asymptomatic matched controls. 106  
It is important to note that IL-6 is significantly elevated not only in urine specimens from 
IC patients, but also in specimens from patients with other urinary tract disorders. 108 This makes 
IL-6 an ineffective biomarker for diagnosis. The remaining three biomarkers have been linked to 
each other in studies showing APF regulation of HB-EGF and EGF production in the bladder 
urothelial cells. 109, 110 APF has been found to decrease levels of HB-EGF and increase levels of 
EGF in IC patients compared to asymptomatic controls and patients with bacterial cystitis. 103 
These findings indicate that APF play an important role in the process of bladder urothelial cell 
proliferation through its regulation of HB-EGF and EGF production.  
To summarize, since 1915, the diagnosis of IC has been one of exclusions and remains so 
today. Finding a specific diagnostic tool for IC diagnosis is not a rapid process; it requires much 
intensive efforts, research, and highly committed patients who are willing to help and participate 
in researches.   
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2.2.5 Treatment Options 
Because the etiology of IC is poorly understood, treating IC is one of the greatest challenges for 
health care providers. In fact, there are currently no universally effective therapies available.  
Interestingly, in comparison to all the other common symptoms of IC, pain remains the hallmark 
of this disease. Pain can be classified to nociceptive, visceral, or naturopathic. IC pain often 
includes all the three types and this makes the treatment very complex and extremely difficult. 111 
According to the several etiological theories presented previously, treatment options 
should be based on three general principles; first, restoring epithelial function by using 
heparinoids (compounds with a structure similar to that of GAG), second, modulating neuronal 
activity by using antidepressant, and third, controlling allergies by using antihistamines. 36 In 
fact, there are several treatment options. Currently the most frequently used treatment is either an 
oral one or an invasive one which could be intravesical and/or surgical. The following sections 
will provide a summary of these options.  
2.2.5.1 Oral Treatment for Interstitial Cystitis 
2.2.5.1.1 Nonsteriodal Anti-inflammatory Drugs (NSAIDs), Narcotics and Antihistamines 
NSAIDs are the first oral treatment options prescribed to IC patients. The anti-inflammatory 
effect reduces inflammation, if exists, through inhibiting the production of prostaglandin. 
Unfortunately, however, NSAIDs have been ineffective in many IC patients. 111 
Several types of narcotics are used; Nalmefene is one of them. It is a long acting opiate 
antagonist that has been used to treat IC pain with only limited success. Nalmefene can decrease 
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mast cell degranulation and it showed a 50% reduction in suprapubic bladder pain in clinical 
study. 111 Further studies still need to be conducted on this treatment.  
The main aim of using antihistamines in first line treatment is to decrease mast cell 
activity and thus reduce the development of pain caused by the degranulation of these cells. The 
efficacy of antihistamine varies and the most commonly used antihistamine for IC treatment has 
been Hydroxyzine. Its mechanism of action includes blocking both mast cells secretion and H1-
receptors. 111 Interestingly, animal studies showed that Hydroxyzine can inhibit the release of 
substance P as well. 112 Inhibiting substance P and histamine are thought to reduce hyperemia 
and fibrosis respectively. 
2.2.5.1.2 Tricyclic Antidepressants (Amitriptyline) 
Amitriptyline is one of the most prescribed tricyclic antidepressants. It differs from all the 
previous oral treatments in its ability to treat the neuropathic pain in IC patients. 111 Although the 
use of Amitriptyline has been started since 1987, its efficacy was proven only in 2004 in a 
randomized clinical trial. 113 The investigators in that trial showed that 63% of IC patients were 
satisfied with Amitriptyline compared to 4% in the placebo group. How Amitriptyline relieves 
pain is still to be further clarified. Its effects on urinary frequency symptoms and bladder 
capacity, however, are more readily explained by its concomitant anticholinergic properties. 
Furthermore, Amitriptyline has antihistaminic properties, thus it is able to block H1-receptors on 
the mast cell as well. 111 
2.2.5.1.3 Immunosuppressive Agents 
Immunosuppressive agents (such as prednisone and cyclosporine) are thought to reduce the 
inflammatory response in the bladder, and to treat empirically the autoimmune processes related 
to IC. Recently, in a small study in Canada of 14 patients with the ulcerative type of IC who 
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were treated daily with 25 mg of prednisone, the investigators reported a 69% decrease in pain 
symptoms among the IC patients. 114 This study was very restrictive because of the small sample 
size; it also only included ulcerative IC patients. Nevertheless, this new study opens a new option 
of treatment for IC pain. 
Like prednisone, cyclosporine has shown some early promise. A recent study in Finland 
assessed the effects of long term treatment (more than 1 year) with cyclosporine (started at 3 
mg/kg/day, gradually decreasing to as low as 1 mg/kg/day) on 23 IC patients. 115 The 
investigators reported that 20 out of the 23 IC patients were completely relieved of pain. Despite 
this impressive result, there is still a need for larger randomized clinical trials to clearly 
demonstrate the therapeutic benefits of both prednisone and cyclosporine before they are used as 
a new treatment option. 
2.2.5.1.4 Pentosan Polysulfate Sodium (PPS) (Elmiron®) 
Because this study tests the efficacy of PPS (Elmiron®) as a new intravesical therapy for IC, 
more details about this treatment option is to be presented here. PPS is indicated for the initial 
and maintenance treatment of interstitial cystitis. It is one of the most frequently used oral 
treatment options. It is actually the only oral agent that is approved by the Food and Drug 
Administration (FDA) for the treatment of IC (the approval date was 9/26/1996). 116 
General Description 
Pentosan polysulfate sodium is a semi-synthetic sulfate polysaccharide similar to heparin-like 
macromolecular carbohydrate derivative which chemically and structurally resembles 
glycosaminoglycans. Figure 2-1 shows the chemical structure of PPS. 
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Figure  2-1: Chemical Structure of Pentosan Polysulfate Sodium 
 
It is a white odorless powder, slightly hygroscopic, and soluble in water to 50% at pH 6. 
It has a molecular weight of 4,000 to 6,000 Dalton. 117 PPS brand name is Elmiron® that is 
formulated for oral use. Elmiron® is supplied in white opaque hard gelatin capsules containing 
100 mg of PPS. 
Pharmacological Properties 
PPS is a weak anticoagulant (1/15 the activity of heparin) and has been used to prevent 
thrombotic disease. 117 Several theories have been suggested to explain the PPS mechanism of 
action. Yet, its exact mechanism still unknown. The use of PPS was on the basis of GAG theory; 
PPS can augment and repair the GAG layer of the bladder, and consequently relieve IC 
symptoms. 111 Intravesical pretreatment with PPS was shown to reduce the damage done by the 
cytotoxic substance acrolein in transitional cells in the bladder of female rats. 118 More 
specifically, the treatment worked through enhancing the GAG layer. In human, PPS has been 
reported to reduce bladder permeability based on the potassium sensitivity test. 119 IC patients 
who were treated with PPS and showed clinical improvement in their symptoms were more 
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likely to have reduction in potassium sensitivity in their bladder at the end of the study compared 
to IC patients who did not show any improvement.  
Another suggested mechanism is that PPS may have anti-adherence properties. Animal 
studies showed that PPS reduced the adherence of agents like calcium and protein to the urinary 
bladder of rabbit. 120 Furthermore, bacterial adherence to acid treated rabbit bladders was brought 
back to control levels by treatment of the bladder with PPS. These studies showed that pretreated 
bacteria with PPS had no effect on the bacteria’s ability to adhere to acid treated bladder which 
supports the general hypothesis that the effect of PPS lies on what PPS does on injured bladder 
wall rather than what it does to bacteria.  
PPS also may have a cytoprotective effect that leads to reduction of the inflammation of 
bladder mucosa accompanying IC. In vitro studies showed that PPS inhibits the stimulation of 
connective tissue mast cell and mucosal mast cells, which, in turn, results in a significant 
reduction in histamine secretion. 121, 122 
Pharmacokinetic Properties 
Administration, Absorption, and Distribution 
PPS is given orally, usually 100 mg t.i.d., on an empty stomach. Pharmacokinetic studies showed 
that the absorption of the administered dose is ≈ 3% (dosage not reported) 120 or less than 1% for 
an oral, single 1500 mg dose.123 Animal studies showed that PPS is distributed by lymphatic 
system and blood, possibly through macrophages, to different parts of the body. 124 PPS is 
distributed to the uroepithelium of the genitourinary tract. Lesser amounts can be found in bone 
marrow, lung, liver, periosteum, skin, and spleen. Animal studies showed that erythrocyte 
penetration is very low. 117 It should be noted that, since no studies were conducted to show the 
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effect of food on PPS, for safety PPS must be administered either one hour before or two hours 
after meals. 
Metabolism 
It is metabolized through both partial desulfation (occurs in the liver), and partial 
depolymerisation (occurs in the kidney). Both desulfation and depolymerisation can be saturated 
with the continued administration of PPS.117  Simon et al. reported that most of the administered 
dose of radiolabeled PPS (200µCi less than 15 mg) (84%) was excreted in feces as intact PPS, 
while a smaller percentage (6%) was excreted in urine as low molecular weight and desulfated 
PPS. 125 
Excretion 
After orally administered radiolabeled PPS, the elimination half-life in urine was determined to 
be 4.8 hours for unchanged drug. 117 Importantly, a single dose of PPS can completely eliminated 
from the body in 144 hours. 120 
In human excretion studies (included 3 healthy male volunteers), approximately 3.5% of 
the administered PPS (radiolabeled) excreted in the urine. 117 Interestingly, after multiple doses 
of PPS, the urine excretion of radioactivity was found to be approximately 11% of the 
administered dose. 117, 120 This indicates that very small dose of PPS reaches the site of action 
(bladder) after oral administration. 
Side Effects and Drawbacks 
PPS is usually well tolerated. The main documented side effects can be divided into two main 
classes according to frequency: 117  
• Side effects with frequency between 1% and 4% include: alopecia, diarrhea, nausea, 
headache, rash, dyspepsia, abdominal pain, liver function abnormalities and dizziness. 
                                                                                                                                                             62 
• Side effects with frequency less than 1% include: digestive (vomiting, mouth ulcer, 
colitis, esophagitis, gastritis, flatulence, constipation, anorexia, gum hemorrhage), 
hematological (anemia, ecchymosis, increased prothrombin time, increased partial 
thromboplastin time, leucopenia, thrombocytopenia), hypersensitive reactions (allergic 
reactions, photosensitivity), skin (pruritus, urticaria) and special senses (conjunctivitis, 
tinnitus, optic neuritis, amblyopia, retinal hemorrhage). 
 There are two main drawbacks of oral PPS; first, it is expensive (approximately 
US$100-150/month) and second, it may take 3 to 6 months of PPS therapy before improvement 
can be felt. 78 
2.2.5.2 Invasive Treatment for Interstitial Cystitis 
When oral treatment does not help the patient in relieving the pain, the option of invasive 
treatment is the one to use. Intravesical therapy (the direct instillation of medication into the 
bladder using catheter through the urethra) is one of the mainstays in the treatment of IC. It 
targets the bladder mucosal lining and /or bladder wall inflammation, resulting in relief of pain, 
frequency and urgency symptoms. Although several intravesical agents are used to treat IC 
patients, the FDA has approved only one of them for IC Intravesical therapy; named Rimso-50® 
(dimethyl sulfoxide: DMSO). 126 There are two main types of intravesical therapy; either single 
or multiple drug therapy. Multiple drug therapy is developed to add another therapeutic effect to 
the pharmacological effect of DMSO. For example, steroid or heparin may be added to DMSO 
because of their anti-inflammatory effects. 127 
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2.2.5.2.1  Intravesical Therapy 
Several factors can affect the efficacy of any treatment among which the route of administration 
is the major one. The variability of success of oral medications can be relayed to the 
pharmacokinetic of these medications which includes absorption, metabolism and renal 
excretion. The fact that only small amount of active ingredient reaches the bladder leads to the 
reduction in the effectiveness of the oral therapies, besides the need of higher doses for longer 
duration, which, in turn, increases the possibility of side effects.  
Intravesical therapy overcomes many of these disadvantages. By applying intravesical 
therapy, high dose will reach the bladder easily without being affected by metabolism process, 
drug interaction, liver or gastrointestinal functions. Furthermore, very few side effects can occur 
because of the poor absorption through the bladder itself. On the other hand, intravesical therapy 
has certain disadvantages such as the possibility of urinary tract infection due to catheterization, 
patient discomfort in addition to the costs related to visits, waiting time and the need for 
anesthesia. 35 
Until now, double blind studies of intravesical therapies have not been performed 
because of limitations of study design. For instant, DMSO produces a garlic breath, while 
sodium oxychlorosene lavage (Clorpactin®) is painful and needs general or regional anesthesia 
before instillation. Thus, it is very difficult to keep these drugs from being recognized. 35  
 
The present study examined the efficacy of Elmiron® (Pentosan Polysulfate Sodium) 
as a new intravesical drug. Two examples of Intravesical therapy are presented here. 
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2.2.5.2.2  Hydrodistension 
Although cystoscopy with hydrodistension is a method used to diagnose IC, it is also a 
therapeutic procedure. The efficacy of hydrodistension has proven to be variable. 128 
Hydrodistension must be done under general anesthesia followed by distending the bladder at 80 
cm water pressure for 2-8 minutes. 27 The response rate can range from 12% to 70%. The 
mechanism by which this method help in reducing the pain among IC patients is believed to be a 
mechanical stretch of the bladder mucosa and damage to the submucosal neuronal plexus. By 
this way, the transmission of pain through the afferent fibers will be decreased. 111 Another 
possible mechanism is that hydrodistension may cause all the bladder mast cells to degranulate at 
once, thus the symptoms remain quiescent until another mast cells migrate. It has been suggested 
that distension lead to sloughing the defective epithelium, and this let the new epithelium to grow 
back with a normal function. 27 The therapeutic effect of hydrodistension is last for 
approximately 3-6 months. After that period, patients may repeat the hydrodistension to obtain 
another period of prolonged improvement.  
2.2.5.2.3  Dimethyl Sulfoxide (DMSO) 
DMSO is the only intravesical FDA-approved drug for the treatment of IC. It has many 
pharmacologic properties: anti-inflammatory, analgesic, muscle relaxant, mast cell stimulation, 
and collagen dissolution. It is a widely-used drug for IC because of its affordability, ease of 
office administration, and proven safety. 35 Studies that assessed the efficacy of DMSO are still 
ongoing and the results show moderate improvement, however, with high relapse rate. The 
mechanism of action is believed to happen due to the ability of DMSO to deplete substance P 
and to stimulate mast cell degranulation. 111 Perez-Marrero et al. reported an improvement in IC 
pain in 93% of patients compared to 35% in the saline placebo group. But they also indicated 
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that 59% of the patients relapsed in the following month. 129 In another recent study in Europe 
which included 28 IC patients, a modest response to DMSO instillation was reported. 130 
2.3 EFFICACY OF PENTOSAN POLYSULFATE SODIUM (PPS) 
2.3.1 Studies that Assessed the Efficacy of Oral PPS 
Several studies have evaluated the efficacy of PPS as an oral treatment for IC. 27-33 Although the 
results were not consistent, the general trend in these studies is acknowledging the significant 
efficacy of oral PPS for IC patients with a response rate between 27-42%; 36 the details about 
each of these studies are presented in the following paragraphs. Importantly, one recent meta-
analysis included only prospective randomized double blind clinical trials that compared oral 
PPS with placebo, confirmed that oral PPS is more efficacious than placebo in the treatment of 
pain, urgency, and frequency symptoms of IC. The results of this study showed that oral PPS is 
not significantly different from placebo in the treatment of nocturia in particular. 131 
Till now, approximately seven studies have assessed the efficacy of oral PPS, with the 
clinical trial design as the most widely used one. 27-33 Most of these studies compared the efficacy 
of oral PPS to placebo. The sample sizes of these studies ranged from 62 to 380 participants per 
study. Most of the study populations were females, white, and with average age ranged from 
42.5 to 45.5 years. Table 2-4 provides a summary of each of these studies. More details can be 
found in the following paragraphs. 
Parsons is one of the earliest researchers who studied the efficacy of PPS. In 1987, 
Parsons et al. conducted a randomized double blind study that included 62 IC patients from two 
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different medical centers. 29 Patients were randomized to either drug or placebo with a dose of 
either 100 mg three times daily or 200 mg twice daily based on the medical center they attend. 
After 3 months, if patients failed to respond to treatment, cross over to placebo was begun (from 
drug to placebo or vise versa). If the patient responded to the drug, he or she returned in 3 more 
months, and if there still was a positive response, cross over to placebo was instituted. To 
complete the study, a patient has to fail drug arm and placebo arm, or to have 2 successive visits 
(6 months) with positive results. The primary outcome was improvement in symptoms. A 3 day, 
voiding volume records were obtained from each patient in each visit as well. The results showed 
that PPS did significantly better than placebo in improving all symptoms (pain has the best 
improvement). Moreover, objective improvement in average voided volumes was greater with 
PPS than with placebo. 
In the same year, Holm-Bentzen et al. conducted another double blind clinical controlled 
multicenter trial, and showed opposite results to that of Parsons et al. 27 A total of 115 patients 
with painful bladder disease (according to clinical and /or cystoscopic records) were recruited 
from 7 different centers and divided into two different protocols with two different inclusion 
criteria. In both protocols, patients were randomized to receive either 200 mg of PPS or placebo 
capsules twice daily for 4 months. Every month patients have to fill a symptom score scale. The 
study showed that for both protocols there were no significant differences between the pre- and 
post-trial symptom values in either PPS or placebo group. Furthermore, the study failed to show 
any difference in the symptom urgency between the two groups in both protocols. A significant 
increase in the bladder capacity (determined by cystoscopy) in the PPS group was found. 
Importantly, dividing the patients into two protocols may affect the statistical power of the study 
which in turn may be responsible for the negative results of this trial. 
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In 1993, Parsons et al. conducted another randomized double blind clinical trial that 
included a larger number of IC patients (148 patients) from 7 different centers. 30 Patients were 
randomly assigned to receive 100 mg of PPS or placebo 3 times a day for three months. Data 
about the efficacy of PPS was collected through a follow-up questionnaire completed by the 
patients at the end of the treatment period. A global assessment form was completed by patients 
to evaluate any change in their condition as either “worse”, “no better”, or “improved”. The 
improvement levels were: “slight (25%)”, “moderate (50%)”, “great (75%)”, and “no symptoms 
(100%)”. Successful therapy was defined when a patient reports at least 50% overall 
improvement in his/her symptoms. The investigators provided an evaluation for overall 
improvement after examining the patient and reviewing the data provided on the symptom 
scales. The volumes and numbers of void were collected for 3 consecutive days before and after 
3 months of treatment. Data about pain and urgency were also collected before and after 3 
months of treatment. About 32% of patients on PPS showed significant improvement compared 
to 16% of those in placebo. Moreover, patients on PPS showed a significant decrease in pain and 
urgency and a significant increase in the void volume in comparison to placebo group. 
Mulholland et al. showed the same results in their double blind placebo controlled trial 
that included 110 well-documented IC cases from 5 different centers, and continued for 3 
months. 28 In this study, patients were randomly assigned to receive either 100 mg of PPS or 
placebo 3 times a day. Data about symptoms and laboratory values were collected at baseline and 
12 weeks after the start of treatment. Similar to the trial described above, Mulholland et al. used 
patient global assessment and investigator assessment forms plus pain and urgency scales to 
assess the efficacy of the trial treatment. The volumes and numbers of void were also collected. 
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The study showed a significant overall improvement among patients on PPS compared to those 
on placebo. 
In 2000, Waters et al. conducted a retrospective analysis and follow-up survey to 
determine the efficacy and safety of oral PPS. 31 A total of 27 cases and 27 controls were enrolled 
into the study. Both cases and controls should be diagnosed as interstitial cystitis at least 1 year 
before the study. Cases had to be on PPS therapy at least 8 weeks, while controls had to be 
taking at least one oral medication as a treatment for IC. Data about disease-related symptoms 
and overall changes over time were collected. Cases provided information about IC symptoms 
before the beginning of therapy and up to current use, or at the point of cessation of therapy. On 
the other hand, controls reported changes in symptoms during the 12 months before the 
interview. Like most of the above mentioned clinical trials, this study showed that symptoms in 
both groups improved over time; however, the improvement was significantly greater among IC 
cases. Interestingly, no change occurred in the rate of nocturia in the PPS group compared to the 
control group. 
Compared to all the above described trials, Sant et al. were the first to test the efficacy of 
oral PPS compared to another drug, and for a longer follow-up period (24 weeks). 32 Although 
their trial was a pilot one, they were the first to consider the level of symptoms’ severity as one 
of the main inclusion criteria. In this way, they eliminated the bias that could be resulted from 
the level of response to treatment due to the severity of symptoms. The target sample size was 
136 IC patients, however only 121 were randomized in a 2 X 2 factorial study design that 
included 4 arms (PPS (100 mg/3 times a day), Hydroxyzine (50 mg/ at bedtime), placebo, and a 
combination of hydroxyzine and PPS). The primary endpoint was a participant reported global 
response assessment at 24 weeks compared to the baseline. Other endpoints were the O’Leary-
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Sant IC Symptom and Problem Index, the University of Wisconsin Symptom Score, patient 
reported symptoms of pain/discomfort and urgency, and a result of 24 hours voiding log. All the 
outcomes were evaluated at baseline, and after 3, 7, 10, 17, and 24 weeks of randomization. The 
results of this trial showed no significant difference in the response rate for hydroxyzine 
compared to placebo. Furthermore, a non-significant trend was seen in PPS group compared to 
placebo. In general there were no treatment differences in any of the secondary endpoints. 
Recently in 2005, Nickel et al. were the first to test both the onset of effect and dose-
response effect for PPS in a randomized double blind, parallel-group, multicenters study. 33 A 
total of 380 patients were enrolled from 30 different sites and randomized to 100, 200, or 300 mg 
of PPS 3 times daily. About 230 subjects completed the 32 week study. The primary endpoint 
was O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI); a four-item questionnaire validated 
as an outcome parameter in IC. Score 15 and above was considered as severe symptoms. The 
secondary endpoint was the patient’s overall global assessment. Data were collected at baseline, 
and after 4, 8, 12, 16, 24, and 32 weeks of the beginning of the study. Although significant 
improvements in the ICSI scores from baseline to endpoint were observed in the three different 
groups, the responses to the three different dosages were not statistically different. Moreover, the 
percentages of responders to any of the three doses (showed 50 to 100% improvement) increased 
steadily over time. This demonstrates that the duration of therapy is more important than the 
dosage itself. The main limitations in this trial included the lack of comparable placebo group, of 
sufficient power due to the low completion rate of 60%, and of generalizability, as this trial only 
included patients with moderate to severe symptoms. This makes it not applicable to extend the 
results on early diagnosed patients. 
 
 Table  2-4: Summary of Studies that Assessed the Efficacy of Oral Pentosan Polysulfate Sodium (1987-2005) 
 
AUTHOR 
YEAR 
JOURNAL 
 
TYPE OF STUDY 
DOSE 
DURATION 
 
 
SAMPLE SIZE 
 
CHARACTERISTICS 
 
DIAGNOSTIC CRITERIA 
 
OUTCOMES 
 
RESULTS AND NOTES 
Parsons et al., 
1987 
J Urol. 
RDBPCT* 
Two centers cross over 
design 
 
100mg PPS t.i.d  or 
200mg PPS d.i.d 
or placebo 
 
6 months 
 
 
62 IC patients 
90% female, 10% male  
? Had at least 1 year symptoms 
? Negative urine culture and cytology 
? Hunner’s ulcer or glomerulations after 
cystoscopy with hydrodistension 
? Biopsy proved  inflammation 
 
Improvement was 
defined from patient 
global assessment as 
reporting at least 
50% improvement 
? Improvement was observed 
in all symptoms 
? Remission were observed in 
40-60% of subjects versus 
18-39 % for placebo 
? Pain was the most sensitive 
symptom to show good 
response followed by  
urgency and nocturia 
 
The cross over mainly to 
increase sample size in each arm 
 
Holm-Bentzen et 
al., 1987 
J Urol. 
RDBPCT * 
Multi centers 
(7centers) with two 
different protocols 
 
200mg PPS d.i.d or 
placebo 
 
4 months 
115 IC patients 
 
43 Protocol A 
100% female  
 
72 Protocol B 
85% female, 15% male 
 
All patients must have: 
? At least 1 year symptoms or 
cystoscopic evidence 
? Negative urine cultures  
 
Protocol A: 
>28 mast cell/mm2 in detrusor muscle in 
bladder biopsy 
 
Protocol B: 
? All patient had mast cell < 28/mm2 
? 3 or more voiding /night 
? >10 total  points on a define symptom 
scales of pain, frequency, nocturia, 
dysuria 
 
 
Clinically 
improvement was 
defined as a 
decrease of at least 1 
point in the mean 
total symptom score 
values 
? No difference between pre 
and post trial in regards to   
symptoms, urodynamics, 
cystoscopic appearance and  
mast cell counts 
? Significant increase in the 
cystoscopically determined  
bladder capacity in the 
sodium   
? pentosan polysulfate group 
in protocol A was found 
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 AUTHOR 
YEAR 
JOURNAL 
TYPE OF STUDY 
DOSE 
DURATION 
 
SAMPLE SIZE 
 
CHARACTERISTICS 
DIAGNOSTIC CRITERIA OUTCOMES RESULTS AND NOTES 
Table 2-4 Cont’d
Mulholland et al., 
1990 
Urology. 
RDBPCT* 
Multi centers (5 
centers) 
 
100mg PPS t.i.d  or 
placebo 
 
3 months 
110 IC patients 
 
89%female, 11% male 
To be included patients must have: 
? Moderate urgency in 5 point scale 
? Frequency of at least 10 voids/day 
? Nocturia at least 2/night 
? Pain as recorded on a 5 point analog 
scale 
? Had at least 1 year symptoms 
? Failed previous therapy e.g. RMSO, 
Cloropactin® 
? Average voided volume 200ml or less 
? Negative urine culture and cytology 
? Cystoscopy with hydrodistension 
showed glomerulations or ulceration 
with capacity of 800ml or less 
 
Main exclusions: 
? <18 years old 
? Pregnant or lactating 
? Use of anticoagulant therapy 
? Chronic use of narcotic 
? Allergy to PPS 
? Use of artificial sweeteners 
? History of treatment with PPS within 6 
weeks of the study 
 
Improvement was 
defined from patient 
global assessment as 
reporting at least 
25% improvement 
Treatment was 
considered to be 
successful if there 
was: 
 
? A decrease in 
pain of 1 point or 
more 
? A decrease in 
urgency of 1 point 
or more 
? A decrease of 3 or 
more per day in 
frequency of 
urination 
? An increase in 
urine volume of 
20ml or more / 
void  
? Of patients on treatment 28% 
showed significant   
improvement (>25%)     
compared to 13% of those on   
placebo 
? For pain and urgency, the 
improvements due to PPS   
compared with placebo were    
statistically significant or 
approached significance. 
? Voided volume, favored the 
treatment over placebo but 
not significant 
? No differences in frequency 
were observed between the 
two groups 
 
Parsons et al., 
1993 
J Urol. 
RDBPCT* 
Multi centers (7 
centers) 
 
100mg PPS t.i.d  or 
placebo 
 
3 months  
148 IC patients 
 
100% female 
 
Patients must have: 
? Anesthetic bladder capacity  (350-
1000ml) 
? >8 void / day 
? Average voided volume :50 to 200cc 
? Nocturia 1 to 2 times/ night 
Patients lack 1  or 2 of the above criteria 
entered if they have: 
? pain and or moderate urgency 
? Negative cytology and cultures 
Improvement was 
defined from patient 
global assessment as 
reporting at least 
50% improvement 
 
 
 
? Treatment was 
considered to be  
? Of patients on treatment 32% 
showed significant 
improvement compared to 
16% of those on placebo 
? Patient on drug showed 
significant decrease in pain  
and urgency 
? An average increase of more 
than 20ml in voided volume 
was reported among patients  
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 AUTHOR 
YEAR 
JOURNAL 
TYPE OF STUDY 
DOSE 
DURATION 
 
SAMPLE SIZE 
 
CHARACTERISTICS 
DIAGNOSTIC CRITERIA OUTCOMES RESULTS AND NOTES 
Table 2-4 Cont’d
Parsons et al., 
1993 
J Urol. 
Cont’d 
  ? Cystoscopic finding of glomerulations 
     Main exclusions: 
? <18 years old 
? Pregnant or lactating 
? Use of anticoagulant therapy 
? Chronic use of narcotic 
? Allergy to PPS 
? Use of artificial sweeteners 
? History of treatment with PPS within 4 
weeks of the study 
 
successful if there 
were: 
? A decrease in 
pain of 1 point or 
more 
? A decrease in 
urgency of 1 point 
or more 
on treatment
Waters et al., 
2000 
J Am Osteopath 
Assoc. 
Retrospective case 
control study 
 
27 Cases 
27 Controls 
 
Gender NI** 
All participants  
? Had IC diagnosis at least 1 year  
? Had persistent symptoms  
? Undergone at least 1 cystoscopy with 
hydrodistension 
? Negative urine culture 
Cases: 
? Had to be on PPS for at least 8 weeks 
Controls 
? Had to be taking at least one oral 
medication 
For cases: changes 
in symptoms since 
they start using PPS. 
For controls: 
changes in 
symptoms during 
the 12 months 
before the interview. 
Changes in frequency, urgency, 
and pain were significantly 
greater among cases. 
No change in nocturia was 
observed. 
 
Study population used 
concomitant medications 
 
 
 
Sant et al., 2003 
J Urol. 
2X2 Factorial study 
design double blind  
 
Two treatment 
effects and 4 
different groups: 
? 100mg PPS t.i.d  
? 50mg/at bed time 
hydroxyzine 
? Combination of 
PPS and 
hydroxyzine 
136 IC patients (121 
Respondents) 
89% female  
 
 
 
 
To be included patients: 
? Had to be >18 years old 
? Had IC diagnosis at least 1 year  
? Had performed cystoscopy with 
hydrodistension followed the 
NIDDK 
 
All patients had moderate symptoms 
of frequency (at least 11 daily), pain 
(at least 4 in 0-9 scale) for at least 24 
weeks before to study entery 
Responders were 
those who either 
moderately or 
markedly 
improved inpatient 
global assessment ( 
a 7 point centered 
scale that assess 
the overall 
change) 
? No significant difference 
in global response 
between hydroxyzine and 
no hydroxyzine groups. 
There was a trend for 
higher response in PPS 
arm compared to no PPS 
arm 
? The combined therapies 
demonstrated the highest 
response rate followed by 
PPS alone and  
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AUTHOR 
YEAR 
JOURNAL 
TYPE OF STUDY 
DOSE 
DURATION 
 
SAMPLE SIZE 
 
CHARACTERISTICS 
DIAGNOSTIC CRITERIA OUTCOMES RESULTS AND NOTES 
Sant et al., 2003 
J Urol. 
Cont’d 
? Placebo 
 
24 weeks 
       hydroxyzine alone 
? No statistically significant 
differences between the 
main treatments in 
symptom changes over 
time for any secondary 
outcomes 
Nickel et al., 
2005 
Urology. 
Randomized double 
blind ranging dose trial   
Multi centers (30 
centers) 
 
 
 
 
100mg PPS t.i.d 
200mg PPS t.i.d 
300mg PPS t.i.d 
 
 
 
32 weeks 
380 IC patients (230 
Completed the study) 
 
90% female 
10% male  
 
 
 
Diagnoses with IC confirmed by : 
? Symptomology history for 6 months 
or longer 
? Positive cystoscopy with 
hydrodistension (glomerulations or 
Hunner ulcers) conducted at least 6 
weeks before the trial and combined 
with urgency and pain 
? Negative urine analysis 
 
Patients were excluded if: 
? They would be using other therapies 
for IC 
? Pregnant or lactating 
? Had liver problems 
? Use Coumadin, anticoagulants, 
heparin 
? (For complete information return to 
the paper) 
Responders were 
defined as those 
who reported 
moderately greatly 
improved or no 
symptoms in the 
patient global 
assessment 
 
 
 
? For the three dosage of the 
PPS. A clinically response 
rate was observed 
? No significant differences in 
efficacy among the three 
doses were reported  
? The response appear to 
increase with increasing the 
duration but not the dose 
 
 
Main limitation is lack of 
comparable group 
60% completion rate 
 
Patients could continue using 
antidepressant and antihistamine 
but not start to use during the 
trial 
   *    RDBPCT : Randomized double blind placebo-controlled clinical trial  
d’
  **   NI: Not identified 
4 Cont
 
 
 
 
-Table 2
 
 2.3.2 Major Problems in Studies Conducted to Assess the Efficacy of PPS 
Several clinical trials were conducted to test the efficacy of PPS; however it is generally not 
appropriate to compare the results between these trials for several reasons. First of all, the fact 
that IC is such a debilitating syndrome with unknown pathogenesis and no clear diagnostic 
criteria makes it difficult to know if the study population of each of these trials were similar in 
disease severity or not. For example, each trial used different criteria to identify IC cases. 
Second, very few studies considered the level of symptoms’ severity and its effect on response to 
the tested treatment. In fact, most of the previously described trials did not differentiate the study 
population in the terms of severe, moderate, or early diagnosed cases which may have affected 
the degree of response to the tested treatment, and thus biased the results. Moreover, although the 
previous trials mentioned both their primary and secondary endpoints, very few of them 
described, in detail, the instruments used to collect the data, or the criteria used to determine the 
responders clearly. This limitation disables the ability of other researchers to utilize these studies 
or work on refinement of the methods that were used before. 
2.3.3 Pentosan Polysulfate Sodium as a New Intravesical Therapy 
Using PPS as an intravesical therapy is a new hope for IC patients. Most of the studies that 
assessed its efficacy as an intravesical therapy were not published, conducted as pilot studies, or 
performed outside USA. 
To the best of our knowledge, the only published clinical trial that assessed the efficacy 
of PPS as an intravesical therapy was done by Bade et al in the Netherlands in 1997. 37 It was a 
very small clinical trial that included only 20 IC patients all of whom were females, and followed 
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 them for 3 months. This trial was based on a very small pilot study in which 6 IC patients 
received intravesical instillation of PPS (300 mg in 50 ml of 0.9% sodium chloride), and 4 of 
them showed long-term symptomatic, objective remissions, and excellent tolerance to the 
treatment. 132 As a result, Bade et al. accomplished the first clinical trial to assess the efficacy of 
intravesical instillation of PPS among IC patients. Participants were randomized to receive either 
intravesical PPS (300 mg in 50 ml of 0.9% sodium chloride) or a placebo applied twice a week 
for 3 months. Data about symptoms, bladder capacity, voiding volumes and urinary frequency 
were assessed after the 3 months. Furthermore, the long term outcome of those who decided to 
continue the treatment was obtained. Significant symptomatic relief was reported in 4 of those 
who received the intravesical PPS compared to 2 with placebo. Moreover, a significant increase 
in bladder capacity was reported among patients who were treated with PPS compared to placebo 
group. Interestingly, 18 months after the beginning of the study, symptom relief was reported by 
eight patients of those who were still receiving PPS and in 4 on placebo. Importantly, the 
instillations of PPS were done by participants at home during the whole study except for the first 
visit, when it was done by a professional nurse. This may have introduced bias to the results, as 
there was no way to know if PPS instillations were valid and reliable, or if the participants 
performed all the required instillations. 
In USA, the only study that has been conducted so far to evaluate the effect of direct 
bladder application of PPS on the symptoms of IC among 31 females IC patients was the one by 
Davis et al. 38 They used O’Leary-Sant’s IC Symptom Problem Questionnaire, Parsons’ Patient 
Symptom Scale (PUF), and the pain index to assess the efficacy. After receiving 5 instillations of 
PPS over 21 months, participants reported 39.43% of reduction in average pain score and 15% or 
more of reduction in the other three assessment scale scores.  
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 The present study is the first clinical trial in USA that was conducted to assess the 
efficacy of intravesical instillation of PPS in the bladder. 
2.4 EPIDEMIOLOGY OF IC 
2.4.1 IC Prevalence 
Although there have been several attempts to estimate the prevalence of IC, most of these 
attempts have not been based upon representative populations. Furthermore, among a few studies 
which can be classified as population-based, discrepancies exist in the estimated prevalence 
rates. The main reasons for the discrepancies could be related to the use of different diagnostic 
criteria, geographical variation, and the statistical methods which the investigators used to 
calculate the prevalence rates. Table 2-5 provides a summary of the main studies that attempted 
to estimate the prevalence rate of IC. More details can be found in the following paragraphs. 
In 1975, Oravisto was the first investigator to conduct a population-based study to 
provide an accurate estimate of both prevalence and incidence of IC in Helsinki, Finland and the 
surrounding area. 7 There were approximately 974,305 inhabitants (523,794 female and 450,511 
male) in the study area. The total number of IC patients at the time of the diagnosis was 103 (95 
female and 8 male) based on  review of hospital records, history of chronic voiding symptoms, 
sterile urine, and bladder biopsy showing fibrosis, edema, and /or lymphatic infiltration. Oravisto 
reported the joint prevalence rate to be 10.6 cases per 100,000 inhabitants for the total population 
and the prevalence rate among females to be 18.1 cases per 100,000 women. Because the number 
of men was too small, the investigator did not calculate the prevalence rate for males.  
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 In the Netherlands, Bade et al. conducted a cross-sectional study to determine the 
prevalence rate of IC. 133 An urologist-based questionnaire was used to assess prevalence. The 
questionnaire had 3 parts: 1) epidemiological section: included questions about the average 
number of patients seen per year with chronic micturation disorders, and the number, average 
age and gender of interstitial cystitis patients, as well as additional information about the disease 
history and present symptoms, 2) diagnostic section: included questions regarding diagnostic 
investigations and diagnostic criteria for interstitial cystitis patients, and 3) therapy section: 
included questions about the most common therapy modalities, and what are the first, second and 
third choices.  The questionnaire was sent to 235 urologists; however, only 153 participated in 
the study. About 122 responses were found to be completed and used in estimating the 
prevalence rate. The prevalence rate was reported to be 8 to 16 cases per 100,000 female 
patients. This was in line with the prevalence rate calculated by Oravisto. 7  
In Japan, Ito et al. estimated the prevalence rate of IC through sending a questionnaire to 
300 chief urologists at major hospitals to determine the number of patients with interstitial 
cystitis. 134 The questionnaire included questions similar to those were in the previous study by 
Bade et al. 133 Responses were received from 262 urologists (response rate 87.3%) out of the 300, 
and were used in the analysis. Most Japanese urologists used two or more diagnostic criteria with 
bladder biopsy, the most common diagnostic procedure. Based on the result of the survey, the 
prevalence rates were estimated to be 1.2 per 100,000 patients and 4.5 per 100,000 female 
patients, with the female to male ratio of 5.8:1. Interestingly, this low prevalence rate may be 
explained by the presence of racial effect and/or the lack of awareness among Japanese 
urologists and patients about interstitial cystitis. 
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 Held et al. were the first to estimate the prevalence rate of IC in USA. 2 Data from a 
random survey of 127 board-certified urologists were utilized. Three different ways were used to 
calculate the prevalence rate using information reported by the urologists on the percentage of 
female IC patients, the total number of visits for cystitis, and the total number of diagnosed IC 
patients in their practice. The three estimated values of the prevalence rate were 16.3 per 
100,000, 25.1 per 100,000, and 76.3 per 100,000 with an average rate of 36.6 per 100,000.  
In 1994, Jones et al. conducted another study to estimate the prevalence rate of IC in 
USA. 11 They relied on participants’ self-reports of previous diagnosis of IC in 1989 National 
Household Interview Survey. Approximately 20,561 adults were asked if they ever had 
symptoms of urinary tract infection that lasted 3 months or longer, and if they were told that they 
had painful bladder syndrome or IC. About 118 participants in the total sample were classified as 
having IC (110 female and 8 male). The study reported that 0.5% of the civilian non-
institutionalized population stated having IC and that the female/male ratio was 9:1. 
Interestingly, the data which were used in this study were based on self-reports with no verifiable 
medical record. This may have introduced misclassification bias to the results. 
Curhan et al. conducted another study in 1999 to determine IC prevalence among women 
in the US. 3 Data from the Nurse Health Study (NHS) I and II were used for that purpose. 
Although the data about IC diagnosis were self-reported like that in Jones et al.’s study, Curhan 
et al. evaluated the accuracy of self-reports using medical records and the diagnostic criteria of 
the National Institute of Health for enrollment in research studies of IC. Surprisingly, the 
prevalence of IC was 67 per 100,000 women in NHS II and 52 per 100,000 women in NHS I. 
This study showed that the prevalence rate of IC in the US is more than 50% greater than 
previously reported ones and 3 fold greater than one reported in Europe. 
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 Most recently, Clemens et al. used a comprehensive managed care patient’s database in 
Pacific Northwest (Kaiser Permanente Northwest database) to estimate the prevalence of IC in 
both men and women. 12 Kaiser Permanente is the largest non-profit health maintenance 
organization in the United States, serving 8.2 millions in 9 states and the District of Columbia. 
After applying a specific exclusion criteria there were 136,400 women and 120,553 men in the 
study population. The investigators used 4 definitions of IC to calculate the prevalence rate as 
follows: 1) patients assigned a diagnosis of IC (International classification of Disease [ICD]-9 
595.1) , 2) patients assigned a diagnosis of IC without any of specific exclusion criteria (used in 
most epidemiological studies) , 3) patients assigned a diagnosis of IC who had undergone 
cystoscopy during the study period, and 4) patients assigned a diagnosis of IC who had 
undergone cystoscopy with hydrodistension for IC during the study. The prevalence rate of IC 
was 197 per 100,000 women and 41 per 100,000 men (definition 1), 158 per 100,000 women and 
28 per 100,000 men (definition 2), 99 per 100,000 women and 19 per 100,000 men (definition 
3), and 45 per 100,000 women and 8 per 100,000 men (definition 4). Based on any of the above 
definitions the female to male ratio for each estimate was 5:1, which was close to the ratio 
reported by Ito et al. in 2000 in Japan. This recent study is very important because it shows that 
the IC prevalence rates in USA are significantly higher for women and men than previously 
published estimates. Furthermore, the men now account for higher proportion of patients than 
previously reported.  
Interestingly, several researchers argued about the validity of the previously estimated 
prevalence rates. 4, 5, 6 They stated that all the previous studies were based on formerly diagnosed 
cases rather than evaluate the prevalence of symptoms accompanied IC. Early cases start with 
only one symptom while advanced cases experience multiple severe symptoms, thus using 
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 classic criteria to diagnose IC would underestimate the prevalence. In fact, when traditional 
diagnostic criteria are strictly applied, up to two thirds of IC cases may be missed. 96 As a result, 
three recent studies (one in Finland, one in Vienna and the other one in USA) were conducted to 
estimate the prevalence rate of IC using criteria that based on evaluating IC according to the 
symptoms.  
In Finland, Leppilahti et al. evaluated IC prevalence using O’Leary–Sant IC Symptom 
and Problem Index questionnaire in a population based study. 5 Approximately 2,000 women 
were randomly selected from Finland and enrolled in the study.  Women with a high symptoms 
and problem score (each ≥12) including nocturia ≥ 2 and pain ≥ 2, excluding urinary tract 
infection and pregnancy, were assumed most likely to have IC. According to this definition, 
Leppilahti et al. indicated that IC is more common in Finland than previously estimated with a 
prevalence of 300 per 100, 000 (clinically confirmed probable cases) to 680 per 100,000 women 
(probable and possible cases). 
In Vienna 2006, Temml el al determined the prevalence of IC using O’Leary–Sant IC 
Symptom and Problem Index questionnaire. 6 The investigators used the same definition of IC 
case that was used by Leppilahti et al. 5 The overall prevalence rate of IC was estimated to be 
306 per 100,000 women. 
Rosenberg et al. repeated the study by Leppilahti et al, 4 however in USA. They used two 
validated surveys that were developed to help in evaluating IC based on symptoms (O’Leary-
Sant (OLS) IC Symptom and Problem Index, and the Pelvic Pain and Urgency/Frequency (PUF) 
patient symptom scale), thus the mild cases will not be under estimated. According to their study, 
which was conducted in primary care office and included 1,218 women, the prevalence rate of 
IC in women based on the result from OLS survey was 575 per 100,000. This result was close to 
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 Leppilahti et al. population based study. 5 On the other hand, the prevalence rate which was 
based on PUF was much higher (12,600 per 100,000 women). The results from this study 
suggests that the prevalence rate among US women somewhat between the above two estimated 
numbers. It is worthy of note that OLS was not design as a screening test, however to evaluate 
the development of established IC, while PUF was validated as a screening tool for IC. 23, 24 
Interestingly, previous use of the PUF by Parsons et al., 24 in a random sample of 317 
women attending IC lectures suggested that nearly 22% of women in the general population may 
have IC (1 in 4.5 women). This was based on computing the expected number of women who 
would have positive potassium sensitivity test as a function of observed PUF scores and the prior 
probability of being normal versus not normal, using reduced logistic regression model. To test 
that hypothesis, Parsons et al. conducted another study in 2004 among all female members of the 
University of California, San Diego third-year medical students. 135 They used PUF and 
intravesical potassium sensitivity test (PST) to determine IC cases. Females with score 7 or 
greater were asked to undergo clinical evaluation including PST. Interestingly, Parsons et al. 
identified probable IC (PUF score 7 or greater) in 30.6% and documented IC (PUF score 7 or 
greater with positive PST) in a minimum of 10% of study population. This study supports the 
previous two studies and indicates that IC may be a chronic disease with higher prevalence rate 
than previously estimated. According to this study, the estimated prevalence of IC in US should 
be increased from approximately 1.5 million to perhaps 25 to 30 million women. 
In summary, the literature about the prevalence rate of IC still insufficient and poor. 
Most of the studies have been conducted among females and very few included males. 
Moreover, all the interests were directed to the adult population, and provided no information 
about IC in children. Also, all the estimates until now were based on white population at most. It 
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is interesting to speculate that there may be racial differences in the frequency of IC, because the 
rate among Japanese women has been reported to be less than that of the US women. 134 Despite 
all the previous limitations, one can cautiously conclude that there might be an increase in the 
estimated prevalence rate of IC since 1975 among both women and men and that the increase 
seems to be faster among men and may be responsible for decreasing the ratio between female 
and male from 9:1 to 5:1.  
Importantly, in order to be able to determine the exact prevalence rate of IC we need 
diagnostic criteria with high specificity to be applied in all the studies. It is worthy of note that 
most of the previous studies used different methods to identify IC cases. Some of these studies 
relied on self-reported symptoms. Other studies were procedures based to confirm the diagnosis 
of IC. This has the potential to introduce misclassification bias in some studies and 
underestimation in other studies. Thus, we still need well-designed epidemiological studies that 
base on strong accurate diagnostic criteria and include different races, ethnic, and ages groups to 
determine the exact prevalence rate of IC. 
 Table  2-5: Summary of the Studies that Estimated the Prevalence Rate of Interstitial Cystitis Worldwide (1975-2006) 
 
AUTHOR 
YEAR 
JOURNAL 
 
TYPE OF STUDY 
SETTING 
 
 
SAMPLE SIZE 
 
DIAGNOSIS OF IC BASED ON 
 
RESULTS 
 
NOTES 
 
Outside USA 
 
Oravisto, 1975 
Ann Chir 
Gynaecol Fenn. 
Cross-sectional 
Finland 
974,305 Males and 
females 
 
? Hospital records review 
? History of IC 
Chronic voiding symptoms, sterile urine, bladder 
biopsy showing fibrosis, edema, and/or lymphatic 
infiltration 
103 IC cases 
(95 female, 8 male) were 
identified out of  974,305  
 
 
Joint prevalence rate 
10.6/100,000 inhabitant 
Females prevalence rate 
18.1/100,000 women 
 
 
Bade et al., 
1995 
J Urol. 
Cross-sectional 
The Netherlands 
235 Urologists (122 
responded) 
Urologist based questionnaire Included 3 parts: 
? Epidemiological section                                              
The average number of patients seen per year with 
chronic micturation disorders, the number, average 
age and gender of interstitial cystitis patients treated, 
the disease history and presenting symptoms 
? Diagnostic section 
? Diagnostic investigations and diagnostic criteria for 
IC) 
? Therapy section:  
? Common therapy , first, second and third choices of 
therapy 
Female prevalence rate  
8-16 cases/100,000 female 
patients 
The most common 
diagnostic 
procedure based on 
counts of mast cells 
 
Only 48 percent of 
the responders 
reported interstitial 
cystitis in male 
patients, with a 
male-to-female 
ratio of less than 
1:10 
 
 
Ito et al., 2000 
Br J Urol. 
Cross-sectional 
Japan 
300Chief urologists 
(262 responded) 
Urologist based questionnaire  
Collected the following information: 
? The total number of patients with IC per year, the 
patient's age and sex, their chief complaints and 
disease  
 
Joint prevalence rate 
1.2/100,000 patients 
Female prevalence rate 
4.5/100,000 female  
The most common 
diagnostic 
procedure based  
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AUTHOR 
YEAR 
JOURNAL 
 
 
TYPE OF STUDY 
SETTING 
 
SAMPLE SIZE 
 
DIAGNOSIS OF IC BASED ON 
 
RESULTS 
 
NOTES 
Outside USA 
 
Ito et al., 2000 
Br J Urol. 
 Cont’d 
  history, the total number of all patients and their sex 
distribution, the criteria used by each urologist, and the 
first, second and third choice of therapy 
 
patients on biopsy result 
Leppilahti et 
al., 2005* 
J Urol. 
Cross-sectional 
Finland 
2000 Females 
(1331 Responded) 
selected randomly 
from Finnish 
population register 
 
?Patients who had classified as either moderate or 
severe cases by O’Leary Sant and who had no urinary 
tract infection were invited for clinical examination 
? If IC was suspected base on these examinations a 
cystoscopy with hydrodistension was performed  
? Probable IC was based on NIDDK 
? Possible IC was assigned if other bladder diseases 
were excluded but the severity of all NIDDK criteria 
were not strictly achieved 
32 had  moderate or 
severe IC out of 
1331  
21 of 32 underwent 
clinical evaluation 
3 had probable IC and 4 
had possible IC 
 
After correction: 
The estimated prevalence     
 rate: 
possible cases: 
300/100,000 women 
Probable and possible 
cases: 
680/100,000 women 
 
Total O’Leary 
score: 
0-3 no symptoms 
4-6 mild 
7-11 moderate 
12+ severe 
 
No diagnosis 
confirmation or 
excluding IC could 
be made among  8 
patients with 
moderate or severe 
symptoms 
Temml et al., 
2006* 
Eur Urol. 
Cross-sectional 
Vienna 
 
 
 
 
 
 
 
 
 
 
981 Women 
Attending 
voluntary health 
survey in Vienna 
Women who got ≥12 in each of the ICSI and ICPI and 
had ≥2 nocturia, and ≥2 score in pain assessment scale 
after excluding urinary tract infection and pregnancy 
were considered as most likely to have IC 
 
 
 
 
 
 
 
 
3 had a high risk for IC 
symptoms based on OLS 
out of 981 women 
 
The overall prevalence 
rate: 
306/100,000 
Total O’Leary 
score: 
0-3 no symptoms 
4-6 mild 
7-11 moderate 
12+ severe 
These scores 
grouped to: 
0-6 no risk of IC 
7-13 minimal risk 
14-23 moderate risk 
24-36 high risk 
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AUTHOR 
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JOURNAL 
 
 
TYPE OF STUDY 
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SAMPLE SIZE 
 
DIAGNOSIS OF IC BASED ON 
 
RESULTS 
 
NOTES 
 
Inside USA 
 
Held et al., 
1990 
Interstitial 
Cystitis. New 
York: 
Springher-
Verlag 
Cross-sectional 
USA 
127 Chief 
urologists 
Three different ways were used to calculate the 
prevalence rate: 
? Information reported by the urologists on the 
percentage of female IC patients 
? The total number of visits for cystitis 
? The total number of diagnosed IC patients in their 
practice  
Estimated prevalence 
rates: 
16.3/100,000 
25.1/100,000 
76.3/100,000  
Average rate of 
36.6/100,000 
 
 
Because this study 
was only published 
in book, it was not 
easy to gather 
complete 
information about 
the method of 
calculating the 
prevalence rate 
 
Jones et al., 
1994 
J Urol. 
Cross-sectional 
USA 
20,561 Adults 
males and females 
(participated in the 
National Household 
Survey) 
Based on Self-report, participants were asked: 
? If they ever had symptoms of a urinary tract infection 
that persist for 3 months or longer 
? If they were told that they had IC  
118 IC cases were 
identified out of 
20,561 adults  
 
0.5% of the civilian non-
institutionalized 
population would state 
having IC. 
 
573/100,000 civilian non-
institutionalized 
population 
 
Male to female is 
1:9 
Curhan et al., 
1999 
J Urol. 
Cross-sectional 
USA 
184,583 Females 
(participants in the 
nurse health study I 
n= 91,155, and II  
n= 93,428) 
All participants were asked in a questionnaire: 
? Whether IC had ever been diagnosed by cystoscopy 
? All participants who answered yes were sent a 
supplementary questionnaire to gather more 
information 
? Self-reported IC was confirmed from medical records 
? NIDDK were used but were not applied completely 
 
Based on that IC cases were classified into: 
110 IC cases were 
identified out of 
184,583 (participants in 
the nurse health study I = 
47 out of 91,155, II = 63 
out of 93,428) 
 
The estimated prevalence 
rates: 
In Nurse II :67/100,000 
The study 
population is much 
healthy and  more 
educated  
 
Nurse II younger 
than Nurse I 
showed higher 
prevalence 
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JOURNAL 
 
 
TYPE OF STUDY 
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SAMPLE SIZE 
 
DIAGNOSIS OF IC BASED ON 
 
RESULTS 
 
NOTES 
 
Inside USA 
 
Curhan et al., 
1999 
J Urol. 
Cont’d 
  Definite:  
? Report of  positive cystoscopy with hydrodistension 
? Biopsy demonstrated chronic cystitis 
? Negative urine cytology 
Probable: 
? Report of  positive cystoscopy 
Possible: 
? Letter stated that patient underwent cystoscopy with or 
without distension with diagnostic impression of IC 
 
In Nurse I: 52/100,000 The inclusion of 
probable and 
possible may 
overestimate the 
prevalence rate 
 
Only 6.4% of self-
reported were 
correctly 
confirmed.  
If we apply this to 
the study by Jones 
the prevalence rate 
will reduce to 
56/100,000 
Parsons et al., 
2004 
Urology 
Cross-sectional 
USA 
52 Females (all 
female members of 
the third year 
medical student 
class at the 
university of 
California 
?Patients who had PUF score of 7 or greater and 
positive PST 
5 IC out of 
52 females  
 
10% had IC (5/52) 
This indicates that the 
prevalence of IC is not 1.5 
million but 25 to 30 
million women  
This study 
combined a 
screening tool with 
clinical diagnostic 
tool 
 
The result could be 
more than 10% as 
those 5 only who 
accept to perform 
the PST 
 
Clemens et al., 
2005 
J Urol. 
Cross-sectional 
USA 
136,400 Females 
120,553 Males 
 
Kaiser Permanente 
Northwest 
Comprehensive  
? From medical record identify cases with primary or 
secondary diagnosis as IC 
? Applied exclusion criteria that was used in most 
epidemiological studies 
 
269 Women with IC were 
identified out of 
136,400 Female 
49 men with IC were 
identified out of 120,553 
Male 
Male to female is 
1:5 in all the 4 
definitions 
 
Cannot be 
generalized like all  
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AUTHOR 
YEAR 
JOURNAL 
 
 
TYPE OF STUDY 
SETTING 
 
SAMPLE SIZE 
 
DIAGNOSIS OF IC BASED ON 
 
RESULTS 
 
NOTES 
Inside USA 
 
Clemens et al., 
2005 
J Urol. 
Cont’d 
 managed care 
patient data base 
4 Definition of IC were used: 
? Patients assigned a diagnosis of IC (international 
classification) 
? Patients assigned a diagnosis of IC without any of the 
exclusion criteria used in most Epi studies 
? Patients assigned a diagnosis of IC without any of the 
exclusion criteria used in most Epi studies but 
undergone cystoscopy 
? Patients assigned a diagnosis of IC without any of the 
exclusion criteria used in most Epi studies but 
undergone cystoscopy with hydrodistension 
 
Definition1: 
197/100,000 female 
41/100,000 men 
 
Definition2: 
158/100,000 female 
28/100,000 men 
 
Definition3: 
99/100,000 female 
19/100,000 men 
 
Definition4: 
45/100,000 female 
8/100,000 men 
 
previous studies as 
most of the 
population were 
whites 
Rosenberg et 
al., 2005* 
J Urol. 
 
Cross-sectional 
USA 
1218 Women from 
Primary care office 
? Using 2 validated surveys, namely the O'Leary-Sant 
(OLS) IC symptom and problem index, and the Pelvic 
Pain and Urgency/Frequency (PUF) patient symptom 
scale. 
 
? Probable IC was defined by an OLS composite score 
of 24 or greater (12 or greater on both the symptom 
and problem indices including symptomatic pain and 
nocturia scores of 2 or greater as used in the Finnish 
study). 
   
 
? Probable IC based on PUF score was determined by 
estimating the likelihood of a positive potassium 
sensitivity test. 
161 IC (7 probable cases 
based on OLS, 154 based 
on PUF) were identified 
out of  1218 women from 
primary care office 
 
The estimated prevalence 
rate: 
575/100,000  
Based on O’Leary-Sant 
instrument 
12,600/100,000  
Based on PUF instrument 
 
 
    * IC prevalence was based on the prevalence of IC symptoms 
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 2.4.2 IC Incidence 
Very few studies conducted to estimate the incidence rate of IC. During the period between 1962 
and 1971, Oravisto reported a minimal annual incidence rate of 0.66 cases per 100,000 
inhabitants in the city of Helsinki and the surrounding area. 7 The annual incidence rate among 
females during the same period has been reported to be 1.2 cases per 100,000 women. Latter in 
1987, Held et al. estimated the incidence rate of IC in the US to be 2.6 per 100,000, which is four 
times higher than that reported in Finland by Oravisto. 2 Suggestions provided to explain the 
difference in estimating IC incidence rate in the two studies included; using different diagnostic 
criteria and the low response rate (26%) in Held et al. study.  
In 2003, Roberts et al., estimated the incidence rate of IC in Olmsted County, MN, USA. 
136 The findings were consistent with the general idea that IC is a rare disease. Residents of 
Olmsted County who had received a physician-assigned diagnosis of IC during the period 1976 
to 1996 were included in the study. 20 Patients were identified during the study period (16 
females and 4 males). The overall age- and sex adjusted incidence rate was 1.1 per 100,000 
population. The age-adjusted incidence rates were 1.6 per 100,000 in females and 0.6 per 
100,000 in males.  
Recently in 2005, Clemens et al. estimated IC incidence rate using Kaiser Permanente 
Northwest database during the period 2002 to 2003 to be 21 per 100,000 women and 4 per 
100,000 men. 12 Although this study indicated that the incidence rate of IC significantly 
increased since 1975, great care should be applied when drawing a conclusion. It is worthy of 
note that the same limitations found in studies that estimated prevalence can be also found here. 
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 The diagnostic criteria which were not consistent in incidence studies plus geographical variation 
between study populations adds to the confused state of multiple reported incidence rates of IC.   
2.4.3 Possible Risk Factors 
Several possible risk factors have been identified from reviewing the literature of the 
epidemiology of IC. Surprisingly, very few epidemiological studies were conducted to identify 
these risk factors among one single population. The following sections summarize the possible 
risk factors of IC based on the results of different epidemiological and clinical studies.  
2.4.3.1 Gender & Age at Onset 
Women are more frequently diagnosed with IC than men. They make up 90% of patients with 
IC. 137 Recent studies reported female to male ratio to be approximately 5:1 12, 134 instead of 9:1. 
11 Because the correct diagnosis is often made several years after the actual onset of the disease, 
the onset age has moved to older age. In women, the duration of symptoms before the diagnosis 
is reported to be around 5 to 7 years 3 compared to 4 years in men. 138 The onset of IC usually 
occurs between 30 and 70 years of age, 139 with a median age of 43. 140 The prevalence of the 
disease appears to be increasing among young and middle aged women. 96 In women, the 
diagnosis generally peaks in the third to sixth decades of life. 18 On the other hand, the mean age 
at diagnosis among men has been reported to be 67 years old, which is older than that in women. 
138 There is a strong belief that IC in men is misdiagnosed by nonbacterial prostatitis and benign 
prostatic hypertrophy. 
Although, the NIDDK mandates that patient with age younger than 18 years is an 
automatic exclusion criterion for IC, there is increasing evidence that the syndrome can affect 
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 children as well. Epidemiological survey on adults with IC indicates that symptoms sometimes 
begin in childhood. 20 A history of childhood bladder symptoms is reported by 10% to 28% of IC 
patients. 2, 18 Close et al. retrospectively reviewed the chart of 20 children referred for chronic 
sensory urgency, frequency and bladder pain who underwent cystoscopy with hydrodistension. 
According to their small study, the onset age among children ranged from 2 to 11 years with a 
median age of 4.5. 141 Definitely, prospective studies are needed to study the association between 
childhood disease and the development of IC later in life. 
2.4.3.2 Race 
Most of the studies that were conducted to describe the epidemiology of IC included mainly 
whites (more than 90%). Thus, the data about the distribution of IC among different races are 
very limited. According to Held et al., IC has been more common among Jewish women (14%) 
compared to the general population (3%). 2 In 1993, Sant retrospectively reviewed the patients 
database at the IC Center, New England Medical Center and reported IC among 8.5% of study 
population, with 3% being African American, 3.5% Hispanic American, and 2% Asian 
American. 142 Although the clinical and the endoscopic findings as well as response to treatment 
were similar in both minority and the rest study population, the average duration of symptoms 
before diagnosis was 2.9 years in minority compared to 13 months in the rest of the study 
population. This could be due to low economic status that decreases the access to health care. 
Recently, Forrest et al. characterized IC in men in a study included 92 IC cases. Approximately 
83% of the study populations were white and 17% were American Indians of Cherokee descent. 
143 More effort is needed to encourage minority population to participate in IC health research in 
order to delineate how race play a role in IC. 
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 2.4.3.3 Genetics 
Evidence increases that the syndrome may have a genetic component. Case reports of strikingly 
high prevalence of IC within first-degree relatives are substantiated by various studies that 
suggested a genetic susceptibility to the disorder. 144 In a pilot study, Warren et al. reported that 
adult female first degree relatives of IC patients may have a prevalence of IC 17 times that found 
in the general population. 145 Another evidence of the genetic component of IC came through 
Parsons et al. 146 Urgency/frequency problems in female relatives were reported by 35% of 466 
patients with IC and by 33% of 166 patients with urethral syndrome. 
2.4.3.4 Hormones 
Several evidences support the importance of considering hormonal effect when studying IC. 
Given that the majority of IC patients are females and the clinical literature suggests a flare in IC 
symptoms during premenstrual period, 64, 147, 148 a direct influence of gonadal hormones and 
estrogen may be considered. Theoharides et al. showed that estradiol may influence 
pathophysiological responses via bladder mast cells expressing high affinity estrogen receptors. 
147 Estrogen may modulate neurogenic inflammation by interacting with substances that 
participate in the pathogenesis of neurogenic inflammation such as substances P. 149 The 
clarification of the importance of hormones in the understanding and treatment of IC may 
produce applications of selective modulation of pain control. 
2.4.3.5 Dietary Factors 
It has been reported that several food could initiate an attack of urgency and frequency and cause 
a flare-up of IC symptoms. 13, 150, 151 These food can be divided into two main categories; those 
stimulate histamine and serotonin release from the stomach and those with high levels of 
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 biogenic amines (tryptophan, phenylalanine, tyrosine, and tyramine). The selective metabolites 
of these biogenic amines have the ability to bind to the sulfate groups of polysaccharides in the 
GAG layer and inactivate their hydrophilic properties. As a result of that a break in the mucous 
layer will develop. 150  
Attention was drawn to the possible association between food and IC symptoms during 
clinical studies, when IC patients reported relief of pelvic pain when they were on specific 
dietary programs and deleted certain food. IC patients who consumed less amount of coffee 
compared to the general experienced less exacerbating IC symptoms. 151 Furthermore, acidic, 
alcoholic, and carbonated beverages are reported as drinks that increased IC pain in more than 
50% of the patients. 18 
2.4.3.6 Co-morbid Conditions 
Different conditions have been documented among IC patients. Approximately half IC patients 
have allergies where the mast cell activation may contribute to the pathogenesis of both allergies 
and IC. Irritable bowel syndrome, generalized pain disorder, autoimmune diseases such as lupus 
erythematosis and Sjögren’s (SHOW-grins) syndrome also have been observed in conjunction 
with IC. Furthermore, higher incidence of chronic fatigue, multiple sclerosis, fibromyalgia and 
migraine have been reported among IC patients. 13 
2.4.4 Factors Associated With the Severity of IC symptoms 
Very limited literature was found about factors that may be associated with the severity of IC 
symptoms. 6, 17, 152 Moreover, several limitations can be addressed in these studies and called for 
further investigations. Temml et al. identified correlations for IC symptoms among women 
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 attending a voluntary health survey project in Vienna. 6 The investigators used O’Leary-Sant IC 
Symptom and Problem Index mainly to identify IC cases. Women with high (≥12) symptom and 
problem scores including nocturia (>2) and pain were considered most likely to have IC. The 
researchers reported psychological stress and bowel disorders as important factors associated 
with symptom severity after adjusting for age and BMI. It is important to mention that Temml et 
al.’s study was a questionnaire-based analysis and no individual underwent a thorough urologic 
evaluation. This put a question mark on the validity of the diagnosis of IC in the study. 
Simon et al.  studied the characteristics of 424 IC patients participated in the Interstitial 
Cystitis Data Base (ICDB) study by symptom severity. 17 Interestingly, the investigators reported 
that as severity of symptoms increases, there appears to be a slight, non-significant trend toward 
greater age. Moreover, patients with severe symptoms tend to be less educated, less likely to be 
employed, and reported a smaller household income. The study also showed that bladder 
volumes at first sensation and at maximal capacity were inversely associated with symptom 
severity. Importantly, all the analyses were univariate; therefore the reader cannot tell if all these 
factors independently explain the increase in the severity of symptoms. Furthermore, the 
investigators did not use a validated standardized instrument to measure the dependent variable 
(symptom severity). 
Clemens et al. investigated 174 men with chronic prostatitis and 111 women with IC to 
quantify symptom severity and identify demographic, medical and psychosocial characteristics. 
152 Focusing on women with IC, symptom severity was assessed using the O’Leary-Sant IC 
Symptom and Problem Index. Interestingly, self-reported urinary frequency and urgency, worse 
depression scores, lower educational level and postmenopausal status were independent 
predictors of increased symptom severity among women with IC. Importantly, Clemens et al. 
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used the total O’Leary-Sant score (symptom index and problem index) as a measure of symptom 
severity, which makes their dependent outcome not specifically symptom severity.   Moreover, 
certain covariates in the multivariate models were similar to some questions that make up the 
total O’Leary-Sant score, therefore collinearity can be a problem, although, the investigators 
indicated that no collinearity was found. Regression coefficients biased by collinearity might 
cause variables that demonstrate no significant relationship with the outcome when considered in 
isolation to become highly significant in conjunction with collinear variables, yielding an 
elevated risk of false-positive results (Type I error). Alternatively, multiple regression 
coefficients might show no statistical significance due to incorrectly estimated wide confidence 
intervals, yielding an elevated risk of false-negative results (Type II error). 153  
The current study assessed comprehensively to what extent several factors included; 
socio-demographic, lifestyle, reproductive, clinical and sexual functioning factors affect the 
severity of IC symptoms. 
 
 2.5 HEALTH RELATED QUALITY OF LIFE (HRQL) 
2.5.1 The Importance of Measuring HRQL 
The World Health Organization (WHO) defined Health as “a state of complete physical, mental 
and social well-being and not merely the absence of disease or infirmity”. 154 Early, researchers 
were more interested in measuring the impact of diseases and injury when evaluating human 
health through either using morbidity or mortality statistics. In fact, there are other important 
faces of health that this definition includes and also needed to be assessed. Measuring HRQL 
helps the researchers to determine how a specific event can affect other indicators of human 
health such as mental and social well-being. In order to be able to have a complete picture about 
the impact of specific outcome on human health, it is important to determine how this outcome 
affects all the different aspects of health that the WHO specified in its definition.   
2.5.2 Evolution of HRQL Research 
HRQL assessment provides valuable information to all members of health care system. Interest 
in HRQL assessment has continued to increase in recent years. This can be illustrated from both 
national and international activities. 155-157 Since 1985, The United States Food and Drug 
Administration have been using HRQL measurements in the process of approving any new anti-
cancer drug. 158 In addition to clinical trials, HRQL assessment has evolved into a primary 
outcome measure in health services, acute care, and chronic diseases. 159,160 
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 Interest in HRQL is also seen in international professional societies. The International 
Society for Quality of Life Research (ISQOL) was founded in 1994 to promote research in 
HRQL, the scientific study of HRQL and health care throughout the world. It promotes the 
HRQL measurements from conceptualization to practice and application. Another organization, 
the International Society for Quality of Life Studies (ISQOLS) which promotes the research, 
discussion contributions to the research literature and the teaching in HRQL studies throughout 
the world. 161 
Another proof of increasing the interest in HRQL research is the large number of related 
publications. The term “quality of life” appeared in Index Medicus in 1972 with 15 citations in 
comparison to 52134 citations as in May 2006. Moreover, the first journal focusing on HRQL, 
Quality of Life Research was published in 1992. 161 
2.5.3 Definition of HRQL 
In order to conduct valid HRQL studies or to adequately describe, assess, or discuss HRQL, a 
clear definition of HRQL is required. There is no single definition of the term HRQL. Hunt and 
McKenna pointed out that there was no agreed definition, no theoretical base, inappropriate use 
of measures, lack of the recognition of the social basis of definition and measurements and 
confusion between HRQL and quality of care. 162 Several definitions can be found and most of 
these definitions showed that HRQL is a multidimensional concept. Many experts agreed on the 
subjectivity and dynamism of the concept. 163  
The multidimensional aspect of the HRQL is demonstrated in the several domains that 
have been used to identify HRQL (physical, social, psychological, somatic, and spiritual). Most 
of the studies that assessed HRQL rely on subjective, self-reported measures rather than 
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 objective measures. The use of self-report HRQL became more dominant after several studies 
reported a lack of agreement between the HRQL rating given by the patients, family members, 
and health care providers. 164 The dynamism of the concept reflects the importance of assessing 
the HRQL along a continuum, as HRQL standards for each person may change over time. 
Values and self-evaluations of life may change over time in response to life and health events 
and experience. 
In 1990, Spilker described HRQL assessment through three interrelated levels: a) Overall 
assessment of well-being, b) broad domains such as physical, psychological, economic, and 
social, and c) the components of each domain. 165 On the other hand, the WHO defined HRQL as 
“individuals’ perceptions of their position in life in the context of the culture and value system in 
which they live and in relation to their goals, standards, and concerns”. 157 The WHO definition 
includes six different domains as follows: physical health, psychological state, level of 
independence, social relationship, environmental features and spiritual concerns.  
Like both of the two previous definitions, the workshop on HRQL Research in Cancer 
Clinical Trials cosponsored by the National Cancer Institute, and the Office of Medical 
Applications of Research National Institute of Health, defined HRQL as a multidimensional 
concept “Health Related Quality of Life is the value assigned to duration of life as modified by 
impairments, functional states, perceptions, and social opportunities as influenced by disease, 
injury, treatment, or policy”. 156 Studies by Grant, Padilla and Ferrell demonstrated the need of 
multidimensional definition of the HRQL by identifying four consistent domains: physical well-
being, psychological well-being, social well-being and spiritual well-being. This model has been 
validated through different studies on cancer patients. 166 
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 2.5.4 HRQL Dimensions 
Many researchers agreed that there are four to five basic dimensions of HRQL: 1) physical, 2) 
psychological, 3) social, 4) somatic /disease and treatment related symptoms, and 5) spiritual. 167 
The most used traditional dimension is the physical one. The main questions that assess this 
dimension are about strength, energy, ability to perform activity of daily living and self-care. 
Interestingly, the response of this dimension correlates with the physicians’ estimate of the 
patients’ well-being and functional status. 166 The psychological dimension is unlike the physical 
dimension in that the health care providers poorly estimate the psychology of their patients. The 
main questions that assess this dimension are about anxiety, depression and fear. 168 The third 
dimension reflects the quality of an individual’s relationship with family, friends, and general 
community. The somatic dimension reflects the treatment side effect and the disease symptoms, 
while the spiritual dimension reflects the perception that life has meaning and purpose. 166 Some 
researchers consider the later as part of the psychological dimension. 
2.5.5 Measuring HRQL 
There is no one right way to measure health related quality of life, however, the measure needs 
to be tailored to the aim of the assessment. Consistent with the multidimensional nature of health 
related quality of life, investigators have identified a wide range of measures to tap quality of 
life. These include measures of emotional well-being (for example, measured with indicators of 
life satisfaction and self-esteem), psychological well-being (for example, measured with 
indicators for anxiety, depression, and a wide range of cognitive indicators), social well-being 
and roles (for example, measured with indicators of social support and activities), and physical 
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 health and functioning (for example, measured with scales of self-rated health, disability or 
ability to perform activities of daily living). 169 
Health related quality of life measures can be divided into either generic or specific 
measures. Generic measures assess global relevant concepts such as the ability to function in 
everyday life and emotional well-being. 170 They are not specific to certain disease, age, or 
treatment. For that reason, generic questionnaires are very useful measures that allow for 
comparisons between different conditions. 171 They permit comparison of the HRQL in patients 
with certain disease, like IC, to that of patients without that disease.  
Many generic measures have been developed and their psychometric properties have 
been comprehensively evaluated. 169 Examples of generic quality of life measures include 
Nottingham Health Profile (NHP), Medical Outcome Study (MOS) Short Form-36 Health 
Survey (SF-36), European Quality of Life Index (EuroQOL), and the World Health Organization 
Quality of Life measure (WHOQOL-100). 172 Interestingly, the common health concepts 
represented by the generic instruments include physical, social, and role functioning. Sleep, 
sexual and cognitive functions are represented less frequently. 
On the other hand, specific measures are designed to assess the impact of specific 
condition and its treatment on certain concepts and domains. 173 Examples of disease specific 
measures include the Rheumatoid Arthritis Quality of Life scale (RAQoL) and the European 
Organization for Research and Treatment of Cancer QLQ-C30. 174, 175  
2.5.6 Medical Outcome Study (MOS) Short Form-36 (SF-36) Health Survey 
The SF-36 is a multipurpose, short-form health survey that composed of only 36 questions. It 
yields eight-scale profile of scores as well as physical and mental health summary measures.176 It 
 100
 is referred to as a generic measure because it assesses health concepts that represent basic human 
values that are relevant to everyone’s functional status and well-being. 177 For that reason, the 
SF-36 has been useful in comparing general and specific population, the relative burden of 
diseases, determining the health benefits produced by a wide range of different treatments, and 
screening individual patients. 176 
Importantly, SF-36 has been documented in more than 1000 publications. 176 The number 
of studies that either used or cited SF-36 is increasing significantly. If you made a quick search 
using PubMed, more than 5000 publications will be retrieved.  
The SF-36 was  constructed  through the Medical Outcomes Study (MOS), which was a 
four-year observational study that investigated the changes in physician practice styles and 
patient outcomes under different healthcare settings such as health maintenance organizations, 
large physician groups, or individual physician fee-for-service practices. 178 One of the aims of 
the MOS was to construct reliable and valid tools for measuring and monitoring patient-reported 
functioning and well-being.179 Forty different physical and mental health concepts were used in 
the MOS to assess its aims. The eight health scales of the SF-36 were selected out of these 40 
concepts to represent the most frequently measured concepts in widely used health surveys, and 
those most affected by disease and treatment. 176 The selection process was the most difficult 
stage in developing the SF-36. Health distress, sexual functioning, family functioning, and sleep 
adequacy were among the concepts which seriously considered in the selection process, but not 
chosen. 177 
The eight different domains of the SF-36 include ; physical functioning, role limitations 
related to physical problems, bodily pain, general health perceptions, vitality, social functioning, 
role limitations due to emotional problems, and general mental health. SF-36 includes a single 
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 item that measures change in health over time. 177   All scale scores range from 0 (indicates worst 
health), to 100 (indicates best health). The SF-36 has high construct validity, 177, 180 high internal 
consistency, 177, 181 and high test-retest reliability. 182 
The eight domains of the SF-36 can be grouped into scales that either assess physical 
health (physical functioning, role limitations due to physical, and pain scales) or mental or 
emotional health (the mental health, role limitation due to emotional problems, and social 
functioning scales). 176 Related to physical health, the physical functioning scale assesses 
limitations in performing normal physical activity, such as walking, carrying groceries; the role 
limitations due to physical problems measures disability that is related to any physical problem; 
while the pain scale measures the severity and limitations due to the pain. On the other hand, 
scales that measured mental health and emotional health assess that through mental functioning 
and role limitations due to emotional problems such as disability to mental problem. 
Interestingly, vitality, general health perceptions, and social functioning scales have been found 
to measure both physical and mental domains simultaneously. 183 Two summary scores can be 
presented according to factor analysis; Physical Component Summary (PCS) or Mental 
Component Summary (MCS). 184 Figure 2-1 shows how the 36 items in the SF-36 can be 
summarized in just two component summary scales. 
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        § Reprinted with permission from Spine, 2000; 25(24):3130-9, Ware JE. SF-36 Health Survey Update. Copyright© 2000                  
               LIPPINCOTT  WILLIAMS & WILKINS  
            * Significant correlation with Other Summary Measures 
 
         Figure  2-2: SF-36 Measurement Model § 
 
Table 2-6 gives the reader more details about how these two summary scales correlated with the 
eight SF-36 domains, in addition to the interpretation of extreme scores in each of the SF-36 
domains, and the two summary scales. 
 Table  2-6: Summary Information About SF-36 Domains (Scales) and Physical and Mental Component Summary Measures * 
                        
CORRELATIONS 
 
NUMBER OF 
  
DEFINITION (% OBSERVED)E 
 
Domains 
(Scales) 
PCSA MCSA Items Levels Mean±SDC 
 
RD Lowest Possible Score Highest Possible Score 
Physical 
Functioning 
(PF) 
.85 .12 10 21 84.5±23.3 .93 Very limited in performing all physical 
activities, including bathing or dressing 
(0.8%) 
Performs all types of physical activities 
including the most vigorous without 
limitations (38.8%) 
Role-Physical 
(RP) 
.81 .27 4 5 80.9±34.0 .89 Problems with work or other daily activities 
as a result of physical health (10.3%) 
No problems with work or other daily 
activities (70.9%) 
Bodily Pain 
(BP) 
.76 .28 2 11 75.2±23.7 .90 Very severe and extremely limiting pain 
(0.6%) 
No pain or limitations due to pain (31.9%) 
General Health 
(GH) 
.69 .37 5 21 71.9±20.3 .81 Evaluates personal health as poor and 
believes it is likely to get worse (0.0%) 
Evaluates personal health as excellent (7.4%) 
Vitality 
(VT) 
.47 .65 4 1 60.9±20.9 .86 Feels tired and worn out all of the time 
(0.5%) 
Feels full of pep and energy all of the time 
(1.5%) 
Social 
Functioning 
(SF) 
.42 .67 2 9 83.3 ± 22.7 .68 Extreme and frequent interference with 
normal social activities due to physical and 
emotional problem (0.6%) 
Performs normal social activities without 
interference due to physical or emotional 
problems (52.3%) 
Role-Emotional 
(RE) 
.16 .78 3 4 81.3 ±33.0 .82 Problems with work or other daily activities 
as a result of emotional problems (9.6%) 
No problems with work or other daily 
activities (71.0%) 
Mental Health 
(MH) 
.17 .87 5 6 74.7 ±18.1 .84 Feeling s of nervousness and depressions all 
of the time (0.0%) 
Feels peaceful, happy, and calm all of the 
time (0.2%) 
PCSA 
 
 
5 67B 50.0 ±10 .92 Limitations in self-care, physical, social, and 
role activities, severe bodily pain, frequent 
tiredness health rated “poor” (0.0%) 
No physical limitations, disabilities, or 
decrements in well-being, high energy level,  
health rated “excellent” (0.0%) 
MCSA 5 93B 50.0 ±10 .88 Frequent psychological distress, social and 
role disability due to emotional problems, 
health rated “poor” (0.0%) 
Frequent positive affect, absence of 
psychological distress and limitations in 
usual social/role activities due to emotional 
problems, health rated “poor” (0.0%) 
*   Reprinted with permission from Spine, 2000; 25(24):3130-9, Ware JE. SF-36 Health Survey Update. Copyright©2000 LIPPINCOTT  WILLIAMS & WILKINS  
A   PCS: Physical Component Summary, MCS: Mental Component Summary. 
B    Number of levels observed at baseline; scores rounded to the first decimal place (n= 2474). 
C    Score for eight domains are the percentage of the total possible score achieved for each domain. Score for PCS and MCS are T-scores. 
D    R: Reliability. 
E    Percentage observed come from general US population sample. 
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 2.5.7 Factors Associated With Poor Quality of Life in IC Patients 
Identifying factors that are independently associated with decrements in HRQL in IC patients is 
of great interest when it comes to study the impact of IC symptoms on HRQL. Up to now, only 
one recent study investigated these factors among IC patients.185 Nickel et al. studied 217 women 
with moderate/severe IC who were enrolled in a clinical trial of intravesical bacillus Calmette-
Guerin. Both PCS and MCS from SF-36 were used as dependent variables. Data from O’Leary-
Sant IC Symptom and Problem Index, University of Wisconsin Interstitial Cystitis Inventory 
(WICI) and Medical Outcomes Study sexual functioning scale were also collected. Moreover, 
the investigators constructed three composite indexes from O’Leary-Sant IC Symptom and 
Problem Index, pain/urgency Likert scales and 24-hour voiding dairy to document the severity, 
frequency and bother of pain, urinary urgency and frequency. The final multivariate models 
showed that employment status, pain composite index score and Medical Outcomes Study sexual 
functioning scale predicted PCS, while only Medical Outcomes Study sexual functioning scale 
remained strong predictor of MCS. It is important to mention that the investigators in this study 
assessed several IC clinical measures that are expected to be highly correlated with each other. 
Moreover, it was not clear in the article if the authors included all these measures in the 
multivariate analysis or if they picked the highly significant variables. Furthermore, the above 
described study focused mainly on socio-demographic, IC clinical factors and sexual functioning 
that impair the two main composite summary scales. We still need to know in more details the 
effect of all these factors add to other lifestyle and reproductive factors on each domain of HRQL 
as well.  
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 2.5.8 Impact of IC on Health Related Quality of Life 
Interstitial Cystitis is a devastating urinary tract disorder. Until now, we do not know the exact 
causes of it, the best way to diagnose it or the effective method to treat it. People who are 
diagnosed with IC suffer from severe painful symptoms and experience several difficulties that 
can greatly affect their health related quality of life. When IC remains unrecognized and the 
symptoms continue to be untreated for years, the impact of IC on patient’s life cannot be 
overstated. The burden of IC extends far beyond symptoms of pelvic pain, and urgency into the 
physical, social, role limitation, and emotional functioning and well-being of patients. IC leads to 
social isolation, severe disability, unemployment, depression and even suicide. 14, 15 In fact, 
approximately 50% of IC patients are unable to work full time, and more than 60% of IC patients 
experience dyspareunia. 16 
Real examples from letters that have been sent to Interstitial Cystitis Association (ICA) 
are listed here to show the severe impact of IC on the life of the patients. One woman wrote 
describing her suffering “years of non stop pain, 40 to 60 bathroom trips a day, little sleep, lots 
of tests, 12 doctors, hundreds of allergy shots, diets, antibiotics, and six unnecessary operations”.  
Another woman wrote “if I had cancer, I would know sooner or later that I would be either in 
remission or dead, but with IC, I only suffer day after day, without hope of getting better. So 
many times I have thought of killing myself to get out of the pain and mental suffering caused by 
this disease.” 16 
Studies that assessed the impact of IC on the health related quality of life can be divided 
into two main types; studies used general questions to collect data about HRQL, and that which 
used standardized instruments. In the following section we will review both types. 
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 2.5.9 Studies that Used General Questions to Assess HRQL in IC Patients 
In 1987, Held et al. assessed health related HRQL for 3 series of patients with IC, including 64 
cases enrolled by random sample of urologists, 902 females with IC who are member of the 
Interstitial Cystitis Association, and a matched sample (119 participants) of the general US 
population. 2 Held et al. did not use a validated instrument to assess the health related quality of 
life; however they had specific questions about quality of life. Their study showed that IC 
patients were 3 to 4 times as likely to report thoughts of suicide and 5 times as likely to have 
been treated for emotional problems as the general population. 
Koziol et al. in their survey to determine the natural history of IC reported that 94.3% of 
IC patients find travel to be difficult or impossible, 89.9% reported that leisure activities 
adversely affected, while 88.2% indicated that sleep is difficult. 18 In another study that included 
565 IC patients, Koziol assessed the effect of IC on HRQL using questions about psychological 
factors such as feelings of fatigue, impact of disease on employment and anxiety. 20 The results 
showed that a large proportion of IC patients experienced excessive fatigue and adverse effects 
on employment due to their illness. 
More recently in 2006, Temml et al. studied the HRQL and sexuality of IC patients. They 
included 981 women of those attending a voluntary health survey project in Vienna in their 
study. 6 Data about IC symptoms were collected using the O’Leary-Sant (OLS) IC Symptom and 
Problem Index. Furthermore, 16 questions were used to assess HRQL and 5 questions to assess 
sexuality. IC symptoms were found to have a significant impact on HRQL and sexuality. More 
than half of the women with a moderate or high risk for IC (identify using the O’Leary-Sant 
(OLS) IC Symptom and Problem Index) had an impaired HRQL due to burning in the urethra, 
pain in the lower abdomen, and pain in the bladder. Temml et al. indicated that women with 
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 moderate to high risk of IC had 5 fold higher prevalence pain during orgasm, and 3 fold 
increased risk of pain in the vagina after sexual activity.   
2.5.10 Studies that Used Standardized Questionnaires to Assess HRQL in IC Patients 
Although clinical case series suggest that the impact of IC on health related quality of life is 
severe and debilitating, very few epidemiological studies that used standardized instruments can 
be found. Furthermore, comparison between these studies is limited because each study used 
different methods to present HRQL data (some used HRQL domains, other used items from 
HRQL domains), different diagnostic criteria, different comparison group to measure the impact 
of IC on HRQL. In general all the studies support the potential impact of IC on HRQL. Table 2-
7 provides summary of these studies. More details can be found in the following paragraphs. 
The Interstitial Cystitis Data Base Study (ICDB Study) is an important study that was 
conducted to determine the treated history of IC and to identify common patients’ characteristics. 
17 It is a longitudinal, multicenter, observational study sponsored by the National Institute of 
Diabetes, Digestive, and Kidney diseases (NIDDK). Data about the health related quality of life 
in IC patients were collected as part of this study using the SF-36 validated instrument. In 1997, 
Simon et al. published preliminary baseline descriptive statistics from this study. 17 
Approximately 424 patients (388 females, 36 males) completed the SF-36 HRQL questionnaire. 
The study showed that overall symptom score correlated inversely with health related quality of 
life. Patients with severe symptoms significantly report having greater limitations in basic daily 
functions. Overall, 7.8% of IC patients reported poor general health, 54% reported that they had 
limitations in work or other activities, 38.5% reported limitations in lifting groceries, 8.3% in 
bathing and dressing, and 71.7 % had interference in social activities. Although the study used 
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 SF-36 to assess health related quality of life, this paper did not provide specific details about 
which domain is the most affected and how the HRQL can be changed with time. 
In 2000, Michael et al. conducted a study to determine the HRQL among women with IC 
participated in the Nurses’ Health Study I and II. 21 The SF-36 was used to collect data about 
HRQL from all the participants in the Nurses’ Health Study I and II. Only data collected from IC 
self-reported patients confirmed with medical records (99 patients) were used for comparison. 
After adjusting for age and co-morbid conditions, women with IC had significantly lower scores 
in 5 of the 7 health related quality of life dimensions (including role/physical, bodily pain, 
vitality, social function, and mental health) compared to women without IC. Although, this study 
showed that there is considerable variability in the 7 dimensions of health related HRQL among 
IC patients compared to the previous study by Simon, 17 several limitations can be defined. First, 
because the study population was nurses, selection bias may have been introduced to the study. 
As a result, healthier group of women with IC were included in this study. This might 
underestimate the effect of IC on HRQL. Second, the investigators excluded confirmed IC cases 
(11 cases) if they did not answer the SF-36 from the analysis. This may bias their results 
especially if those women were severely ill. Finally, Michael et al. included women who 
reported initiation of IC symptoms after completing the HRQL instrument (9 cases), thus we do 
not know if the worsening in HRQL scores was a result of these symptoms or of other conditions 
among those cases.  
In 2002, Rothrock et al. focused on the impact of IC on mental health. They conducted a 
case control study that included clinical sample of 65 females with previous diagnosed IC and 40 
age matched controls. 22 They used SF-36 to assess HRQL, Beck Depression Inventory (BDI) 
and (Hamilton Rating Scale for Depression (HRSD)) to assess depression symptoms. IC patients 
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reported significantly poor health related quality of life than controls in all the 7 domains of the 
SF-36 (physical function, role/physical, bodily pain, vitality, social function, role/emotional, 
mental health). Interestingly, time since diagnosis was not associated with depressive symptoms 
or any aspect of HRQL except for role limitations due to emotional problems. Regarding the 
depression symptoms, IC patients reported greater depressive symptomatology on the BDI 
compared to controls as well as on the HRSD. This study also showed that patients with severe 
disease (measured using 3 symptom severity questions developed for the National Institutes of 
Health Interstitial Cystitis Database (ICDB) Study 17) reported significantly greater limitations in 
physical, social functioning, and mental health than patients with mild diseases. However, 
patients with severe disease did not have more depressive symptoms. The main limitation in this 
study was related to the use of non-standardized tool to classify IC cases into mild, moderate and 
severe, which may have introduced misclassification bias to the results. Furthermore, the authors 
did not adjust for important confounders like age and co-morbid conditions or even assessed if 
these covariates had significant effects on their results. 
 Table  2-7: Summary of the Studies that Assessed the Impact of IC on HRQL Using SF-36 (Generic Standardized HRQL 
Instrument) (1997-2002) 
 
AUTHOR 
YEAR 
JOURNAL 
 
 
TYPE OF 
STUDY 
SETTING 
 
 
SAMPLE SIZE 
CHARACTERISTICS OF 
STUDY POPULATION 
 
 
DIAGNOSIS OF IC 
 
 
 
RESULTS 
 
NOTES 
Simon et al., 1997 
Urology 
Cohort study 
USA 
The ICDB Study 
 
424 IC patients 
388 Females    
36  Males 
 
91% White  
Used the NIDDK criteria. with some changes 
In specific: The ICDB forgoes the NIDDK requirement 
that patients undergo a baseline cystoscopy to 
determine the presence of glomerulations or classic 
Hunner’s ulcer 
 
 
Definition of symptom severity: 
Based on self-reported frequency, urgency and pain 
? Frequency was actual average daily frequency from 
3 day voiding log 
? Urgency was based on the following question: over 
the past four weeks how often have you had the 
urge to urinate on a scale of 3 response 
? Pain was based on the following question: how 
much bodily pain  you had during the previous 4 
weeks on a scale of 3 response 
? The total score of the three questions was used to 
divide cases into three categories mild (3-5), 
moderate (6-7) severe (8-9) 
Patients in the ICDB 
study possessed a 
less than desirable 
QOL 
 
Patients with severe 
symptoms reported 
greater limitations in 
basic daily functions 
 
 
 
 
 
 
 
 
 
 
? The results based on the 
baseline data 
? The severity of symptoms 
was based on self- 
reported as answers for 
three questions. No 
previous validations or 
standardization done for 
these questions. 
? The categories did not 
have equal width 
? Association between 
severity and QOL was 
presented for selected 
items not domains 
? So this study did not 
show which domain 
would associated with 
symptom severity 
Michael et al., 
2000 
J Urol. 
 
 
Cross-sectional 
study 
USA 
The Nurse 
Health Study I, 
II 
 
15419 Participants 
99 IC Cases 
All participants were asked in a questionnaire: 
? Whether IC had ever been diagnosed by 
cystoscopy 
? All participants who answered yes were sent a 
supplementary questionnaire to gather more 
information 
? Self-reported IC was confirmed from medical 
records 
? NIDDK were used but were not applied completely 
Based on the above criteria, IC cases were classified 
into: 
There was an 
impairment in all 
domains except for 
role /emotional and 
physical functioning 
after adjusting for 
age and co-morbid 
conditions compared 
to healthy women 
 
 
? Study population 
healthier than normal IC 
patients as they were 
nurses 
 
? Including probable and 
possible cases may over 
estimate IC and lead to 
misclassification 
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STUDY 
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DIAGNOSIS OF IC 
 
 
 
RESULTS 
 
NOTES 
Michael et al., 
2000 
J Urol. 
(Cont’d) 
  Definite:  
? Report of  positive  cystoscopy with 
hydrodistension 
? Biopsy demonstrated chronic cystitis 
? Negative urine cytology 
Probable: 
? Report of  positive cystoscopy 
Possible 
? Letter stated that patient underwent cystoscopy 
with or without distension with diagnostic 
impression of IC 
IC women experience 
less decrement in 
physical functioning 
compared to arthritis 
patients but not 
hypertension patients 
 
IC women showed 
greater differences in 
vitality and mental 
healthy compared to 
rheumatoid arthritis 
or hypertensive 
patients 
 
? No relation between 
severity of symptoms and 
HRQL or which domain 
is most likely to be 
affected by severity of 
symptoms. 
Rothrock et al., 
2002 
J Urol. 
Case control 
study 
USA 
65 Case 
40 Controls 
 
100% Females 
Cases: 
? Selected from department of urology patients 
? Diagnosed with IC based on NIDDK 
 
Controls: 
? Two controls for each 3 cases 
? Matched on age, use of OC and HRT 
 
Definition of symptom severity: 
Based on self-reported frequency, urgency and pain 
? Frequency was actual average daily frequency from 
3 day voiding log 
? Urgency was based on the following question: over 
the past four weeks how often have you had the 
urge to urinate on a scale of 3 response 
? Pain was based on the following question: how 
much bodily pain due have you had during the 
previous 4 weeks on a scale of 3 response 
 
Patients showed 
significant poorer 
quality of life than 
controls in all 
domains of the SF-36 
 
Symptom severity 
and HRQL: 
 
Greater symptom 
severity was related 
to poor physical and 
social functioning 
and mental health 
 
 
Correlations between 
symptoms and QOL 
domains:
Table 2-7 Cont’d
? Controls were selected 
from general population 
not from clinic thus they 
may healthier than cases 
? Although it is matched 
study non-conditional 
analysis was used 
? No information about the 
distribution of cases by 
severity of symptoms was 
provided 
? Non of the symptom self- 
measured was 
standardized 
? Correlation between self- 
reported symptom 
severity and the physician 
rating was low 0.42 but 
significant  
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DIAGNOSIS OF IC 
 
 
 
RESULTS 
 
NOTES 
Rothrock et al., 
2002 
J Urol. 
(Cont’d) 
  ? The total score of the three questions was used to 
divide cases into three categories mild (3-5), 
moderate (6-7) severe (8-9) 
Greater pain 
correlated 
significantly with 
vitality, social 
functioning, role 
limitation due to 
physical, mental 
health 
 
Frequency was 
correlated with 
physical functioning 
only 
 
Urgency was 
correlated with pain 
and social 
functioning 
? No adjusting for Co-
morbidity or age (20-81) 
? Poor presentation of the 
results without any p 
values or correlations 
parameter 
 
d’Cont7-Table 2
 2.5.11 Health Related Quality of Life as an Outcome in IC Clinical Trials 
Although all the previous studies that assessed the impact of IC on HRQL reported that IC 
patients had significant impaired quality of life compared to healthy population, 2, 6, 17, 18, 20-22 
only two IC clinical trials considered using HRQL as an outcome. 186, 187 Furthermore, both of 
these trials assessed the improvement in HRQL as a result of therapies other than PPS.  
Peters et al. were one of those who used HRQL as one of their outcomes when they 
assessed the efficacy of intravesical Tice strain Sacillus Calmette-Guerin as a new therapy for IC 
in a double blind placebo randomized clinical trial.186 The trial included 30 IC patients who 
randomized into two balanced arms (either treatment or placebo). Peters et al. used Rand-36 
questionnaire to assess the impact of the trial treatment on HRQL. In general, the study showed 
that treatment group improved more than the placebo group in all the eight domains of the Rand-
36 questionnaire (physical functioning, role limitations caused by physical health problems, role 
limitations caused by emotional problems, social functioning, emotional well-being, 
energy/fatigue, pain, and general health perceptions). However, statistically significant 
improvements were reported in only two domains; social functioning and fatigue domains. 
The second trial was conducted in 2004 by Oyama et al. The researchers used the SF-12 
questionnaire to assess the impact of transvaginal manual therapy of the pelvic floor musculature 
(Thiele massage) among females with IC on HRQL Physical and Mental Summary Components. 
187 The study included 21 IC patients who underwent transvaginal massage using the Thiele 
technique twice a week for 5 weeks. HRQL were evaluated before massage, at protocol 
conclusion and at a mean of 4.5 months after therapy completion (long-term follow-up). 
Statistically significant improvements were reported in both Physical and Mental Summary 
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 Components after 5 weeks of the study. Interestingly, after 4.5 months of the completion of the 
protocol the improvements in the Physical Component Summary and Mental Component 
Summary of the SF-12 Quality-of-Life Scale were no longer statistically significant. 
In summary, there is a limitation in considering HRQL as one of the main outcomes in 
IC clinical trials despite the impairment effect of IC on patient’s HRQL.  
2.6 GENERAL SUMMARY 
Interstitial cystitis is a chronic idiopathic inflammatory bladder syndrome of unknown causes 
and pathogenesis.  Despite the ongoing efforts to understand this debilitating syndrome, research 
is still required. After reviewing the literature from different aspects of IC, several gaps could be 
identified. There is a lack of well-designed epidemiological studies to determine the exact 
prevalence and incidence as well as the potential risk factors of IC. These important 
epidemiological concepts will not be determined unless highly specific diagnostic criteria are 
developed. These criteria should be able to identify all possible IC cases and not only the 
moderate and/or the severe cases. In order to be able to develop these criteria more efforts should 
be directed toward the etiology and the pathogenesis of IC. More animal, laboratory and clinical 
studies are needed to aid in constructing an etiological model of IC. 
The present study was developed to answer questions in two main aspects of the IC 
literature as follows; the health related quality of life in IC patients and the efficacy of a new 
intravesical therapy (PPS) for IC. Assessing both aspects are very important to improve the 
quality of life in IC patients.  
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 Focusing on the literatures of HRQL as an important standard, of the evaluation of IC 
patients’ life experience, several unanswered questions arise. Although we know that IC patients 
experience substantial impairment in different dimensions of their health related quality of life, 2, 
6, 17, 18, 20-22 limited efforts have been directed to understand that comprehensively. We need to 
know if the severity of IC symptoms impairs each domain of HRQL to the same level or not with 
the use of validated, standardized tools and adjusting for possible covariates. Another question 
involves: which symptom of IC (pelvic pain, urinary frequency, urinary urgency and/ or 
nocturia) brings the greatest impairment to HRQL? 
Answering these two important questions may help to modify the treatment of IC toward 
the symptom that is most likely to impair quality of life in IC patients. Furthermore, we may be 
able to direct our efforts to improve the specific domain of HRQL that is most likely to be 
impaired according to the severity of the IC condition. 
The efficacy of PPS as a new intravesical therapy needs to be investigated. The use of 
PPS as an oral therapy has been shown to provide a substantial improvement effect on IC 
symptoms; the flaw in the use of oral PPS is that progress in symptom reduction has been well 
documented to take 3 to 6 months. 27-33  Because intravesical therapy has several advantages over 
the oral therapy that are related to increase the concentration of the treatment in the site of action 
and to decrease the effect of metabolism on the active ingredient, 35  it is  important to test the 
efficacy of PPS as an intravesical therapy. Particularly, after it showed substantial improvement 
effects on IC symptoms as an oral therapy. Only one trial, before ours, was conducted to assess 
that with promising results. 37 Because that trial was very small and based on self-catheterization 
of the medication at home without any monitoring from the investigators of the study, another 
clinical trial was needed to overcome these limitations and to assess the efficacy of PPS 
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extensively. It is crucial to determine how PPS improves IC symptoms, and which of these 
symptoms is most likely to respond to this medication. 
Although we know that the quality of life in IC patients is impaired, none of the clinical 
trials that assessed the efficacy of PPS as an oral therapy used HRQL as a major outcome. This 
trial assessed if intravesical PPS improved the quality of life in IC patients. Moreover, it also 
examined which domain was most likely to be improved. The following chapter presents details 
about the protocol of the study and the statistical analysis plan that we used to assess each aim of 
our study. 
 3.0  METHODS 
3.1 STUDY DESIGN 
The randomized clinical trial is considered the gold standard with regard to test the efficacy of a 
new treatment. It enables the researchers to evaluate the efficacy of therapeutic, preventive and 
other measures in both clinical medicine and public health. Randomization makes the trials 
extremely powerful in comparison to prospective cohort studies; since it provides comparable 
groups at the beginning of the trial, which assures that the difference in the outcome can only be 
attributed to the new intervention. 188 Furthermore, randomization prevents the investigators 
from consciously or unconsciously assigning better prognosis patients to a treatment that they 
hope will be superior, thus it reduces selection bias. One more benefit of randomization is that it 
prevents confounding, as it is the only technique which can control for known and unknown risk 
factors or confounding variables; if the process of subject allocation is performed correctly, 
randomization is resistant to external manipulation. Thus, it is expected that known and unknown 
prognostic variables are randomly distributed between study groups, and that randomization will 
create study groups having similar incidence of the disease or outcome when the treatment under 
evaluation has no effect. Using the clinical trial design is better than the cohort design as we will 
have more control over the exposure, something very important for causality and the validity of 
any association. 188 
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 As we mentioned previously, it was not applicable to conduct blinded studies to test the 
efficacy of the well-defined intravesical therapies because of study design limitations. The fact 
that dimethyl sulfoxide (DMSO), the only intravesical approved therapy by the FDA, produces 
garlic breath made testing its efficacy impossible by using a double blind randomized clinical 
trial design. Moreover, other commonly used intravesical therapy named sodium oxychlorosene 
lavage (Clorpactin®) is very painful and needs general or regional anesthesia when 
administered, which makes it not suitable to be tested in a blind clinical trial without being 
recognized. 
The intravesical instillation of Elmiron® , Pentosan Polysulfate Sodium (PPS), avoids all 
the previous limitations in both DMSO and sodium oxychlorosene lavage. Furthermore, its use 
as oral therapy proved a greater efficacy over placebo in several blind randomized placebo 
trials.27-30, 32, 33 Intravesical instillation of PPS is still very recent. Until now, only one small 
clinical trial was conducted in the Netherlands to test the efficacy and safely of intravesical PPS. 
37  
The present study is the first, randomized, double blind, placebo-controlled trial in the 
US that tested the effect of intravesical PPS on the severity of IC symptoms and the health 
related quality of life (HRQL) in IC patients. It also examined the factors that may associate 
with both symptom severity and impairment in HRQL in IC patients, and assessed the 
correlations between symptom severity and impairment in the different domains of HRQL at 
baseline in a cross-sectional design. 
Most of the results of the clinical trial part of this dissertation were recently published in 
The Journal of Urology. 189 We represented these results in more details (with permission from 
Elsevier) in the next chapter.  
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 Forty females diagnosed with IC within one year were recruited and randomized (after 
obtaining signed informed consent) to receive either intravesical PPS plus oral PPS (treatment 
group) or intravesical placebo plus oral PPS (placebo group). Twenty subjects received 
intravesical PPS and 20 subjects received intravesical placebo, twice weekly for six weeks. Both 
clinical arms received 200 mg oral PPS two times daily during the entire study period (18 
weeks). 
The blinding process of this study was monitored, assessed and recorded by an 
independent pharmacist who was aware of each subject designation (treatment or placebo) 
should the need for un-blinding occur. 
3.2 STUDY POPULATION 
Because all the prevalence studies up to now showed females as the most likely gender to be 
diagnosed with IC, only females with IC were recruited. Females who were older than 18 years 
old, diagnosed with IC within one year and previously untreated with PPS were recruited to 
participate in the trial. The National Institute of Diabetes, Digestive, and Kidney diseases 
(NIDDK) exclusion and inclusion criteria were used to determine who should be enrolled. Lists 
of exclusion and inclusion criteria are following.  
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 3.2.1 Exclusion Criteria 
Female was excluded from the study if: 
• She had a bladder capacity of greater than 350 ml on awake cystometrogram using water 
filling medium. 
• She showed absence of intense urge to void with the bladder filled to 150 ml with water 
filling medium on cystometrogram using a fill rate of 30 ml to 100 ml per minute. 
• She demonstrated biphasic involuntary bladder contractions on cystometrogram using 
filling rate of 30 ml to 100 ml per minute. 
• She demonstrated an absence of nocturia. 
• She had frequency of urination of less than eight times per day in a twenty four (24) hours 
period. 
• Her symptoms are relieved by antimicrobials, urinary antiseptics, anitcholinergics, or 
antispasmodics. 
• She had a diagnosis of bacterial cystitis within a three month period, documented by a 
positive culture. 
• She had recurrent bladder or lower urethral calculi. 
• She had active genital herpes with a three month period. 
• She had uterine, cervical, vaginal or urethral cancer. 
• She has been administered cyclophosphamide or any agent that causes chemical cystitis. 
• She had tubercular cystitis. 
• She had radiation cystitis. 
• She had benign or malignant bladder tumor. 
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 • She had symptoms of vaginitis. 
• She had evidence of vesicle urethral reflux or urethral diverticula. 
• She had neurogenic bladder dysfunction. 
• She had a prior urinary diversion. 
• She was receiving investigational   drug(s) at the time of enrollment. 
• She was receiving or having had prior therapy with oral PPS at the time of enrollment. 
• She was pregnant or lactating at the time of enrollment. 
3.2.2 Inclusion Criteria 
Female was enrolled if she met the following criteria: 
• She was eighteen years of age or older and capable of giving consent. 
• She was diagnosed with IC within one year of entering the study.   
• A cystoscopic examination under anesthesia with hydrodistension and photo documentation 
was done within one year of entry into the study, and bladder biopsies were performed only 
if carcinoma was suspected. 
• She demonstrated a documented sterile bacterial urine culture. 
• She had a score of at least four on the pain scale, five on the O’Leary-Sant Symptom Index 
and four on the O’Leary-Sant Problem Index at baseline. 
• Female of child-bearing potential must test negative for pregnancy prior to treatment or 
provide documentation for having undergone the following:  hysterectomy or tubal ligation. 
Females who were physiologically capable of becoming pregnant must voluntarily sign a 
pregnancy waiver included within the informed consent.  If a subject became pregnant 
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 during the course of this study, the subject must inform the principal investigator within one 
working day of learning of the pregnancy. 
3.2.3 Subject Consent 
All participants signed an informed consent that contained California Experimental Subject’s 
Bill of Rights, and described clearly the protocol of the trial, which includes the purpose of the 
study, expected risks, benefits, durations, inconveniences and invasive procedure. A complete 
copy of study informed consent can be found in Appendix A. 
Two copies were obtained; one for the patient and the other one for the investigator 
record. All subjects were informed that there are no obligations to participate and subjects may 
withdraw at any time without prejudice to future medical care.  No financial compensation was 
given to the study participants. 
3.2.4 Recruitment 
The target was to recruit 40 IC female patients based on the sample size justification that is 
presented in the power calculation section of this chapter. The recruitment process started on 
April 2004 and end on August 2006. Because two subjects dropped out after randomization; one 
subject dropped out directly before receiving any treatment while the second one dropped out 
after 4 weeks of the trial, another 2 subjects were recruited to replace them. More details about 
sample size flow chart can be found in the first section of chapter 4. 
All trial participants were recruited from the clinical patients of Citrus Valley Medical 
Research, Inc. Glendora, CA.  Female candidates, who were older than 18 years, and were 
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 diagnosed with IC within one year, were invited to participate in the trial. Informed consents 
were obtained from those who agreed to participate. Only candidates who met the previously 
specified exclusion and inclusion criteria, and signed an informed consent were enrolled and 
randomized into two arms. 
3.3 RANDOMIZATION 
A randomization scheme was generated through SAS statistical software. Restricted (Blocked) 
randomization with a size of 4 per block was used to allocate participants into two balanced 
groups (treatment and placebo). The randomization scheme was created by Ortho-McNeil 
Pharmaceutical, Inc., The drug company, which funded the trial and supplied the intervention 
medications. The randomization code was kept by an independent pharmacist until the end of the 
trial, and was given to the statistician after all the required information has been collected.  
3.4 PROCEDURE FOR ALLOCATING TRIAL MEDICATIONS 
All participants received oral PPS 200 mg (2 capsules) twice a day for a total daily dose of 400 
mg during the study period (18 weeks). Oral PPS capsules were administered either one hour 
prior to meals or two hours after meals. 
The 40 participants were allocated into two balanced groups (treatment or placebo) 
according to the randomization scheme which was created by Ortho-McNeil Pharmaceutical, 
Inc. The treatment arm, which included 20 participants administered intravesical PPS 200 mg (2 
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 capsules) mixed with 30 ml sterile normal buffered saline twice per week for the first six weeks 
of the study. The placebo arm, which included the remaining 20 participants administered 
intravesical placebo of 30 ml sterile buffered normal saline twice per week for the same period. 
Figure 3-1 shows a flowchart of the study design. 
 
 
First 6 weeks 
From week 7 to week 18 
   Randomization 
N=20 
Treatment group 
Oral PPS (200 mg /twice a 
day) + intravesical PPS 
(twice a week) 
 N=20 
Placebo group 
Oral PPS (200 mg /twice a 
day) + intravesical 
placebo (twice a week) 
N=20 
Treatment group 
Oral PPS (200 mg /twice a 
day) 
N=20 
Placebo group 
Oral PPS (200 mg /twice a 
day) 
Eligible Subjects 
N=40 
 
            Figure  3-1: Flowchart of the Study Design 
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 3.5 STUDY MAIN OUTCOMES 
The present study had several aims that were assessed using two different study designs. The 
cross-sectional design was used to determine the main socio-demographic, lifestyle and clinical 
factors that were associated with either the severity of IC symptoms or the impairment in HRQL 
in IC patients. The same design was also used to assess the correlations between the severity of 
IC symptoms and the impairment in the different domains of HRQL. Because of the limitation of 
the cross-sectional design, we cannot tell which of the studied variables are the outcomes, and 
which are the exposures. 190 
On the other hand, a randomized clinical trial design was used to assess the efficacy of 
the combination of oral PPS and intravesical PPS compared to oral PPS and intravesical placebo. 
Using this design, we can easily determine which variables are the outcomes and which are the 
exposures. The main outcomes to measure the efficacy of the combination of oral PPS and 
intravesical PPS were changes in: symptom severity, response to trial intervention (defined as 
any improvement in any of the following: overall IC condition, urgency and urinary frequency as 
reported by patient), health related quality of life and sexual activity. Different measurement 
tools were used to collect data about each of the above listed outcomes. Table 3-1 provides a 
summary of the current study main outcomes, measurement tools and the corresponding 
evaluation endpoints.  
 
 
 
 
 
 126
    Table  3-1: Evaluation Endpoints of Clinical Trial Efficacy Outcomes 
EFFICACY OUTCOMES 
Outcomes Measurement  Tools Evaluation Endpoints 
IC symptoms: 
Since enrollment: 
• Change in the severity of IC 
symptoms 
 
 
• O’Leary-Sant ICSI & ICPI (score 
0-36) 
• PUF instrument (score 1-35) 
• Pain assessment scale (score 1-9) 
• Urgency scale (score 1-5) 
• Urinary frequency (voiding log) 
• Nocturia (voiding log) 
 
 
All tools: 
• At week 6 (when patients 
completed all required instillations) 
• At week 12 and week 18 
Response to trial intervention: 
Since enrollment: 
• Overall change in IC condition 
• Change in urinary frequency 
• Change in urgency 
 
 
 
• Patient global assessment 
 
 
• At week 18  
 
HRQL and Sexual functions: 
Since enrollment: 
• Change in HRQL 
• Change in sexual desire 
• Change in sexual arousal 
 
 
• SF-36 
• Sexual function assessment VAS 
• Sexual function assessment VAS 
 
All tools: 
• At week 4, week 18 
 
 
 
3.5.1 Instruments that Measure Change in Symptom Severity  
These instruments can be divided into two main types; the first measures the overall level of 
symptom severity through providing a total score e.g. O’Leary-Sant Interstitial Cystitis Symptom 
Index (ICSI) and the Problem Index (ICPI) and Pelvic Pain and Urgency/Frequency (PUF) 
Questionnaire. The second one measures the level of severity in each IC symptom separately e.g. 
pain assessment scale, urgency scale and voiding log. 
The following sections describe each of these instruments in more detail. 
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 3.5.1.1 O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index 
(ICPI) 
The interstitial cystitis symptom index and problem index were designed to capture the most 
important voiding and pain symptoms, and to assess how problematic patients find them in the 
clearest and most concise manner possible. 23 Each index contains 4 items that measure either the 
frequency of certain IC symptoms (including urinary urgency and frequency, night-time 
urination, and pain or burning) or how much has each of these symptoms been a problem for IC 
patient. 23 The maximum score of ICSI is 20, while for the ICPI is 16. ICSI can be categorized to 
indicate the level of severity of IC symptoms as follows: (0-6) indicating mild symptoms, (7-14) 
moderate, and (15-20) severe symptoms. Thus, a score of 15 or greater in the ICSI indicates 
severe symptoms. 33 The initial validation of this instrument was conducted among 45 newly 
diagnosed patients with IC from three urology practices in the United States. The control group 
was 67 women from the routine gynecological care with no voiding symptoms. 23 Interestingly, 
in the validation of the indices for measuring urinary symptoms and their impact, very few 
interstitial cystitis patients scored lower than six on either index, whereas very few controls 
scored as high as six. 23 An ICSI score of greater than or equal to five was found to be 94% 
sensitive and 50% specific for interstitial cystitis/painful bladder. 191 O’Leary-Sant Interstitial 
Cystitis Symptom Index (ICSI) was also validated in prospective treatment studies and the 
results showed that it is a valid, reliable, and responsive measure of change in IC symptoms. 102 
Finally, it is important to mention that both indices are not intended as screening tests, 
even though they appear to discriminate between patients with and without IC. However, those 
indices should be used as an adjunct in the diagnosis and should be useful in the evaluation and 
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 management of patients with IC. 23 A copy of the O’Leary-Sant Interstitial Cystitis Symptom 
Index (ICSI) and the Problem Index (ICPI) can be found in Appendix B. 
3.5.1.2 Pelvic Pain and Urgency/Frequency (PUF) Questionnaire 
 
The Pelvic Pain and Urgency/Frequency (PUF) questionnaire was published most recently and 
studied in a large population of both urologic and gynecologic pelvic pain patients. 24 It was 
designed by Parsons CL. to include questions that directly reflect a wide variety of symptoms 
experienced by IC patients. The questionnaire included 8-question symptom scales that were 
designed to measure the presence and severity of IC symptoms, and how much the patients are 
affected by those symptoms. One third of these questions assesses urinary frequency issues, 
second third of the questions assesses urgency, and the last third assesses pelvic pain (pain 
anywhere in the pelvis: vagina, labia, lower abdomen, urethra, perineum, testes, penis, or 
scrotum), and pain associated with sexual intercourse. 
The PUF is very easy to administer and can be completed within 5 minutes. Two separate 
scores are obtained: one reflects symptom level, while the other reflects the bother level. Both 
scores can be added to provide a total symptom and bother score. The maximum total score is 35 
while the minimum recorded score among healthy participant is < 2. A total score of 10 points or 
more clearly indicates a very high probability that the patient has IC. 44 The intravesical 
potassium sensitivity test (PST) was used to validate the PUF scale, as a new screening test, in a 
study that included: urologic patients who were suspected to have IC, gynecologic patients with 
pelvic pain, controls and women attending lectures about IC. 24 Positive potassium sensitivity is 
known to be associated with a bladder epithelial dysfunction present in most individuals with IC. 
The results showed that a total score of 10 to 14 indicates 74% chance of having IC, 15 to19 
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 indicates 76% chance of having IC, and 20 or higher indicates 91% chance of having IC. A copy 
of the Pelvic Pain and Urgency/Frequency (PUF) Questionnaire can be found in Appendix C. 
3.5.2 Other Instruments that Measure Change in Symptoms Level 
3.5.2.1 Pain Assessment 
The single most reliable indicator of the existence and intensity of pain is the patient’s self-
report. 192 Several self-report measurement scales are available. The main three common self-
report measurement tools that are used for the assessment of pain intensity and affective distress 
in adults and children are: 1) numerical rating scale (NRS); 2) visual analog scale (VAS); and 3) 
adjective rating scale (ARS). Interestingly, each of these tools can be a valid and reliable 
instrument as long as endpoints and adjective descriptors are carefully selected. 192 In the present 
study, an adjective rating scale was used to assess the level of pain at baseline and at each visit 
during the study period. The same scale was also used to determine the level of pain during 
voiding (section 3.5.2.2). The scale composes of nine different pain levels; as level one indicates 
no pain and no symptoms, while level nine-ten indicates that the subject suffers from the worst 
pain, and he or she is in the hospital. This scale can be categorized into three different classes as 
follows: 1-3 indicates mild pain, 4-6 indicates moderate pain, and 7-9 indicates severe pain. This 
scale was used successfully in previous studies, 32, 193, 194 and validated in clinical intervention. 195 
A copy of the pain assessment instrument can be found in Appendix D. 
3.5.2.2 Voiding Log 
Voiding Log is an important tool to measure several IC symptoms. It can measure urinary 
frequency, nocturia and urgency. It asks patient to record the time at which he or she urinates for 
 130
 24 hours. It also requires the patient to place a star next to the times he or she recorded when 
wake up in the middle of sleep to urinate. Each time the patient records a void, he or she has to 
assign an urgency number that reflects his or her urgency level at time of urination on an urgency 
scale (1-5); as 1 indicates no symptom, while 5 indicates severe symptom. Patients also have to 
assign a pain level at time of void using the pain assessment scale (section 3.5.2.1). Several 
studies used successfully voiding log as a secondary outcome, and some of them collected that 
for more than one day, while others collected data for only 24 hours. 32, 193, 194  The 
responsiveness of Voiding Log was recently assessed and showed positive result. 195 In the 
present study, patients were asked to record each time they urinate during a period of 24 hour 
each time they have to submit a log. A copy of the Voiding Log instrument can be found in 
Appendix E. 
3.5.3 Patient Global Assessment  
In order to be able to determine the response rate of the combination of oral PPS and intravesical 
PPS compared to oral PPS and intravesical placebo, patient global assessment instrument was 
used.  
This instrument is also called the Patient’s Overall Rating of Improvement of Symptoms 
(PORIS), and was previously used as the primary treatment outcome measure in two IC clinical 
trials. 28, 30   In the original version of this instrument, patient is asked to rate his or her symptoms 
compared to the baseline as worse, no change (0%), slightly improved (25% improvement), 
moderately improved (50% improvement), greatly improved (75% improvement), and symptoms 
gone (100% improvement). 
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 Interestingly, some researchers expressed the opinion that the PORIS should be expanded 
to contain two or more negative values rather than the single negative value, worse, so it would 
in theory be more balanced. 196 Although no information was found about validity of this 
instrument, it was used successfully in previous studies. 28, 30    
The present study used a different version of the patient global assessment questionnaire. 
189  This version was used in a previous clinical trial (sponsored by Bioniche Life Sciences Inc., 
Canada, 2003). The Canadian trial assessed the safety and efficacy of Cystistat® (Sodium 
Hyaluronate) as a treatment of IC. 197 This version of patient global assessment evaluates the 
overall change in IC condition since enrollment in the study.  It measures the level of change 
with: worse, no change, and improved as the possible outcomes. It also measures the level of 
improvement with: moderate, greatly improved, and completely improved as the possible 
outcomes. The global assessment also allowed the patients to evaluate the changes in urgency 
and urinary frequency using the same outcomes as overall change in the IC condition. 
Responders were defined as those who reported improved as a possible outcome. This definition, 
for responders, was chosen based on the design of this version of the patient global assessment, 
and it reflects all the corresponding outcomes of improvement (moderately, greatly and 
completely). A copy of the patient global assessment instrument can be found in Appendix F. 
3.5.4 Medical Outcome Study (MOS) Short Form-36 (SF-36) Health Survey 
The SF-36 survey is a widely used instrument to assess HRQL. It is a multi-purpose, short-form 
health survey with only 36 questions that assess eight HRQL domains as follows; physical 
functioning, role-limitations due to physical problems, bodily pain, general health perceptions, 
vitality, social functioning, role-limitations due to emotional problems, and general mental 
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 health. The SF-36 includes a single item that measures the change in health over time. The 
questions are designed to be easy to understand and relevant to most people's lives. The form 
only takes 5 to 10 minutes to be completed. The original score of each domain ranged from 0 to 
100. A zero indicates a worse HRQL while 100 indicates excellent HRQL. 
Each domain has a specific number of items scatters within the SF-36 survey, and a 
specific number of levels reflects the level of the scale and identifies how much the domain or 
scale is precise. The larger the number of levels the most precise the scale is. 
Previous studies showed that the eight domains of HRQL in the SF-36 can be 
summarized in just two summary scales; the PCS and the MCS. Physical functioning, role-
physical, and bodily pain were found to be highly correlated with the physical component and 
contribute most to the scoring of the PCS measure. 176, 184 On the other hand, the mental 
component was found to be correlated most highly with the mental health, role-emotional, and 
social functioning scales, which also contribute most to the scoring of the MCS measure. 
Interestingly, three of the scales (vitality, general health, and social functioning) have noteworthy 
correlations with both components. 
It is important to mention that the most precise (least coarse) scales are those with 20 or 
more levels included; physical functioning, general health, vitality, and mental health. They also 
define the widest range of health status, and, therefore, usually produce the least skewed score 
distributions. The relatively coarse role disability scales included role-physical and role-
emotional, each measure only four or five levels across a restricted range, and, therefore usually 
have the most problems with ceiling and floor effects. 176 Because each of PCS and MCS 
measures hundreds of levels of health and extend the range of measurement to higher and/or 
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 lower levels than the eight sub-scales, individuals rarely score at the very top or the very bottom 
of the PCS or MCS scales; this is a major advantage. 198 
The importance of assessing these two summary scales as valuable outcomes in drugs 
efficacy studies is related to the ability to determine which aspects of health are most likely to be 
affected with the tested therapy. In particular, scales that load highest on the physical component 
are most responsive to treatments that change physical morbidity, whereas scales loading highest 
on the mental component respond most to drugs and therapies that target mental health. 176  
The SF-36 is a valid instrument. It showed high construct validity, 177, 180 high internal 
consistency, 177, 181 and high test retest reliability.182 A copy of the SF-36 Health Survey can be 
found in Appendix G. 
3.5.5 Sexual Function Assessment Visual Analog Scale 
This instrument was designed to assess sexual function. The sexual function assessment includes 
two visual analog scales that assess sexual desire and sexual arousal domains, and one numerical 
scale (0-4) that assesses the frequency of experiencing painful intercourse if happened. 
The visual analog scales consist of a line that is 10 cm in length, with “None” at one end 
and “High” at the other end. Patients are required to make a vertical stroke along the line that 
best describes the amount of either sexual desire or sexual arousal that he or she felt during the 
past month. 
The numerical scale which assess the frequency of experiencing painful intercourse if 
exist ranges from 0 to 4; as 0 indicates not at all while 4 indicates always. Sexual function visual 
Analog Scale was used successfully in previous studies. 199, 200 A copy of the Sexual Function 
Assessment Visual Analog Scale can be found in Appendix H. 
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 3.6 SAFETY MEASURES 
Although assessing the safety of intravesical PPS is out of the scope of the present study, we find 
it is important to let the reader know more about all the safety measures that were collected 
during the study period to ensure safety of the study subjects.  
The use of PPS directly in the bladder is new, for that reason the following safety measures were 
collected and followed during the study period: 
• Within thirty days of the study enrollment, a thorough history and complete physical 
examination were conducted 
• Blood chemistry included; Complete Blood Count (CBC), Blood Urea Nitrogen (BUN) 
and Creatinine electrolytes were performed within the thirty days prior to the first 
instillation of PPS and six weeks following the last instillation of PPS (at week 12) 
• At baseline, week one through week six, one hour following each intravesical instillation 
and at week twelve hepatic function panel, Activated Partial Thromboplastin Time 
(APTT), Prothrombin time, and platelet count were performed 
• For women who were able to become pregnant, pregnancy waiver forms were obtained 
voluntarily and the suitable birth control methods were used. Pregnancy tests were also 
performed prior to enrollment and by the completion of the study 
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 3.7 PRE-STUDY ENROLLMENT PROTOCOLS 
All candidates who signed informed consent underwent cystoscopic examinations with 
hydrodistension (with bladder biopsy if carcinoma is suspected) to determine the presence of 
either glomerulations or Hunner’s ulcer within one year prior to the beginning of the study. An 
urodynamic evaluation includes cystometrogram, uroflow, and ultrasound to measure post void 
residual, was completed within one year prior to the beginning of the trial as well.  
30 days prior to the beginning of the trial, physical examinations were conducted by the 
investigator, and the following laboratory measures were performed as part of the pre-enrollment 
evaluation: 
• CBC, BUN, Creatinine, electrolytes 
• Routine urinalysis, urine culture and sensitivity 
• Urine and blood sample for biomarkers and hormonal study to be preserved 
• Pregnancy test as required 
• Hepatic Function Panel 
• APTT 
• Prothrombin Time 
• Platelet count 
Information about concomitant medical conditions and current medications were 
collected prior to the beginning of the study. 
Baseline data were collected one week prior to randomization and included demographic 
and reproductive history, O’Leary-Sant Interstitial Cystitis Symptom and Problem Index, Pelvic 
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 Pain and Urgency/ Frequency Patient Symptom Scale (PUF), pain assessment, voiding log, SF-
36 HRQL questionnaire, and sexual function assessment. 
3.8 STUDY FLOW CHART 
The total duration of the trial was 18 weeks, in which all participants were treated with oral PPS 
(200 mg twice daily). The intravesical instillation of either PPS or placebo was performed only 
during the first six weeks of the trial; twice per week (in two visits each week). Participants had 
to return for follow-up assessments at week 12 and 18 of the study. Different assessments and 
laboratory testes were completed and performed during the study period according to a well 
specified study flow chart (a complete flow chart of the trial with all assessment instruments can 
be found in Appendix I). The following section will summarize the protocols and procedures 
during the study period. 
3.8.1 Study Protocol for the First Six Weeks of the Trial 
Within thirty days of the pre-study examination, subjects were randomized into two parallel arms 
based on the randomization scheme that was created by Ortho-McNeil Pharmaceutical, Inc. 
Intravesical instillations were given twice a week, in two visits per week, for the first six 
weeks of the trial. In the first visit of each week, culture and sensitivity of a catheterized urine 
specimen were performed. A clean-catch urine specimen was collected and tested with a reagent 
strip, a Multistix® 8SG, for urine analysis, to rule out any urinary infection before each 
intravesical instillation. If the clean-catch urine (Multistix® test) specimen showed a positive 
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 result for the possibility of infection (a positive Multistix® test shows: leukocytes, nitrites, and 
blood in any degree) the investigator evaluates the participant and determines if the participant 
can continue to receive the intravesical instillation or not. 
At each visit (visit one and visit two) of each week all the following assessments were 
performed: hepatic function panel, APTT, Prothrombin time, platelet count, adverse events, 
concomitant medications, O’Leary-Sant Interstitial Cystitis Symptom and Problem Index, Pelvic 
Pain and Urgency/ Frequency Patient Symptom Scale (PUF), Pain Assessment, and subject 
global assessment. 
A 24 hour voiding log was dispensed to all participants at visit two of each week and 
collected back at visit one of the next week prior to instillation. The participant completed the 24 
hour voiding log for any 24 hour they selected during the period in which they had the log. 
The SF-36, HRQL questionnaire, was completed on week four at visit one, while the 
sexual assessment function was completed on week four and week six at visit one of each of the 
previous specified weeks. 
3.8.2 Study Protocol for Assessment Visit: Week 12 
After the completion of the sixth week of the intravesical instillation, participants returned for 
follow-up assessments on the 12th and 18th week of the trial. 
On the 12th week of the trial different follow-up assessments were performed and included: 
• Urodynamic evaluations included: uroflow and ultrasound to measure the post void 
residual   
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 • Laboratory measures included: CBC, BUN, Creatinine, electrolytes, routine urinalysis, 
urine culture and sensitivity, hepatic function panel, APTT, Prothrombin time and platelet 
count  
• A 24 hour voiding log was completed within one week of the week 12th visit 
• A competition of: O’Leary-Sant Interstitial Cystitis Symptom and Problem Index, Pelvic 
Pain and Urgency/ Frequency Patient Symptom Scale (PUF), Pain Assessment and 
Patient Global Assessment 
• Reporting of any adverse events 
• Reporting of any concomitant medications 
3.8.3 Study Protocol for Final Follow-up Visit: Week 18 
Participants had to return again at the 18th week of the trial for the final follow-up which 
included the following: 
• A complete physical examination 
• An urodynamic evaluation included uroflow and ultrasound to measure post void residual 
• Laboratory investigations included: urinalysis, culture and sensitivity, pregnancy test (if 
applicable) 
• A 24 hour voiding log was completed within 1 week, prior to, week 18th visit 
• A competition of: O’Leary-Sant Interstitial Cystitis Symptom and Problem Index, Pelvic 
Pain and Urgency/ Frequency Patient Symptom Scale (PUF), Pain Assessment, Health 
Related Quality of Life Questionnaire (SF-36), Sexual Function Assessment, and Patient 
Global Assessment  
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 • Reporting of any adverse events 
• Reporting of any concomitant medications 
• Self-reported weight and height of the participants  
3.9 METHODS OF PREPARING AND DISPENSING CLINICAL TRIAL 
MEDICATIONS 
Trial medications PPS, for both oral administration and intravesical instillation were provided by 
Ortho-McNeil Pharmaceutical, Inc. in the form of 100 mg capsules.  
3.9.1 Oral PPS (Elmiron®) 
Oral PPS was provided in a ready pharmaceutical form (100 mg capsule) to be directly dispensed 
to study participants. A designated staff from Citrus Valley Medical Research, Inc. was 
responsible for dispensing the oral medication to each participant in the trial. Thirty four PPS 
100 mg capsules were provided to each participant in one bottle each week for the first six weeks 
of the study. This equates to seven days of an oral dose of PPS 200 mg (2 capsules) twice per 
day, morning and evening doses, which equal to a total dose of 400 mg or 4 capsules per day. Six 
additional capsules were dispensed because of the possibility of scheduling conflict of one day. 
Doses for the remaining 12 weeks of the study were dispensed during two visits.  In the second 
visit of the sixth week of the trial, participants were provided 180 capsules divided equally into 6 
bottles (30 capsules /bottle) for each of the upcoming six weeks (until their first follow-up 
assessment visit at week 12 of the trial). Twelve additional capsules (two in each bottle) were 
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 dispensed for the morning dose of the next treatment week, the possibility of scheduling conflict 
of one day, and/ or any unexpected condition. On their first follow-up visit at week 12 
participants were received the last 180 capsules divided equally into 6 bottles (30 capsules 
/bottle) for each of the last six weeks of the trial with another 12 extra capsules (two in each 
bottle) for unexpected condition. 
3.9.1.1 Drug Accountability 
In order to ensure compliance of oral PPS, adequate records on receipts, use, return, loss or other 
disposition of study medication were maintained. A specific study medication accountability 
form supplied by Ortho-McNeil Pharmaceutical was used for that purpose. All bottles of oral 
PPS which were dispensed at each visit were returned at each subsequent visit and were retained 
for verification. 
3.9.2 Intravesical PPS 
Treatment arm received intravesical instillation of PPS 200 mg (2 capsules) mixed in 30           
ml of sterile normal buffered saline twice a week for the first six weeks. 
Preparation of the intravesical PPS was assigned to an independent pharmacist who was 
un-blinded to the randomization code in order to prepare the appropriate solution for instillations. 
This person complied with the double blind requirement of the study and charged for preparing 
the intravesical instillations. 
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 3.9.2.1 Procedures of Intravesical PPS Preparation 
Sterile intravesical PPS was prepared using the following procedures: 
• The content of two 100 mg Elmiron® capsules is emptied into a 30 ml of sterile buffered 
normal saline inside the B-D LAMINAR FLOW STERILE HOOD 
• The above solution stands for a maximum dissolution for 30 minutes followed by 
filtration through a particulate matter filter (4.5 microns)  
• A re-filtration is performed through another 4.5 microns filter until the solution becomes 
clear 
• A final filtration is done through a 0.22 micron filtered for sterilization 
• The final filtrate is placed in a sterile empty vial 
The final product must be administered within 4 hours of preparation, for that reason, 
intravesical instillation was labeled within a four hour expiration time. 
3.10 PROCEDURES FOR CATHETERIZATION AND INTRAVESICAL 
INSTILLATION OF THE STUDY PRODUCT 
The following procedures were used in both the intravesical instillation of PPS or placebo and 
were done by either the principal investigator of the study or a well-trained nurse under the 
supervision of the principal investigator: 
• The participant was asked if she wish to void  
• The participant had to drink 8 oz of ArrowheadTM Mountain Spring water 
• The principal investigator explained the complete procedure and the needed time to the 
participant 
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 • Privacy was provided to the participant to prepare herself and lay in the required position 
• Principal investigator or the nurse had to wash his or her hand and to wear sterile powder 
free synthetic surgical gloves 
• A 8F LoFric® catheter was used in all intravesical instillation procedures and was 
prepared according to standard criteria listed on its package (sterile water was used as 
wetting solution) 
• A 4 oz sterile specimen cup was removed from packaging to be used during the process 
to collect any post void residual (urine sample) 
• Antiseptic solution of antimicrobial soap was prepared to be used during catheterization 
and instillation  
• Study product was given by the un-blinded staff member directly before instillation 
because of the short expiration period 
• Study product was drawn from the sterile vial into sterile syringe to be ready for use 
• The perineal area was cleaned with the previously prepared antiseptic solution 
• A preparatory prophylaxis (Lidocaine Hydrochloride Jelly, USP 2% 100 mg (20 mg/ml)) 
was applied to the catheter tip first and then to the perineum. The purpose of the 
prophylaxis was to prevent urethral spasms and the perineal sensitivity 
• Under sterile conditions, the LoFric® catheter was introduced into the bladder by either 
the principal investigator or the nurse under the supervision of the principal investigator 
• Any post void residual was emptied into the sterile specimen 4oz cup (sent for urine 
culture and sensitivity test at visit one from each week) 
• The previous procedures were done as part of the prophylaxis part of the instillation 
process 
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 • Before instilling the study product, an intravesical instillation of 8 ml of 1% Lidocaine 
and 3 ml of 8.4% sodium bicarbonate was instilled into the bladder  
? The purpose of instilling the 8 ml of 1% Lidocaine was to provide a topical and 
short acting anesthetic to the bladder membrane, thus prevent bladder and urethral 
spasms, and the possible uncontrolled expulsion of the study medication or placebo 
from the bladder. The effect of the topical anesthetic of the 1% Lidocaine is sixty to 
ninety minutes 
? The purpose of instilling the 3 ml of 8.4% sodium bicarbonates was to prepare the 
bladder membrane for the absorption of the 1% Lidocaine by alkalizing the acids in 
any urine residual  
• Five minutes was given as a waiting period for the full effect of the bladder lining 
preparation of the prophylactic short acting anesthetic 
• After those five minutes, the intravesical instillation of either  PPS or placebo was 
conducted followed by removing the catheter, and asking the participant to retain the 
solution for a minimum of thirty minutes to a maximum of sixty minutes 
• Time at which the instillation completed was recorded 
• The participant was asked to drink 8 oz of ArrowheadTM Mountain Spring water 
• The participant was asked to clean the perineal area to remove antiseptic solution 
• The participant was asked to void to get out the study product, in case she cannot void 
within one hour of catheterization. 8F LoFric® catheter was used again to remove the 
study solution 
• Time of voiding was recorded as well 
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 3.11 COLLECTING URINE AND BLOOD SPECIMENS  
According to the study flow chart, urine specimens were collected for both urine analysis and 
urine culture and sensitivity as follows: 
• At week one through week six (in both visit one and visit two of each week) before each 
intravesical instillation a clean catch urine specimen was collected for urine analysis 
(using a reagent strip, a Multistix® 8SG), to rule out a urinary tract infection before the 
study instillation was performed 
• At week one through week six (in visit one of each week) at the time of catheterization 
and prior to intravesical instillation a sterile catheterized urine specimen was collected for 
laboratory use for a documented urine culture and sensitivity test 
• Blood specimens were drawn one hour post the completion of study drug instillation for 
the purpose of assessing any effect on hepatic function panel, APTT, prothrombin time, 
and platelet count 
3.12 LABORATORY MEASURES  
All laboratory measures included CBC, BUN, Creatinine, electrolytes, routine urinalysis, urine 
culture and sensitivity, hepatic function panel, APTT, prothrombin time, and platelet count were 
performed in one single lab to ensure the reliability of these measures. 
Quest Diagnosis Inc.; California was responsible for all the laboratory analysis of the present 
study. It used fixed standard norms during the whole study period. 
 
 145
 3.13 ETHICAL CONSIDERATION, DECLARATION OF HELSINKI AND IRB 
APPROVAL 
Ethical approval was obtained for the whole study protocol as well as informed consent. The 
study was conducted according to the principles of the Declaration of Helsinki and part 50 of the 
FDA code of Federal Regulations Title 21 (Appendix J). 
IRB approval was obtained from IRB board of Foothill Presbyterian Hospital, Glendora, 
CA, and IRB board of the University of Pittsburgh, PA (Appendix K). The protocol of the study 
was also approved by Food and Drug Administration (FDA) and Ortho-McNeil Pharmaceuticals, 
Inc. 
3.14 STATISTICAL ANALYSIS 
SPSS version 13.0 (SPSS, Inc., Chicago IL) and Stata version 10 (StataCorp LP., College Station 
TX) were used to conduct all statistical analyses. 
3.14.1  Justification of the Statistical Analysis Approach 
In order to be able to use parametric methods in statistical analysis, several assumptions related 
to the distribution of the data must be hold. If these assumptions about the shape of the 
distribution are not made, and if the central limit theorem also inapplicable, because the sample 
size is small, then non-parametric methods, which require fewer assumptions about the shape of 
the distribution, must be used. 201 
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 Sample size is an important factor that often limits the applicability of tests based on the 
assumption that the sampling distribution is normal. We can assume that the sampling 
distribution is normal even if we are not sure that the distribution of the variable in the 
population is normal as long as the sample size is large enough (e.g., 100 or more observations). 
202 Thus, the inferences of the parametric technique are based on the large sample properties.  
With our sample size of 40, the properties may not be applied. Therefore, the general analytical 
approach that we used to assess the study aims was the non-parametric one.  
As we mentioned previously in the recruitment section (3.2.4.) of this chapter, two subjects 
dropped out; subject one dropped out directly after randomization and before giving us any 
chance to collect her baseline data (placebo group) while subject two dropped out after 4 weeks 
of the study due to clinical reason related to her medical history and not to the trial intervention 
(treatment group). In order to keep the projected sample size of 40, two additional subjects were 
recruited; the first of them received the same intervention that was assigned to subject one while 
the second case received the same intervention that was assigned to subject two. In total, 42 
subjects signed an informed consent, of whom 40 subjects received all the required instillations 
of either PPS or placebo. All the available data at baseline were used to assess the first three aims 
of the current study (n=41). For the rest of the study’s aims which were based on clinical trial 
design, intention to treat analysis approach with Last Observation Carried Forward method 
(LOCF), to deal with missing and dropouts, were used (treatment group: n=21, placebo group: 
n=20).  
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 3.14.2 Power Calculations 
This is a single center pilot project in the design of double blind randomized placebo-controlled 
trial.  Preliminary data showed that using intravesical instillation of PPS can reduce the O’Leary-
Sant Interstitial Cystitis Symptom Index score from 14.3 to 11.1 (about 3.2 over an average) 
during a treatment period of 17.59 week. 38 This justifies the use of a sample size of 40 
assessable patients (20 per arm) in this trial. This sample size provided 80% power to detect a 
difference of 2.25 in the mean total O’Leary-Sant Interstitial Cystitis Symptom Index score at 
endpoint between the treatment group and the placebo group (based on two sample t test with SD 
of 2.5, and a significant level of alpha =0.05, two sided). 
Because we used non-parametric analysis approach to assess the aims of the present 
study, no power calculation was performed for any of our aims.  
3.14.3 General Descriptive Statistical Analysis 
As a first step, general descriptive analyses were performed at baseline for the total study 
population (n=41) as well as by the study groups (treatment group =21, placebo group = 20) to 
provide a complete and a clear description of the current study population, and to assess if the 
randomization process produced two comparable groups or not. 
3.14.3.1 Descriptive Statistics at Baseline  
Descriptive statistics included socio-demographic (age, race, educational level, employment 
status, marital status), lifestyle (smoking history, BMI), reproductive history (age at menarche, 
ever pregnant, number of pregnancy, menopausal status, type of menopause, use of hormone 
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 replacement therapy (HRT) and oral contraceptive (OC)), clinical characteristics (cystoscopic 
findings, severity of IC symptoms, number of co-morbid conditions, concomitant treatments, 
voided volume), scores of all instruments that were used to assess IC symptoms (O’ Leary Sant 
IC Symptom Index and Problem Index, PUF, pain assessment, urgency assessment, number of 
voids during waking hours and number of voids during night), scores of HRQL domains (SF-36) 
and scores of sexual function domains (sexual assessment visual analog scales) were performed 
at baseline for the total study population and by the study groups. Continuous variables were 
presented as median (25th and 75th percentiles), while categorical variables were presented as 
proportions. Fisher’s exact test and Chi-square test were used to examine if there were 
differences between the two groups (treatment and placebo) for categorical variables, while 
Mann-Whitney U test (the non-parametric version of the two independent samples t test) was 
used if the variables were continuous.  
3.14.3.2 Oral PPS Compliance 
Because both groups administered oral PPS during the entire study period and because it is well 
known that oral PPS has a significant improvement effect on IC symptoms, 27-30, 32, 33 it was very 
important to assess oral PPS compliance by study groups. We wanted to be sure that both groups 
achieved similar level of oral PPS compliance during the entire study period and during the first 
six weeks of the trial in particular (when one group received the intravesical therapy while the 
other received the placebo). In this way we were able to identify if the compliance was a 
potential confounder in the current study or not. 
The proportion of oral PPS compliance was calculated for each week of the trial by 
dividing the total number of capsules that was administered ( the number of dispensed capsules – 
the number of returned capsules) during that week by 28 capsules (the total number of capsules 
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 that the participants should administer during each week). Oral PPS compliance during each six 
weeks period (first six weeks, second six weeks and third six weeks) was the average of the 
weekly compliance during each six week period (for example, the compliance during the first six 
weeks was the summation of the compliance in week 1, 2,3,4,5 and 6 divided by 600). 
3.14.4 Statistical Analysis for the First Aim 
Our first aim was: To determine to what extent socio-demographic, lifestyle, reproductive and 
clinical factors are associated with symptom severity and impairment in HRQL in women 
diagnosed with IC. 
We hypothesize that age, education, smoking history, menopausal status, and co-morbid 
conditions will be associated with symptom severity, and that the same factors, with the 
exception of smoking history, will also be associated with impairment in HRQL in women 
diagnosed with IC. 
All available data at baseline (n=41) were used to assess this aim. Two main stages were 
performed as described below: 
3.14.4.1 Data Management and Manipulation 
3.14.4.1.1 Preparing HRQL Domain Scores 
Data from the SF-36 questionnaire were entered using SPSS statistical software. In order to be 
able to calculate scores for the different domains of the SF-36, 10 items in the SF-36 were 
recoded (reversed and/or recalibrate). Those 10 items scattered in 5 different scales: bodily pain, 
general health, vitality, social functioning, and mental health. The main idea behind that is to 
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 ensure that a higher item value indicates better health on all the SF-36 items and scales. Missing 
item responses were recorded with mean substitution if a respondent answered at least half of the 
items in a multi-item scale (or half plus one in the case of scales with an odd number of items). 
177 Raw domain scores were calculated by adding the raw scores of the items that form each 
domain. All domain raw scores were converted into the final scores that range from 0-100 using 
a specific formula described in the SF-36 health survey manual and interpretation guide. 177 This 
step is important to enable the researchers from comparing their results with other published 
results of the SF-36. Score checking (calculating scores for randomly selected cases by hand, 
testing correlations between items and domain, etc) 177 was performed to ensure that all scores 
were calculated correctly. Finally, norm-based scores were calculated for each of the eight 
domains through using the means and the standard deviation of the 1998 general US population 
score for the corresponding SF-36 scale as described in physical and mental summary scales user 
manual. 184  
3.14.4.1.2 Preparing IC Symptom Severity Score 
Two validated instruments were used to collect data about IC symptoms; The O’Leary-Sant 
Interstitial Cystitis Symptom Index (ICSI), and the Pelvic Pain and Urgency/Frequency (PUF) 
Questionnaire. The first one was designed to evaluate changes in IC symptoms while the second 
one was designed to use as a screening test. Therefore, we used the ICSI mainly to classify IC 
cases into three different classes as follows:  ICSI scores from 0 to 6 = mild symptoms, from 7 to 
14 = moderate and from 15 to 20 = severe symptoms.   An ICSI score of greater than or equal to 
six was found to be 90% sensitive and 95% specific for interstitial cystitis/painful bladder. 23 
Furthermore, these cut of points were used successfully in previous studies. 32 
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 Because only moderate and/or severe cases were included in the current study, we 
decided to use the severity of IC symptom score as a continuous variable rather than categorical 
one. 
3.14.4.2 Analysis Plan 
The main idea from this step was to determine any important covariate that may confound the 
tested association between the severity of IC symptoms and the impairment in HRQL domains in 
the second aim of the current study. 
Univariate associations between the severity of IC symptoms (ICSI score) and each of the 
socio-demographic variables (age, race, marital status, educational levels and employment status 
),  the lifestyle factors (smoking history and BMI), the reproductive factors (ever pregnant, 
number of pregnancy, menopausal status, use of hormone replacement therapy (HRT) or oral 
contraceptive (OC)) and the clinical and  sexual factors (the number of concomitant chronic 
conditions, presence of glomerulations, presence of Hunner’s ulcers, having sexual intercourse, 
sexual desire and sexual arousal) were tested using either non-parametric correlation for 
continuous variables or Mann-Whitney U test and Kruskal-Wallis test for categorical variables. 
The same analyses were performed to assess the univariate associations between each of the 
above listed factors and the eight HRQL domains of the SF-36 instrument. 
Multivariate median regression were performed to assess if the factors which were found 
to be associated with either the severity of IC symptoms or each score of the SF-36 domains in 
the univariate analyses were confounded by age and/ or co-morbidity. 
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 3.14.5 Statistical Analysis for the Second Aim 
Our second aim was: To determine if symptom severity is correlated with impairment in all 
HRQL domains after adjusting for confounders that will be identified from assessing the Specific 
Aim 1 of this study. 
We hypothesize that symptom severity will be associated with impairment in physical 
function, social function and mental health domains of HRQL and that these associations will not 
be significantly altered after adjusting for lifestyle and socio-demographic factors. 
All available data at baseline (n=41) were used to assess this aim. Bivariate non-
parametric correlations between each of the eight domain scores of the SF-36 (physical 
functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotion, 
mental health) and the severity of IC symptoms (ICSI score) were performed.  Non-parametric 
median regression was used to adjust for any possible confounders.  
3.14.6 Statistical Analysis for the Third Aim 
Our third aim was: To determine which symptom (pain, urinary frequency, nocturia and/or 
urgency) is most likely to impair IC patients’ HRQL represented by Physical Component 
Summary (PCS) and Mental Component Summary (MCS) of the SF-36 instrument.  
We hypothesize that there will be variability in the effect of each symptom on PCS and 
MCS scales, and that pain will be the symptom most likely to impair both summary components. 
All available data at baseline (n=41) were used to assess this aim. The statistical analysis 
to assess this aim consisted of two main stages as follows: 
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 3.14.6.1 Data Management and Manipulation 
The main dependent variable was the score for each of the physical and mental summary scales. 
The main independent variables were baseline pain scores (general pain and pain during 
urination using pain assessment scale), urinary frequency (from voiding log), nocturia (from 
voiding log) and urgency score (urgency scale). 
The algorithm published in the SF-36 physical and mental health summary scales user 
manual 184 was applied to the SF-36 SPSS file. Three main steps were performed to calculate the 
two summary scales PCS and the MCS as follows: 
? The first step was standardizing each of the eight scales of the SF-36 by using a Z-score 
transformation. A Z-score for each scale was computed by subtracting the mean of the 
1998 general US population score from each SF-36 scale and dividing the difference by 
the corresponding scale standard deviation. 
? The second step involved the computation of the aggregate scores for the physical and 
mental components using the physical and mental factor score coefficients from the 
1990 general US population. For example, to compute the aggregate physical 
component score, each SF-36 scale, Z score from the first step was multiply by its 
respective physical factor score coefficient this was followed by summing the eight 
products. 
? The last step was the transformation of each component score to norm-based scores 
(mean=50, SD=10). This was done by multiplying each aggregate component scale 
score by 10 and adding the resulting product to 50. 
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 3.14.6.2 Analysis Plan 
Because we expect that the occurrence of each of the IC symptoms is not independent of each 
other, which mean patient can suffer from all these symptoms together, the first step of the 
analysis was to perform bivariate non-parametric Spearman correlations between these 
symptoms to determine the degree of dependency. Possible confounders for the associations 
between each of the IC symptoms and each of the summary component scales were determined 
by univariate analyses. Non-parametric Spearman correlations between each of the IC symptoms 
and each summary scale (PCS and MCS) separately were performed to determine the unadjusted 
associations. Finally multivariate median regression was used to adjust for the main study 
covariates as well as all other well known covariates. 21, 203 
3.14.7 Statistical Analysis for the Remaining Aims 
Using the clinical trial design, the remaining aims (the fourth, fifth, sixth, seventh, eighth and 
ninth) were assessed. These aims test the efficacy of the trial treatment on the following four 
main outcomes: 
• IC symptoms through the fourth and fifth aims  
• Proportion of responders through the sixth aim 
• HRQL domains and the two summary scales (PCS and MCS) through the seventh and 
the eighth aims  
• Sexual function domains through the ninth aim 
Table 3-1 provides a summary of all these outcomes and the main measurement tools 
that were used to collect them as well as the main endpoints. The statistical analyses for the 
remaining six aims were performed in two main stages as follows: 
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 3.14.7.1 Descriptive Statistical Analysis 
As a first step in assessing the remaining six aims of the current study, time plots (stratified by 
study groups) of the median scores of the following outcome measures were performed; thus we 
have a complete picture about the change in the main study outcome over time: 
• The PUF total score (1-35) as well as its components (symptom score (1-23) and 
bothering score (0-12))  
• The O'Leary-Sant total score (0-36) as well as its components (symptom index score 
(0-20 and problem index score (0-16))  
• The pain assessment score, urgency score, urinary frequency and nocturia  
• The median of PCS and MCS  
• The median of each of the SF-36 domain  
• The median of both the sexual desire and sexual arousal scale  
3.14.7.2 Testing the Efficacy of the Trial Intervention  
Although the performed statistical analyses for the last six aims were approximately similar, we 
preferred to present the analysis for each aim separately for the reader convenience. 
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  3.14.7.2.1 Statistical Analysis for the Fourth Aim 
Our fourth aim was: To determine if the intravesical instillation of PPS plus the administration 
of oral PPS will reduce symptom severity more than oral PPS plus intravesical placebo at the 
following endpoints: week 6, week 12, and/or week 18 of the trial.  
We hypothesize that the use of both intravesical PPS and oral PPS for the first 6 weeks 
of the trial will improve IC symptoms significantly more than the use of oral PPS and 
intravesical placebo. 
This study used two validated instruments to collect data about the overall severity of IC 
symptoms; the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and the Problem Index 
(ICPI), 23 and the Pelvic Pain and Urgency/Frequency (PUF) Questionnaire.24  
The O’Leary-Sant composes of two indices. The ICSI includes questions about the main 
four IC symptoms (urgency, urinary frequency, nocturia, and pain), while the ICPI assess how 
much each symptom has been a problem for a patient. Thus it gives a complete picture of IC. 23 
On the other hand, the PUF includes questions that assessed how sexual activity may affect by 
IC symptoms, specifically pain and urgency. PUF also includes questions about the four main IC 
symptoms and how much they bother the patient. 24 Thus each instrument may provide extra 
information over the other one, for that reason we used both instruments to assess this aim. 
To test our fourth aim, changes in the total score of the O’Leary-Sant and the PUF 
instruments as well as in their components (ICSI & ICPI of O’Leary-Sant, symptom score & 
bother score of PUF) were calculated by subtracting scores at each of the above specified 
endpoints from baseline scores. Negative sign was inserted to indicate a reduction in symptom 
severity (equates improvement). As a first step, it was of great interest for us to test if there were 
significant change in the scores of the O’Leary-Sant, the PUF instrument and their components 
 157
 from baseline to each endpoint in each arm separately. Wilcoxon signed-rank test (the non-
parametric version of the paired t test) was used for that. On the other hand, Mann-Whitney U 
test (the non-parametric version of the two independent samples t test) was used to assess if the 
change in the total score of the O’Leary-Sant and the PUF instruments as well as their 
components from baseline to each endpoint in the treatment group was greater than that in the 
placebo group.  
3.14.7.2.2 Statistical Analysis for the Fifth Aim 
Our fifth aim was: To determine which symptom (pain, urgency, nocturia and/or urinary 
frequency) is most likely to be improved as a result of administering either intravesical PPS plus 
oral PPS or intravesical placebo plus oral PPS at the following endpoints: week 6, week 12, 
and/or week 18 of the trial.   
We hypothesize that pain will be the most improved symptom as a result of 
administering either intravesical PPS plus oral PPS or intravesical placebo plus oral PPS at each 
endpoint. 
To test this aim, changes in pain score (general pain), urgency score, urinary frequency 
and nocturia were calculated from baseline to each of the above specified endpoint. Negative 
sign was inserted to indicate a reduction in the severity of each symptom (equates improvement). 
Wilcoxon signed-rank test was used to determine if these changes at each endpoint were 
significant in each study arm separately.   
It was also of great interest for us to test if the change in each outcome was significantly 
more among the treatment group in comparison to the placebo group at any of the specified 
endpoint. Mann-Whitney U test was used for that. 
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 3.14.7.2.3 Statistical Analysis for the Sixth Aim 
Our sixth aim was: To determine if the proportion of responders (defined by those who reported 
any improvement through patient global assessment instrument) is significantly more among 
those who received both intravesical PPS and oral PPS (treatment group) in comparison to those 
who received intravesical placebo and oral PPS (placebo group) by the end of the study (at week 
18). 
We hypothesize that the proportion of responders will be significantly more among the 
treatment group compared to the placebo group at week 18 of the study. 
To assess this aim, responders were defined as those who evaluated the changes in their 
overall IC condition, urinary frequency and/or their urgency since enrollment as improved 
through the patient global assessment instrument at the end of the study. Chi-square or Fisher’s 
exact test was used to test if the proportion of responders among the treatment group was 
significantly greater than that among the placebo group. Because the current study included only 
moderate or severe IC cases, it was also of great importance to determine the level of 
improvement among responders (moderately improved, greatly improved or completely 
improved) in each group and to test if the differences were statistically significant using Chi-
square or Fisher’s exact test as required. 
3.14.7.2.4 Statistical Analysis for the Seventh Aim 
Our seventh aim was: To test if the intravesical instillation of PPS plus the administration of 
oral PPS will improve IC patients’ HRQL represented by Physical Component Summary (PCS) 
and Mental Component Summary (MCS) of the SF-36 more than intravesical placebo plus oral 
PPS at week 4 and/or at the end of the trial (at week 18). 
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 We hypothesize that the use of both intravesical PPS and oral PPS will improve HRQL 
in IC patients significantly more than the use of intravesical placebo plus oral PPS at both 
endpoints. 
To test this aim, changes in PCS and MCS were calculated from baseline to each of the 
above specified endpoint. Negative sign was inserted to indicate a reduction in the score of the 
two components of the quality of life (equates impairment). As a first step, Wilcoxon signed-
rank test was used to determine if these changes at each endpoint were significant in each study 
arm separately. Then, Mann-Whitney U test was used to test if the change in each summary 
component was significantly more among the treatment group in comparison to the placebo 
group at any of the specified endpoint. 
3.14.7.2.5 Statistical Analysis for the Eighth Aim 
Our eighth aim was: To determine which domain of HRQL is most likely to be improved as a 
result of administering either intravesical PPS plus oral PPS or intravesical placebo plus oral PPS 
at week 4 and/or at the end of the trial (at week 18).  
We hypothesize that the use of either intravesical PPS plus oral PPS or intravesical 
placebo plus oral PPS will not have the same improvement effect on all HRQL domains at both 
endpoints, and that administering intravesical PPS plus oral PPS will significantly improve all 
HRQL domains by the end of the trial.  
The results from the seventh aim give a general idea about the effect of the trial treatment 
on HRQL represented by the summary components. This aim provides more details about the 
previous aim and determines the exact domains that improved as a result of the trial treatment. 
To test the eighth aim, changes in each domain of the SF-36 from baseline to each of the 
above specified endpoint were calculated. Negative sign was inserted to indicate a decrease in 
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the score of the domains of the quality of life (equates impairment). Wilcoxon signed-rank test 
was used to determine if these changes at each endpoint were significant in each study arm 
separately.   
It was also of great interest for us to test if the change in each domain was significantly 
more among the treatment group in comparison to the placebo group at any of the specified 
endpoint. Mann-Whitney U test was used for that. 
3.14.7.2.6 Statistical Analysis for the Ninth Aim 
Our ninth aim was: To determine if the administration of both intravesical PPS and oral PPS 
will improve sexual function more than intravesical placebo and oral PPS at week 4 and/or at the 
end of the trial (at week 18).  
We hypothesize that the use of both intravesical PPS and oral PPS will improve sexual 
function of IC patients more than the use of intravesical placebo and oral PPS at both endpoints.  
Similar to the above described analyses, changes in sexual desire score and sexual arousal 
score from baseline to each endpoint were calculated. Negative sign was inserted to indicate a 
reduction in the score of the sexual function domains (equates impairment). This was followed 
by testing if these changes from baseline to each endpoint were significant in each treatment 
group using Wilcoxon signed-rank test. Mann-Whitney U test was used to test if these changes 
were significantly more among the treatment group in comparison to the placebo group at each 
endpoint. 
 4.0  RESULTS 
4.1 RECRUITMENT AND FLOW DIAGRAM OF SUBJECT PROGRESS 
All the study subjects were recruited from the patients of the study clinical site (Citrus Valley 
Medical Research Inc., Glendora, CA) during the period from April 2004 to August 2006. 
Initially, 40 subjects were assessed for eligibility and participated in the trial. Two subjects 
dropped out; the first subject (placebo group) did not start the study because of a conflict with 
her work schedule while the second subject (treatment group) discontinued receiving the trial 
intervention after 4 weeks of the study because she had water retention which was not related to 
the trial intervention. Therefore, another two subjects were enrolled; the first of them received 
the same intervention that was assigned to the first drop out while the second received the same 
intervention that was assigned to the second drop out. At the end of the trial, 40 subjects 
completed all the required instillations of either the PPS or the Placebo during the first six weeks 
of the study. There was one early termination (at week 12) among the placebo group; she 
received intravesical heparin after week 12 of the trial (a medication that was not allowed per the 
trial protocol) thus, she became no longer evaluable. 
Intention to treat analysis (ITT) approach with last observation carried forward (LOCF) 
method (to handle missing) was used. This resulted in a total of 41 participants (treatment =21, 
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 placebo =20) available for the final analysis. Figure 4-1 provides a flow diagram of subjects’ 
progress during each phase of the study. 
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            *Reprinted with permission from Journal of Urology, 2008; 179(1): 177-85, Edward L. Davis, Samar R. El Khoudary, Evelyn O. Talbott,      
Josephine Davis, Lisa J. Safety and Efficacy of the Use of Intravesical and Oral Pentosan Polysulfate Sodium for Interstitial Cystitis: A 
Randomized Double Blind Clinical Trial. Copyright© 2008 Elsevier. 
 
        Figure  4-1: Flow Diagram of Subjects' Progress Through the Phases of the Trial * 
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 4.2 DESCRIPTIVE RESULTS  
4.2.1 Descriptive Results for the Total Study Population (n = 41) at Baseline 
4.2.1.1 Socio-Demographic Profile  
This was a convenience sample of IC patients identified by physicians at Citrus valley Medical 
Research Inc. Glendora, CA. All study subjects were females diagnosed with IC within one year 
of the beginning of the study, and previously untreated with either intravesical or oral PPS. The 
median age was 37.8 years old with a wide range from 20 to 71 years old. In spite of this wide 
range, subjects were distributed uniformly (~ 25% in each category) into four different age 
groups as follows: 20-29, 30-39, 40-49 and 50+. The majority of the study participants were 
Caucasian ~71% (29/41). Moreover, Hispanic constituted ~20% (8/41) while the remainder 
proportion ~9% (4/41) included Black, Asian and other races. Approximately 56% (23/41) of the 
study subjects were married, ~24% (10/41) never married, ~12% (5/41) divorced and ~7% (3/41) 
were classified as either widowed or other status. Interestingly, ~68% (28/41) of our study 
population had at least post-secondary education (≥13 years of education) while ~29% (12/41) 
had secondary education (9-12 years of education) and only 1 subject had elementary education 
(≤ 8 years of education). Therefore, 40 subjects had at least a high school degree. Although our 
study subjects were moderate to severe IC cases, 78% (32/41) were able to maintain 
employment. Of those who were employed, about 28% (9/32) classified their job area as 
professional, ~22% (7/32) as managerial/administration, ~9% (3/32) as clerical, ~9% (3/32) as 
service and ~31% (10/32) as other. The nine unemployed subjects were classified as homemaker 
(6/9) or unemployed not disabled (2/9) or unemployed disabled (1/9). Table 4-1 shows the 
baseline demographic of the total study population. 
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    Table  4-1: Baseline Demographic Characteristics of the Total Study Population (n=41) 
CHARACTERISTICS N BASELINE DATA   
 
Age                     
Median  
(25th percentile , 75th percentile) 
 
41  
37.8 
(28.1, 44.9) 
Age Categories  % 
20-29                     
30-39                     
40-49                     
50+                    
41
11 
12 
10 
8
 
26.8 
29.3 
24.4 
19.5 
 
Ethnicity           % 
Caucasian              
Black                     
Hispanic                
Asian                     
Other                     
 
41
29 
2 
8 
1 
1
 
70.7 
  4.9 
19.6 
  2.4 
  2.4 
Marital Status   % 
Married                   
Widowed               
Divorced             
Never Married    
Other                      
 
41
23 
1 
5 
10 
2
 
56.1 
  2.4 
12.2 
24.4 
  4.9 
Education   (years)         
Median  
(25th percentile , 75th percentile) 
 
41  
14 
(12, 15) 
 
Education         % 
Elementary              
Secondary               
Post-Secondary        
 
41
1 
12 
28
 
  2.4 
29.3 
68.3 
Employment      % 
Employed                
Not Employed         
40
32 
9
 
78 
22 
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4.2.1.2 Reproductive and Lifestyle Profile  
Table 4-2 shows the main reproductive and lifestyle factors of the current study participants. The 
median age at menarche was 13 years old; 75% of the study subjects reached puberty age at 13.5 
years old or younger. About 76% (31/41) of the participants were ever pregnant and 
approximately half of them (17/31) had from 1 to 2 pregnancies while the remainder had either 
3-4 pregnancies (9/31) or 5+ pregnancies (5/31). More than half of the subjects ~63% (26/41) 
were not menopausal (had menstrual period during the previous 12 months of the baseline 
interview). For those who reached menopause ~37% (15/41), the main type of menopause was 
surgical ~ 60% (9/15) while natural menopause was reported by 33% (5/15) and menopause as a 
result of drug therapy by ~7% (1/15). About 88% (36/41) of the current study population ever 
used oral contraceptive while ~29% (11/38) ever used hormone replacement therapy.  
In term of the main lifestyle factors about the current study population: smoking history 
and Body Mass Index (BMI); more than 50% of the participants were ever smoked (24/41). The 
median BMI was 24.4 Kg/m2. Moreover, more than 50% of the current study population fall into 
the normal and/or underweight category (BMI < 25 Kg/m2) while ~29% were classified as over 
weight (BMI: 25 Kg/m2-29 Kg/m2) and ~17% were considered as obese (BMI ≥ 30 Kg/m2) 
according to the CDC definitions. 204 
 
 
 
 
 
 
     Table  4-2: Baseline Reproductive and Lifestyle Characteristics of the Total Study    
    Population (n=41)  
CHARACTERISTICS N BASELINE DATA    
Age at Menarche  (Year)      
Median  
(25th percentile , 75th percentile) 
 
41  
13 
(12, 13.5) 
Ever Pregnant                % 
Yes                                    
No                                      
 
41
31 
10 
 
75.6 
24.4 
Number of Pregnancies  % 
1-2                                       
3-4                                       
5+                                          
 
31
17 
9 
5
 
54.8 
29.0 
16.2 
 
Menopausal Status         %                 
Menopause                        
Not Menopause                 
 
41
15 
26
 
36.6 
63.4 
Type of Menopause       % 
Surgical                             
Natural                              
Drug Therapy                    
 
15
9 
5 
1
 
60 
33 
  7 
Ever Used OC                % 
Yes                                    
No                                      
 
41
36 
5
 
87.8 
12.2 
 
Ever Used HRT A           % 
Yes                                      
No                                        
  
38
11 
27
 
28.9 
71.1 
Ever Smoked                  % 
Yes                                       
No                      
41
24 
17
 
58.5 
41.5 
 
BMI B  (Kg/m2) 
Median  
(25th percentile , 75th percentile) 
 
41  
24.4  
(21.9, 27.5) 
BMI B                              %  
< 25 Kg/m2  
25-29 Kg/m2 
≥ 30 Kg/m2 
 
41
22 
12 
7
 
53.7 
29.3 
17.1 
 
A Three were missing at baseline 
B  BMI: body mass index. BMI was based on self-reported weight and height at week18 
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 4.2.1.3 Clinical Characteristics Profile  
Table 4-3 summarizes the major clinical characteristics of the study participants. According to 
the O’Leary-Sant IC symptom index score categories, our subjects were classified as either 
having moderate ~46% (19/41) or severe IC symptoms ~51% (21/41). Only one participant was 
classified as having mild IC symptoms. According to the results of cystoscopy with 
hydrodistension, all the study subjects had glomerulations. Furthermore, ~76% (31/41) of them 
had severe glomerulations while ~15% (6/41) had moderate glomerulations and ~9% (4/41) had 
mild glomerulations. Hunner’s ulceration was found among ~15% (6/41) of the study subjects. 
Interestingly, the subject who was classified as having mild IC symptoms according to the 
O’Leary-Sant IC symptom index score categories can be reclassified as severe IC case based on 
the results of her cystoscopy with hydrodistension. In fact, she had severe glomerulations and 
two Hunner’s ulcerations.  
Because of the complexity of IC condition and the multifactorial etiologies, patients often 
cannot use only one medication to manage their devastating symptoms. As we mentioned 
previously, IC treatment is currently prescribed on the basis of a patient’s symptoms. Therefore, 
the study participants were allowed to continue using their medications while participating in the 
study. About 76% (31/41) of the participants used antihistamines during the study period, ~56% 
(23/41) used narcotics and/ or analgesics, ~ 54% (22/41) used antidepressants and ~34% (14/41) 
used antispasmodics. Several co-morbid conditions were reported among study population such 
as endometriosis, irritable bowel syndrome, stress, depression, fibromyalgia…etc. The median 
number of co-morbid conditions was 3, and 75% of the participants had 5 or less co-morbid 
conditions. In terms of the voided volume at baseline, both the results from urodynamics and 
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 cystometrogram showed small bladder capacity of the study participants. The median bladder 
capacity based on urodynamics was 153 ml while it was 131 ml based on cystometrogram. 
 
   Table  4-3: Clinical Characteristics of the Total Study Population at Baseline (n=41)  
CHARACTERISTICS N BASELINE DATA   
Severity of IC Symptoms A   %                 
Mild            (0-6) 
Moderate    (7-13) 
Severe        (14-20) 
 
41
1 
19 
21
 
  2.4 
46.3 
51.3 
Glomerulations  % 
Yes 
No 
 
41
41 
0
 
100 
    0 
Severity of Glomerulations B    %        
Mild 
Moderate 
Severe 
 
41
4 
6 
31
 
  9.7 
14.6 
75.7 
Hunner’s Ulcers % 
Yes 
No 
 
41
6 
35
 
14.6 
85.4 
Types of Concomitant Medications C   % 
Narcotics and/or  Analgesics             (yes) 
Antihistamines                                   (yes) 
Antispasmodics                                  (yes) 
Antidepressants                                  (yes) 
 
41
23 
31 
14 
22
 
56.1 
75.6 
34.1 
53.7 
Number of Co-morbid Condition D 
Median (25th percentile , 75th percentile) 
 
41  
   3 (2, 5) 
Uroflow Volume (ml) E 
Median  (25th percentile , 75th percentile) 
 
41  
153 (72.5, 231) 
Cystometrogram (CMG) (ml) F 
Median (25th percentile , 75th percentile) 
 
33  
131 (72.5, 230) 
A    Severity of IC symptoms was based on the O’Leary-Sant Interstitial Cystitis Symptom Index score, range from 0-20 
B    Severity of glomerulations was based on the following clinical definitions developed by the PI: 
Glomerulations: Being a red, ulcerative bladder lesion that looks like a stain “glomerulations that is a collection of capillaries in one area.  
In the bladder these lesions are not a collection of capillaries but they are areas of local inflammation most likely caused by a collection 
of mast cells suddenly degranulating and causing an intense local inflammatory reaction, I.E. ulceration and bleeding 
Mild glomerulations: Few submucosal glomerulations i.e. 0-2-5 lesions per cystoscopic view, associated with submucosal vascular 
injection.  Vascular injection meaning that the mucosa turns red but there are none to only a few glomerulations 
Moderate glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are greater than 10 but 
less than 15 glomerulations per cystoscopic view 
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Table 4-3 Cont’d 
Severe glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are submucosal 
glomerulations too numerous to count in nearly all of the bladder cystoscopic views.  This can be with or without “Hunner’s Ulcers”, 
which are patches of bladder membrane where glomerulations blend into a large greater than 1.0cm, patch of bladder tissue 
C  The concomitant medications was defined as follows: Antispasmodics (Oxytrol, Detrol LA, Ditropan XL, Sanctrua, Vesicare), Cyclic 
antidepressants (Elavil, Zoloft), Antihistamines (Allerga, Clarinex,Nyquil, Atarax), Analgesics and Narcotics (Ultracet, pyridium, 
Vicodin, Darvocet, Ambien, Morphine, Lidocaine) 
D  Co-morbid conditions were conditions that were active during the trial or may exacerbate IC symptoms e.g.: endometriosis, irritable 
bowel syndrome, stress, depression, fibromyalgia, hypertension, diabetes...etc. 
E   Based on Uroflowmetry measures. 
F   CMG was too painful for 8 of the study participants; treatment (n=15) and placebo (n=18). 
4.2.1.4 Severity of IC Symptoms  
Table 4-4 shows the severity of IC symptoms in two different ways. The results from either 
O’Leary-Sant instrument or PUF instrument provide a cumulative score that reflects the severity 
of all symptoms together. On the other hand, the results from single scale for each symptom 
show the severity of each symptom independently. The median total score of the O’Leary-Sant 
instrument (0-36) was 26, which indicates severe IC symptoms. Moreover, 75% of the study 
participants reported a total score of 30 or less. In terms of the component indices of the 
O’Leary-Sant instrument, the median score of the symptom index (0-20) was 14 while of the 
problem index (0-16) was 12. O’Leary et al. reported that almost no IC cases had a score less 
than 6 on either component indices, while almost no controls had a score as high as 6.23 The 
results from PUF instrument were consistent with the results from O’Leary-Sant index; the 
median total score of the PUF instrument (1-35) was 22. Moreover, 75% of the subjects reported 
a total score of 25.5 or less. The median score of the PUF symptom component (1-23) was 14 
while of the bother component (0-12) was 8. Interestingly, a PUF total score of 15 or more is 
associated with about 84% chance of having a positive potassium sensitivity test (a strong 
indication of IC). 24  
With regard to the severity of each IC symptom separately; the median level of pain (1-9) 
was 4 (equates moderate level of pain). The median level of urgency (1-5) was 3 (equates 
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 moderate level of urgency). About 50% of the study participants reported 12 voids or less during 
waking hours and 2 voids or less during sleeping hours.  
 
   Table  4-4: Baseline IC Symptom Scores of the Total Study Population (n=41)*  
STUDY MAIN OUTCOMES  BASELINE SCORES 
O’Leary-Sant Total Score (0-36) A 
O’Leary-Sant ICSI B Score (0-20) 
O’Leary-Sant ICPI B Score (0-16) 
 
26 (19, 30) 
14 (10, 16) 
12 (9.5, 14) 
PUF B Total Score (1-35) C  
PUF Symptom Score (1-23) 
PUF Bother Score (0-12) 
 
22 (18.5, 25.5) 
14 (12, 17) 
  8 (6, 9) 
Pain Assessment  Score (1-9) D 
 
  4 (4, 5) 
Urgency Scores (1-5) E, F 
 
  3 (2.6, 3.5) 
Number of Voids During Waking Hours 
 
12 (9.5, 17) 
Number of Voids During  Sleeping Hours 
 
  2 (1, 4) 
   *   Data were presented as median (25th percentile, 75th percentile)   
   A   O’Leary et al. reported that almost no IC patients had a score less than 6 on either index (ICSI, or ICPI), while           
          almost no controls had a score as high as 6 23 
   B  ICSI: Intestinal Cystitis Symptom Index, ICPI: Intestinal Cystitis Problem Index, PUF:  Pain and Urgency/    
         Frequency Patient Symptom Scale 
   C   A PUF total score of 15 or more was associated with about 84% chance of having a positive PST, a strong indication   
         that IC may be present 24 
    D  A score of 1 indicates no pain; a score of 9 indicates severe pain 
    E  Mean of urgency scores from voiding log (24 hour period) 
    F  A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
 
4.2.1.5 Quality of Life of Study Participants (HRQL) 
Tables 4-5 and 4-6 show HRQL scores in comparison to normative samples of the US females 
from the 1990 and the 1998 general social surveys respectively. 177, 184 Table 4-5 shows the 
scores of the SF-36’ eight domains of the current subjects in comparison to a normative sample 
of the US females (ages: 18-65+) from the general social survey, 1990. 177 All the scores in this 
table were presented in the original format: (0-100) as 0 indicates poor HRQL while 100 
indicates excellent HRQL. Interestingly, the scores of the eight domains were much lower than 
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those of the normative sample of the US females. The median score of the physical functioning 
domain among our subjects was 65 compared to 90 among the normative sample; the median 
score of the role-physical domain was 25 compared to 100; of the bodily pain domain was 32 
compared to 74; of the general health domain was 52 compared to 72; of the vitality domain was 
25 compared to 60; of the social functioning domain was 50 compared to 87.5; of the role-
emotional domain  was 33.3 compared to 100 and of the mental health domain was 60 compared 
to 80 among the normative sample. Therefore, our subjects reported the lowest scores (<34) in 
vitality, role-physical, bodily pain and role-emotional domains.  
Table  4-5: Baseline Scores of SF-36 Domains for the Total Study Population and a Normative Sample of USA Females (Ages 
18-65+)/ General Social Survey, 1990 
HEALTH RELATED QUALITY OF LIFE 
DOMAINS A 
CLINICAL TRIAL 
POPULATION  
N=41 
SCORES  
US FEMALE SAMPLE 177 
N=1,412 
NORMS  
 
Physical Functioning 
 
61.5±29.4  
65 (40, 87) 
 
81.5±24.6 
90 (65, 100) 
Role-Physical 
 
31.1±36.6 
25 (0, 50)     
 
77.6±36.2 
100 (50, 100) 
Bodily Pain 
 
33.5±19.5 
32 (22, 41)     
 
73.6±24.3 
74 (52, 100) 
General Health 
 
52.7±22.3 
52 (32, 72)   
 
70.6±21.5 
72 (57, 85) 
Vitality 
 
29.4±20.8    
25 (12.5, 42.5)  
 
58.4±21.5 
60 (45, 75) 
Social Functioning 
 
50.0±33.2 
50 (25, 75)  
 
81.5±23.7 
87.5 (62.5, 100) 
Role-Emotional 
 
51.2±40.2 
33.3 (0, 100)     
 
79.5±34.4 
100 (66.7, 100) 
Mental Health 
 
57.3±19.1 
60 (40, 72)     
 
73.3±18.7 
80 (64, 88) 
*  Data were presented as mean ± SD, median (25th percentile, 75th percentile) 
A  Score for each domain ranges between 0-100: 0 indicates worse HRQL and 100 indicate excellent HRQL 
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Table 4-6 provides norm-based scores of the eight domains and the two component 
summary scales (PCS and MCS) of the SF-36 in comparison to those of a most recent normative 
sample of the US females (ages: 18-65+) from the general social survey, 1998. Calculating the 
norm-based scores of both the SF-36 domains and the two summary component scales makes it 
possible to compare those scores with each others as well as with the norm-based score of the 
normative sample from the US females. Any score above or below 50 is above or below the 
average and each one difference in the score is one tenth of a standard deviation. Both the PCS 
and MCS of the study population were extremely below the average (medians: 37.7, 39.4 
respectively). Moreover, the two summary scores were lower than the norm-based scores of the 
normative sample as well (medians from normative sample: 52.6, 52.3 respectively). Therefore, 
the reader should expect that all the norm-based scores of the domains that constitute the two 
summary components will be below the average (<50). In fact, all the norm-based scores of the 
eight domains were below both the average (<50) and the normative US female sample scores. 
The median score of the physical functioning domain among the study population was 42.5 
compared to that of the normative US female sample (52.9), of the role-physical domain was 35 
compared to 56.2, of the bodily pain domain was 33.6 compared to 50.7, of the general health 
domain was 41.5 compared to 50.9, of the vitality domain was 34.9 compared to 49.1, of the 
social functioning domain was 35.4 compared to 57.1, of the role-emotional domain was 34.3 
compared to 55.3 and of the mental health domain was 41.4 compared to 50.4 among the 
normative USA female sample, 1998. Thus, the current study subjects reported the lowest norm-
based scores (≤35) in bodily pain, role-emotional, vitality and role-physical domains. 
 
Table  4-6: Norm-Based Scores A of the 8 Domains, PCS and MCS/ SF-36 for the Total Study Population at Baseline and a 
Normative Sample of USA Females (Ages 18-65+)/ General Social Survey, 1998 
HEALTH RELATED QUALITY OF LIFE 
DOMAINS 
CLINICAL TRIAL POPULATION  
N=41 
NORM-BASED SCORE 
 
US FEMALE SAMPLE 184
N=1,198 
NORM-BASED SCORE 
Physical Functioning 
 
41±12.3  
42.5 (32, 51.7) 
 
48.6±10.7 
52.9 (44.6, 57.1) 
Role-Physical 
 
36.8±10.3 
35 (28, 42.1)     
 
49.2±10.3 
56.2 (42.1, 56.2) 
Bodily Pain 
 
33.8±8.4 
33.6 (29.3, 37.5)     
 
49.4±10.3 
50.7 (41.8, 55.9) 
General Health 
 
41.9±10.5 
41.5 (32.2, 50.9)   
 
49.8±10.2 
50.9 (43.9, 57.9) 
Vitality 
 
37±9.8    
34.9 (28.9, 43.1)  
 
49.4±10.4 
49.1 (42, 56.2) 
Social Functioning 
 
35.4±14.4 
35.4 (24.6, 46.3)  
 
49.3±10.4 
57.1 (40.9, 57.1) 
Role-Emotional 
 
39.9±12.7 
34.3 (23.7, 55.3)     
 
49.7±10.1 
55.3 (44.8, 55.3) 
Mental Health 
 
39.8±10.8 
41.4 (30, 48.2)     
 
49.1±10.4 
50.4 (43.6, 57.3) 
PCS B 
 
38.3±9.5 
37.7 (32.1, 47.3) 
 
49.2±10.6 
52.6 (43.5, 56.9) 
MCS B 
 
39.1±12 
39.4 (28.6, 49.5) 
 
49.5±10.4 
52.3 (44, 57.2) 
  A  Norm-based scores: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one tenth of a standard deviation 
  B PCS: Physical Component Summary, MCS: Mental Component Summary 
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4.2.1.6 Sexual Function Characteristics 
Table 4-7 provides descriptive information about sexual function of the total study population at 
baseline. Approximately 72.5% (29/40) of our subjects reported that they had sexual intercourse 
during the previous month of the baseline assessment. Moreover, ~ 38% (11/29) of those who 
had sexual intercourse stated that they experienced painful intercourse always, 24.1% (7/29) 
stated that they experienced painful intercourse usually about 75% of the time, 20.7% (6/29) 
stated that they experienced painful intercourse sometimes less than 25% of the time, 13.8% 
(4/29) stated that they experienced painful intercourse sometimes about 50% of the time, and 
only one subject stated that she never experienced painful sexual intercourse. Both the sexual 
desire and sexual arousal scores were less than 5 cm on the visual analog scale (0-10 cm). About 
50% of the study subjects marked their sexual desire as 3.3 cm or less, while their sexual arousal 
as 2.6 cm or less. 
 
 
 
 
 
 
 
 
 
 
    Table  4-7: Baseline Sexual Function Characteristics of the Total Study          
   Population 
SEXUAL FUNCTION VARIABLES 
 
N* BASELINE RESULTS 
 
Had Sexual Intercourse A                        % 
Yes 
 No 
 
 40 
29 
11 
 
72.5 
27.5 
Experience Painful Intercourse A  %
Not at all 
Sometimes, less than 25% of the time 
Sometimes, about 50% of the time 
Usually, about 75% of the time 
Always 
 
29
1 
6 
4 
7 
11
 
  3.4 
20.7 
13.8 
24.1 
37.9 
 
Sexual Desire (0-10cm) A, B 
    Median (25th percentile, 75th percentile)     
 
40  
3.3 (0.9, 5) 
Sexual Arousal (0-10cm) A, B 
Median (25th percentile, 75th percentile)    
  
40  
2.6 (1.2, 5.1) 
*    N =40, one was missing at baseline 
A  All sexual assessments were assessed for the previous month to the baseline. 
B  Both sexual desire and sexual arousal were based on visual analog scale (0-10cm); 0 =none while 10= high. 
4.2.2 Descriptive Results by Study Group: Treatment (n=21) and Placebo (n=20) at 
Baseline 
The results in this section describe the study population by study group. The main purposes of 
that were: to give a complete description about each group and to test if the two groups were 
comparable in relation to their demographic, lifestyle, reproductive, clinical history and severity 
of IC symptoms. Therefore, we can determine if there were any other factors that we should take 
in consideration while assessing the efficacy of the trial intervention. 
4.2.2.1 Socio-Demographic Profile  
Table 4-8 shows the demographic characteristics of the two study groups. Importantly, the two 
groups were comparable in terms of age, ethnicity, marital status, education and employment 
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 status. The median age of the treatment group was 36.9 years old while of the placebo group was 
38.7 years old, p=0.5. There were slightly more Caucasian in the treatment group 76.2% (16/21) 
compared to the placebo group 65% (13/20) and slightly more Hispanic in the placebo group 
25% (5/20) compared to the treatment group 14.3% (3/21). Moreover, the treatment group 
included 2 Black (9.5%) while the placebo group included one Asian (5%) and one from another 
racial classification (5%), the differences in the ethnicity distribution did not reach significant 
level, p=0.3.  
About 52.4% (11/21) of the treatment group and 60% (12/20) of the placebo group were 
married, 23.8% (5/21) of the treatment group and 25% (5/20) of the placebo group were never 
married and 19% (4/21) of the treatment and 5% (1/20) of the placebo group were divorced. The 
remainder proportions were either widowed or had other marital status (treatment group: 0% and 
4.8%, placebo group: 5% and 5%, respectively).  
Both groups had a similar level of education; the median years of education among the 
treatment group was 14 years and among the placebo group was 13.5 years, p=0.2. Although 
81% (17/21) of the treatment group were employed compared to 75% (15/20) of the placebo 
group, the difference was not statistically significant, p=0.7. 
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         Table  4-8: Baseline Demographic Characteristics by Study Group  
CHARACTERISTICS TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Age (Yrs) 189 
Median (25th percentile, 75th percentile) 
 
 
36.9 (32, 45.1) 
 
38.7 (26, 42.7) 
0.5 
Ethnicity 189        % 
Caucasian              
Black                     
Hispanic                
Asian                     
   Other                      
 
76.2 
  9.5 
14.3 
  0 
  0 
 
65 
  0 
25 
  5 
  5 
0.3 
Marital Status   %                           
Married                 
Widowed              
Divorced              
Never Married     
   Other   
                
 
52.4 
  0 
19 
23.8 
  4.8 
 
60 
  5 
  5 
25 
  5 
0.8 
Education (Yrs)          
Median (25th percentile, 75th percentile) 
 
14 (12.5, 16) 
 
 
13.5 (12, 14) 
0.2 
Employment       % 
Employed                
   Not Employed       
   
 
81 
19 
 
75 
25 
0.7 
           * Mann-Whitney U test for continuous variables, Chi-square test or Fisher's exact test for categorical variables 
 
4.2.2.2 Reproductive and Lifestyle Profile 
Table 4-9 summarizes the reproductive and lifestyle characteristics of the two study groups. No 
significant differences were found between the two groups in any of the studied variables. Both 
groups had comparable age at menarche (median was 13 years old among both of the treatment 
and the placebo groups, p=0.6). About 71.4% (15/21) of the treatment group and 80% (16/20) of 
the placebo group were ever pregnant, p=0.7. Furthermore, 53.3% (8/15) of those who were ever 
pregnant among the treatment group and 37.5% (6/16) among the placebo group had at least 3 
pregnancies, p=0.7.  
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 With regard to menopausal status, the majority of the placebo group 75% (15/20) and 
about 52% (11/21) of the treatment group were not currently menopausal (had menstrual period 
during the previous 12 months of the baseline interview), p=0.2. For those who reached 
menopause, the main type of menopause among the treatment group was the surgical menopause 
70% (7/10) while natural menopause was the main type among the placebo group 60% (3/5), 
p=0.3. Most of the subjects in the two groups ever used oral contraceptive (18/21 (85.7%) of the 
treatment group, 18/20 (96%) of the placebo group, p=1). On the other hand, the majority of the 
subjects in the two groups were never used hormone replacement therapy (14/20 (70%) of the 
treatment group, 13/18 (72.2%) of the placebo group, p=0.8). Regarding smoking history of the 
two groups, 12 subjects from each group ever smoked (57.1% in the treatment group and 60% in 
the placebo group, p=0.9). The BMI was also comparable among the two groups; the median 
BMI in the treatment group was 24.7 Kg/m2 compared to 23.7 Kg/m2 among the placebo group, 
p=0.5. 
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         Table  4-9: Baseline Reproductive and Lifestyle Characteristics by Study Group  
CHARACTERISTICS TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Age at Menarche (Yrs)         
Median (25th percentile, 75th percentile) 
 
 
13 (12,13) 
 
13 (12, 14) 
0.6 
Ever Pregnant    % 
Yes                                    
No                                      
 
 
71.4 
28.6 
 
80 
20 
 
0.7 
Number of Pregnancy  % 
1-2                                       
3-4                                       
5+                                          
 
46.7 
33.3 
20 
 
62.5 
25 
12.5 
 
 
0.7 
Menopausal Status      %                      
Menopause                        
   Not Menopause    
              
 
47.6 
52.4 
 
25 
75 
 
0.1 
Type of Menopause     % 
Surgical                             
Natural                              
Drug Therapy  
                   
 
70 
20 
10 
 
40 
60 
  0 
 
0.3 
Ever used OC             % 
Yes                                      
    No  
 
 
85.7 
14.3 
 
90 
10 
0.9 
Ever used HRT A            % 
Yes                                      
    No  
                                       
 
30 
70 
 
27.8 
72.2 
 
0.8 
Ever Smoke                    % 
Yes                                       
    No               
 
57.1 
42.9 
 
60 
40 
 
0.9 
BMI B  (Kg/m2) 
Median (25th percentile, 75th percentile) 
 
 
24.7 (22.5, 28,6) 
 
23.7 (21.7, 27.1) 
0.5 
* Mann-Whitney U test for continuous variables, Chi-square test or Fisher's exact test for categorical variables 
A Three were missing at baseline; 1 in the treatment group and 2 in the placebo group 
B  BMI: body mass index. BMI was based on self-reported weight and height at week18 
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 4.2.2.3 Clinical Characteristics Profile 
Table 4-10 shows the main clinical characteristics of the two groups. Both groups had a 
comparable clinical history in relation to all the assessed characteristics. There was no significant 
difference in the level of severity of IC symptoms between the two groups. About 57.1% (12/21) 
of the treatment group and 45% (9/20) of the placebo group were classified as having severe IC 
symptoms while 42.9% (9/21) of the treatment group and 50% (10/20) of the placebo group were 
classified as having moderate symptoms, and only one subject of the placebo group was 
classified as having mild IC symptoms, (p=0.6).  
In terms of the results from cystoscopy with hydrodistension, all the subjects in the two 
groups had glomerulations. Although 85% (17/20) of the placebo group compared to 66.7% 
(14/21) of the treatment group had severe glomerulations, the difference did not reach a 
significant level (p=0.2). Hunner’s ulcer was reported among 25% (5/20) of the placebo group 
compared to only 4.8% (1/21) of the treatment group, however this noted difference was not 
significant (p=0.09).  
Because the study subjects were allowed to continue using medications that help them in 
managing their condition, it was very important to be sure that the use of these medications was 
comparable among the two groups. Both groups showed similar use of narcotics and/or 
analgesics (52.4% (11/ 21) among the treatment group compared to 55% (11/20) among the 
placebo group, p= 0.9), antihistamines (85.7% (18/21) among the treatment group compared to 
65% (13/20) among the placebo group, p=0.2), antispasmodics (33.3% (7/21) among the 
treatment group compared to 35% (7/20)among the placebo group, p=0.9) and of antidepressants 
(57.1% (12/21) among the treatment group compared to 55% (11/20) among the placebo group, 
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 p=0.9). In terms of co-morbidity, the two groups reported comparable number of co-morbid 
conditions (median= 4 in the treatment group and 3 in the placebo group, p=0.4).  
The bladder capacity measured by either urodynamics or cystometrogram indicated very 
small capacity among the two study groups. The median bladder capacity based on urodynamics 
was 149 ml among the treatment group and 174.5 ml among the placebo group, p=0.9. On the 
other hand, the median bladder capacity based on cystometrogram was 131 ml among the 
treatment group and 136 ml among the placebo group, p=0.7. 
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         Table  4-10: Baseline Clinical Characteristics by Study Group  
CHARACTERISTICS TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Severity of IC Symptoms A   %                 
Mild            (0-6) 
Moderate    (7-13) 
Severe        (14-20) 
 
 
  0 
42.9 
57.1 
 
  5 
50 
45 
0.6 
Severity of Glomerulations B    %        
Mild 
Moderate 
Severe 
 
 
19 
14.3 
66.7 
 
  0 
15 
85 
0.2 
Hunner’s Ulcers 189                       % 
Yes 
No 
 
 
  4.8 
95.2 
 
 
25 
75 
0.09 
Types of Concomitant Medications C   % 
Narcotics and/or  Analgesics          (yes) 
Antihistamines                                (yes) 
Antispasmodics                               (yes) 
Antidepressants                               (yes) 
 
 
52.4 
85.7 
33.3 
57.1 
 
55 
65 
35 
55 
0.9 
0.2 
0.9 
0.9 
Number of Co-morbid Condition D 
Median (25th percentile , 75th percentile) 
 
 
    4 (2, 6) 
 
    3 (2, 4.8) 
0.4 
Uroflow Volume (ml) E   189 
Median  (25th percentile , 75th percentile) 
 
 
149 (67, 231) 
 
174.5 (91, 232) 
0.9 
Cystometrogram (CMG) (ml) F  189 
Median (25th percentile , 75th percentile) 
 
 
131 (58, 270) 
 
136 (90, 227.5) 
0.7 
* Mann-Whitney U test for continuous variables, Chi-square test or Fisher's exact test for categorical variables 
A  Severity of IC symptoms was based on the O’Leary-Sant Interstitial Cystitis Symptom Index score, range from 0-20 
B   Severity of glomerulations was based on the following clinical definitions developed by the PI: 
Glomerulations: Being a red, ulcerative bladder lesion that looks like a stain “glomerulations that is a collection of capillaries in one 
area.  In the bladder these lesions are not a collection of capillaries but they are areas of local inflammation most likely caused by a 
collection of mast cells suddenly degranulating and causing an intense local inflammatory reaction, I.E. ulceration and bleeding 
Mild glomerulations: Few submucosal glomerulations i.e. 0-2-5 lesions per cystoscopic view, associated with submucosal vascular 
injection.  Vascular injection meaning that the mucosa turns red but there are none to only a few glomerulations 
Moderate glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are greater than 10 
but less than 15 glomerulations per cystoscopic view 
Severe glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are submucosal 
glomerulations too numerous to count in nearly all of the bladder cystoscopic views.  This can be with or without “Hunner’s Ulcers”, 
which are patches of bladder membrane where glomerulations blend into a large greater than 1.0cm, patch of bladder tissue 
C    The concomitant medications was defined as follows: Antispasmodics (Oxytrol, Detrol LA, Ditropan XL, Sanctrua, Vesicare), Cyclic 
antidepressants (Elavil, Zoloft), Antihistamines (Allerga, Clarinex,Nyquil, Atarax), Analgesics and Narcotics (Ultracet, pyridium, 
Vicodin, Darvocet, Ambien, Morphine, Lidocaine) 
D   Co-morbid conditions were conditions that were active during the trial or may exacerbate IC symptoms e.g.: endometriosis, irritable 
bowel syndrome, stress, depression, fibromyalgia, hypertension, diabetes...etc. 
E    Based on Uroflowmetry measures. Treatment (n=20) & placebo (n=20) 
                    F    CMG was too painful for 8 of the study participants. Treatment (n=15) & placebo (n=18) 
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 4.2.2.4 Severity of IC Symptoms  
Table 4-11 presents the baseline scores of IC symptoms (measured by O’Leary-Sant, PUF 
instruments, pain scale, urgency scale and voiding log) by the two groups. No significant 
difference was reported in any of these scores between the study groups. The results from both 
the O’Leary-Sant and the PUF instruments showed that the two groups had similar level of IC 
symptom severity. With regard to O’Leary-Sant instrument (0-36), the median total score was 26 
among the treatment group and 23 among the placebo group, p=0.4. The scores from the two 
component of the O’Leary-Sant (ICSI (0-20) and ICPI (0-16)) were also comparable between the 
two groups. The median ICSI score was 14 among the treatment group and 12 among the 
placebo group (p=0.4), while the median ICPI score was 13 among the treatment group and 11.5 
among the placebo group (p=0.2). In terms of the PUF score (1-35), the median total score was 
23 among the treatment group and 21.5 among the placebo group, p=0.9. The results from both 
the PUF/symptom component and the PUF/bother component were not significantly different by 
the study group (median PUF symptom score =14 among the treatment group and 14 among the 
placebo group, p=0.9, median PUF bother score =8 among the treatment group and 7.5 among 
the placebo group, p=0.8).  
With regard to the level of each symptom of IC, both pain (1-9) and Urgency (1-5) were 
evaluated as moderate by both groups (median pain score = 4 among the treatment and 4.8 
among the placebo group; p= 0.3, median urgency score = 3.5 among the treatment and 3 among 
the placebo group, p= 0.1). Both groups reported approximately similar number of voids during 
waking hours (median= 12 among the treatment group and 14.5 among the placebo group, p= 
0.3) and during sleeping hours (median= 2 among the treatment group and 2 among the placebo 
group, p= 0.7). 
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        Table  4-11: Baseline IC Symptom Scores by Study Group* 189 
STUDY MAIN OUTCOMES  TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
O’Leary-Sant Total Score (0-36) A 
O’Leary-Sant ICSI B Score (0-20) 
O’Leary-Sant ICPI B Score (0-16) 
 
26 (18.5, 32) 
14 (10.5, 17) 
13 (8.5, 15) 
23 (19.3, 30) 
12 (10, 16) 
11.5 (10, 14) 
 
0.4 
0.4 
0.2 
PUF B Total Score (1-35) C  
PUF Symptom Score (1-23) 
PUF Bother Score (0-12) 
 
23 (18.3, 25.5) 
14 (11.5, 17) 
  8 (6, 9) 
21.5 (18.3, 26.5) 
14    (12.3, 17) 
  7.5 (6, 9.8) 
0.9 
0.9 
0.8 
Pain Assessment  Score (1-9) D 
 
  4 (4, 5)   4.8 (4, 5.8) 0.3 
Urgency Scores (1-5) E, F 
 
  3.5 (2.6, 3.6)   3 (2.5, 3.2) 0.1 
Number of Voids During Waking 
Hours 
 
12 (9, 16) 14.5 (10, 18.8) 0.3 
Number of Voids During  Sleeping 
Hours 
 
  2 (1, 4)   2 (1, 4) 0.7 
   *  Data were presented as median (25th percentile, 75th percentile). P values: Mann-Whitney U test for continuous variables. 
   A   O’Leary et al. reported that almost no IC patients score less than 6 on either index (ICSI, or ICPI), while almost no    
         controls score as high as 6 23 
   B  ICSI: Intestinal Cystitis Symptom Index, ICPI: Intestinal Cystitis Problem Index, PUF:  Pain and Urgency/    
         Frequency Patient Symptom Scale 
   C   A PUF total score of 15 or more is associated with an 84% chance of having a positive PST, a strong indication that     
         IC may be present 24 
    D  A score of 1 indicates no pain; a score of 9 indicates severe pain 
    E  Mean of urgency scores from voiding log (24 hour period) 
    F  A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
 
4.2.2.5 Quality of Life by Study Group (HRQL) 
Tables 4-12 and 4-13 show the scores of SF-36 in the original format (0-100) and in the norm-
based format (T-scores) for the two groups respectively. Table 4-12 shows the scores of the SF-
36’ eight domains by study group in the original format: (0-100) as 0 indicates poor HRQL while 
100 indicates excellent HRQL. There was no significant difference in any of the eight domain’ 
scores between the two groups. The differences between groups in the scores of the physical 
functioning domain (median=65 among both the treatment group and the placebo group), the 
role-physical domain (median=0 among the treatment group and 37.5 among the placebo group), 
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 the bodily pain domain (median=31 among the treatment group and 32 among the placebo 
group), the general health domain (median=42 among the treatment group and 57.3 among the 
placebo group), the social functioning domain (median=37.5 among the treatment group and 
56.3 among the placebo group) and of the role-emotional domain  (median=33.3 among the 
treatment group and 66.7 among the placebo group) did not reach significant level, p≥0.1. 
Interestingly, there was a marginal significant difference (0.1> p ≥0.05) in the score of the 
vitality domain (median=20 among the treatment group and 32.5 among the placebo group) and 
the score of the mental health domain (median=56 among the treatment group and 66 among the 
placebo group) between the study groups. 
 
       Table  4-12: Baseline Scores of the SF-36 Domains by Study Group* 189 
HEALTH RELATED 
QUALITY OF LIFE 
DOMAINS A 
TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Physical Functioning 
 
65 (45, 85) 65 (36.3, 89.7) 0.9 
Role-Physical 
 
  0 (0, 50) 37.5 (0, 68.8) 0.3 
Bodily Pain 31.0 (16, 41) 
 
32 (22, 48.5) 0.5 
General Health 
 
42 (27.5, 67) 57.3 (40.5, 80.8) 0.1 
Vitality 
 
20 (10, 27.5) 32.5 (20, 57.5) 0.06 
Social Functioning 
 
37.5 (25, 62.5) 56.3 (28.1, 96.9) 0.2 
Role-Emotional 
 
33.3 (0, 100) 66.7 (33.3, 100) 0.2 
Mental Health 
 
56 (32, 68) 66 (56, 75) 0.07 
   *   Data were presented as median (25th percentile, 75th percentile). P value: Mann-Whitney U test for continuous variables 
   A  SF-36 includes eight different domains. The score of each domain ranges between 0 and 100.  0 = worse quality of life while 100                    
         =excellent quality of life 
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 Table 4-13 presents the norm-based scores of both the eight domains and the two 
components summary scales (PCS and MCS) of the SF-36 by study group. As it was reported 
earlier among the total study population, all the scores in the two groups were below the average 
(<50). Importantly, there was a significant difference in the mental component summary scale 
score between the two groups (median= 35.7 among the treatment group and 44.5 among the 
placebo group, p=0.03). On the other hand no significant difference was reported in the score of 
the physical component summary scale (median= 37.7 among the treatment group and 38.6 
among the placebo group, p=0.9). Therefore, the reader should expect either a significant 
difference or a marginal significant difference between the two groups in relation to the scores of 
the domains that constitute the mental component summary scale.  Both the differences between 
the two groups in the scores of vitality domain (median= 32.5 among the treatment group and 
38.4 among the placebo group) and mental health domain (median= 39.1 among the treatment 
group and 44.8 among the placebo group) were marginal significant (0.1> p ≥0.05). 
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       Table  4-13: Norm-Based Scores A of the 8 Domains, PCS and MCS/ SF-36 by    
       Study Group* 
HEALTH RELATED 
QUALITY OF LIFE 
DOMAINS 
TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Physical Functioning 
 
42.5 (34.1, 50.9) 42.5 (30.4, 52.8) 0.9 
Role-Physical 
 
28 (28, 42.1) 38.6 (28, 47.4) 0.3 
Bodily Pain 33.2 (26.8, 37.5) 
 
33.6 (29.3, 40.7) 0.5 
General Health 
 
36.8 (30.1, 48.5) 44 (36.1, 55) 0.1 
Vitality 
 
32.5 (27.8, 36) 38.4 (32.5, 50.2) 0.06 
Social Functioning 
 
30 (24.6, 40.9) 38.1 (25.9, 55.8) 0.2 
Role-Emotional 
 
34.3 (23.7, 55.3) 44.8 (34.3, 55.3) 0.2 
Mental Health 
 
39.1 (25.5, 45.9) 44.8 (39.1, 49.9) 0.08 
PCS B 
 
37.7 (32.6, 44.9) 38.6 (31.9, 48.3) 0.9 
MCS B 
 
35.7 (25.3, 43.7) 44.5 (37.2, 51.9) 0.03 
*  Data were presented as median (25th percentile, 75th percentile). P value: Mann-Whitney U test for continuous variables 
A  Norm-based scores: all scores above or below the 50 are above or below the average, respectively, in the 1998     
   general US population. Each one difference in score is one tenth of a standard deviation 
B  PCS: Physical Component Summary, MCS: Mental component summary 
 
4.2.2.6 Sexual Function Characteristics by Study Group 
Table 4-14 presents the main sexual function characteristics at baseline for the two groups in the 
study. Both groups reported having sexual intercourse during the previous month of the baseline 
assessment in a comparable manner (76.2% (16/21) among the treatment group and 68.4% 
(13/19) among the placebo group, p=0.6). The difference in the distribution of experiencing 
painful sexual intercourse was not significant among those who were sexually active in the two 
groups, p=0.3.  
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 About 37.5% (6/16) of those who were sexually active in the treatment group and 38.5% 
(5/13) of those in the placebo group stated that they experienced painful intercourse always. 
Interestingly, the placebo group showed more sexual desire compared to the treatment group 
(medians= 3.9 cm and 1.7 cm respectively) and this difference reach a marginal significant level, 
p=0.08. On the other hand, the two groups reported similar level of sexual arousal (median=2.4 
cm among the treatment group and 3 cm among the placebo group, p=0.5). 
 
     Table  4-14: Baseline Sexual Function Characteristics by Treatment Group  
SEXUAL FUNCTION VARIABLES TREATMENT 
N = 21 
 
PLACEBO  
N =19 * 
 
P* 
VALUE 
Had Sexual Intercourse A                       % 
Yes 
 No 
 
 
76.2 
23.8 
 
68.4 
31.6 
0.6 
Experience Painful Intercourse A  %
Not at all 
Sometimes, less than 25% of the time 
Sometimes, about 50% of the time 
Usually, about 75% of the time 
Always 
 
 
  6.3 
31.3 
12.5 
12.5 
37.5 
 
  0 
  7.7 
15.4 
38.5 
38.5 
0.3 
Sexual Desire (0-10cm) A, B  189 
    Median (25th percentile, 75th percentile)  
 
 
  1.7 (0.5, 4.5) 
 
  3.9 (2.2, 5.5) 
0.08 
Sexual Arousal (0-10cm) A, B   189 
Median (25th percentile, 75th percentile)   
 
 
  2.4 (0.7, 4.9) 
 
  3 (1.2, 5.8) 
0.5 
*  
One was missing at baseline. P value: Mann-Whitney U test for continuous variables, Chi-square test or Fisher's exact test  
    for categorical variables 
A  All sexual assessments were assessed for the previous month to the baseline visit 
B   Both sexual desire and sexual arousal were based on visual analog scale (0-10cm), 0 = none while 10 = high 
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 4.2.3 Oral PPS Compliance During the Study Period  
Table 4-15 shows oral PPS compliance during the study period for all the study subjects. 
Compliance was defined as the percentage of the oral PPS administered dose per each study 
week as described previously in the method section. About 50% of the study population 
administered 96.4% or less during the entire period of the study. The medians of compliance 
during the first, second and third six weeks period were comparable (median= 96.4 during first 
six weeks, 97.6 during second six weeks, 97.6 during third six weeks). 
 
        Table  4-15: Oral PPS Compliance of the Total Study Population (n=41) by Study     
        Period* 
DESCRIPTION PERCENTAGE 
Total Compliance A  
 
96.4 (81.7, 99.2) 
Compliance During Week 1 to Week 6 B
 
96.4 (90.5, 98.8) 
Compliance During Week 7 to Week 12C
 
97.6 (88.7, 100) 
Compliance During Week 13 to Week 18 D
 
97.6 (81, 100) 
 *  Data were presented as median (25th percentile, 75th percentile)   
A  The average of weekly compliance for 18 weeks; compliance was calculated for each week of the trial by dividing    
      the total number of capsules that were administered during that week by 28 capsules (the total number of capsules       
    that the participants should administer during each week). 
B  The average of weekly compliance for the first six weeks (week 1 to week 6) 
C  The average of weekly compliance for the second six weeks (week 7 to week 12) 
D  The average of weekly compliance for the third six weeks (week 13 to week 18) 
 
Table 4-16 summarizes oral PPS compliance by study group during the entire period of 
the study as well as during the first, second and the third six weeks of the study. Both groups 
administered more than 95% of the required oral PPS therapy during the 18 weeks period. 
Importantly, no significant differences were reported among the two groups in terms of total 
compliance during the entire study period (median= 96 among the treatment group and 97 among 
the placebo group, p=0.6), compliance during week 1 to week 6 (median= 95.2 among the 
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 treatment group and 97 among the placebo group, p=0.6), compliance during week 7 to week 12 
(median= 96.4 among the treatment group and 98.8 among the placebo group, p=0.1), and 
compliance during week 13 to week 18 (median= 96.4 among the treatment group and 98.2 
among the placebo group, p=0.5).  
 
Table  4-16: Oral PPS Compliance During Study Period by Study Group* 
DESCRIPTION TREATMENT 
 N = 21 
PLACEBO  
N =20 
P* 
VALUE 
Total Compliance A  
 
96 (80.4, 99.2) 97 (92.1, 99.1) 0.6 
Compliance During Week 1 to 
Week 6 B 
 
95.2 (86.3, 100) 97 (90.8, 98.8) 0.6 
Compliance During Week 7 to 
Week 12C 
 
96.4 (78, 100) 98.8 (95.2, 100) 0.1 
Compliance During Week 13 
to Week 18 D 
 
96.4 (72, 100) 98.2(87.4, 100) 0.5 
*  Data were presented as median (25th percentile, 75th percentile).  P value: Mann-Whitney U test for  continuous variables. 
A The average of weekly compliance for 18 weeks; compliance was calculated for each week of the trial by       
      dividing the total number of capsules that were administered during that week by 28 capsules (the total number   
    of capsules that the  participants should administer during each week). 
B  The average of weekly compliance for the first six weeks (week 1 to week 6) 
C  The average of weekly compliance for the second six weeks (week 7 to week 12) 
D  The average of weekly compliance for the third six weeks (week 13 to week 18) 
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 4.3 ASSOCIATION RESULTS 
4.3.1 Factors that Were Found to be Associated With the Severity of IC Symptoms 
(Univariate Analysis) 
4.3.1.1 Socio-Demographic Factors 
Table 4-17 presents the univariate associations between ICSI score (measures the severity of IC 
symptoms) and certain demographic factors at baseline. Interestingly, there were no significant 
differences among the four age categories of the study population in terms of ICSI scores. The 
median, the 25th percentile and the 75th percentile were comparable and indicated no significant 
association between age and the severity of IC symptoms, p=0.7. Although, Caucasian subjects 
reported higher score of ICSI (score ≥ 14 equates severe level of IC symptoms) compared to not 
Caucasian subjects (median=15, median=11, respectively), the difference was not significant, 
p=0.1. Interestingly enough, martial status was found to be univariately, significantly associated 
with ICSI score; married subjects reported a lower ICSI score (median=11) compared to 
currently not married subjects (median=16), p=0.02. On the other hand, both educational level 
and employment status were not found to be associated with ICSI score. Subjects who had either 
an elementary or secondary educational level reported comparable ICSI score (median=13) to 
those who had post-secondary level of education (median=14), p=0.9. Moreover, the ICSI score 
of those who were currently employed (median=13.5) was not significantly different from those 
who were not employed (median=14), p=0.8.   
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     Table  4-17: Univariate Associations Between the Severity of IC Symptoms (ICSI      
    Scores) and Certain Demographic Factors at Baseline (n=41) 
DEMOGRAPHIC FACTORS N ICSI SCORES (RANGE: 0-20)* 
 
P* 
VALUE 
Age Categories 
20-29 
30-39 
40-49 
50+ 
 
41
11 
12 
10 
8
 
14 (10, 16) 
14 (8.5, 16.8) 
12 (9.5, 15.3) 
14.5 (11.5, 17.8) 
0.7 
Ethnicity            
Caucasian              
Not Caucasian A                  
 
41
29 
12
 
15 (10.5, 16.5) 
11 (8.5, 14.8) 
0.1 
Marital Status    
Married                   
Currently not married B                  
 
41
23 
18
 
11 (8, 15) 
16 (12.8, 17) 
0.02 
Educational Levels 
Elementary &  Secondary               
Post-Secondary        
 
41
13 
28
 
13 (10.5, 17) 
14 (10, 16) 
 
0.9 
Employment Status 
Employed 
Not Employed 
 
41
32 
9
 
13.5 (10, 16) 
14 (10.5, 16.5) 
0.8 
*  Data were presented as median (25th percentile, 75th percentile). P value: Mann-Whitney U test or Kruskal-Wallis test  
A Not Caucasian = Black, Hispanic, Asian and other 
B  Currently not married = widowed, divorced, never married and other 
4.3.1.2 Reproductive and Lifestyle Factors 
Table 4-18 shows the univariate associations between the ICSI score and certain reproductive 
and lifestyle factors. With the exception of menopausal status, all the other assessed factors were 
not found to be associated with the ICSI score. Subjects who were ever pregnant had a slightly 
lower ICSI score (median=13) than those who were not’ (median=15), p=0.7. Moreover, subjects 
who experienced from 1 to 2 pregnancies reported a higher, but not significant, ICSI score 
(median=14) compared to those who had 3 or more pregnancies (median=12), p=0.6. 
Interestingly, IC cases who were not currently menopausal reported significant lower ICSI score 
(median=11.5) compared to the menopausal cases (median=16), p=0.02.  
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 Both the use of OC and HRT were not found to be associated with ICSI score. Subjects who had 
ever used OC or HRT reported a comparable score (median=13.5, 15, respectively) to those who 
had never used OC or HRT (median=14, 13, respectively), p=0.9, 0.3, respectively. In addition, 
the median ICSI score for those who had ever smoked (median=14) was not significantly 
different from those who had never smoked (median=13), p=0.8. 
 
   Table  4-18: Univariate Associations Between the Severity of IC Symptoms (ICSI     
   Scores) and Certain Reproductive History and Lifestyle Factors at Baseline (n=41) 
REPRODUCTIVE & 
LIFESTYLE FACTORS 
N ICSI SCORES (RANGE: 0-20)* 
 
P* 
VALUE 
Ever Pregnant           
Yes                                    
No                                      
 
41
31 
10
 
13 (10, 16) 
15 (10, 16.3) 
0.7 
Number of Pregnancies   
1-2                                       
3+                                       
 
31
17 
14
 
14 (10, 17) 
12 (8.8, 16) 
0.6 
Menopausal Status                          
Menopause                        
Not Menopause                 
 
41
15 
26
 
16 (13, 17) 
11.5 (9.5, 16) 
 
0.02 
Ever Used OC             
Yes                                    
No                                      
 
41
36 
5
 
13.5 (10, 16.7) 
14 (10.5, 16) 
0.9 
Ever Used HRT A            
Yes                                      
No                                        
  
38
11 
27
 
15 (11, 18) 
13 (10, 16) 
0.3 
Ever Smoked                   
Yes                                       
No            
           
41
24 
17
 
14 (10, 16) 
13 (10.5, 16.5) 
0.8 
*  Data were presented as median (25th percentile, 75th percentile). P value: Mann-Whitney U test  
A Three were missing at baseline 
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 4.3.1.3 Clinical and Sexual History Factors 
Table 4-19 shows the univariate associations between ICSI score and certain clinical and sexual 
history factors. We were not able to determine if the presence of glomerulations was associated 
with the severity of IC symptoms score, as all our study population had glomerulations. 
Although, we expected to find significant associations between either the severity of 
glomerulations or the presence of Hunner’s ulcer and ICSI score, none of these were significant. 
The median ICSI score was 15.5 among those who had mild glomerulations; 15.5 among those 
who had moderate glomerulations and 13 among those who had severe glomerulations, p=0.4. 
Furthermore, those who had Hunner’s ulcer reported a comparable ICSI score (median=14) to 
those who had not’ (median=14), p=0.8. Interestingly, there were a significant association 
between ICSI score and having sexual intercourse during the month before the baseline 
interview. IC cases who had sexual intercourse during the month before the baseline interview 
reported significantly lower ICSI scores (median=13) than those who had not’ (median=17), 
p=0.03. 
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   Table  4-19: Univariate Associations Between the Severity of IC Symptoms (ICSI     
   Scores) and Certain Clinical and Sexual History Factors at Baseline (n=41) 
CLINICAL AND SEXUAL 
HISTORY FACTORS 
N ICSI SCORES (RANGE: 0-20)* 
 
P* 
VALUE 
Severity of Glomerulations A 
Mild 
Moderate 
Severe 
 
41
4 
6 
31
 
15.5 (9, 18.3) 
15.5 (12.3, 17.3) 
13 (10, 16) 
0.4 
Presence of Hunner’s Ulcer 
Yes 
No 
41
6 
35 
 
14 (8.3, 16.5) 
14 (10, 16) 
0.8 
Had Sexual Intercourse  B 
Yes 
No 
40
29 
11 
 
13 (10, 15.5) 
17 (11, 18) 
0.03 
 *   Data were presented as median (25th percentile, 75th percentile). P value: Mann-Whitney U test or Kruskal-Wallis test   
 A  Severity of glomerulations was based on the following clinical definitions developed by the PI: 
Glomerulations: Being a red, ulcerative bladder lesion that looks like a stain “glomerulations that is a collection of capillaries in one area.  
In the bladder these lesions are not a collection of capillaries but they are areas of local inflammation most likely caused by a collection of 
mast cells suddenly degranulating and causing an intense local inflammatory reaction, I.E. ulceration and bleeding 
Mild glomerulations: Few submucosal glomerulations i.e. 0 -2-5 lesions per cystoscopic view, associated with submucosal vascular 
injection.  Vascular injection meaning that the mucosa turns red but there are none to only a few glomerulations 
Moderate glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are greater than 10 but less 
than 15 glomerulations per cystoscopic view 
Severe glomerulations: On hydrodistension, the bladder membrane turns red with vascular injection and there are submucosal 
glomerulations too numerous to count in nearly all of the bladder cystoscopic views.  This can be with or without “Hunner’s Ulcers”, which 
are patches of bladder membrane where glomerulations blend into a large greater than 1.0cm, patch of bladder tissue 
 B  One was missing at baseline. Subjects were asked if they had sexual intercourse during the month previous to the baseline assessment
  
198
4.3.1.4 Co-morbidity, BMI and Sexual Function Domains 
Table 4-20 presents both the spearman correlation coefficients and the p values for the bivariate 
correlations between ICSI scores and each of the number of co-morbid conditions, BMI, sexual 
desire and sexual arousal. A weak non-significant positive correlation was found between the 
number of co-morbid conditions and ICSI score (ρ=0.2, p=0.3). Moreover, weak non-significant 
correlations were found between ICSI score and each of the BMI (ρ= -0.1, p=0.6), sexual desire 
score (ρ= -0.3, p=0.09) and sexual arousal score (ρ= -0.2, p=0.1).  
 
   Table  4-20: Correlations Between the Severity of IC Symptoms (ICSI* Score: 0-20), Co-   
    morbidity, BMI and Sexual Function Domains at Baseline (n=41) 
FACTORS SPEARMAN CORRELATION 
COEFFICIENTS 
 
P 
VALUE
Number of Co-morbid Conditions A 
 
 0.2 0.3 
BMI B 
 
-0.1 0.6 
Sexual Desire C -0.3 
 
0.09 
Sexual Arousal C -0.2 
 
0.1 
*  ICSI: interstitial cystitis symptom index, 0 indicates no symptoms, 20 indicates severe symptoms 
A   Four subjects had no co-morbid conditions.  Co-morbid conditions were conditions that were active during the trial or    
     may exacerbate IC symptoms e.g.: endometriosis, irritable   bowel syndrome, stress, depression, fibromyalgia, hypertension,    
     diabetes...etc. 
B     BMI: body mass index. BMI was based on self-reported weight and height at week18 
C    One was missing at baseline. Sexual desire and sexual arousal were based on visual analog scale (0-10 cm), 0= none while 10 = high.        
     Subjects were asked to evaluate their sexual desire and sexual arousal during the month previous to the baseline assessment 
 
 
 
 
 4.3.2 Factors that Were Found to be Associated With the Severity of IC Symptoms 
(Multivariate Regression) 
Because of sample size limitation we were not able to include more than 4 predictors in the 
multivariate model. When we included sexual activity to the model, standard errors changed 
significantly and at the same time sexual activity became no longer associated with symptom 
severity. Therefore, the final model only tested marital status and menopausal status adjusting for 
age and co-morbidity using multivariate median regression.  
Table 4-21 shows the regression coefficients, 95% CI and p values for each of the 
previously identified factors that were found to be associated with ICSI score (in the univariate 
assessments) after adjusting for age and co-morbidity. According to the univariate assessments, 
both being currently not married and menopausal were found to be significantly associated with 
greater severity of IC symptoms. Before adjusting for the well known covariates (age and 
number of co-morbid conditions), 21, 203 both factors (marital status: being married and 
menopausal status: being menopausal) in the primary model were found to have an independent 
significant association with the severity of IC symptoms (β= -4, p=0.03, β= 4, p=0.04, 
respectively). Interestingly, after adjusting for age and co-morbidity, only marital status 
remained highly significant in the model. The median ICSI score for married subjects was found 
to be ~ 4 points less than the median score for currently not married subjects, p=0.03. On the 
other, the association between menopausal status and the severity of IC symptoms was no longer 
significant after including both age and number of co-morbid conditions in the final model,  
p=0.2. This indicates that both age and co-morbidity may be considered as important 
confounders for this association. 
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            Table  4-21: Results of Multivariate Median Regression for ICSI (0-20) Score and     
            the Factors that Were Found to be Associated With ICSI Score in the Univariate  
            Assessment after Adjusting for Both Age and Co-morbidity (n=41) 
INDEPENDENT VARIABLEA DEPENDENT VARIABLE 
ICSI SCORES* 
β SE P 
Value 
95%CI 
Age 
 
0.04 0.09 0.7 -0.15 , 0.23 
Number of Co-morbid Conditions A
 
0.15 0.27 0.6 -0.39 , 0.70 
Marital status B 
 
-3.85 1.75 0.03 -7.41 , -0.29 
Menopausal Status B 
 
 3.38 2.51 0.2 -1.72 , 8.47 
* ICSI: interstitial cystitis symptom index, 0 = no symptoms; 20 = severe symptoms 
A Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or may  
   exacerbate IC symptoms e.g.: endometriosis, irritable   bowel syndrome, stress, depression, fibromyalgia, hypertension, 
   diabetes...etc 
B  Reference category: currently not married; currently not menopausal 
 
 
4.3.3 Factors that Were Found to be Associated With HRQL in IC Subjects (Univariate 
Analysis) 
Because we used the norm-based score format for all the SF-36 domains in our analysis, it was 
very easy to define the impairment (below average) in any of the SF-36’ domains. All scores 
above or below the 50 are above or below the average in the 1998 general US population.184 
Therefore, any score below 50 indicates an impairment in HRQL.  
4.3.3.1 Socio-Demographic Factors 
Table 4-22 presents the results of the univariate associations between each of the eight domains 
of the SF-36 and certain demographic factors at baseline. Interestingly, only employment status 
was found to be significantly associated with the physical functioning domain. Subjects who 
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 were currently employed reported a better physical functioning score (median=46) than those 
who were not’ (median=24), p=0.03. Moreover, marital status showed a marginal significant 
association with the physical functioning domain. Married subjects reported a better physical 
functioning score (median=49) compared to currently not married subjects (median=37), p=0.06.  
With regard to role-physical, bodily pain, general health and social function domains, 
only marital status was found to be significantly associated with each one of these domains. 
Interestingly, married IC cases consistently reported a greater (better) score of role-physical, 
bodily pain, general health and social function domains (median scores = 42, 37, 46, 37 and 41, 
respectively) compared to currently not married cases (median scores = 28, 29, 36, 32, and 27, 
respectively), p=0.001, 0.003, 0.01, 0.03 and 0.01, respectively. In terms of role-emotional 
domain, none of the tested factors was found to be associated. However, both marital status and 
educational level showed marginally significant associations. Similar to what we reported above, 
married IC cases showed greater role-emotional score (median= 45) than currently not married 
cases (median= 34), p=0.08. Moreover, cases who had an elementary and/or secondary level of 
education reported greater role-emotion score (median= 55) compared to those who had post-
secondary level of education (median= 34), p=0.06.  
Finally, none of the tested variables was found to be significantly associated with mental 
health domain. The associations between mental health score and age and/or marital status were 
found to be marginally significant. IC cases who were 50 years old or more reported the highest 
mental health score among all the 4 age categories (20-29: median=39; 30-39: median= 36; 40-
49: median= 45; 50+: median= 49), p=0.06. Furthermore, married IC cases showed a better 
mental health score (median= 46) than currently not married IC cases (median= 39), p=0.08.  
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In summary, it would appear that marital status is a very important factor that found to 
be associated either significantly or marginally significantly with each of the SF-36 domains in 
the univariate assessments at baseline. 
 
Table  4-22: Univariate Associations Between Each of the Eight Domains of the SF-36 and Certain Demographic Factors at Baseline 
(n=41) 
DEMOGRAPHIC 
FACTORS 
N SF-36 DOMAINS A 
PF RP BP GH VT SF RE MH 
Age Categories 
20-29 
30-39 
40-49 
50+ 
41 
11 
12 
10 
8 
 
47 (32, 53) 
43 (25, 52) 
43 (34, 55) 
40 (24, 49) 
 
35 (28, 42) 
32 (28, 49) 
35 (28, 42) 
28 (28, 53) 
 
33.6 (25, 37) 
29 (24, 41) 
36 (29, 40) 
38 (29, 41) 
 
39 (34, 46) 
38 (29, 55) 
41 (31, 52) 
46 (38, 51) 
 
37 (32, 51) 
32 (28, 42) 
36 (29, 48) 
35 (26, 39) 
 
35 (25, 46) 
33 (21, 41) 
35 (25, 57) 
33 (25, 54) 
 
34 (34, 45) 
29 (24, 53) 
34 (32, 55) 
55 (29, 55) 
 
39 (30, 44) 
36 (23, 46) 
45 (31, 49) 
49 (46, 52) 
P* values 0.8 0.9 0.5 0.6 0.6 0.8 0.4 0.06 
 
Ethnicity            
Caucasian              
Not CaucasianB                 
 
41 
29 
12 
 
 
42 (34, 51) 
47 (20, 55) 
 
 
28 (28, 42) 
39 (28, 49) 
 
 
34 (29, 37) 
33 (29, 46) 
 
 
39 (31, 51) 
43 (35, 53) 
 
 
32 (29, 42) 
37 (27, 51) 
 
 
35 (25, 44) 
30 (26, 50) 
 
 
34 (24, 55) 
40 (26, 55) 
 
 
44 (31, 49) 
36 (28, 46) 
P* values 0.9 0.4 0.5 0.4 0.4 0.9 0.9 0.4 
 
Marital Status    
Married                   
Currently not marriedB      
 
41 
23 
18 
 
 
49 (34, 55) 
37 (31, 47) 
 
 
42 (28, 49) 
28 (28, 30) 
 
 
37 (29, 46) 
29 (24, 35) 
 
 
46 (36, 56) 
36 (29, 44) 
 
 
37 (32, 51) 
32 (27, 37) 
 
 
41 (25, 57) 
27 (23, 35) 
 
 
45 (34, 55) 
34 (24, 47) 
 
 
46 (32, 53) 
39 (27, 46) 
P* values 0.06 0.001 0.003 0.01 0.03 0.01 0.08 0.08 
 
Education Levels 
Elementary &  
Secondary                          
Post-Secondary        
 
41 
13 
 
28 
 
 
42 (24, 52) 
 
42 (32, 52) 
 
 
35 (28, 46) 
 
31 (28, 42) 
 
 
37 (29, 44) 
 
33 (29, 37) 
 
 
51 (36, 56) 
 
38 (32, 48) 
 
 
37 (27, 49) 
 
34 (32, 42) 
 
 
30 (25, 57) 
 
35 (25, 41) 
 
 
55 (34, 55) 
 
34 (24, 45) 
 
 
48 (29, 52) 
 
39 (30, 46) 
P* values 0.7 0.8 0.3 0.1 0.7 0.7 0.06 0.1 
 
Employment Status 
Employed 
Not Employed 
 
41 
32 
9 
 
 
46 (35, 53) 
24 (20, 48) 
 
 
31 (28, 42) 
42 (28, 49) 
 
 
34 (29, 37) 
29 (27, 42) 
 
 
40 (33, 51) 
42 (30, 56) 
 
 
34 (28, 42) 
40 (30, 54) 
 
 
33 (25, 45) 
41 (22, 57) 
 
 
34 (24, 55) 
45 (29, 55) 
 
 
40 (31, 46) 
46 (27, 53) 
P* values 0.03 0.5 0.9 0.8 0.2 0.6 0.5 0.6 
*  P value: Mann-Whitney U test or Kruskal-Wallis test   
A   Norm-based scores were presented as median (25th percentile, 75th percentile), all scores above or below the 50 are above or below the average, respectively, in the 1998    general US population. Each 
one difference in score is one tenth of a standard deviation. PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT:     vitality, SF: social function, RE: role-emotional, 
MH: mental health 
B   Not Caucasian = Black, Hispanic, Asian and others. Currently not married = widowed, divorced, never married and others 
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4.3.3.2 Reproductive and Lifestyle Factors 
Table 4-23 shows the results of the univariate associations between each of the eight domains of 
the SF-36 and certain reproductive and lifestyle factors at baseline. With the exception of being 
sexually active during the previous month of the baseline interview, none of the tested 
reproductive and lifestyle factors was found to be significantly associated with physical 
functioning domain of the SF-36. IC cases who indicated that they had sexual intercourse during 
the month before the baseline interview reported a significantly better physical functioning 
domain score (median= 47) compared to those who had not any sexual intercourse during the 
same period (median=30), p=0.02.  
None of the tested variables was found to be significantly associated with the role-
physical domain score, however, both ever use of OC and HRT showed marginal significant 
associations with role-physical domain score. IC subjects who never used either OC or HRT 
reported a better role-physical score (median= 49; 42, respectively) compared to those who ever 
used OC or HRT (median= 28; 28, respectively), p=0.05, 0.06, respectively.  
With regard to bodily pain, general health, social functioning and role-emotion domains, 
none of the tested factors was found to be significantly associated with any of them. Only, 
“having sexual intercourse during the month before the baseline interview” was found to be 
significantly associated with vitality domain score. Subjects who had sexual intercourse during 
the month previous to baseline interview reported a better vitality domain score (median= 35) 
than those who had not’ (median= 28), p=0.01.  
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Interestingly, being ever pregnant was found to be significantly associated with mental 
health domain score. IC cases who indicated that they were ever pregnant showed better mental 
health score (median= 44) than those who were not (median= 31), p=0.04. 
4.3.3.3 Co-morbidity, BMI and Sexual Function Domains 
Table 4-24 presents both the spearman correlation coefficients and the p values for the bivariate 
correlations between each of the eight domains of SF-36, co-morbidity, BMI and sexual function 
domains at baseline. Weak significant negative correlations were found between the number of 
co-morbid conditions and each of the physical functioning (ρ= -0.4, p=0.02), bodily pain (ρ= -
0.4, p=0.02) and role-emotional (ρ= -0.3, p=0.04) domains. On the other hand, BMI was found to 
be negatively correlated with each of the general health domain (ρ= -0.3, p=0.05) and vitality 
domain (ρ= -0.3, p=0.02). None of the tested variables was found to be significantly correlated 
with any of the role-physical, social functioning and/or mental health domains. 
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Table  4-23: Univariate Associations Between Each of the Eight Domains of SF-36 and Certain Reproductive History and 
Lifestyle Factors at Baseline (n=41) 
REPRODUCTIVE & 
LIFESTYLE 
FACTORS 
N SF-36 DOMAINS A 
PF RP BP GH VT SF RE MH 
Ever Pregnant           
Yes                                    
No                                      
41 
31 
10 
 
43 (34, 52) 
34 (28, 51) 
 
35 (28, 49) 
28 (28, 37) 
 
34 (29, 42) 
31 (20, 37) 
 
44 (32, 53) 
36 (31, 44) 
 
35 (32, 44) 
32 (27, 42) 
 
41 (25, 52) 
27 (18, 37) 
 
45 (34, 55) 
29 (24, 47) 
 
44 (32, 50) 
31 (25, 41) 
P* values 0.4 0.2 0.08 0.1 0.4 0.1 0.1 0.04 
 
Number of Pregnancies   
1-2                                      
3+                                       
 
31 
17 
14 
 
 
43 (29, 50) 
46 (34, 55) 
 
 
35 (28, 42) 
35 (28, 56) 
 
 
29 (29, 42) 
37 (29, 46) 
 
 
44 (32, 54) 
44 (34, 54) 
 
 
35 (32, 44) 
36 (27, 47) 
 
 
30 (26, 44) 
41 (29, 57) 
 
 
45 (34, 55) 
40 (24, 55) 
 
 
41 (36, 47) 
46 (31, 53) 
P* values 0.4 0.4 0.3 0.7 0.8 0.2 0.8 0.2 
 
Menopausal Status               
Menopause                        
Not Menopause                 
 
41 
15 
26 
 
 
38 (24, 49) 
47 (34, 53) 
 
 
28 (28, 42) 
35 (28, 44) 
 
 
29 (29, 37) 
34 (28, 39) 
 
 
42 (29, 51) 
42 (32, 51) 
 
 
35 (28, 40) 
35 (33, 45) 
 
 
30 (25, 46) 
35 (25, 48) 
 
 
34 (24, 55) 
40 (32, 55) 
 
 
48 (25, 53) 
39 (30, 46) 
P* values 0.2 0.1 0.9 0.9 0.4 0.9 0.9 0.1 
 
Ever Used OC             
Yes                                    
No                                      
 
41 
36 
5 
 
 
42 (32, 52) 
42 (20, 51) 
 
 
28 (28, 42) 
49 (35, 56) 
 
 
33 (29, 37) 
37 (29, 49) 
 
 
43 (33, 51) 
36 (29, 47) 
 
 
34 (28, 42) 
36 (31, 55) 
 
 
30 (25, 41) 
57 (30, 57) 
 
 
34 (24, 55) 
55 (34, 55) 
 
 
40 (31, 48) 
46 (27, 55) 
P* values 0.5 0.05 0.2 0.3 0.3 0.1 0.2 0.6 
 
Ever Used HRT B            
Yes                                     
No                                       
 
38 
11 
27 
 
 
38 (24, 51) 
47 (34, 53) 
 
 
28 (28, 35) 
42 (28, 49) 
 
 
37 (29, 37) 
34 (29, 42) 
 
 
46 (37, 56) 
39 (32, 51) 
 
 
35 (25, 42) 
35 (32, 44) 
 
 
30 (25, 41) 
41 (25, 52) 
 
 
34 (24, 55) 
45 (34, 55) 
 
 
48 (25, 50) 
39 (30, 46) 
P* values 0.3 0.06 0.8 0.3 0.6 0.5 0.6 0.1 
 
Ever Smoked                   
Yes                                     
No                      
 
41 
24 
17 
 
 
42 (32, 48) 
49 (33, 54) 
 
 
31 (28, 42) 
35 (28, 49) 
 
 
31 (25, 37) 
37 (29, 42) 
 
 
38 (32, 47) 
46 (35, 56) 
 
 
35 (31, 44) 
35 (28, 48) 
 
 
33 (21, 54) 
35 (27, 44) 
 
 
34 (24, 45) 
45 (29, 55) 
 
 
40 (31, 46) 
46 (28, 52) 
P* values  0.2 0.6 0.1 0.08 
 
 
 
0.9 0.5 0.3 0.5 
 REPRODUCTIVE & 
LIFESTYLE 
FACTORS 
N SF-36 DOMAINSA 
PF RP BP GH VT SF RE MH
 
Had Sexual  
Intercourse C 
Yes 
    No 
 
40 
 
29 
11 
 
 
 
 
47 (34, 53) 
30 (19, 42) 
 
 
 
35 (28, 49) 
28 (28,35) 
 
 
 
34 (29, 40) 
29 (20, 37) 
 
 
 
44 (32, 53) 
37 (32, 46) 
 
 
 
35 (32, 46) 
28 (25, 36) 
 
 
 
35 (25, 46) 
30 (19, 41) 
 
 
 
34 (29, 55) 
34 (24, 55) 
 
 
 
39 (30, 46) 
46 (25, 48) 
P* values  0.02 0.09 0.4 0.3 0.01 0.3 0.8 0.8 
Table 4-23 Cont’d
*  P value: Mann-Whitney U test or Kruskal-Wallis test   
A   Norm-based scores were presented as median (25th percentile, 75th percentile), all scores above or below the 50 are above or below the average, respectively, in the 1998    general US population. Each 
one difference in score is one tenth of a standard deviation. PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role-emotional, 
MH: mental health 
B   Three were missing at baseline 
      C   One was missing at baseline. Subjects were asked if they had sexual intercourse during the month previous to the baseline assessment 
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Table  4-24: Correlations Between Each of the Eight Domains of SF-36 and Co-morbidity, BMI and Sexual Function Domains 
at Baseline (n=41) 
FACTORS SPEARMAN CORRELATION COEFFICIENTS 
SF-36 DOMAINS A 
PF RP BP GH VT SF RE MH 
ρ* p ρ p ρ p ρ p ρ p ρ p ρ p ρ p 
Number of Co-
morbid 
Conditions B 
 
-0.4 0.02 -.3 0.1 -0.4 0.02 -0.1 0.3 -0.2 0.1 -0.3 0.1 -0.3 0.04 -0.2 0.3 
BMI C 
 
0.06 0.7 0.1 0.5 0.0 0.9 -0.3 0.05 -0.3 0.02 0.06 0.7 0.2 0.3 0.03 0.8 
Sexual Desire D 
 
0.02 0.9 -0.1 0.4 0.06 0.7 0.06 0.7 0.2 0.2 0.2 0.2 -0.04 0.8 -0.05 0.8 
Sexual Arousal D 
 
0.1 0.5 -0.2 0.2 -0.02 0.9 -0.02 0.9 0.2 0.3 0.09 0.6 -0.1 0.5 -0.06 0.7 
*  Spearman correlation coefficient 
A    Norm-based scores, all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one   
     tenth of a standard deviation. PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role-emotional, MH:    
     mental health 
B     Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or may exacerbate IC symptoms e.g.: endometriosis,  
       irritable   bowel syndrome, stress, depression, fibromyalgia, hypertension, diabetes...etc. 
      C     BMI: body mass index. BMI was based on self-reported weight and height at week18 
D   One was missing at baseline. Both sexual desire and sexual arousal were based on visual analog scale (0-10 cm), = none while 10 = high. Subjects were asked to evaluate their sexual desire and    
       sexual arousal during the month previous  to the baseline assessment 
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4.3.4 Factors that Were Found to be Associated With the Impairment in HRQL 
(Multivariate Regression) 
In order to assess if the above defined associations between each of the eight domains of SF-36  
and the determined factors from the univariate assessments were confounded by age or co-
morbidity, and can independently explain the variation in SF-36 domain scores, multivariate 
median regressions were performed. 
Table 4-25 shows the regression coefficients and p values for each of the previously 
identified factors that were found to be significantly associated with each domain of SF-36 (in 
the univariate assessments) after adjusting for age and co-morbidity. In the univariate 
assessments, both being sexually active and currently employed were found to be significantly 
associated with a better physical functioning score. In the primary multivariate model which 
included only those two factors (being employed and being sexually active), only employment 
status was found to be significantly associated with physical functioning score after adjusting for 
being sexually active (β= 18.9, p=0.004). Interestingly, when we included both age and number 
of co-morbid conditions to the primary model, the same results were obtained. In particular, only 
employment status remained a highly significant factor after adjusting for age, co-morbidity and 
being sexually active. The median physical functioning score for an employed subject was found 
to be ~ 21 points more than the median score for a currently unemployed subject, p=0.01.  
For the role-physical domain, only marital status was found to be significantly associated 
in the univariate analysis. Moreover, never used oral contraceptive was found to be marginally 
significantly associated with role-physical in the univariate analysis. Interestingly in the primary 
 model which included both marital status and never used OC only marital status remained 
significant in the model. After adjusting for age and co-morbidity both marital status (being 
married) and never used OC were found to be independently associated with better role-physical 
domain score. 
With regard to bodily pain, both increase in number of co-morbid conditions and being 
currently not married were found to be significantly associated with lower bodily pain score in 
the univariate assessments.  
After adjusting for age in the final model, only number of co-morbid conditions was 
significantly associated with bodily pain score. The median bodily pain score was found to be 
reduced by approximately 1.47 point for a subject whose number of co-morbid conditions is one 
higher than another subject’s, p=0.01. In addition, marital status was not significantly associated 
with bodily pain score after adjusting for age and co-morbidity.  
General health domain was found to be significantly affected by both marital status and 
BMI in the univariate assessments. Both factors (marital status and BMI) were found to be 
independently associated with the general health domain in the primary multivariate model (β= 
12.7, p=0.02; β= -1.06, p=0.008, respectively) Interestingly, after including both age  and co-
morbidity to the final model, only BMI was a highly significant factor that can independently 
explain the variation in the general health domain. The median general health score was found to 
be reduced by approximately 1.05 point for a subject whose BMI is 1 Kg/m2 higher than another 
subject’s, p=0.007. Moreover, marital status was no longer an independent factor that may 
explain the variation in the general health score based on the final model.  
On the other hand, none of the variables which were found to be significantly associated 
with vitality score in the univariate assessments (marital status, being sexually active and BMI) 
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was significant either in the primary model or in the final model, after adjusting for age and co-
morbidity.  
In terms of social functioning, only marital status was found to be significantly associated 
with it in the univariate assessments. Interestingly, after adjusting for both age and co-morbidity, 
marital status remained an important factor that can independently explain the variation in social 
functioning domain. The median social functioning score for a married subject was found to be 
~13 points more than the score for a currently not married subject, p=0.01.  
With regard to role-emotion domain, only number of co-morbid conditions was found to 
be significantly associated with it univariately. After adjusting for age, co-morbidity remained an 
independent factor that can explain the variation in the role-emotion domain. Furthermore, the 
median role-emotion score was found to be reduced by approximately 2.87 point for a subject 
whose number of co-morbid conditions is one higher than another subject’s, p=<0.001.  
Finally, mental health score was found to be associated with ever pregnant in the 
univariate assessments. This association was significant, even, after adjusting for both age and 
co-morbidity. The median mental health score for a never pregnant subject was found to be ~9 
points less than the median score of an ever pregnant subject, p=0.003.  
In summary, the results from multivariate median regression showed that marital status 
can no longer be considered as an independent variable that may explain the variation in any of 
the bodily pain, general health, vitality, role-emotion and the mental health domains after 
adjusting for age and co-morbidity, in particular. Marital status was found to be an independent 
factor that can explain only the variation in social functioning domain of the HRQL in IC cases.  
Table  4-25: Results of Multivariate Median Regression for Each Domain of the SF-36 and the Factors that Were Found to be 
Associated With Each Domain in the Univariate Assessments after Adjusting for Both Age and Co-morbidity (n=41) 
INDEPENDENT 
VARIABLE AND 
COVARIATES 
 
SF-36 DOMAINS A 
PF RP BP GH VT SF RE MH 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
Age 
 
0.08 0.8 -0.06 0.13  0.14 0.4 0.29 0.2 0.23 0.4 0.11 0.6 0.53 0.01 0.35 0.002 
Number of Co-
morbid Conditions 
B 
0.19 0.9 -0.94 0.008 -1.47 0.01 -0.29 0.7 -084 0.3 -1.64 0.04 -2.87 <0.001 -0.65 0.03 
Employed C 
 
21.1 0.01 ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ 
Had Sex C,D 
 
8.69 0.3 ------ ------ ------ ------ ------ ------ 4.47 0.5 ------ ------ ------ ------ ------ ------ 
Married C 
 
------ ------ 8.49 0.006 7.34 0.06 9.14 0.08 6.9 0.2 13.09 0.01 ------ ------ ------ ------ 
BMIE 
 
------ ------ ------ ------ ------ ------ -1.05 0.007 -0.37 0.3 ------ ------ ------ ------ ------ ------ 
Never Use OC C 
 
------ ------ 12.7 0.007 ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ 
Never Pregnant C 
 
------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -9.52 0.003 
A    Norm-based scores, all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one tenth of a standard deviation.    
     PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role-emotional, MH: mental health 
B   Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or may exacerbate IC symptoms e.g.: endometriosis, irritable   bowel syndrome,      
     stress, depression, fibromyalgia, hypertension, diabetes...etc. 
C   Reference category: Not employed; did not have sex; currently not married; ever use oral contraceptive; ever pregnant 
D   One was missing at baseline (n=40). Subjects were asked if they had sexual intercourse during the month previous to the baseline assessment 
E   BMI: body mass index. BMI was based on self-reported weight and height at week18 
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4.3.5 Associations Between the Severity of IC Symptoms (ICSI Score) and the Eight 
Domains of the SF-36 
The following sections present our main findings of assessing the second aim of this dissertation. 
After determining to what extent socio-demographic, lifestyle, reproductive and clinical history 
factors were associated with both the severity of IC symptoms as well as the quality of life in IC 
patients, it was crucial to examine the association between the severity of IC symptoms and the 
HRQL after adjusting for the main covariates that were identified from assessing the first aim of 
this study. 
4.3.5.1 Unadjusted Associations 
Table 4-26 shows the Spearman correlation coefficients and the p values for the bivariate 
correlations between the ICSI score and each of the eight domains of the SF-36. Interestingly, 
the severity of IC symptoms was found to be negatively correlated with each of the physical 
functioning (ρ = -0.4, p=0.007), role-physical (ρ = -0.4, p=0.005), bodily pain (ρ = -0.5, 
p=0.001), and the social functioning domain (ρ = -0.5, p=0.001). Moreover, both bodily pain and 
social functioning domains showed the greatest impairments as a result of the increase in the 
severity of IC symptoms score.  Another weaker negative correlation was found between the 
severity of IC symptoms and the general health domain; however, it was marginally significant 
(ρ = -0.3, p=0.06).  
 
 
 
     Table  4-26: Unadjusted Correlations Between the ICSI (0-20) Score and the Eight    
    Domains of SF-36 at Baseline (n=41) 
SF-36 DOMAINS A SEVERITY OF IC SYMPTOMS 
ICSI SCORES B 
Spearman Correlation 
Coefficients 
ρ 
P Value 
Physical Functioning -0.4 0.007 
Role-Physical -0.4 0.005 
Bodily Pain -0.5 0.001 
General Health -0.3 0.06 
Vitality -0.3 0.1 
Social Functioning -0.5 0.001 
Role-Emotional -0.1 0.6 
Mental Health -0.1 0.5 
A   Norm-based scores, all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population.      
    Each one difference in score is one tenth of a standard deviation.  
B   ICSI: interstitial cystitis symptom index, 0 = no symptoms; 20 = severe symptoms 
4.3.5.2 Adjusted Associations 
Table 4-27 presents the results of the multivariate regressions between each domain of the SF-36 
and the ICSI score after adjusting for the well known covariates in the literature (age and co-
morbidity) 21, 203 and the covariates which were identified for each quality of life domain from 
the univariate analyses (section 4.3.3).  
After adjusting for age, number of co-morbid conditions and employment status, ICSI 
score remained negatively associated with physical functioning score. The median physical 
functioning score was found to be reduced by approximately 1.54 point for a subject whose ICSI 
score is 1 point greater than another subject’s. Although this magnitude of variation in the 
median physical functioning score was very small, it was highly significant, p=0.007. On the 
other hand, after adjusting for age, co-morbidity, marital status and ever use of oral 
contraceptive, ICSI score was no longer a significant independent factor that may explain the 
variation in role-physical functioning score.  
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 With regard to the effect of the severity of IC symptoms on bodily pain domain, even 
after adjusting for age, co-morbidity and marital status, ICSI score remained a significant factor 
in the model. The median bodily pain  score was found to be reduced by approximately  0.83 
point for a subject whose ICSI score is 1 point greater than another subject’s, p=0.04.  
In the unadjusted analysis, ICSI score was found to be negatively correlated with general 
health score, this correlation was marginally significant (Table 4-25). After adjusting for age, 
number of co-morbid conditions, marital status and BMI, ICSI score was a significant predictor 
of general health score.   The median general health  score was found to be reduced by 
approximately  1.62 point for a subject whose ICSI score is 1 point greater than another 
subject’s, p=0.001.   
On the other hand, similar to what we reported in the unadjusted analysis (Table 4-25), 
ICSI score was not found to be associated with the variation in either vitality domain or role-
emotion domain after adjusting for study covariates. However, the magnitude of variation in 
vitality score was found to be significantly explained by marital status (ß=8.8, p=0.002) when 
ICSI score, age, co-morbidity and BMI were included in the model. Moreover, the magnitude of 
variation in role-emotion was found to be significantly explained by number of co-morbid 
conditions (ß=-2.68, p<0.001) after adjusting for ICSI score and age. Interestingly, ICSI score 
was found to be negatively associated with social functioning score in the unadjusted analyses 
(Table 4-25). After adjusting for age, number of co-morbid conditions, and marital status, this 
association was no longer significant. The reverse was found with mental health domain; there 
was no significant association between ICSI score and mental health score in the unadjusted 
analysis (Table 4-25). However, after adjusting for age, co-morbidity, and ever pregnant, ICSI 
score was a significant predictor of mental health domain. The median mental health score was 
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found to be reduced by approximately  0.56 point for a subject whose ICSI score is 1 point 
greater than another subject’s, p=0.01.  
In summary, the results from multivariate median regression showed that the severity of 
IC symptoms (represented by ICSI score) is significantly associated with the impairment 
(reduction) in physical functioning, bodily pain, general health and mental health domains of 
HRQL in IC patients after adjusting for study covariates as well as age and co-morbidity.
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Table  4-27: Results of Multivariate Median Regression for each Domain of the SF-36 and the ICSI (0-20) Score after 
Adjusting for Certain Covariates at Baseline (n=41) 
INDEPENDENT 
VARIABLE AND 
COVARIATES 
 
SF-36 DOMAINS A 
PF RP BP GH VT SF RE MH 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
β P 
Value 
ICSI B 
 
-1.54 0.007 -0.57 0.08 -0.83 0.04 -1.62 0.001 0.18 0.6 -1.27 0.3 -0.48 0.4 -0.56 0.01 
Age 
 
0.31 0.08 -0.04 0.7 0.06 0.6 0.30 0.03 0.07 0.5 -0.09 0.8 0.47 0.02 0.48 <0.001
Number of Co-
morbid Conditions 
C 
-1.33 0.05 -0.80 0.003 -1.33 0.003 -0.21 0.6 -0.86 0.03 -1.67 0.2 -2.68 <0.001 -0.86 0.003 
Employed D 
 
4.07 0.4 ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ 
Married D 
 
------ ------ 9.19 <0.001 6.47 0.04 3.94 0.3 8.8 0.002 7.7 0.3 ------ ------ ------ ------ 
BMI E 
 
------ ------ ------ ------ ------ ------ -0.69 0.004 -0.32 0.09 ------ ------ ------ ------ ------ ------ 
Never use OC D 
 
------ ------ 12.57 0.001 ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ 
Never Pregnant D 
 
------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -4.0 0.05 
A  Norm-based scores, all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one    
tenth of a standard deviation. PF: physical functioning, RP: role-physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role-emotional, MH: mental health 
B  ICSI: interstitial cystitis symptom index, 0 indicates no symptoms, 20 indicates severe symptoms 
C  Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or may exacerbate IC symptoms e.g.: endometriosis, irritable   bowel syndrome,    
   stress, depression, fibromyalgia, hypertension, diabetes...etc 
D  Reference category: Not employed; currently not married; ever use oral contraceptive; ever pregnant 
E  BMI: body mass index. BMI was based on self-reported weight and height at week18 
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4.3.6 Effect of IC Symptoms on PCS and MCS of HRQL  
In the previous section (4.3.5) we described how the severity of IC symptoms (ICSI score: 
cumulative score that reflects the severity of pain, urgency, urinary frequency and nocturia 
together) can affect each domain of the quality of life in IC patients (eight domains of the SF-36 
instrument). This section shows which IC symptom, in particular, is significantly associated with 
the quality of life represented by the two summary component scales: the physical component 
summary (PCS) and the mental component summary (MCS) scales.  Results from simple non-
parametric correlations as well as multivariate median regression were presented in the following 
sections. 
4.3.6.1 Bivariate Correlations Between IC Symptoms  
Because we expected that the occurrence of each symptom of IC is not an independent event, it 
was very important to assess the degree and significance level of co-linearity between IC 
symptoms. Table 4-28 shows both the correlation coefficients and the p values for bivariate 
correlations between IC symptoms (pain, urinary frequency, nocturia and urgency). Interestingly, 
there were significant positive correlations between pain and urgency (ρ = 0.4, p=0.01) and 
between urinary frequency and nocturia (ρ = 0.4, p=0.01). Furthermore, a marginal significant 
positive correlation was observed between pain and urinary frequency (ρ = 0.3, p=0.07).  This in 
fact, indicates that we cannot include either both pain and urgency or both urinary frequency and 
nocturia in the same model if we want to determine which symptom can independently explain 
the variation in any of quality of life summary component scales (PCS and MCS). 
  
Table  4-28: Bivariate Correlations Between IC Symptoms at Baseline (n=41) 
 PAIN SCORE A URINARY 
FREQUENCY 
NOCTURIA B 
ρ* p ρ p ρ p 
Pain Score A 
 
______ ______ ______ ______ ______ ______ 
Urinary Frequency 
 
0.3 0.07 ______ ______ ______ ______ 
Nocturia 
 
0.2 0.2 04 0.004 ______ ______ 
Urgency Score B 0.4 0.01 0.02 0.9 0.1 0.5 
 
* Spearman correlation coefficient 
 A  A score of 1 indicates no pain; a score of 9 indicates severe pain. Pain during voididng shows the same correlations as general pain  
 B  A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
 
4.3.6.2 Factors that Were Found to be Associated With PCS and/ or MCS Scales 
Although, we determined the factors that were associated with the quality of life in IC patients 
previously in this chapter (sections: 4.3.3 and 4.3.4), it was important to know how these factors 
will affect the component summary scales of the SF-36 as well. This step was crucial to 
determine the covariates that we will need to adjust for when assessing how each symptom of IC 
affects each summary component of quality of life. 
4.3.6.2.1 Socio-Demographic Factors 
Table 4-29 presents the univariate associations between each of the quality of life summary 
component scales and certain demographic factors at baseline. It was not a surprise for us to find 
that marital status was the only demographic factor found to be associated with PCS as we 
previously, in this chapter, reported that marital status was significantly associated with the 
component domains of this summary scale (role-physical, bodily pain, general health), Table 4-
22.  Similar to what we observed earlier, married subjects showed a better physical component 
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 scale score  (median = 40.6) compared to currently not married subjects (median = 33.7), p=0.03. 
On the other hand, marital status was not found to be associated with the MCS, although, it was 
found to be significantly associated with two component domains (vitality and social 
functioning) of this summary scale, Table 4-22. 
 
Table  4-29: Univariate Associations Between Each of the Quality of Life Summary 
Component Scales and Certain Demographic Factors at Baseline (n=41) 
DEMOGRAPHIC 
FACTORS 
N PCS A 
 
MCS A 
Median (25th percentile, 
75th percentile) 
 
P* 
value
Median (25th percentile, 
75th percentile) 
 
P* 
value
Age Categories 
20-29 
30-39 
40-49 
50+ 
 
41
11 
12 
10 
8
 
37.7 (33.4, 47.5) 
35.4 (28.2, 50.4) 
37.4 (32.9, 44.8) 
39.1 (26.7, 41.1) 
0.9  
38.2 (32.7, 39.8) 
34.9 (24.7, 47.2) 
39.1 (28.2, 57.3) 
48.2 (39.8, 51.5) 
0.3 
Ethnicity            
Caucasian              
Not Caucasian B                  
 
41
29 
12
 
36.8 (31.9, 44.7) 
39.2 (32.5, 51.1) 
0.4  
39.8 (28.9, 49.5) 
38.6 (27.8, 51.2) 
0.8 
Marital Status    
Married                   
Currently not married C         
 
41
23 
18
 
40.6 (33.5, 51.0) 
33.7 (26.5, 38.8) 
0.03  
42.2 (38.2, 51.5) 
34.2 (25.9, 42.3) 
0.1 
Education Levels 
Elementary &  Secondary     
Post-Secondary        
 
41
13 
28
 
37.6 (29.3, 44.9) 
38.1 (32.3, 47.4) 
0.8  
49.2 (31.2, 54.6) 
38.0 (27.9, 41.6) 
0.07 
Employment Status 
Employed 
Not employed 
 
41
32 
9
 
39.1 (33.4, 48.3) 
32.0 (26.6, 41.9) 
0.2  
38.8 (27.1, 48.4) 
49.2 (34.5, 54.6) 
0.2 
* P value: Mann-Whitney U test or Kruskal-Wallis test   
A  PCS: Physical Component Summary, MCS: Mental component summary. Both PCS and MCS are norm-based scores: all scores above or 
below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one tenth 
of a standard deviation 
B   Not Caucasian = Black, Hispanic, Asian and other 
C   Currently not married = widowed, divorced, never married and other 
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 4.3.6.2.2 Reproductive and Lifestyle Factors 
Table 4-30 shows the univariate associations between each of the quality of life summary 
component scales and certain reproductive history and lifestyle factors at baseline. Only being 
sexually active during the month previous to the baseline interview was found to be significantly 
associated with a better PCS score. Subjects who had sexual intercourse during the month 
previous to the baseline interview reported a greater PCS score (median = 48.5) compared to 
those who had not’ (median = 39.6), p=0.006. On the other hand, none of the assessed factors 
was found to be significantly associated with MCS score. 
 
Table  4-30: Univariate Associations Between Each of the Quality of Life Summary 
Component Scales and Certain Reproductive History and Lifestyle Factors at Baseline 
(n=41) 
REPRODUCTIVE & 
LIFESTYLE FACTORS 
N PCS A 
 
MCS A 
Median (25th percentile, 75th 
percentile) 
 
P* 
value 
Median (25th percentile, 75th 
percentile) 
 
P* 
value 
Ever Pregnant           
Yes                                    
No                                      
 
41 
31 
10 
 
37.7 (33.2, 47.5) 
36.1 (25.8, 47.4) 
0.3  
39.8 (31.7, 50.0) 
29.9 (24.5, 40.9) 
0.06 
Number of Pregnancies   
1-2                                       
3+                                       
 
31 
17 
14 
 
37.6 (32.7, 42.4) 
40.1 (32.9, 52.4) 
0.5  
39.5 (33.7, 47.3) 
48.0 (28.5, 52.0) 
0.6 
Menopausal Status               
Menopause                        
Not Menopause                 
 
41 
15 
26 
 
33.6 (26.7, 40.6) 
38.8 (33.4, 48.6) 
0.1  
45.3 (30.0, 50.0) 
38.6 (27.1, 49.0) 
0.5 
Ever Used OC             
Yes                                    
No                                      
 
41 
36 
5 
 
37.6 (32.3, 47.4) 
39.6 (29.1, 47.7) 
0.9  
38.8 (27.9, 49.1) 
54.6 (31.6, 57.4) 
0.1 
Ever Used HRT B            
Yes                                      
No                                        
  
38 
11 
27 
 
33.2 (26.6, 41.2) 
39.9 (33.7, 48.5) 
0.1  
45.3 (24.2, 50.0) 
38.9 (27.1, 48.8) 
0.6 
Ever Smoked                   
Yes                                      
No                 
41 
24 
17 
 
34.1 (32.3, 41.1) 
40.6 (29.4, 49.9) 
0.2  
38.8 (27.1, 49.5) 
39.4 (30.4, 50.6) 
0.7 
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Table 4-30 Cont’d
REPRODUCTIVE & 
LIFESTYLE FACTORS 
N PCS A 
 
MCS A 
Median (25th percentile, 75th 
percentile) 
 
P* 
value 
Median (25th percentile, 75th 
percentile) 
 
P* 
value 
Had Sexual  Intercourse C 
Yes 
No 
40 
29 
11 
 
 
48.5 (39.9, 8.7) 
39.6 (26.7, 9.1) 
 
0.006  
49.0 (38.9, 11.3) 
52.0 (40.0, 14.2) 
0.9 
*  P value: Mann-Whitney U test or Kruskal-Wallis test   
A   PCS: Physical Component Summary, MCS: Mental component summary. Both PCS and MCS are norm-based scores: all scores above or 
below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one tenth of a 
standard deviation 
B  Three were missing at baseline 
C  One was missing at baseline. Subjects were asked if they had sexual intercourse during the month previous to the baseline assessment 
 
4.3.6.2.3 Co-morbidity, BMI and Sexual Function Domains 
Table 4-31 describes the bivariate correlations between each of the quality of life summary 
component scales and certain factors (co-morbidity, BMI and sexual domains) at baseline. 
Interestingly, none of these factors was found to be significantly correlated with any of the two 
summary component scales. Moreover, a negative marginally significant correlation was found 
between the PCS score and the number of co-morbid conditions (ρ = -0.3, p=0.09). 
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     Table  4-31: Correlations Between Each of the Quality of Life Summary Component      
    Scales and Co-morbidity, BMI and Sexual  Function Domains at Baseline (n=41) 
 
FACTORS 
SF-36 SUMMARY COMPONENETS 
 
PCS A 
 
MCS A 
ρ* p ρ* p 
Number of Co-morbid Conditions B 
 
-0.3 0.09 -0.2 0.1 
BMI C 
 
-0.1 0.6  0.04 0.8 
Sexual Desire D 
 
-0.01 0.9  0.1 0.8 
Sexual Arousal D 
 
 0.03 0.9 -0.03 0.9 
*   Spearman correlation coefficients 
A      PCS: Physical Component Summary, MCS: Mental component summary. Both PCS and MCS are norm-based scores: all scores above     
        or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one    
      tenth of a standard deviation 
B   Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or may exacerbate IC  
       symptoms e.g.: endometriosis, irritable  bowel syndrome, stress, depression, fibromyalgia,  hypertension, diabetes...etc 
C     BMI: body mass index. BMI was based on self-reported weight and height at week18 
D    One was missing at baseline. Both sexual desire and sexual arousal were based on visual analog scale (0-10cm), 0    
     = none while 10 = high. Subjects were asked to evaluate their sexual desire and sexual arousal during the month previous to the baseline  
     assessment 
 
 
4.3.6.3 Unadjusted Bivariate Correlations Between Each of the PCS and MCS 
Scales and Each of the IC Symptoms  
Table 4-32 shows the bivariate correlations between each of the quality of life component 
summary scales and each symptom of IC. Interestingly, all symptoms were found to be 
significantly negatively correlated with the PCS score, but not with the MCS score.  Both pain 
and urinary frequency symptoms showed the strongest negative correlations with PCS score (ρ= 
-0.5, p=0.002 and ρ= -0.5, p=0.003, respectively) among the IC symptoms. On the other hand, a 
weak negative correlation was reported between pain and MCS, however, it was not significant 
(ρ= -0.3, p=0.09). In fact, these results were consistent with what we reported previously (Table 
4-26, 4-27); severity of IC symptoms was found to be significantly associated with the reduction 
in the scores of three of the component domains of the PCS (physical functioning, bodily pain 
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and general health domains) and only one of the component domains of the MCS (Mental 
health). 
 
    Table  4-32: Correlation Coefficients and P values for Correlations Between Each of the    
    PCS and MCS scale and IC Symptoms at Baseline (n=41) 
 
FACTORS 
SF-36 SUMMARY COMPONENETS 
 
PCS A 
 
MCS A 
ρ* p ρ* p 
Pain Score B 
 
-0.5 0.002 -0.3 0.09 
Urinary Frequency 
 
-0.5 0.003 0.1 0.8 
Nocturia 
 
-0.3 0.03 0.2 0.2 
Urgency Score C 
 
-0.4 0.02 0.1 0.6 
*  Spearman correlation coefficients 
A   PCS: Physical Component Summary, MCS: Mental component summary. Both PCS and MCS are norm-based   
    scores: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US    
    population. Each one difference in score is one tenth of a standard deviation 
 B   A score of 1 indicates no pain; a score of 9 indicates severe pain. Voiding pain was found to be significantly correlated     
    with PCS (ρ=-0.4, P=0.004) and not significantly correlated with MCS (ρ=-0.2, P=0.1) 
 C  A score of 1 indicates no urgency; a score of 5 indicates severe urgency. 
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4.3.6.4 Adjusted Associations Between Physical Component Summary Scale and 
Each of the IC Symptoms 
Because none of the IC symptoms showed any significant correlation with MCS scale in the 
unadjusted analysis (section 4.3.6.3), we did not expect that these results will be significantly 
changed after adjusting for age and co-morbidity. On the other hand, it was crucial to perform 
further examination to determine if the significant associations which we reported in the previous 
section (section 4.3.6.3) between the PCS scale and each of the IC symptoms will be altered 
after adjusting for age, co-morbidity and the main study covariates.  
Table 4-33 shows the results of the multivariate median regression models between PCS 
scale score and each of the IC symptoms after adjusting for age, co-morbidity and marital status. 
Importantly, because our sample size is small, each time we fit a model and found that the 
addition of a certain covariate had not a significant effect on either the regression coefficients or 
the p values, we selected the parsimonious model (model with the least number of covariates) as 
our final model. This was the case when we included being sexually active variable into each 
model.  
Interestingly, after adjusting for age, co-morbidity and marital status in each model, only 
pain during voiding (model 1) and nocturia (model 3) were found to be significantly associated 
with lower PCS score. The median PCS score was found to be reduced by approximately 2.79 
point for a subject whose score of pain during voiding is 1 point higher than another subject’s, 
p=0.04.  On the other hand, the median PCS score was found to be reduced by approximately 1.8 
point for a subject whose average number of nocturia during an 24 hour period is 1 greater than 
 another subject’s, p=0.01. Importantly, the magnitude of variation in PCS score that can be 
explained by urgency (model 4: ß=-5.45, p=0.1) was large, however, not statistically significant. 
 
   Table  4-33: Multivariate Median Regression Models for the PCS and Each Symptom of    
   IC after Adjusting for Age, Co-morbidity and Marital Status at Baseline (n=41) 
INDEPENDENT VARIABLE  PCS A 
β P Value 
Model (1) 
Pain B 
Age 
Number of Co-morbid ConditionsC 
Marital Status D 
 
-2.79 
-0.07 
 0.05 
 8.92 
 
0.04 
0.7 
0.9 
0.05 
 
Model (2) 
Urinary Frequency 
Age 
Number of Co-morbid Conditions 
Marital Status 
 
 
-0.49 
-0.03 
-0.63 
 6.76 
 
0.09 
0.8 
0.1 
0.1 
Model (3) 
Nocturia 
Age 
Number of Co-morbid Conditions 
Marital Status 
 
 
-1.80 
 0.19 
-0.76 
 6.50 
 
0.01 
0.3 
0.2 
0.1 
Model (4) 
Urgency E 
Age 
Number of Co-morbid Conditions 
Marital Status 
 
-5.45 
-0.01 
-0.48 
 4.79 
 
0.1 
0.9 
0.4 
0.3 
 
A    PCS: Physical Component Summary, a norm-based score. All scores above or below the 50 are above or below  
       the average, respectively, in the 1998 general US population. Each one difference in score is one tenth of a standard  
     deviation. 
B   Pain during voiding. A score of 1 indicates no pain; a score of 9 indicates severe pain 
C   Four subjects had no co-morbid conditions.  Co-morbid conditions are conditions that were active during the trial or    
     may exacerbate IC symptoms e.g.: endometriosis, irritable   bowel syndrome, stress, depression, fibromyalgia,     
     hypertension, diabetes...etc. 
D    Marital status: married or currently not married (widowed, divorced, never married and other). Currently not    
     married is the reference group. 
 E   A score of 1 indicates no urgency; a score of 5 indicates severe urgency. 
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4.4 EFFICACY RESULTS  
4.4.1 Severity of IC Symptoms  
As mentioned previously in chapter three of this dissertation, severity of IC symptoms was 
measured using two well-known validated instruments: O’Leary-Sant interstitial cystitis 
symptom and problem index and PUF instrument. Both total score from O’Leary-Sant 
instrument and from PUF instrument were used as well as their components: ICSI score and ICPI 
score of the O’Leary-Sant instrument and symptoms score and bother score of the PUF 
instrument. 
4.4.1.1 Changes in the Severity of IC Symptoms Among Treatment and Placebo 
Groups Over the Study Period 
 
Figure 4-2 shows time plots of O’Leary-Sant total score, ICSI score and ICPI score for both 
study groups. Both treatment and placebo groups showed a decreasing trend in the severity of IC 
symptoms over the study period. Interestingly, the reduction in O’Leary-Sant total score as well 
as in ICSI and ICPI scores appeared to be more among the treatment group compared to the 
placebo group. The same decreasing trend can be observed in Figure 4-3 which shows time plots 
of PUF total score, symptoms score and bother score for both study groups. Once again, the 
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reductions in PUF total score as well as in symptoms score and bother score appear to be more 
among the treatment group in comparison to the placebo group. 
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*  Scores were presented as median. 
* Total_Placebo: Total O’Leary_Sant score for placebo, Total_Treatment: Total O’Leary_Sant score for treatment, ICSI_Placebo: Interstitial cystitis symptom index score for placebo, 
ICSI_Treatment: Interstitial cystitis symptom index score for treatment, ICPI_Placebo: Interstitial cystitis problem index score for placebo, ICPI_Treatment: Interstitial cystitis problem index 
score for treatment 
 
        Figure  4-2: Time Plots of the O'Leary-Sant Total Score, ICSI Score and ICPI Score by Study Group 
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* Scores were presented as median 
* Total_Placebo: Total PUF score for placebo, Total_Treatment: Total PUF score for treatment, Symptom_Placebo: Symptom score for placebo, Symptom_Treatment: Symptom score for     
Figure  4-3: Time Plots of the PUF Total Score, Symptom Score and Bother Score by Study Group 
   treatment, Bother_Placebo: Bother score for placebo, Bother_Treatment: Bother score for Treatment  
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4.4.1.2 Effect of Trial Treatment and Placebo on the Severity of IC 
Symptoms 
Both study groups showed statistically significant improvement in the severity of IC 
symptoms at each endpoint (week 6, week 12 and week 18) in comparison to the 
baseline, (p<0.05). Table 4-34 presents the changes in the scores of the severity of IC 
symptoms (O’Leary-Sant index and PUF instrument) from baseline to each endpoint 
among the treatment group. At each endpoint, the treatment group showed statistically 
significant improvement (reduction) in the severity of IC symptoms, measured by both 
O’Leary-Sant and PUF instruments, compared to the baseline. Moreover, by the end of 
the trial, treatment group showed ~46% reduction in O’Leary-Sant total score and ~30% 
reduction in PUF total score compared to the baseline (p<0.001).  
Significant improvement in the severity of IC symptoms was also reported among 
the placebo group at each endpoint in comparison to the baseline, Table 4-35. At week 
18, placebo group showed ~ 35% reduction in O’Leary-Sant total score and ~28% 
reduction in PUF total score in comparison to the baseline (p<0.001).  
Table 4-36 shows the changes in the scores of the severity of IC symptoms from 
baseline to week 6, week 12 and week 18 between study groups. Interestingly, the 
treatment group reported statistically significant changes from baseline to week 12 in 
both O’Leary-Sant total score and ICSI score compared to the placebo, (changes in 
O’Leary-Sant total score: -12 vs -5.5 , p value =0.04, respectively; changes in ICSI score: 
-6 vs -3, p value =0.03, respectively).  
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Moreover, greater reduction in the changes in O’Leary-Sant total score as well as 
in ICPI score from baseline to week 18 were reported among the treatment group in 
comparison to the placebo group, (changes in O’Leary-Sant total score: -12 vs -8 , p 
value =0.07, respectively; changes in ICPI score: -6 vs -4, p value =0.05, respectively). 
No significant differences were observed in PUF total score, PUF symptoms score 
and/or PUF bother score from baseline to any endpoint between the study groups. 
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Table  4-34: Changes in IC Symptom Severity Scores from Baseline to Week 6, Week 12 and Week 18 in the Treatment 
Group* 
 
OUTCOMES 
SCORES OF TREATMENT GROUP (N=21) 
AT : 
Baseline 
 
Week 6 
 
Change B-
W6* 
P B Week 12 ChangeB-
W12* 
P B Week 18 ChangeB-
W18* 
P B 
O’Leary-Sant Total 
Score (0-36) 
O’Leary-Sant ICSI A  
(0-20) 
O’Leary-Sant ICPI A  
(0-16) 
 
26 (18.5, 32) 
 
14 (10.5, 17) 
 
13 (8.5, 15) 
16 (8.5, 26) 
 
  8 (4.5, 14) 
 
  8 (3.5, 13) 
-7 (-3, -14.5) 
 
-4 (-1.5, -8) 
 
-3 (-1.5, -7) 
<0.001 
 
<0.001 
 
<0.001 
12 (7.5, 20.5) 
 
  7 (5,10.5) 
 
  5 (3, 10) 
-12 (-6.5, -16.5) 
 
  -6 (-3, -7.5) 
 
  -6 (-3, -8.5) 
 
<0.001 
 
<0.001 
 
<0.001 
9 (6.5, 22) 
 
5 (4, 11) 
 
4 (2.5, 11) 
 
-12 (-7.5, -16.3) 
 
 -6 (-3.5, -9) 
 
 -6 (-3.5, -8.5) 
<0.001 
 
<0.001 
 
<0.001
PUF1 Total Score 
(1-35) 
PUF Symptom Index  
(1-23) 
PUF Bother Index   
(0-12) 
  
23 (18.3, 25.5) 
 
14 (11.5, 17) 
 
  8 (6, 9) 
 
15 (12, 21.8) 
 
10 (8, 15.3) 
 
  5 (4, 8) 
-4 (0, -8.8) 
 
-3 (0, 5.5) 
 
-1 (0, -2.8) 
0.002 
 
0.002 
 
0.005 
13 (10, 19.5) 
 
  8 (7, 12.5) 
 
  5 (3, 7) 
 
-6 (-3, -10.5) 
 
-5 (-2, -7) 
 
-2.5 (-1, -3.5) 
<0.001 
 
<0.001 
 
0.001 
13 (8.5, 19) 
 
 9 (6, 12) 
 
 4 (3, 7) 
-7 (-4, -13) 
 
-4 (-2, -7.5) 
 
-3 (-1.8, -4.5) 
<0.001 
 
<0.001 
 
<0.001
*  Data were presented as median (25th, 75th percentiles), negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A    ICSI: interstitial cystitis symptom index, ICPI: interstitial cystitis problem index, PUF: pain and urgency/frequency patient symptom scale 
B    Wilcoxon Sign Rank test  
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Table  4-35: Changes in IC Symptom Severity Scores from Baseline to Week 6, Week 12 and Week 18 in the Placebo Group* 
 
OUTCOMES 
SCORES OF PLACEBO GROUP (N=20) 
AT : 
Baseline 
 
Week 6 
 
Change B-
W6* 
P B Week 12 ChangeB-
W12* 
P B Week 18 ChangeB-W18* P B 
O’Leary-Sant Total 
Score (0-36) 
O’Leary-Sant ICSI A  
(0-20) 
O’Leary-Sant ICPI A  
(0-16) 
 
23 (19.3, 30) 
 
12 (10, 16) 
 
11.5 (10, 14) 
16 (10, 25.5) 
 
  9 (6, 14.3) 
 
  8 (4.5, 11.8) 
-4 (-1.3, -12) 
 
-2 (0, -4.8) 
 
-2 (-1, -5) 
0.001 
0.003 
0.002 
16.5 (10, 25) 
 
  8.5 (6, 13.8) 
 
  7.5 (4, 11) 
-5.5 (-3, -9) 
 
-3 (-1.3, -4) 
 
-3 (-1, -5) 
0.001 
0.001 
0.001 
15.5 (7, 21) 
 
  7.5(4.3, 12) 
 
  8 (2.5, 10.8) 
-8 (-3.3, -13)
 
-4 (-3, -7.5)  
 
-4 (-0.3, -5)  
<0.001 
 
<0.001 
 
0.001 
PUF1 Total Score 
(1-35) 
PUF Symptom Index  
(1-23) 
PUF Bother Index   
(0-12) 
  
21.5 (18, 26.5) 
 
14   (12.3, 17) 
 
 7.5 (6, 9.8) 
 
17.5 (10, 22) 
 
12 (6.5,14.8) 
 
  6 (3, 7.8) 
-3.8 (-1.3, -7.8) 
 
-2 (-1, -5.5) 
 
-1.8 (-1, -3) 
 
 
<0.001 
 
0.001 
0.001 
15 (11, 20) 
 
10 (7, 13.8) 
 
  5.2 (4, 7) 
-5.8 (-3, -10)
 
-4   (-2, -6.5)  
 
-1.8 (-1, -3.8)  
<0.001 
 
<0.001 
0.001 
15 (10, 18.5) 
 
10 (6.3, 12.8) 
 
  5 (3, 6) 
-6 (-3, -13)
 
-4.5 (-2.3, -8)  
 
-3 (-1, -5)  
<0.001 
 
<0.001 
 
<0.001 
*  Data were presented as median (25th, 75th percentiles),, negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A    ICSI: interstitial cystitis symptom index, ICPI: interstitial cystitis problem index, PUF: pain and urgency/frequency patient symptom scale 
B    Wilcoxon Sign Rank test 
 
Table  4-36: Changes in IC Symptom Severity Scores from Baseline to Week 6, Week 12 and Week 18 Between Study 
Groups*189 
 
OUTCOMES 
BASELINE TO WEEK 6* BASELINE TO WEEK 12* BASELINE TO WEEK 18* 
Treatment Placebo P B Treatment Placebo P B Treatment Placebo P B 
O’Leary-Sant Total 
Score (0-36) 
O’Leary-Sant ICSI A  
(0-20) 
O’Leary-Sant ICPI A  
(0-16) 
 
-7 (-3, -14.5) 
 
-4 (-1.5, -8) 
 
-3 (-1.5, -7) 
-4 (-1.3, -12) 
 
-2 (0, -4.8) 
 
-2 (-1, -5) 
0.2 
 
0.2 
0.3 
-12 (-6.5, -16.5) 
 
  -6 (-3, -7.5) 
 
  -6 (-3, -8.5) 
 
-5.5 (-3, -9) 
 
-3 (-1.3, -4) 
 
-3 (-1, -5) 
0.04 
0.03 
0.06 
-12 (-7.5, -16.3) 
 
  -6 (-3.5, -9) 
 
  -6 (-3.5, -8.5) 
-8 (-3.3, -13)
 
-4 (-3, -7.5)  
 
-4 (-0.3, -5)  
0.07 
0.1 
 
0.05 
PUF1 Total Score 
(1-35) 
PUF Symptom Index  
(1-23) 
PUF Bother Index   
(0-12) 
  
-4 (0, -8.8) 
 
-3 (0, 5.5) 
 
-1 (0, -2.8) 
-3.8 (-1.3, -7.8) 
 
-2 (-1, -5.5) 
 
-1.8 (-1, -3) 
 
 
0.8 
 
0.9 
0.6 
  -6 (-3, -10.5) 
 
  -5 (-2, -7) 
 
  -2.5 (-1, -3.5) 
-5.8 (-3, -10)  
 
-4   (-2, -6.5)  
 
-1.8 (-1, -3.8)  
0.6 
0.6 
0.7 
  -7 (-4, -13) 
 
  -4 (-2, -7.5) 
 
  -3 (-1.8, -4.5) 
-6 (-3, -13)
 
-4.5 (-2.3, -8)  
 
-3 (-1, -5)  
0.7 
0.8 
0.9 
*  Data were presented as median (25th, 75th percentiles), negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A    ICSI: interstitial cystitis symptom index, ICPI: interstitial cystitis problem index, PUF: pain and urgency/frequency patient symptom scale 
B    Mann-Whitney test 
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4.4.2 IC Symptoms (Pain, Urgency, Urinary Frequency and Nocturia) 
In the previous section (4.4.1), we presented the effect of the trial interventions on the 
severity of IC symptoms in general. In this section we present the effect of the trial 
interventions on each IC symptom separately, in order to determine which symptom 
(pain, urgency, urinary frequency and/or nocturia) is most likely to be improved as a 
result of administering either intravesical PPS plus oral PPS or intravesical placebo plus 
oral PPS at the following endpoints: week 6, week 12, and/or week 18 of the trial.   
4.4.2.1 Changes in Each of the IC Symptoms Among Treatment and Placebo 
Groups Over the Study Period 
Figures 4-4, 4-5, 4-6 and 4-7 show time plots of pain score, urgency score, number of 
voids during day time (urinary frequency) and number of voids during sleeping time 
(nocturia) for both study groups respectively. Interestingly, both treatment and placebo 
groups showed a decreasing trend in the scores of pain and of urgency as well as in the 
number of voids during daytime and during sleeping hours over the study period. 
Although the descriptive results by study group in section (4.2.2.4) showed that the two 
groups had comparable pain and urgency scores at baseline as well as comparable urinary 
frequency and nocturia, the treatment group showed more reduction (improvement) in 
each of IC symptoms over time compared to the placebo group. 
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     Figure  4-4: Time Plots of the Pain Score by Study Group 
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   Figure  4-5: Time Plots of the Urgency Score by Study Group 
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    * Data were presented as median 
 
 Figure  4-6: Time Plots of the Number of Voids During Day Time (Urinary Frequency) by Study Group 
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 *  Data were presented as median 
 
 Figure  4-7: Time Plots of the Number of Voids During Night Sleeping (Nocturia) by Study Group 
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4.4.2.2 Effect of Trial Treatment and Placebo on IC Symptoms 
Table 4-37 shows the changes in IC symptoms from baseline to week 6, week 12 and 
week 18 in the treatment group. At each endpoint, the treatment group reported a highly 
statistically significant reduction (improvement) in both pain and urgency scores 
compared to the baseline. Moreover, by the end of the trial, treatment group showed 
~50% reduction in pain score and ~17% reduction in urgency score compared to the 
baseline (p<0.005). Significant reduction in nocturia (number of voids during sleeping) 
was reported at the end of the trial in comparison to the baseline. (~50% reduction, 
p=0.002). No significant improvement was observed in urinary frequency (number of 
voids during daytime) at any endpoint in comparison to the baseline.  
Table 4-38 presents the changes in IC symptoms from baseline to week 6, week 
12 and week 18 in the placebo group. Interestingly, significant reduction (improvement) 
was observed in pain score as well as in urinary frequency at each endpoint in 
comparison to the baseline. Furthermore, at week 18, placebo group reported ~ 42% 
reduction in pain score and ~21% reduction in the number of voids during daytime 
(urinary frequency) compared to the baseline. Similar to the treatment group, placebo 
group showed significant reduction in the number of voids during sleeping time only at 
the end of the trial compared to the baseline (~50% reduction, p=0.01). Importantly, 
placebo group did not show significant improvement in urgency score at any endpoint in 
comparison to the baseline. 
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Table 4-39 shows the changes in IC symptoms from baseline to week 6, week 12 
and week 18 between study groups. Interestingly, The placebo group reported 
significantly more reduction in the urinary frequency from baseline to week 6 compared 
to the treatment group, (changes in urinary frequency: -2.5 vs -1, p value =0.04, 
respectively). No significant differences were observed in pain score, urgency score 
and/or nocturia from baseline to any endpoint between the study groups. 
 
 
Table  4-37: Changes in IC Symptoms from Baseline to Week 6, Week 12 and Week 18 in the Treatment Group* 
 
OUTCOMES 
TREATMENT GROUP (N=21) 
Baseline 
 
Week 6 
 
Changes B-
W6* 
P D Week 12 Change B-
W12* 
P D Week 18 Change B-
W18* 
P D 
Pain Scale (1-9) A 
 
4 (4, 5) 2 (2, 4) -1 (0, -2)  0.004 2 (1.5, 3.8) -2 (-0.5, -3)  0.001 2 (1, 3) -2 (-1, -3)  0.001
Urgency Scale (1-5) B 
 
3.5 (2.6, 3.6) 2.9 (2, 3.4) -0.4 (0.1, -1)  0.008 2.9 (2, 3.4) -0.6 (-0.1, -1)  0.007 2.6 (2, 3) -0.6 (0, -1.2)  0.007
Voiding Frequency C 
 
12 (9, 16) 10 (7, 15) -1 (3, -2.5)  0.8 8 (7, 15.5) -2 (1.5, -3.5) 0.1 9 (7, 16.5) -1 (0, -3)  0.1 
Nocturia C 
 
2 (1, 4) 1 (1, 3) 0 (0, -1)  0.08 2 (1, 3) 0 (1. 5, -1) 0.8 1 (0, 2) -1 (-0.5, -2)  0.002
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A   A score of 1 indicates no pain; a score of 9 indicates severe pain 
B    A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
C   Voiding frequency: number of voids during day time, Nocturia: number of voids during night sleeping 
D    Wilcoxon Sign Rank test 
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Table  4-38: Changes in IC Symptoms from Baseline to Week 6, Week 12 and Week 18 in the Placebo Group* 
 
OUTCOMES 
PLACEBO GROUP (N=20) 
Baseline 
 
Week 6 
 
Change B-W6* P D Week 12 Change B-
W12* 
P D Week 18 Change B-
W18* 
P D 
Pain Scale (1-9) A 
 
4.8 (4, 5.8) 2.5 (2, 5) -1.5 (-0.3, -3)  0.007 3 (1.3, 5) -1.5 (0, -3)  0.001 2.5 (1.3, 4) -2 (0, -3)  0.001
Urgency Scale (1-5) B 
 
3 (2.5, 3.2) 2.9 (2, 3.5) -0.2 (0.5, -0.8) 0.4 3 (1.9, 3.4) -0.2 (0.4, -1.1) 0.3 2.8 (2, 3.4) -0.4 (0.2, -0.9) 0.09 
Voiding Frequency C 
 
14.5 (10, 18.8) 10 (8, 14.5) -2.5 (-1, -4.8)  0.001 11 (8, 14.5) -2 (-0.3, -4.8)  0.003 9 (7, 15) -3 (-1, -7)  0.001
Nocturia C 
 
2 (1, 4) 2 (1, 3.8) -0.5 (0.8, -2) 0.4 2 (0, 2) -0.5 (0, -2.8)  0.09 1 (0, 2) -1 (0.8, -2)  0.01 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A   A score of 1 indicates no pain; a score of 9 indicates severe pain 
B   A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
C   Voiding frequency: number of voids during day time, Nocturia: number of voids during night sleeping 
D    Wilcoxon Sign Rank test 
 
Table  4-39: Changes in IC Symptoms from Baseline to Week 6, Week 12 and Week 18 Between Study Groups*189 
 
OUTCOMES 
BASELINE TO WEEK 6* BASELINE TO WEEK 12* BASELINE TO WEEK 18* 
Treatment Placebo P D Treatment Placebo P D Treatment Placebo P D 
Pain Scale (1-9) A 
 
-1 (0, -2)  -1.5 (-0.3, -3)  0.5 -2 (-0.5, -3)  -1.5 (0, -3)  0.7 -2 (-1, -3)  -2 (0, -3)  0.7 
Urgency Scale (1-5) B 
 
-0.4 (0.1, -1)  -0.2 (0.5, -0.8) 0.3 -0.6 (-0.1, -1)  -0.2 (0.4, -1.1) 0.4 -0.6 (0, -1.2)  -0.4 (0.2, -0.9) 0.3 
Voiding Frequency C 
 
-1 (3, -2.5)  -2.5 (-1, -4.8)  0.04 -2 (1.5, -3.5) -2 (-0.3, -4.8)  0.4 -1 (0, -3)  -3 (-1, -7)  0.05 
Nocturia C 
 
0 (0, -1)  -0.5 (0.8, -2) 0.9 0 (1. 5, -1) -0.5 (0, -2.8)  0.3 -1 (-0.5, -2)  -1 (0.8, -2)  0.8 
 *  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates improvement) 
A    A score of 1 indicates no pain; a score of 9 indicates severe pain 
B    A score of 1 indicates no urgency; a score of 5 indicates severe urgency 
C   Voiding frequency: number of voids during day time, Nocturia: number of voids during night sleeping 
D    Mann-Whitney test 
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4.4.3 Proportion of Responders and Level of Improvement Among Responders in Both 
Study Groups at the End of the Trial (Week 18) 
As it was mentioned previously in chapter three of this dissertation, responders to trial 
interventions were defined as those who reported any level of improvement in their overall 
condition, urinary frequency or in their urgency at the end of the trial (After 18 weeks).  
Figure 4-8 shows the proportion distribution of responders who reported any level of 
improvement in their overall condition by study group at week 18. It also shows the proportion 
distribution of the level of improvement among responders in each group. The proportion of 
subjects who reported any level of improvement in their overall condition were comparable 
among the two study groups (treatment: 85.7%, placebo: 90%, p>0.9). 189 Interestingly, 72.2% of 
the responders in the treatment group reported that their overall condition was greatly improved 
at week 18 compared to 33.3% of the responders in the placebo group (p value: 0.04). 189 
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*    Responders were defined as those who reported any level of improvement in their overall condition at the end of the trial. Fisher’s  
      exact p value >0.9 
**  Levels of Improvement in overall condition among responders were moderately improved, greatly improved and/ or completely    
      improved. Fisher’s exact p value was 0.04 
 
Figure  4-8: Proportion Distribution of Responders and Level of Improvement in Overall 
Condition in Both Study Groups at the End of the Trial 
 
According to Figure 4-9, all subjects of the treatment group reported improvement in 
their urgency (considered responders) in comparison to 80% of the placebo group, p=0.04. 189 
Moreover, reporting urgency as greatly improved was more among responders in the treatment 
group compared to that among responders in the placebo group (61.9% vs. 37.5%, p=0.2). 189 
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   *    Responders were defined as those who reported any level of improvement in their urgency at the end of the trial. Fisher’s exact p  
       value 0.04 
**  Levels of Improvement in urgency among responders were moderately improved, greatly improved and/ or completely improved.    
      Fisher’s exact p value was 0.2 
 
  Figure  4-9: Proportion Distribution of Responders and Level of Improvement in Urgency    
  in Both Study Groups at the End of the Trial 
 
Similar results were found when we asked the study subjects to report if they had any 
improvement in their urinary frequency after 18 weeks of the study, Figure 4-10. Interestingly, 
all subjects in the treatment group reported improvement in their urinary frequency (considered 
responders) after 18 weeks of the beginning of the study in comparison to 80% in the placebo 
group, p=0.04. 189  
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 Moreover, about 61.9% of the responders in the treatment group reported that their 
urinary frequency symptom was greatly improved since baseline in comparison to 37.5% of the 
responders in the placebo group, p=0.2. 189 
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   *    Responders were defined as those who reported any level of improvement in their urinary frequency at the end of the trial. Fisher’s   
      exact p value 0.04 
**  Levels of Improvement in urinary frequency among responders were moderately improved, greatly improved and/ or completely    
      improved.  Fisher’s exact p value was 0.2 
 
  Figure  4-10: Proportion Distribution of Responders and Level of Improvement in Urinary    
  Frequency in Both Study Groups at the End of the Trial 
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4.4.4 Health Related Quality of Life (HRQL) 
SF-36 was used to assess the effect of the trial interventions on HRQL. The efficacy of the 
combination of intravesical and oral PPS was assessed using each of the component summary 
scales (PCS and MCS) as well as each domain of the SF-36 (physical functioning, role-physical, 
bodily pain and general health (physical component domains), vitality, social functioning, role-
emotion and mental health (mental component domains)) as an outcome.  The scores of either 
the two component summary scales or the domains of the SF-36 were calculated in the norm-
based score format. Therefore, all scores above or below the 50 are above or below the average, 
respectively, in the 1998 general US population. Each one difference in score is one tenth of a 
standard deviation. 
4.4.4.1 Changes in HRQL Scores Among Treatment and Placebo Groups Over the 
Study Period 
Figures 4-11 presents the time plots of PCS and MCS for both study groups. Both treatment and 
placebo groups showed an increasing trend in their PCS and/or MCS over the study period.  In 
terms of the component domains of each summary scale, Figures 4-12 and 4-13 show similar 
pattern of change in the scores of either the physical component domains (physical functioning, 
role-physical, bodily pain and general health) or the mental component domains (Vitality, social 
functioning, role-emotion and mental health), respectively, among both the study groups. In 
general increasing trends in each domain were observed among both study groups. 
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      *    Scores were presented as median. 
      *    PCS_Placebo: physical component summary score for placebo, PCS_Treatment: physical component summary score for treatment, MCS_Placebo: mental component summary score for placebo,  
           MCS_Treatment: mental component summary score for treatment. 
 
  
 Figure  4-11: Time Plots of the PCS and MCS Norm-based Scores by Study Group 
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     *     Scores were presented as median. 
     *     PF_Placebo: physical functioning score for placebo, PF_Treatment: physical functioning score for treatment, RF_Placebo: role-physical score for placebo, RF_Treatment: role-physical score for     
            treatment, BP_Placebo: bodily pain score for placebo, BP_Treatment: bodily pain score for treatment, GH_Placebo: general health score for placebo, GH_Treatment: general health  score for       
            treatment. 
 
    
Figure  4-12: Time Plots of the SF-36 Physical Component Domain Norm-based Scores by Study Group
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       *     Scores were presented as median. 
       *     VT_Placebo: vitality score for placebo, VT_Treatment: vitality score for treatment, SF_Placebo: social functioning score for placebo, SF_Treatment: social functioning score for treatment,     
              RE_Placebo: role-emotional score for placebo, RE_Treatment: role-emotional score for treatment, MH_Placebo: mental health score for placebo, MH_Treatment: mental health scores   for     
              treatment. 
 
   
Figure  4-13: Time Plots of the SF-36 Mental Component Domain Norm-based Scores by Study Group 
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4.4.4.2 Effect of Trial Treatment and Placebo on HRQL in IC Patients 
4.4.4.2.1 PCS and MCS Scores 
Table 4-40 shows the changes in each of the PCS scale and MCS scale from baseline to week 4 
and week 18 in the treatment group. Interestingly, only at the end of the study (after 18 weeks) 
treatment group reported a highly statistically significant increase (improvement) in both 
component summary scales compared to the baseline. Moreover, by the end of the trial, 
treatment group showed ~17.9% increase in PCS score and ~21.8% increase in MCS score 
compared to the baseline (p<0.0001).  
Table 4-41 presents the changes in each of the PCS scale and MCS scale from baseline to 
week 4 and week 18 in the placebo group. Significant improvement (increase) was reported in 
PCS score at week 4 (median change = 4, p=0.002) and at week 18 (median change = 7.5, 
p=0.001) compared to the baseline. On the other hand, no significant improvement was observed 
in MCS score either at week 4 or at week 18 compared to the baseline. 
Table 4-42 shows the changes in PCS and MCS scores from baseline to week 4 and week 
18 between the study groups. No significant differences were observed in PCS score from 
baseline to any endpoint between the study groups. On the other hand, treatment group reported 
significantly more increase in MCS score from baseline to week 4 compared to the placebo 
group (2 vs -0.6, p value =0.04, respectively).  
Because the treatment group reported significantly lower MCS score (median=35.7) 
compared to the placebo group (median=44.5) at baseline, p=0.03 (Table 4-13), it was very 
important to repeat the previous test, however, after adjusting for baseline score. Importantly, 
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after adjusting for baseline score, no significant differences were observed in the change in MCS 
score from baseline to any endpoint between the treatment and the placebo groups (p>0.05). 
 
 
Table  4-40: Changes in PCS and MCS Scores from Baseline to Week 4 and Week 18 in the Treatment Group* 
 
OUTCOMES 
TREATMENT GROUP (N=21) 
Baseline 
 
Week 4 
 
Change B-W4* P C Week 18 Change B-W18* P C 
PCS A 
 
38 (32.6, 44.9) 38.5 (30.6,  48.7) 0 (-2.4, 5.9)  0.5 45.3 (38.1, 57.2) 6.8 (2.8, 13.1)  <0.0001 
MCS B 
 
35.7 (25.3, 43.7) 40.4 (30.6, 51) 2 (-1.9, 12.1)  0.06 42.5 (34.8, 54.8) 7.8 (1.7, 14.7)  <0.0001 
   *  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment)  
A    PCS = physical component summary scale. Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US     
     population. Each one difference in score is one tenth of a standard deviation 
B    MCS = mental component summary scale. Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US   
     population. Each one difference in score is one tenth of a standard deviation 
C    Wilcoxon Sign Rank test 
 
 
 
 
Table  4-41: Changes in PCS and MCS Scores from Baseline to Week 4 and Week 18 in the Placebo Group* 
 
OUTCOMES 
PLACEBO GROUP (N=20) 
Baseline 
 
Week 4 
 
Change B-W4* P C Week 18 Change B-W18* P C 
PCS A 
 
38.6 (31.9, 48.3) 43.7 (35.2,  52.1)  4 (0.9, 7.9)  0.002 48.2 (35.3, 54.8) 7.8 (0.8, 14.4)  0.001 
MCS B 
 
44.5 (37.2, 51.9) 42.9 (33.2, 52.9) -0.6 (-6.5, 3.4)  0.3 46.5 (38.5, 53.7) 1.8 (-2.5, 9.5)  0.2 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    PCS = physical component summary scale. Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US     
     population. Each one difference in score is one tenth of a standard deviation 
B    MCS = mental component summary scale. Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US   
     population. Each one difference in score is one tenth of a standard deviation 
C    Wilcoxon Sign Rank test 
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Table  4-42: Changes in PCS and MCS Scores from Baseline to Week 6 and Week 18 Between Study 
Groups* 
 
OUTCOMES 
 
BASELINE TO WEEK 4* 
 
BASELINE TO WEEK 18* 
Treatment Placebo P C Treatment Placebo P C 
PCS A 
 
0 (-2.4, 5.9)  4 (0.9, 7.9) 0.08 6.8 (2.8, 13.1)  7.8 (0.8, 14.4)  0.9 
MCS B 
 
2 (-1.9, 12.1) -0.6 (-6.5, 3.4)  0.04 7.8 (1.7, 14.7)  1.8 (-2.5, 9.5)  0.1 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    PCS = physical component summary scale. Norm-based score: all scores above or below the 50 are above or below the        
    average, respectively, in the 1998 general US population. Each one difference in score is one tenth of a standard deviation 
B   MCS = mental component summary scale. Norm-based score: all scores above or below the 50 are above or below the average,     
    respectively, in the 1998 general US population. Each one difference in score is one tenth of a standard deviation. 
C  Mann-Whitney test 
 
4.4.4.2.2 SF-36 Domains 
Table 4-43 shows the changes in each of the SF-36’ domains from baseline to week 4 and week 
18 in the treatment group. After 4 weeks of the study, treatment group reported significant 
improvement (increase) in bodily pain score (median change=3.9, p=0.03) and vitality score 
(median change=2.4, p=0.02) compared to the baseline. Moreover, after 18 weeks of the study, 
the treatment group reported significant improvement (increase) in all the SF-36 domains in 
comparison to the baseline (p<0.05). 
 Table 4-44 presents the changes in each of the SF-36’ domains from baseline to week 4 
and week 18 in the placebo group. Significant improvement (increase) was reported in bodily 
pain score at week 4 (median change = 4.7, p=0.01) compared to the baseline. Marginal 
significant improvement (increase) was also reported in each of the physical functioning score 
(median change = 3.1, p=0.07) and the role-physical score (median change = 3.5, p=0.05) 
compared to baseline. At the end of the trial, the placebo group showed significant improvement 
(increase) in only three domains of the SF-36 compared to the baseline (role-physical: median 
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change = 14.1, p=0.004; bodily pain: median change = 8.9, p= 8.9; vitality: median change = 5.9, 
p= 0.01). 
Table 4-45 shows the changes in each of the SF-36’ domains from baseline to week 4 
and week 18 between the study groups. The treatment group reported greater change 
(improvement) from baseline to week 18 in both general health domain and mental health 
domain compared to the placebo group, however, the differences were marginally significant 
(general health: median change in treatment =3.7 vs. 0 in placebo, p=0.06; mental health: median 
change in treatment=6.8 vs. 1.1 in placebo, p =0.06).  
Because the treatment group reported marginal significant lower vitality score 
(median=32.5) compared to the placebo group (median=38.4) at baseline, p=0.06, and marginal 
significant lower mental health score (median=39.1) compared to the placebo group 
(median=44.8) at baseline, p=0.08 (Table 4-13), it was very important to repeat the previous test, 
however, after adjusting for baseline scores. Importantly, after adjusting for vitality baseline 
score, no significant differences were observed in the change in the vitality score from baseline 
to any endpoint between the study groups. On the other hand, after adjusting for baseline mental 
health score, treatment group continued to show greater marginal significant change (increase) in 
mental health score from baseline to week 18 compared to the placebo group, p=0.05. 
 
Table  4-43: Changes in SF-36 Domain Norm-based Scores from Baseline to Week 4 and Week 18 in the Treatment Group* 
 
OUTCOMES A 
TREATMENT GROUP (N=21) 
Baseline 
 
Week 4 
 
Change B-W4* P B Week 18 Change B-W18* P B 
Physical Functioning 
 
42.5 (34.1, 50.9) 46.7 (34.1, 50.9) 0   (-2.1, 6.2) 0.3 50.9 (39.3, 57.1)   6.3 (1, 10.1) 0.01 
Role-Physical 
 
28    (28, 42.1) 28    (28, 56.2) 0    (0, 7.1) 0.2 56.2 (31.5, 56.2) 14.1 (0, 21.2) 0.005 
Bodily Pain 
 
33.2 (26.8, 37.5) 37.5 (29.3, 46) 3.9 (0, 6.9) 0.03 46.5 (37.5, 55.9) 12 (6.6, 17.8) <0.0001 
General Health 
 
36.8 (30.1, 48.5) 39.2 (32.4, 50.9) 1.4 (-1.6, 5.2) 0.2 39.2 (32.9, 57.9)   3.7 (1, 9.4) 0.002 
Vitality 
 
32.5 (27.8, 36) 34.9 (30.1, 43.1) 2.4 (-1.2, 7.1) 0.02 44.3 (37.2, 56.2)   9.5 (4.7, 16.6) <0.0001 
Social Functioning 
 
30    (24.6, 40.9) 35.4 (24.6, 51.7) 0    (0, 5.4) 0.2 40.9 (30, 57.1) 10.9 (0, 19) 0.003 
Role-Emotional 
 
34.3 (23.7, 55.3) 44.8 (29, 55.3) 0    (0, 10.5) 0.09 55.3 (34.3, 55.3)   5.3 (0, 21.1) 0.01 
Mental Health 
 
39.1 (25.5, 45.9) 39.1 (33.4, 47) 6.8 (-5.7, 10.2) 0.1 45.9 (31.1, 56.1)   6.8 (2.3, 10.2) <0.0001 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one   
    tenth of a standard deviation 
B   Wilcoxon Sign Rank test 
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Table  4-44: Changes in SF-36 Domain Norm-based Scores from Baseline to Week 4 and Week 18 in the Placebo Group* 
 
OUTCOMES A 
PLACEBO GROUP (N=20) 
Baseline 
 
Week 4 
 
Changes B-W4* P B Week 18 Change B-W18* P B 
Physical Functioning 
 
42.5 (30.4, 52.8) 47.7 (35.1, 56.6)  3.1 (-2.1, 7.9) 0.07 52.9 (32.5, 56.6)   2.1 (0, 10.5) 0.06 
Role-Physical 
 
38.6 (28, 47.4) 42.1 (29.7, 56.2)  3.5 (0, 12.4) 0.05 56.2 (36.8, 56.2) 14.1 (0, 19.4) 0.004 
Bodily Pain 
 
33.6 (29.3, 40.7) 37.7 (30.3, 46.4)  4.7 (0, 8.6) 0.01 44.3 (33.6, 54.8)   8.9 (4.4, 17.9) 0.002 
General Health 
 
44 (36.1, 55) 44.6 (33.6, 52.6) -0.5 (-2.3, 2.3) 0.6 46.9 (33.3, 50.9)   0 (-4.7, 4.3) 0.9 
Vitality 
 
38 (32.4, 50.2) 40.8 (31.3, 48.5)  0 (-4.1, 7.1) 0.8 47.9 (37.8, 53.2)   5.9 (-2.4, 13.6) 0.01 
Social Functioning 
 
38.1 (25.9, 55.8) 43.6 (30, 55.8)  0 (0, 5.4) 0.1 49 (32.7, 57.1)   0 (0, 16.3) 0.05 
Role-Emotional 
 
44.8 (34.3, 55.3) 44.8 (23.7, 55.3)  0 (0, 0) 0.6 50.1 (34.3, 55.3)   0 (-7.9, 18.4) 0.4 
Mental Health 
 
44.8 (39.1, 49.9) 45.9 (37.9, 52.7)  2.3 (-2.3, 6.2) 0.3 48.2 (39.7, 52.7)   1.1 (0, 8.5) 0.1 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US population. Each one difference in score is one   
    tenth of a standard deviation 
B   Wilcoxon Sign Rank test 
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Table  4-45: Changes in SF-36 Domain Norm-based Scores from Baseline to Week 4 and 
Week 18 Between Study Groups* 
 
OUTCOMES A 
 
BASELINE TO WEEK 4* 
 
BASELINE TO WEEK 18* 
Treatment Placebo P B Treatment Placebo P B 
Physical Functioning 
 
0   (-2.1, 6.2) 3.1 (-2.1, 7.9) 0.5   6.3 (1, 10.1)   2.1 (0, 10.5) 0.6 
Role-Physical 
 
0    (0, 7.1) 3.5 (0, 12.4) 0.4 14.1 (0, 21.2) 14.1 (0, 19.4) 0.6 
Bodily Pain 
 
3.9 (0, 6.9) 4.7 (0, 8.6) 0.5 12 (6.6, 17.8)   8.9 (4.4, 17.9) 0.5 
General Health 
 
1.4 (-1.6, 5.2) -0.5 (-2.3, 2.3) 0.1   3.7 (1, 9.4)   0 (-4.7, 4.3) 0.06 
Vitality 
 
2.4 (-1.2, 7.1) 0   (-4.1, 7.1) 0.3   9.5 (4.7, 16.6)   5.9 (-2.4, 13.6) 0.1 
Social Functioning 
 
0    (0, 5.4) 0   (0, 5.4) 0.9 10.9 (0, 19)   0 (0, 16.3) 0.4 
Role-Emotional 
 
0    (0, 10.5) 0  (0, 0) 0.2   5.3 (0, 21.1)   0 (-7.9, 18.4) 0.3 
Mental Health 
 
6.8 (-5.7, 10.2) 2.3 (-2.3, 6.2) 0.2   6.8 (2.3, 10.2)   1.1 (0, 8.5) 0.06 
* Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A   Norm-based score: all scores above or below the 50 are above or below the average, respectively, in the 1998 general US    
    population. Each one difference in score is one tenth of a standard deviation 
B    Mann-Whitney test  
 
4.4.5 Sexual Function 
4.4.5.1 Changes in Sexual Function Domain Score Among Treatment and Placebo 
Groups Over the Study Period 
Figures 4-14 presents the time plots of sexual desire and sexual arousal domains for both study 
groups. Interestingly, only the treatment group showed continuous increasing trend in both 
sexual desire and sexual arousal domains over the study period. On the other hand, the placebo 
group showed increasing trend in both dominos only between baseline and week 4, however, 
after that a decreasing trend was reported in sexual arousal domain in particular. 
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        *   Scores were presented as median. 
        *   SD_Placebo: sexual desire scores for placebo, SD_Treatment: sexual desires scores for treatment, SA_Placebo: sexual arousal scores for placebo, SA_Treatment: sexual arousal scores for     
             treatment. 
 
 Figure  4-14: Time Plots of the Sexual Function Domain Scores by Study Group 
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4.4.5.2 Effect of Trial Treatment and Placebo on Sexual function Domain Scores of 
IC Patients 
Table 4-46 shows the changes in each of the sexual function domains from baseline to week 4 
and week 18 in the treatment group. Marginal significant improvement (increase) in sexual 
desire was observed at the end of the trial compared to the baseline (median change=0.7, 
p=0.05). No significant improvement was observed in any of the sexual desire or sexual arousal 
domains after 4 weeks of the study compared to the baseline. 
Table 4-47 presents the changes in each of the sexual function domains from baseline to 
week 4 and week 18 in the placebo group. No significant improvement was observed in any of 
the sexual desire or sexual arousal domains at any endpoint compared to the baseline, p>0.05. 
Table 4-48 shows the changes in each of the sexual function domains from baseline to 
week 4 and week 18 between the study groups. No significant differences were observed in the 
change in any of the two sexual domains from baseline to any endpoint between the two groups. 
Table  4-46: Changes in Sexual Function Domain Scores from Baseline to Week 4 and Week 18 in the Treatment Group* 
 
OUTCOMES A 
TREATMENT GROUP (N=21) 
Baseline 
 
Week 4 
 
Change B-W4* P B Week 18 Change B-W18* P B 
Sexual Desire Score 
 
1.7 (0.5, 4.5) 2    (0.7, 6.5) 0.2 (-0.1, 1.8) 0.1 3    (0.7, 5.7) 0.7 (-0.05, 3.2) 0.05 
Sexual Arousal Score 
 
2.4 (0.7, 4.9) 2.5 (0.6, 6.8) 0    (-0.3, 2.3) 0.5 3.7 (0.7, 7.8) 0.2 (-0.8, 3.6) 0.1 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    All sexual assessments were assessed for previous month period. Sexual desire and sexual arousal were based on visual analog scale (0-10cm): 0 indicates none, while 10 indicates high. 
B    Wilcoxon Sign Rank test 
 
 
 
Table  4-47: Changes in Sexual Function Domain Scores from Baseline to Week 4 and Week 18 in the Placebo Group*  
 
OUTCOMES A 
PLACEBO GROUP (N=20) 
Baseline 
 
Week 4 
 
Change B-W4* P B Week 18 Change B-W18* P B 
Sexual Desire Score 
 
3.9 (2.2, 5.5) 5    (2.7, 6.8) 0.4 (-0.6, 1.4) 0.2 5.1 (1.1, 6.9) 0.7 (-1.5, 1.5) 0.5 
Sexual Arousal Score 
 
3    (1.2, 5.8) 4.7 (0.9, 7.2) 0.5 (-1.1, 3.2) 0.2 3.3 (1.2, 7) 0.6 (-1, 3.5) 0.2 
* Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates impairment) 
A    One was missing at baseline. All sexual assessments were assessed for previous month period. Sexual desire and sexual arousal were based on visual analog scale (0-10cm): 0 indicates none, while 10      
    indicates high. 
B    Wilcoxon Sign Rank test 
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Table  4-48: Changes in Sexual Function Domain Scores from Baseline to Week 4 
and Week 18 Between Study Groups*189 
 
OUTCOMESA 
 
BASELINE TO WEEK 4* 
 
BASELINE TO WEEK 18* 
Treatment Placebo P B Treatment Placebo P B 
Sexual Desire 
Score 
 
0.2 (-0.1, 1.8) 0.4 (-0.6, 1.4) 0.9 0.7 (-0.05, 3.2) 0.7 (-1.5, 1.5) 0.4 
Sexual Arousal 
Score 
 
0   (-0.3, 2.3) 0.5 (-1.1, 3.2) 0.6 0.2 (-0.8, 3.6) 0.6 (-1, 3.5) 0.6 
*  Data were presented as median (25th, 75th percentiles) , negative sign was inserted to indicate a reduction from baseline (equates     
     impairment) 
A    One was missing at baseline. All sexual assessments were assessed for previous month period. Sexual desire and sexual arousal    
    were based on visual analog scale (0-10cm): 0 indicates none, while 10 indicates high. 
B    Mann-Whitney U test 
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5.0  DISCUSSION 
Despite the small sample size, the current study was able to contribute significantly to the 
literature of interstitial cystitis. It provided important information about the quality of life (QOL) 
of IC patients and supported the efficacy of a new therapeutic option for this devastating 
condition. This study attempted to determine to what extent socio-demographic, lifestyle, 
reproductive and clinical history factors as well as sexual function domains affect the severity of 
IC symptoms and the HRQL in IC patients comprehensively. Moreover, the current study 
examined the association between the severity of IC symptoms and the QOL extensively, and 
determined the effect of each IC symptom on the physical component as well as on the mental 
component of the QOL. This study is unique in examining the efficacy of the only approved oral 
therapy for IC in USA applied intravesically on several outcomes.   
The discussion will focus on our primary findings. This will include: the representation of 
our study population compared to other studies, a discussion of the main results from both the 
cross-sectional and the clinical trial parts and finally, directions for future research. 
 5.1 COMPARISON BETWEEN THE CURRENT STUDY POPULATION AND 
OTHER STUDY POPULATIONS 
Our study population is a convenience sample from clinical patients seen in a very large 
urological practice in Southern California. One can argue that they may not be similar to the 
entire IC patients in the community. Assessing how our sample representative to the IC patients 
in the community is not applicable, as there is no specific diagnostic criterion for IC. However, 
we can compare the characteristics of our sample with that from other similar studies. 
Unfortunately, very few studies presented the characteristics of their populations. The Interstitial 
Cystitis Data Base (ICDB) study, sponsored by the NIDDK, is one of the few studies that 
described its population clearly. 17, 194 It is a multicenter, longitudinal, observational study 
designed to determine the treated history of IC and identify common patient characteristics. It 
comprised of 5 clinical centers including multiple hospital in 6 cities in USA (Detroit, Chicago, 
Madison, Oklahoma city, Philadelphia and San Diego). Participants were recruited primarily 
from the available patient pool of each principal investigator in each center. In comparison to the 
ICDB study, our study population was younger (mean: 38.3 vs. 44.3 years old), 17 included less 
Caucasian (70.7% vs. 91%, respectively), no men (0% vs. 8.8%), were more highly educated 
(68.3% post secondary vs. 57.3% college or advanced) and more of our participants were 
currently employed (78% vs. 61.2%). 194 Approximately 80% of the current study population 
were women of perimenopausal age (<49 years old). This is not surprising as the prevalence of 
the disease appears to be increasing among young and middle aged women with a median age of 
43. 96, 140 Only female patients were included in the current study. It has been reported that the 
prevalence of IC is more common among women. Approximately 90% of IC patients are 
females. 137  
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 About 36.6% (15/41) of our study population were menopausal, and more than 50% (9/15) of 
them reached menopause surgically (21.9% of the total study population). Previous studies 
reported high proportion of hysterectomies among IC patients (range: 25.3% - 44.4%). 18, 61, 205 
The present study as well as the previous investigations applied the NIDDK criteria in order to 
enroll IC patients. We therefore, would not expect to detect an extreme discrepancy in the 
clinical profile between our study population and other study populations. According to 
O’Leary-Sant IC Symptom Index (ICSI), the current study population classified mainly as either 
having moderate IC (46.3%, ICSI score: 7-13) or severe IC (51.2%, ICSI score: 14-20); the 
median score is 14. This was approximately similar to the study population of Payne et al., which 
tested the efficacy of intravesical Resiniferatoxin for the treatment of IC (mean ICSI score: 14 
among treatment groups and 13 among the placebo), 206 and the study of Sant et al., which tested 
the efficacy of oral PPS and oral Hydroxyzine in IC patients (mean ICSI score: 13.3). 32 
Applying NIDDK criteria ensures homogeneity and similarity between study populations; 
however, it also leads to misdiagnosing more than 60 percent of patients who were defined by 
researchers as definitely having or likely to have interstitial cystitis. 96 NIDDK criteria only 
define moderate and severe IC cases. About 14.6% (6/41) of our study population had Hunner’s 
ulcers; this is higher than what is expected, it has been reported that approximately 10% of IC 
patients showed Hunner’s ulceration, 94 and less than what was reported in Rothrock et al.’s 
study, which assessed the extent of depressive symptoms and impaired quality of life in a sample 
of female patients with IC compared to healthy controls (19% of IC patients had Hunner’s 
ulcers). 22 Voiding frequency during waking hours among the participants in the current study 
(median 12) was approximately similar to what was reported by Payne et al. (mean range 
between 12.7-14.8 among placebo and treatment groups) 206 and by Nickel et al. (mean: 13.2) 
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 who compared the ordinary dose of PPS with doses two to three times higher in a randomized 
clinical trial. 33 Importantly, further comparison about other medical profile parameters was not 
applicable as the methods used to collect and measure these data were different in each study. 
 
In summary, our IC cases were representative of other IC intervention studies; applied 
a consistent set of criteria and therefore with some reservations the results can be considered 
to be applicable to the universe of moderate and severe IC patients. 
5.2 CROSS-SECTIONAL’S RESULTS (AIMS 1, 2 AND 3) 
The cross-sectional part of the current study determined the main socio-demographic, 
reproductive, lifestyle and/or clinical factors that significantly associated with the severity of IC 
symptoms and the impairment in each domain of the HRQL. It also determined if the severity of 
IC symptoms affects each domain of HRQL, and if each IC symptom is associated with either of 
the two major component of HRQL; physical component and mental component summary 
scales. Interestingly, being currently not married was found to be significantly associated with 
the increase in the severity of IC symptoms after adjusting for age, co-morbidity and menopausal 
status. Furthermore, being unemployed, obese, currently not married, and never being pregnant 
were found to be associated with impaired HRQL in at least one SF-36 subscale after adjusting 
for age, co-morbidity and the main study covariates. Not surprisingly, the severity of IC 
symptoms was an independent predictor of the impairments in physical functioning, bodily pain, 
general health and mental health domains. Finally, pain during urination and nocturia were 
the only symptoms that were found to be associated with the impairment in the physical 
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 component of the HRQL after adjusting for age, co-morbidity and marital status. Interestingly, 
none of the IC symptoms was found to be significantly associated with the impairment in mental 
component of HRQL.  
Interstitial cystitis remains an idiopathic illness characterized by pelvic pain, urinary 
frequency and urgency with substantial morbidity in those affected. Previous researchers have 
studied risk factors for IC, but few have focused on the predictors of symptom severity. 6, 17, 152 
Symptom severity has been associated with higher medical cost. 207 Identifying factors 
associated with increased symptom severity may provide insight into the etiology and/or 
treatment of this difficult condition and decrease health care costs. We investigated the effect of 
socio-demographic, reproductive, lifestyle, clinical factors as well as sexual functioning domains 
on the severity of symptoms among a clinical sample of females with IC. In contrast to other 
researchers, 17 we found that marital status is significantly associated with severity of IC 
symptoms in the univariate analyses. Married patients reported a lower ICSI score compared to 
currently not married. This association remained highly significant, even after adjusting for age, 
co-morbidity and menopausal status. Married patients may have more social support from their 
husbands and families, which increase their ability to accommodate the devastating symptoms of 
IC and thus reduce their stress. It has been suggested that stress may play a role in autoimmune 
and neuroinflammatory syndromes in which the nervous system interacts with the immune 
system. 88, 89 Stress is also known to worsen conditions involving mast cells such as interstitial 
cystitis. 57 The possible role of stress as an etiological factor of IC is thought to be related to its 
ability to activate mast cells through activating the bladder nerve endings, which in turn leads to 
release of Substance P (SP) and neuropeptide that activate local mast cells to secrete vasoactive, 
proinflammatory and nociceptive mediators. 90, 92 The effect of these, in turn, could explain most 
 270
 of the clinical symptoms of IC. However, again were the IC patients who were married 
experiencing fewer symptoms or is it that the worsening of symptoms is related to not being 
currently married, it is difficult relationship to study in a cross-sectional vein, a prospective study 
is necessary to confirm what we found. 
As the severity of symptoms increases, there appears to be a slight trend toward greater 
age. 17 In univariate analyses, Temml et al. reported that the prevalence of moderate/severe IC 
symptoms (using ICSI score: 7-20) was highest (18.8%) in the oldest age group (>=60yr), 
followed by middle-aged women (40-59 yr); (16.7%) and then the youngest (20-39yr) women; 
12.8%. 6 However, age was not significant in the multivariate analyses. This was consistent with 
Clemens et al. 152 who assessed the same association among women diagnosed with IC and men 
diagnosed with chronic prostatitis recruited from an academic urology practice at a tertiary care 
facility in Chicago. We failed to find any trend or possible association between age and severity 
of IC symptoms in both univariate and multivariate analyses. The slight trend which was 
observed by both Simon et al. 17 and Temml et al. 6 was confounded by co-morbidities such as 
bowel disorder, hypertension...etc; it disappeared once both studies adjusted for these covariates. 
It is worthy of note that each of these studies used different methods to identify IC cases as well 
as different criteria to categorize patients according to their symptom severity. For example in 
Temml et al.’s study, 6 women were not diagnosed as IC cases using the NIDDK (cystoscopic 
and urine analysis), however, based on their total score of O’Leary-Sant IC Symptom and 
Problem Index as follows: 0-6 no risk for IC, 7-13 minimal risk, 14-23 moderate risk and 24-36 
high risk for IC.  Temml et al.’s study was a questionnaire-based analysis and no individual 
underwent a thorough urologic evaluation. Also the study population was not generated by 
standard epidemiologic sampling and might therefore be biased.  
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 We did not find any association between educational level and severity of IC symptoms. 
These findings are similar to those reported by Temml et al.; 6 and against the significant inverse 
association that was observed by both Clemens et al. 152 and Simon et al. 17.  Both studies 
reported that women with lower educational level were more likely to report severe symptoms. A 
possible explanation for this inverse association is that less educated individuals may not seek 
treatment at tertiary care centers unless symptoms are quite severe. Another reason could be the 
lack resources for treatment and support, so that more severe symptoms tend to develop with 
time. 152 Our failure to detect this association could be due to the small sample size and to the 
fact that approximately 70% (28/41) of our study population were post secondary educated, thus 
we may have not enough power to find such this association.  
In terms of reproductive history factors, we reported a significant association between 
menopausal status and severity of IC symptoms in the univariate analyses. Menopausal women 
reported significantly higher score of symptom severity compared to currently not menopause. 
After adjusting for age, co-morbidity and martial status, being menopausal was no longer 
associated with more severe IC symptoms. Similar to our univariate analyses, Clemens et al. also 
reported that postmenopausal status is associated with worsening symptoms; however, in 
contrast to our findings from the multivariate analyses, this association remained significant after 
adjusting for educational level, depression, frequency and urgency. 152 After menopause the pH 
of the vagina rises and therefore promotes an alteration in the normal vaginal flora, with 
decreased lactobacilli leading to increased colonization by pathogenic faecal flora. 208 This 
increases the incidence of Urinary Tract Infection (UTI). Furthermore, estrogen deficiency after 
menopause results in generalized urogenital atrophy, therefore, postmenopausal women are at 
increased risk not only of recurrent UTI but also of dyspareunia, vaginal irritation, pruritus, pain, 
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 and symptoms of urgency, frequency, dysuria, and urinary incontinence. 208 While it seems 
probable that the postmenopausal decline in estrogen levels has a major impact on lower urinary 
tract, it is possible that the increase in urinary symptoms at this time is simply due to the aging 
process. 209 Previous studies in women have reported an increased incidence of urinary 
symptoms starting as early as 10 years before the menopause. Importantly, urinary symptoms 
can have a systemic cause and not only as a result of aging. For example, diabetic patients may 
be receiving diuretic therapy for cardiovascular disease, or may be taking other medications that 
affect the bladder. 209 Thus, IC among postmenopausal most likely has a multifactorial etiology. 
Further studies of this issue are required before any meaningful conclusion can be drawn.  
It was surprising that neither severity of glomerulations nor the presence of Hunner’s 
ulcer was significantly associated with severity of IC symptoms. In fact, there is no clear 
correlation between cystoscopic appearance and IC symptom severity. 210 The presence of 
Hunner’s ulcer varies between 6 and 50% in different series of IC patients, 211, 212 which may 
reflect a discrepancy in diagnostic procedures. Interestingly, a positive correlation was reported 
between the ICDB summary severity score and increasingly severe physiological markers, such 
as scar tissue, Hunner’s ulcer and decreased bladder capacity. 17 On the other hand, it has been 
reported that glomerulations are not specific to IC, and they are most likely a reflection of a 
chronically under distended bladder; not all patients with symptoms of IC have glomerulations, 
and not all patients with glomerulations have symptoms of IC. 96 Our failure to report any 
association between the presence of Hunner’s ulcer and severity of IC symptoms could be related 
to our study design, as we only included moderate and severe IC cases. May be there is no 
extensive difference between moderate and severe cases regarding to the presence of Hunner’s 
ulceration. The real differences could be between severe and mild cases or moderate and mild 
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 cases. Further studies are needed to investigate this relationship; because the very narrow range 
of our cases (lack of a full spectrum of disease) may have precluded this finding. 
We observed a significant association between being sexually active during the month 
previous to baseline visit and severity of IC symptoms. Women who had sexual intercourse 
during the month previous to baseline visit reported significantly lower ICSI score. This can be 
explained by two different ways; either being sexually active is a significant predictor of 
reduction of severity of IC symptoms or severe IC symptoms associated with avoiding sexual 
intercourse. Importantly, because of the cross-sectional analysis limitation, we are not able to tell 
which one of these two explanations is the correct. Prospective studies are required to address 
this association comprehensively. 
IC is physically debilitating as well as emotionally distressing for many patients who 
suffer from it. The quality of life for many IC patients has been shown to be worse than that of 
patients undergoing dialysis for end-stage renal disease. 2 In severe cases, patient may have 
voiding frequency up to 60 times a day and nocturia every 20 minutes. As a result of that, patient 
with IC suffers from subsequent sleep deprivation that affects on his/her well-being. IC patient is 
often unable to work and perform daily activities; sometimes he/she is unable to leave home. 2 
More than 94% of IC patients indicated that travel was impossible or difficult, and 69.7% 
reported disruption in family relationships and responsibility. 18  
Previous research showed that patients with interstitial cystitis reported significantly 
poorer QOL than controls across all SF-36 domains including: physical functioning, bodily pain, 
vitality, general health, social functioning, role limitations due to physical and emotional 
problems and mental health (p<0.01). 22 Although we did not have a control group, the negative 
impact on QOL was also demonstrated in our sample of IC patients when we compared their 
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 HRQL scores in the original format (Table 4-5) and in the norm-based format (Table 4-6) with 
those from a normative sample of the US females from the 1990 and the 1998 general surveys, 
within the same age group, respectively. In both tables, the scores of the eight domains were 
extremely lower than those of the normative sample. Ware et al. suggested that a 5-point 
difference on an SF-36 subscale is indicative of a clinically meaningful decrease in QOL. 177 We 
reported subscale difference score between 16 and 46.5 point in the original scales. Clearly the 
degree of impairment experienced by patients with IC is substantial.  
The reader may observe that most of the QOL’s results in the current study were 
presented in the norm-based format.  Using norm-based format has many advantages; when 
interpreting the scores the reader will no longer have to remember the norms for 8 scales because 
the general population norm is built into the scoring algorithm that all scores above or below 50 
can be interpreted as above or below the general population norm. Furthermore, the standard 
deviation for each scale is equalized at 10. Therefore, it’s easier to see exactly how far above (or 
below) the mean the score is in standard deviation units.  Moreover, because all 8 scales are 
scored to have the same standard deviation, comparisons in scores across scales and summary 
measures can be made directly. 184 
Limited studies addressed how socio-demographic, reproductive, lifestyle, clinical 
history factors and/or sexual function domains affect on the HRQL in IC patients. Although of a 
cross-sectional nature, our study is the first to assess the impact of each of these factors on each 
of the eight domains of SF-36. We investigated the above mentioned associations first, without 
including symptom severity to regression models, so we can determine the main covariates of the 
association between symptom severity and QOL. Secondly, we tested the effect of symptom 
severity on each HRQL domain adjusting for all the significant covariates we identified from the 
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 univariate analyses. Therefore, we were able to answer if symptom severity confounds any of the 
previous identified relationships and vise versa. As it was expected, we reported a significant 
association between employment status and physical functioning domain. Being currently not 
employed was significantly associated with impairment in physical functioning in the univariate 
analyses and after adjusting for age, co-morbidity and had sexual intercourse during the month 
previous to the baseline visit.  This was consistent with researches applied to other diseases; 
Papadopoulos et al. who studies predictors of HRQL in type II diabetic patients (52.8% females), 
203 and with Riazi et al. among multiple sclerosis patients (65.3% females). 213 Interestingly, 
employment status was no longer significantly associated with the impairment in physical 
functioning after adjusting for ICSI, age and co-morbidity. This demonstrates the importance of 
severity of IC symptoms over employment status in predicting impairment in physical 
functioning of IC patients. Therefore, it is really the severity of IC symptoms that reduces IC 
patient’s ability to work and thus impairs their physical functioning. 
As social support is an important predictor of QOL, 214 marital status might be expected 
to be significantly associated with impairment of different domains of QOL. This was supported 
in our univariate analyses and some of the multivariate models. In a consistent manner, we 
observed significant associations between being currently unmarried and impairment in each 
of role-physical, bodily pain, general health, vitality and social functioning domains in the 
univariate analyses. However, after adjusting for age, co-morbidity and certain study covariates, 
marital status remained a significant predictor of only social functioning. Interestingly, marital 
status was found to be significantly associated with even more domains (role-emotional, bodily 
pain and vitality) after including ICSI to the models. Similar to what we observed, however 
among type II diabetic patients, Papadopoulos et al. found that being unmarried was a significant 
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 predictor of impairment in vitality domain after adjusting for age, gender and diabetic covariates. 
203 Our finding supported with that of Papadopoulos et al. indicates that lack of social support 
and family relationships have a profound impact on the HRQL in IC patients exactly like the 
impact of the severity of IC symptoms.  However, because of the limitations of the cross-
sectional design of our study, a prospective study is required to determine if IC patients never get 
married because of their pain our was their pain ameliorated because they got married. 
Assessing how reproductive history factors affect on QOL domains reveals some 
interesting findings. We were unable to see if our findings match other’s because we are the first 
to assess these factors. Being sexually active during the month previous to baseline interview 
was found to be significantly associated with better score of physical functioning and vitality in 
the univariate analyses. We were not able to test if these associations were confounded by 
severity of IC symptoms in particular and age, co-morbidity and other study covariates in general 
because of the limitation of the small sample size, which restricted the number of covariates that 
we can adjust for.  
A noteworthy association was that between ever using OC and the impairment in role-
physical domain. Although this association was marginally significant in the univariate analyses, 
once we adjusted for ICSI, age, co-morbidity and marital status it became highly significant. 
This finding supports the previous suggestion about the importance of considering a hormonal 
effect on IC. Given that the majority of IC patients are females and the clinical literature suggests 
a flare in IC symptoms during premenstrual period, 64, 147, 148 a direct influence of gonadal 
hormones and estrogen may be considered. It is possible that the increase of estrogen level 
among those patients who ever used OC increases their symptom severity which in turn impairs 
their role-physical functioning. Theoharides et al. showed that estradiol may influence 
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 pathophysiological responses via bladder mast cells expressing high affinity estrogen receptors. 
147 Clarifying this topic is important because the most notable application of that will be the 
use of hormone to selectively modulate pain sensation and improve quality of life. Reporting 
ever pregnant was found to be significantly associated with better mental health score in both 
univariate analyses and after adjusting for ICSI, age, co-morbidity. This can be explained by the 
importance of motherhood on the mentality of those patients. It also supports the significant 
impact that family relationships might play in improving the quality of life in IC patients. 
Several previous studies in general population and/ or among obese participants reported 
a significant impact of BMI on HRQL. 215, 216 Our results correspond well to these previous 
findings. We observed a marginal significant negative correlation between BMI and general 
health domain. This marginal association became highly significant after including ICSI, age, 
co-morbidity and marital status to the model. IC patients with greater BMI reported worse 
general health score compared to those with lower BMI. This finding supports the substantial 
independent effect of BMI on general health of IC patients and not on physical functioning, like 
one might expect. It is important to mention that BMI in the current study was based on self-
reported heights and weights at week 18 of the study and not at the baseline. However, we didn’t 
notice or record any extreme increase in weight in any of the study participants since baseline. 
Further studies with more accurate measures are required to confirm what we found. 
The extent to which quality of life is consequence of disease severity in patients with IC 
is unclear. Very few studies attempted to investigate that. 17, 22 Our observations about the impact 
of severity of IC symptoms on the different domains of HRQL were semi-consistent with that of 
Rothrock et al. 22 Rothrock et al. reported that greater IC severity was associated with greater 
compromise in physical, social functioning and mental health but not in other quality of life 
 278
 domains. Importantly, Rothrock et al. didn’t adjust for age or co-morbidity or any other 
covariates. In the current study we demonstrated that severity of IC symptoms even associated 
with impairment in domains other than those noticed by Rothrock et al. After adjusting for age, 
co-morbidity and certain study covariates for each domain based on our results from the first 
aim, symptom severity was significantly associated with impairment not only in physical 
functioning and mental health domains but also in bodily pain and general health domains. 
These findings suggest that severity of IC symptoms has profound impact on physical 
component of QOL more than on mental component of QOL. Ware et al. reported strong and 
significant correlations between each of the physical functioning, bodily pain and general health 
and the physical component summary of QOL. 177    
Most IC patients suffer from urgency and frequency in the early stages of the disease. As 
the disease progresses, pain increases in severity and becomes the most dominating and 
debilitating symptom. For many, the pain becomes so severe it significantly impacts their 
personal and professional life. We investigated which of the IC symptoms is associated with the 
impairment in physical component summary (PCS) and/or mental component summary (MCS) 
of QOL. In the univariate analyses, we reported negative significant correlations between each of 
IC symptoms (pain, urinary frequency, nocturia and urgency) and the PCS. On the other hand, a 
marginally significant negative correlation was observed between pain and MCS. Because we 
found significant correlations between pain and urgency and between frequency and nocturia we 
were unable to include any of these together in one model. Therefore, we tested if the significant 
associations between each of the IC symptoms and PCS were independent after adjusting for 
age, co-morbidity and marital status. Pain during voiding and nocturia were found to be 
significantly associated with impairment in the final models (adjusting for age, co-morbidity 
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 and marital status). This coincident with Nickel et al. who studied predictors of PCS and MCS in 
a similar study population. 185 Nickel et al. found significant effect of pain on PCS but not MCS. 
They investigated the effect of frequency and urgency but not nocturia, and none of these impair 
either PCS or MCS. These results highlight the importance of managing pain and nocturia over 
frequency and urgency to improve physical component of IC patients’ QOL.  
5.3 CLINICAL TRIAL’S RESULTS (AIMS 4, 5, 6, 7, 8 AND 9) 
The clinical trial part of the current study investigated for the first time ever in USA, if the 
intravesical use of pentosan polysulfate sodium (PPS) accompanied with oral PPS, the only 
approved oral therapy for IC by FDA, is better than using oral PPS only. Several outcomes were 
assessed and included the changes in O’Leary-Sant IC Symptom and Problem Index, PUF 
instrument, pain and urgency scales, frequency and nocturia from 24 hours voiding log, patient 
global assessment, sexual functioning domains and HRQL. Our findings demonstrated that using 
intravesical PPS simultaneously with oral PPS is an effective therapeutic option. In particular, 
females with IC who received a regimen of intravesical and oral PPS showed a twofold 
reduction in the severity of IC symptoms compared to those who received the oral regimen of 
PPS alone (p=0.04). Furthermore, at the end of the trial, remarkable significant improvements 
in all health related quality of life domains have been reported in the treatment group 
compared to their baseline self evaluation.  
Because of the biochemical nature of PPS (semi-synthetic sulfate polysaccharide) that 
chemically and structurally resembles glycosaminoglycan (GAG), the protective layer of the 
bladder, PPS is considered as a treatment option for IC. When GAG layer is damaged, it allows 
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 many harmful solutes in the urine to leak across the transitional cells to initiate IC symptoms. 217 
PPS is thought to augment the GAG layer of the bladder and repair deficiencies, and thus relieve 
symptoms. Its strong hydrophilic properties attract water molecules to bind tightly to its sulfated 
portion is thought to produce an insulator layer of water between the transitional cells and the 
urine in the bladder that can block highly charged compounds and reduce electrochemical 
interactions. 29 Because only 1-3% of oral PPS reaches the bladder, 34 the therapeutic efficacy of 
PPS should be greater when applied intravesically. Furthermore, using both intravesical and oral 
PPS simultaneously for a specific period of time followed by sustained use of oral PPS may 
empower the therapeutic effect of oral PPS and enhance the proliferation of the GAG layer, to 
produce greater relief and return to normal protective coating faster. 
As we mentioned previously in chapter 2, only one small clinical trial attempted to test 
the efficacy of intravesical PPS in the Netherlands, 1997. 37 It was not applicable to make an 
extensive comparison between the results from our study and the results from the Netherlands’ 
study because of the difference in the study design and the outcomes that were used in each 
study to assess the efficacy of intravesical PPS. In particular, our study used oral PPS plus 
intravesical placebo as a control compared to only placebo in the Netherlands’ study. 
Furthermore, the main outcomes in the Netherlands’ study were urodynamic capacity, 
cystometric volume and mean volume from a 24 hours voiding log. Our study in general was 
consistent with the Netherlands’ study in that instilling intravesical PPS is an effective 
therapeutic option for IC patients. The Netherlands’ study reported significant increase in the 
urodynamic capacity after 3 months among the treatment group. (p=0.04). We did not assess 
that, however we were able to report remarkable significant improvements in other several 
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 outcomes among those who received both intravesical and oral PPS compared to those who 
received only oral PPS.  
In terms of severity of IC symptoms, we used two well-known and validated instruments 
(O’Leary-Sant IC Symptom and Problem Index and PUF instrument) to measure the change in 
the severity of IC symptoms within each group and between the two groups at each study 
endpoint. 23, 24 Interestingly, we reported significant improvement in the severity of IC 
symptoms in both groups from baseline to each endpoint using both instruments. However, we 
only reported statistically significant differences in the improvement in the severity of IC 
symptoms between the two groups using O’Leary-Sant IC Symptom and Problem Index, but not 
the PUF instrument, at week 12 and marginally significant at week 18. It is worthy to mention 
that although both instruments were designed to identify IC cases, O’Leary-Sant instrument 
mainly measures the frequency and the problematic of the four symptoms of IC (voiding 
frequency, urgency, nocturia and pain mainly in the bladder). 23 On the other hand, PUF 
instrument not only measures the frequency and bothersomeness of the four IC symptoms, but 
also the sexual activity and the impact of IC symptoms on it. It also measures the frequency of 
any pain in the pelvis and not only in the bladder. 24 This may explain why we reported 
significant difference in the change of symptom severity using O’Leary-Sant but not PUF. 
Another explanation is related to the design of the O’Leary-Sant instrument; we noticed that our 
study participants completed O’Leary-Sant instrument without any problem compared to PUF. 
The way the questions were presented in the PUF instrument were somewhat confusing for some 
participants and need more explanation. It is important to conduct a study to measure the 
consistency between the two instruments and to correlate the objective measures of IC symptoms 
(cystoscopy and urodynamics) to the subjective measures from each of the two instruments. Our 
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 findings of a significant difference between the two groups at week 12 but not week 6 suggests 
that using both intravesical PPS and oral PPS together for the first 6 weeks enhances the 
proliferation of the protective layer of the bladder, to produce greater relief and return to normal 
protective coating when maintained with oral PPS alone after that. 
As we expected, pain was the only IC symptom that improved in both groups at each 
endpoint. Moreover, nocturia showed significant improvement in both groups only at week 18. A 
noteworthy significant improvement in urgency score was reported among treatment group, but 
not placebo group at each endpoint compared to the baseline. On the other hand, the same was 
reported about urinary frequency, however, among the placebo group. The latter finding may 
surprise the reader. One suggested explanation for this unexpected result is that urine frequency 
can be a misleading symptom as it may affect by other uncontrolled factors. Patients tend to 
restrict their fluid intake during painful periods and increase their fluid intake when pain is 
relieved. 28 Furthermore, a decrease in urinary frequency was found to be accompanied by an 
increase in pain, likely due to higher concentration of irritating agents in the urine. 218 Therefore, 
it is expected that patients who experienced greater improvement in their pain as a result of the 
treatment will increase their fluid intake and thus will have an increase in their urinary frequency 
in comparison to those who experienced less improvement (placebo group). We failed to report 
any significant difference in the changes in individual IC symptoms as measured by pain 
assessment, urgency scale, urinary frequency, and/ or nocturia between the two groups at any 
endpoint. The multifactorial complex nature of IC condition and the wide variation of individual 
IC symptoms within and between patients suggest that the significant improvement in IC is the 
result of improvement in overall condition rather than in a specific symptom. Importantly, our 
study proved the superiority of the combination of intravesical and oral PPS over only oral PPS 
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 using measurers that provide a cumulative picture of the disease such as the O’Leary-Sant IC 
Symptom and Problem Index. Sharp focusing on each symptom may dilute the expected effect 
that we were able to determine using measures that reflect the cumulative picture of IC. Another 
possible reason for not being able to report any significant differences between groups using 
individual IC symptoms measures could be lack of power because of our small sample size. 
More studies with larger sample size are required to clarify that. 
In terms of proportion of responders (defined as participants who reported any level of 
improvement in their overall condition, urgency or urinary frequency after 18 weeks of the trial), 
significant differences were reported for responders in urgency and urinary frequency but not 
in overall condition between the two groups. All participants in the treatment group reported 
improvement in either their urgency or urinary frequency at week18 of the trial compared to only 
80% of the placebo group. Moreover, responders in the treatment group were significantly more 
likely to report “great level of improvement” in their overall condition compared to responders in 
the placebo group. These findings may be biased because of the unbalanced scale of level of 
improvement in the patient global assessment instrument that we used. We were forced to 
consider responders as those who reported any level of improvement because of the design of the 
patient global assessment. There was no “Slightly improved” option available for the question 
“how do you evaluate your level of improvement?” Therefore, those who evaluated their 
improvement as slightly will be obligated to consider themselves as improved moderately (50% 
improvement), which in turn will introduce miss classification bias to the moderate improvement 
level category in particular. It was expected that those who received both intravesical and oral 
PPS will experience moderate to great improvement (50%-75% improvement) while those who 
received only oral PPS will distributed between slightly improved and moderately improved 
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 (25%-50% improvement). For that reason, we observed greater proportion of responders with 
moderate level of improvement among placebo group compared to treatment group and greater 
proportion of responders with great level of improvement among treatment group compared to 
the placebo group in all the three sections of patient global assessment. Another study with well 
balanced version of patient global assessment is required to confirm what we found. 
Although IC has a severe impact on patient quality of life, very few trials which assessed 
the efficacy of oral PPS used HRQL as an outcome. Our study investigated the effect of a 
combination of intravesical and oral PPS on HRQL in IC patients comprehensively. We assessed 
that on both the two component summary scales to identify which of them will be improved (the 
physical or the mental component of QOL). We also assessed the effect of the trial intervention 
on each domain of HRQL to determine which domain in particular will get benefit from the trial 
intervention. Our findings demonstrated the importance of using HRQL as a sensitive measure of 
efficacy. At the end of the trial, the treatment group showed ~ 17.9% increase in PCS score and 
21.8% increase in MCS score compared to the baseline. Moreover, placebo group reported 
significant improvement in the PCS score but not MCS score compared to the baseline. 
Furthermore, the treatment group reported significantly more increase in MCS score from 
baseline to week 4 in comparison to the placebo group. The significant difference in the MCS 
which we observed between the two groups was confounded by the baseline score of the MCS. 
The treatment group reported significantly worse MCS score at baseline compared to the placebo 
group. Interestingly, once we adjusted for MCS baseline score, no significant difference was 
found between the two groups.  
When we examined the effect of the trial treatment on each domain extensively, after 
week 18, the treatment group showed significantly greater improvement in all HROL domains 
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 compared to the baseline while the placebo group reported that in only three domains. 
Moreover, although the treatment group showed better score in each of the eight domains of the 
SF-36, marginally significant greater improvements were only reported in general health and 
mental health domains compared to the placebo. The marginal significant difference in mental 
health score remained even after adjusting for baseline score. These findings suggested that the 
combination of intravesical and oral PPS may improve mental health domain of the HRQL in IC 
patient better than using only oral PPS. Other study with larger sample size is needed to confirm 
what we found. 
With regard to sexual functions, recent study by Nickel et al. 219 that included 128 IC 
patients who were treated with 300 mg/day oral PPS for 32 weeks reported statistically 
significant improvement in sexual function scores at weeks 8, 16, 24, and 32 of the study. The 
authors observed moderately positive significant correlation between reduction in symptom 
index score and sexual function score at the end of study (r = -0.35, P = 0.0002).  The results 
from the current study did not support any superiority of using a combination of oral and 
intravesical PPS over using only oral PPS in improving sexual function. Although the present 
study reported marginal significant improvement in sexual desire at week 18 compared to the 
baseline among the treatment group, it failed to show significant differences between the two 
groups. This could be related to the small sample size that we have. Further studies with larger 
sample size and more comprehensive measures of sexual function are required to clarify this 
effect. 
Our findings cannot be explained by other factors such as the use of concurrent 
medications as well as the compliance with oral PPS. Both groups showed comparable use of 
antihistamines, antispasmodics, antidepressants and analgesics during the entire study period (p 
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 > 0.05). Furthermore, both groups administered more than 95% of the oral PPS during either the 
entire study period or the first, second or third six weeks of the trial.  It is also unlikely that our 
results were biased as we adhered to the LOCF method to handle missing data. The same results 
were found when all the statistical analyses were performed with and without including the drop 
out subject in the treatment group or applying the LOCF method.  
5.4 STRENGTHS AND LIMITATIONS 
The current study had several strengths and limitations. The main strengths were: 1) The present 
study is the first among IC patients that comprehensively assessed the extent to which socio-
demographic, reproductive, lifestyle, clinical history factors and sexual function domains affect 
both the severity of IC symptoms and the HRQL. 2) It is the first to examine the association 
between severity of IC symptom and HRQL extensively after adjusting for important covariates. 
3) It is the first in USA to test the efficacy of intravesical PPS using a powerful study design 
(randomized double blind clinical trial). 4) The current study used several well-known 
standardized instruments to collect baseline data and data about the main clinical trial outcomes. 
4) The intravesical instillation of PPS in the clinical trial part of the current study was done by 
the principal investigator or a well trained nurse which ensure both the validity and reliability of 
the data.  
On the other hand, the major limitations of the present study were: 1) the cross-sectional 
nature of the measurement of socio-demographic and reproductive factors makes impossible to 
assess these measures as risk factors but as being related or not related to the severity of IC 
symptoms and/ or the impairment in HRQL. Therefore, the direction of causality was not be 
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 inferred from our analyses. 2) The small sample size which may reduce the study power to detect 
significant associations between study main outcomes and different covariates. It also limited the 
regression analyses and the number of covariates to be included in multivariate models. 3) Study 
participants of the present study were generally highly educated, females and white, reflecting 
the demographic of the facility population. Therefore, the results may not be generalized to less 
educated patients, men with IC and those of different racial or ethnic groups. 4) The current 
study only included moderate to severe cases. Therefore, the results may not be generalized to 
mild cases, although one can argue that mild cases would not necessarily be bad enough to seek 
care or to show improvement results. 5) Using unbalanced version of patient global assessment 
to define responders may introduce misclassification bias to the results about the efficacy of 
intravesical and oral PPS on patient global assessment, although we tried to reduce that effect by 
defining our responders as those who reported any level of improvement. However, using this 
wide definition for the responders may prevent us from detecting significant differences between 
the responders in the two groups related to the improvement in the overall condition. 
5.5 CONCLUSIONS AND FUTURE RESEARCHES 
The findings from the current study will have significant implications on both IC research and 
well-being of IC patients. The cross-sectional part highlights the substantial impact of family 
relationships and social life on both the severity of IC symptoms and the quality of life in IC 
patients. Married patients who have permanent families and therefore more social activities 
reported less severity of IC symptoms and much better QOL compared to unmarried patients. 
Furthermore, being unemployed, obese, and never being pregnant associated with impaired 
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 HRQL in at least one SF-36 subscale after adjusting for age, co-morbidity and the main study 
covariates. Moreover, severity of IC symptoms compromises mainly the physical component of 
HRQL rather than the mental component. After adjusting for age, co-morbidity and important 
study covariate, severity of IC symptoms was significantly impaired three domains of the 
physical component (physical functioning, bodily pain, general health) and only one domain 
of the mental component of the HRQL (mental health). Noteworthy, only pain and nocturia 
were the main IC symptoms that impair the physical component of HRQL in the patients. These 
findings have important public health significance because they emphasize on the substantial role 
of family relationship in improving patient severity of symptoms and quality of life. They also 
direct the health care providers to focus more on managing pain and nocturia, in particular, as 
urinary frequency and urgency can be controlled by patients through restricting their fluid intake. 
Improving pain and reducing nocturia will have a great impact on the physical functioning of IC 
patients and will improve their well-being.  
On the other hand, the double blind placebo controlled trial part demonstrated the 
efficacy of the use of a multimodal therapy of intravesical and oral PPS for the treatment of 
moderate and severe IC cases. The findings suggests that using both intravesical PPS and oral 
PPS together may enhance the proliferation of the protective layer of the bladder, to produce 
greater relief and return to normal protective coating when maintained with oral PPS alone. 
These findings of great public health evidence as they will open a new option for IC patients to 
reduce their severely devastating symptoms and to improve their quality of life and well-being.  
The results from the two parts of the present study call for several future studies. It is 
very important to conduct a prospective study with larger sample size that include men and 
different racial ethnic groups with mild, moderate and severe IC condition to confirm what we 
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found from the cross-sectional part and to assess extensively the marginally significant 
associations that could be under power because of our small sample size. Because the current 
study showed significant association between menopausal status and the severity of IC 
symptoms, and a highly significant association between ever used OC and impairment in role-
physical domain, it is crucial to assess the role of gonadotropin hormones as well as estrogen on 
the severity of IC symptoms among menopause and perimenopause in a large prospective study. 
It seems that estrogen has different roles on IC based on the menopausal status of the patient. 
The current study showed in the univariate analysis significant impact of sexual function on 
QOL. It will be of great interest to assess this association, however, in prospective study with 
larger and more representative study population. The next step after our randomized trial is to 
test the efficacy of intravesical PPS, however, compared to another intravesical option (such as 
heparin or DMSO). 
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 INFORMED CONSENT 
 
STUDY DRUG:   ELMIRON® (Pentosan Polysulfate Sodium) 
 
PROTOCOL TITLE:  Intravesical Elmiron® Administration(CAPSS-245) 
 
SPONSOR-INVESTIGATOR: Edward L. Davis, M.D 
 
TELEPHONE:   (626) 914-3921 (24 hour number) 
 
You are being asked if you want to take part in a research study of an investigational 
medication called pentosan polysulfate sodium (Elmiron®).  The word investigational means this 
drug is being tested and is not approved in the United States by the U.S. Food and Drug 
Administration (FDA) for intravesical instillation in the treatment of interstitial cystitis(IC).  
Elmiron® has been approved by the Food and Drug Administration (FDA) for the oral use for 
the diagnosis of interstitial cystitis (IC).    
Before agreeing to participate in this research study, it is important that you read and 
understand the following explanation of the proposed procedures.  This statement describes the 
purpose, procedures, benefits, risks discomforts and precautions of the study.  It also describes 
the alternative procedures that are available to you and your right to withdraw from the study at 
any time.  No guarantees or assurances can be made as to the results of the study.  If you are not 
completely truthful with your study doctor regarding your health history, you may harm yourself 
by participating in this study. 
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CONTACT INFORMATION 
 
The study doctor or study staff will answer any questions you have about this research 
study or your participation in the study.  You can ask questions about this research study or your 
participation in the study.  Please call if you have any questions about the study or your 
experience in the study.  Please call right away if you have an injury, illness or side effect. 
Study doctor:  Edward L. Davis, M.D.      Telephone number:  (626) 914-3921  
This study was reviewed by Foothill Presbyterian Hospital (FPH) Institutional Review 
Board (IRB), and ethics committee that is independent of the doctor-sponsor.   The purpose of 
the IRB is to protect the rights and safety of people who volunteer to take part in research 
studies.  You may call if you have questions about your rights as a research participant or a 
complaint or concern about participating in this study.  
FPH IRB is located at 220 South Grand Avenue, Glendora, CA 91741.                       
c/oMr. Larry Fetters, COO, (626)963-8411.  
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to test the theory that the intravesical administration of 
pentosan polysulfate sodium, hereafter identified as Elmiron®, will accelerate the relief of the 
symptoms of interstitial cystitis (IC). This study is based on data collected from Citrus Valley 
Medical Research, Inc. This is a double blind, randomized, and placebo controlled study 
designed to assess the safety and efficacy of intravesical instillation of Elmiron®, in addition to 
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 orally administered Elmiron®.   A placebo contains no active ingredient. This combination of 
intravesical instillation and oral Elmiron® will be compared to oral administration of Elmiron® 
and the intravesical administration of placebo (sterile buffered normal saline) in the treatment of 
IC. 
 
DESCRIPTION OF THE STUDY 
 
You have been invited to participate in this study because you have been diagnosed with 
interstitial cystitis and are over the age of 18. 
The symptoms of IC are characterized by suprapubic, pelvic, low back, inguinal, and 
flank pain, irritative voiding symptoms of frequency, urgency, urination at night and negative 
urine culture.  The theory is that the cellular lining of the bladder (the glycosaminoglycan or 
GAG layer) is defective in IC patients, thus allowing caustic agents in the urine to irritate the 
bladder.  Elmiron® is used orally to replace the GAG layer.  Once this layer is replaced the 
bladder lining may be protected from the caustic effects in urine, and the symptoms of IC may be 
reduced or even disappear. However, one drawback to the oral treatment is the low amount of 
active drug reaching the bladder (1-3% of the oral dose is excreted into the urine) resulting in a 
long lag time before improvement is expected. 
All patients who receive oral treatment with Elmiron® will receive bladder instillations. 
Twenty (20)  subjects will receive Elmiron® through a catheter into the bladder, and  twenty (20) 
subjects will receive placebo through a catheter into the bladder . 
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STUDY PROCEDURES 
 
A total of forty (40) subjects, female, diagnosed with interstitial cystitis and previously 
untreated with Elmiron® will be randomized  according to the study protocol and enter into this 
study.  Twenty (20) subjects, randomized according to the study protocol, will receive 
intravesical instillation of Elmiron® and oral Elmiron®. Twenty (20) subjects, randomized 
according to the study protocol, will receive intravesical instillation of placebo (sterile buffered 
normal saline) and oral Elmiron®. 
Patients, eighteen (18) years or older and diagnosed with interstitial cystitis within one 
year are eligible for inclusion in this study. A cystoscopic examination under anesthesia with 
hydrodistension and photo documentation will be performed within one (1) year of entry into this 
study.  Bladder biopsies will be performed only if carcinoma is suspected. Eligible patients will 
have sterile urine culture-documented as per study protocol.  Patients will require baseline 
symptom scores according to the study protocol.   
 
The subjects who meet the inclusion and exclusion criteria for IC will follow this 
protocol: All forty (40) subjects will be administered Elmiron® 200mg orally, taken  one (1) 
hour prior to meals or  two (2) hours after meals, twice (2x) per day (a total of 400mg per day) 
for eighteen (18) weeks of the study.  All forty (40) of the subjects will have intravesical 
instillations twice (2x) a week for six (6) weeks for a total of twelve (12) instillations.   
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 Baseline (Screening visit – up to 30 days before first instillation visit) 
The following tests and procedures will be completed at your first visit to determine if 
you qualify to participate:  
• You will be asked to read and sign this informed consent if you wish to 
participate in this study 
• Review your medical history 
• A Physical examination (if one has not been done in the last 30 days) 
• A clean-catch urine will be collected.  Your urine will be tested to check the 
functioning of your kidneys and check for any urinary tract infection, pregnancy 
test (if applicable), for possible future biomarker study and hormonal levels.  
• A blood sample will be collected (approximately two (2) tablespoons) to assess 
complete blood count, kidney function, liver function, future biomarker study and 
hormonal levels. 
• You should inform the study doctor of all medications that you use, this includes 
medication prescribed by a doctor or any medication you buy over the counter 
without a prescription. 
• You will be asked to complete questionnaires that relate to your pain and bladder 
symptoms (urgency, frequency), health related quality of life, and sexual function.  
• If you have not previously been examined by a urologist you may have one (1) or 
two (2) extra tests:  an ultrasound to measure how much urine is in your bladder 
after you have been to the bathroom and/or a test where you pass urine into a 
machine that measures the flow, and/or a test to measure how much urine your 
bladder will hold. 
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 If the study doctor determines that you are eligible for this study you will be scheduled to 
return to this office to begin intravesical (bladder) instillations.  You will be given a voiding log 
to keep track of the number of times you urinate within a 24 hour period before returning to this 
office for your first bladder instillation visit. 
 
INSTILLATION WEEKS   
 A total of Six (6) weeks x 2 Bladder Instillations per week = 12 Visits The following 
tests and procedures will be completed at each instillation visit.  If you qualify to continue you 
will be asked to return to this office two times (2x) per week for instillation of the study 
medication. 
If you continue to qualify to participate you will be randomly assigned by chance (like 
the toss of a coin) to receive as part of your instillation Elmiron® or placebo (inactive 
ingredient).   This study is double-blind which means that neither you nor the study doctor will 
know which study treatment you are receiving.  However, this information will be available in 
case of emergency. 
• You should inform the study doctor of all medications that you use, this includes 
medication prescribed by a doctor or any medication you buy over the counter without a 
prescription 
• At weeks one (1) through six (6) (visit one (1) and visit two (2) each week),  before each 
intravesical instillation a clean-catch urine will be collected.  Your urine will be tested to 
check the functioning of your kidneys and check for any urinary tract infection, at visit 
one (1) of each week your urine will be sent to a laboratory for a urine culture and 
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 sensitivity test, which will document the absence or presence of any bacteria in your 
urine. 
• You will be asked to complete questionnaires that relate to your pain and bladder 
symptoms (urgency, frequency), health related quality of life, and sexual function.  
• The study doctor will ask you questions about your health. 
•  You will have a bladder instillation that includes the following. 
1. A self-lubricating catheter of the LoFric® brand will be inserted into your 
bladder.  This is a small diameter tube that is inserted into the opening you usually 
urinate from. 
2. Any urine that is present will be removed through the catheter. 
3. All forty (40) subjects will be administered, as part of the instillation procedure, at 
each visit, a topical application of Lidocaine Hydrochloride Jelly USP 2%, to the 
perineal area and to the tip of the catheter.  The reason for the lidocaine jelly is to 
prevent perineal sensitivity and to prevent urethral spasms.  
4. All subjects will be administered as part of the instillation procedure at each visit 
intravesical instillation of 8ml of 1% lidocaine and 3ml of 8.4% sodium 
bicarbonate, before intravesical instillation of Elimiron® or placebo (sterile 
buffered normal saline).  The 1% lidocaine is a short acting and topical anesthetic.  
The purpose for the instillation of 8ml of 1% lidocaine as part of the instillation 
procedure, is to provide a topical and short acting anesthetic to the bladder 
membrane.  This topical and short acting anesthetic will prevent bladder and 
urethral spasms and the possible uncontrolled expulsion of the study medication 
or placebo from the bladder.  The duration of the anesthetic effect of 1% lidocaine 
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 is sixty (60) to ninety (90) minutes.  The instillation of 3ml of 8.4% sodium 
bicarbonate as part of the instillation procedure, is to prepare the bladder 
membrane for the absorption of the 1% lidocaine by alkalizes the acids in any 
residual urine. 
5. You will then be administered ELMIRON® or placebo.  This instillation should 
be retained in the bladder for a minimum of thirty (30) minutes and a maximum 
of sixty (60) minutes.  
6. A blood sample will be collected (approximately two (2) tablespoons) to assess 
blood coagulation (clotting) time and future biomarker study . The blood sample 
will be collected one (1) hour after the bladder instillation. 
7.  You can leave the study center in one (1) hour after you have voided and a blood 
sample has been collected    If you are unable to void at the required time, 
catheterization will be performed to remove the solution from your bladder. 
 
• You will be given a voiding log at visit two (2) each instillation week to record your 
voiding pattern a 24 hour period of your choice before returning to this office for visit 
one (1) of the next instillation week. 
 
If you develop a urinary tract infection during this study, an appropriate antibiotic will be 
prescribed.  
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FOLLOW-UP VISITS 
 
You will return to this office for two (2) visits following your last study instillation.  For 
the week (twelve) 12 visit (will occur six weeks after you have finished your last study 
instillation) the following assessments will be done.  
• You should inform the study doctor of all medications that you use, this includes 
medication prescribed by a doctor or any medication you buy over the counter without a 
prescription. 
• You will have these tests performed:  a test where you pass urine into a machine that 
measures the flow and an ultrasound to measure how much urine is in your bladder after 
your flow has been measured by a machine.  
• A clean-catch urine specimen will be collected.  Your urine will be tested to check the 
functioning of your kidneys and check for any urinary tract infection, and for possible 
future biomarker study. 
• A blood sample will be collected (approximately two (2) tablespoons)  to assess blood 
coagulation (clotting) time, and future biomarker study. 
• You will be asked to complete questionnaires that relate to your pain and bladder 
symptoms (urgency, frequency), health related quality of life, and sexual function.  
• The study doctor will ask you questions about your health. 
• You will be given a voiding log to keep track of the number of times you urinate within 
a 24 hour period before returning to this office for visit week eighteen (18) in six (6) 
weeks. 
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 For the week eighteen (18) follow-up visit the following assessments will be done  
• You should inform the study doctor of all medications that you use, this includes 
medication prescribed by a doctor or any medication you buy over the counter without a 
prescription. 
• A physical examination will be performed 
• You will have these tests performed:  a test where you pass urine into a machine 
(Uroflow) that measures the flow, and an ultrasound to measure how much urine is in 
your bladder after your flow has been measured by a machine. 
• A clean-catch urine specimen will be collected.  Your urine will be tested to check the 
functioning of your kidneys and check for any urinary tract infection, and a pregnancy 
test (if applicable). 
• You will be asked to complete questionnaires that relate to your pain and bladder 
symptoms (urgency, frequency), health related quality of life, and sexual function.  
• The study doctor will ask you questions about your health. 
• This will be your last study visit. 
 
Some of these procedures might be done as part of your standard of care even if you do 
not take part in the research study.  The study doctor or a member of the study staff can answer 
any questions you may have about the procedures that are not part of your standard of care. 
See the Flow Chart on the next page that further outlines the visit procedures. 
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 Your Responsibilities 
 
If you decide to be in this study, you will have to: 
• Keep all scheduled appointments 
• Complete the voiding logs as instructed. 
• Tell your study doctor about any other medicines that you take, even if it is medicine you 
buy without a prescription. 
• Tell your study doctor about any medical problems that you have. 
• Avoid becoming pregnant while on the study and for 30 days after you leave the study by 
using an effective method of birth control. 
 
If you do not follow the items listed above, you may be removed from the study. 
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 Study Flow Chart* 
  Baseline 
Screening 
 
Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 
 
Wk 6 
Follow-up 
    Wk12 
    Wk 18 
Visits  V1 
 
V2 
 
V1 
 
V2 V1 
 
V2 
 
V1 
 
V2 
 
V1 
 
V2 V1 V2 Wk 
12 
Wk 
18 
Informed Consent 
 X              
Medical History 
 X              
Physical 
Examination X             X 
Cystoscopy/ 
Hydrodistentiom X              
Uroflow X            X X 
Cystometrogram 
 X              
Ultrasound to 
measure Post Void 
Residual 
X            X X 
Urinalysis 
 X X X X X X X X X X X X X X X 
Urine Culture 
& Sensitivity X X  X  X  X  X X  X X 
Complete Blood 
Count X            X  
BUN,Serum 
Creatinine 
Electrolytes 
X            X  
Pregnancy Test  (if 
applicable) X             X 
HepaticPanel, 
APTT, Platelet 
count, Prothrombin 
time 
X X X X X X X X X X X X X X  
Urine/Blood 
Biomarker, 
Hormone level 
X            X  
Quality of Life 
Questionnaire (SF-
36) 
X       X      X 
 
Voiding Log X  X  X  X  X  X  X X  
Pain Assessment 
 X X X X X X X X X X X X X X X 
 
Parson’s Patient 
Symptom  Scale 
X X X X X X X X X X X X X X X 
O’Leary –Sant 
Symptom/Problem 
Index 
X X X X X X X X X X X X X X X 
Sexual Function 
Assessment 
 
X       X   X  X X 
Patient Global 
Assessment X X X X X X X X X X X X X X X 
Elmiron/Placebo 
Instillation 
 
 X X X X X X X X X X X X   
Adverse Events 
Assessment  X X X X X X X X X X X X X X 
Concomitant 
Medication 
 
X X X X X X X X X X X X X X X 
* All assessments must be done within time frame allowed in protocol; 
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OTHER TREATMENTS 
 
Participation in this study is not a substitute for your usual ongoing medical care by your 
regular doctor or specialist.  You do not have to participate in this study to receive treatment for 
your condition.  There may be other ways to treat your condition.  Your study doctor can tell you 
more about these other treatments and their side effects.   
You are strongly encouraged to ask the study doctor about the results of your lab tests 
and other diagnostic procedures.  At your request you will be provided with copies of the results 
to review with your regular doctor or specialist. 
 
BENEFITS  
 
If you are in this study, you will get medical examinations and laboratory tests at no extra 
cost to you.  You will not have to pay for the medicine. Your Interstitial Cystitis might improve, 
but there is no guarantee. 
  
RISKS 
 
You will have blood taken from one of your veins.  The risks of having blood taken from 
your vein include pain, bruising, or infection at the site where blood was taken, and fainting. 
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 There will be twelve (12) bladder instillations. Blood samples will be taken (1) hour after 
each bladder instillation. These blood samples are to assess complete blood count, kidney 
function, liver function, and blood coagulation (clotting) time. 
Elmiron® taken orally can cause some side effects.  They include: a weak anticoagulant 
effect (this effect may increase bleeding times, possibility of rectal bleeding and blood in your 
urine), nausea, diarrhea, liver function abnormalities, and mild hair loss. These are all possible 
side effects of this medicine.   You may or may not have any of these side effects.  A severe 
allergic reaction could be life-threatening.  If researchers learn important new information that 
could change your decision to continue to take part in this study, your study doctor will tell you 
in a timely manner.   
You may experience discomforts associated with catheterization.  These include burning 
when passing urine, blood-tinged urine or urinary frequency following the procedure. 
The cystometrogram which evaluates bladder capacity and urination rate, involves filling 
the bladder with liquid and measuring the bladder’s response.  Catheterization is done for this 
procedure.  You may experience discomfort and a feeling of fullness.  There is also a risk of 
infection and a small amount of bleeding. 
As a part of this study you may be randomized to receive placebo(an instillation without 
study medication).  In this case your symptoms may not improve or may get worse.   
In rare cases the use of local anesthesia (topical lidocaine) may cause and allergic 
reaction, difficulty in breathing, low blood pressure, seizures or death.   
The other risk is that Elmiron® might not work for you.  
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  PREGNANCY 
 
This study may involve unknown risks to a pregnant woman, embryo or fetus.  Therefore 
if you are pregnant or breast feeding you may not participate in this study. 
Subjects of child-bearing potential must test negative for pregnancy prior to 
randomization or provide documentation for having undergone the following:  hysterectomy or 
tubal ligation.  Patients who are physiologically capable of becoming pregnant must be on 
reliable birth control while participating in this study and must remain on reliable birth control 
while in the study.   
Reliable birth control would be intrauterine device (IUD), birth control pills of 
combination type, hormonal implants, injectable contraceptives, surgical sterilization or double 
barrier method.  Please discuss this with your study doctor.   
If a subject or a female partner of a randomized subject becomes pregnant during the 
course of this study, the subject will inform the Principal Investigator within one (1) working day 
of learning of the pregnancy.   
 
UNFORSEEN RISKS 
 
There may be other risks that are unknown.  All drugs have a potential risk of an allergic 
reaction, which if not treated promptly, could become life threatening.    
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 ALTERNATIVE THERAPIES 
 
You do not have to participate in this study to receive treatment for your condition.  You 
may decide to receive no treatment for your disease or other approved therapeutic treatments.  
Your study doctor will discuss with you the risks and benefits of other treatments.  
 
NEW FINDINGS 
 
Any new findings, which may affect your safety or your willingness to continue in the 
study, that become available during your participation in the study will be given to you in a 
timely manner. 
 
COSTS 
 
All study subjects will receive oral Elmiron® at no cost.  The Elmiron® or placebo for 
instillation will be supplied at no cost.  Blood and urine that is collected for possible future 
biomarker study will be done at no cost. 
The tests (culture and sensitivity, routine blood analysis, bladder scan, uroflow, and 
cystometrogram) and clinic visits are considered standard of care and will be billed to your 
insurance company.  
If you develop a documented urinary tract infection during the study and an antibiotic is 
prescribed the sponsor will reimburse the costs of the antibiotic. 
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 You will still be responsible for the cost of your usual ongoing medical care, including 
procedures and non-study medications, that your study doctor or regular doctor requires during 
this study, as part of your usual medical care.  If you have any questions, please ask the study 
doctor or a member of the study staff.   
 
VOLUNTARY PARTICIPATION 
 
Your decision to take part in the research study is voluntary at all times.  If you decide 
not to participate in the study, or if you decide to withdraw from the study before it is complete, 
your routine medical care at this site will not be affected in any way.  There will be no penalty to 
you, and you will not lose any benefits that you are entitled to that are unrelated to the research 
study.   
You may decide to leave the study at any time.  Your study doctor may also decide to 
remove you from the study if you fail to follow instructions, for medical reasons, or for other 
reasons.  There is also the possibility that the study could be stopped before your participation is 
complete.  If you leave the study for any reason please notify the study doctor or a member of the 
study staff.  You will be asked to return to the study doctor to complete the final study activities. 
 
COMPENSATION FOR PARTICIPATION 
 
You will not receive any monetary compensation for participating in this study.  
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 CONFIDENTIALITY 
 
Records of your participation in this study will remain confidential to the extent allowed 
by law.  No material which could personally identify you will be used in any reports on this 
study.   
 
Permission to Release Personal Health Information 
This section explains how personal health information collected about you for the study 
may be used.  Your personal health information includes, but is not limited to, information that 
was collected for your entry into the study and information that is collected during the study.  
The purpose of collecting this information is to allow the study staff and the study doctor to 
conduct the study, to evaluate the study:  
 
Intravesical ELMIRON administration – CAPSS-245, and to analyze the study results.   
 
You may decide not to give permission for the release of your personal health 
information for the study.  In that case, you will not be able to participate in the study.   This is 
because the study staff and/or the study doctor would not be able to collect the information 
needed to evaluate the study: Intravesical ELMIRON administration - CAPSS-245 
The information the study doctor sends to Ortho-McNeil Pharmaceutical, Inc. 
(hereinafter OMP)) does not include your name, address, or social security number.  Instead, the 
study doctor will use your initials and assign a code number to the information that is sent to 
OMP. 
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The study doctor may disclose your personal health information to the Institutional 
Review Board (IRB) and to OMP, including people who work with OMP.  The people who work 
with OMP may include data monitoring committees, contract research organizations, and 
consultants who have contracts with the company to do the study and review the study results.  
Your study records and also your entire medical record may be inspected at the study 
doctor’s office by OMP and/or people who work with OMP and by regulatory authorities in the 
United States, such as the Food and Drug Administration (FDA), or regulatory agencies from 
other countries.  These reviews are done to check on the quality of the study.  
The results of the study may be published in a medical book or journal, or presented at 
meetings for educational purposes.  Neither your name, nor any other personal health 
information that specifically identifies you, will be used in those materials or presentations.    
You may ask the study doctor to see and copy your personal health information related to 
the study.  You may also ask the study doctor to correct any study related information about you 
that is wrong.  You may have to wait until the end of the study to see your study records, so that 
the study can be organized properly.                                        
This permission to share your personal health information for this study does not have an 
expiration date.  If you no longer want to share your personal health information, you may cancel 
your permission at any time by writing to the study staff and/or the study doctor at the address 
below:   
                                   Edward L. Davis, M.D. 
                                   C/O Citrus Valley Medical Research, Inc. 
                                   412 West Carroll Glendora, CA 91741 
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If you cancel your permission after you have started in the study, the study staff and the 
study doctor will stop collecting your personal health information.  Although they will stop 
collecting new information about you, they will need to use the information they have already 
collected to evaluate the study results.  If you start the study and then cancel your permission, 
you will not be able to continue to participate in the study.  This is because the study staff and/or 
the study doctor would not be able to collect the information needed to evaluate the study drug.. 
Ortho-McNeil Pharmaceutical, Inc. will make every effort to keep your personal health 
information private.  But after the study staff or the study doctor share your personal health 
information from the study, federal privacy laws may not keep it private.  There might be laws in 
your state or other federal laws that would protect the privacy of this information.  
 
STUDY FUNDING 
 
Ortho-McNeil Pharmaceutical is paying your study doctor and/or your study doctor’s 
institution to conduct this study.  The amount of this payment is sufficient to cover the study 
doctor’s and/or institution’s expenses to perform the study, but provides no personal financial 
benefit to your study doctor and/or his institution. 
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CONSENT STATEMENT 
 
? I voluntarily agree to participate in this study. 
 
? I understand that the study may be stopped at any time.  If this happens I will no longer 
receive the study medication and planned evaluations. 
 
? I have read and understand the information describing this medical research study in this 
information and consent form 
 
? I authorize the release of my medical records related to this study, including my signed 
consent form. 
 
? I understand that I will receive a singed and dated copy of this consent form. 
 
? I understand that I may withdraw my consent at any time. 
 
? I have had a chance to ask questions and understand the answers given to all my 
questions. 
 
? I have read and received a copy of the California Experimental Subjects Bill of Rights 
which is attached to this consent form. 
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? I have read and understand the pregnancy waiver included in this consent form 
 
 
 
_______________________________________________ 
Printed Name of Participant 
 
 
________________________________________________         ____________ 
Signature of Participant       Date 
 
 
________________________________________________ 
Printed Name of Person Explaining Consent 
 
 
________________________________________________        ____________ 
Signature of Person Explaining Consent    Date 
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APPENDIX B: O’LERAY-SANT IC SYMPTOM AND PROBLEM INDEX 
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APPENDIX C: PELVIC PAIN AND URGENCY/ FREQUENCY (PUF) 
QUESTIONNAIRE 
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APPENDIX D: PAIN ASSESSMENT 
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APPENDIX E: VOIDING LOG 
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 DATE______________SUBJECT INITIALS__________RANDOM #________ 
 
Subject Voiding Log 
 
Please record each time you urinate for a 24 hour period.  Your 24 hour Time period will 
begin when you wake up and will continue until the same time the next day.  (Example if you 
wake up at 8:00 a.m. on the day you should start your voiding log you would end at 8:00 a.m. the 
next day)  Place a star next to the times you record that are when you wake up in the middle of 
your sleep period to urinate.  You will also record a pain number that reflects your pain level at 
the time of urination based on pain scale attached.  You will also assign a *urgency score for 
each urination based on the 1-5 scale at the bottom of this page. 
Time of 
Void 
Pain Urgency Time of 
Void 
Pain Urgency Time of 
Void 
Pain Urgency
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
:   :  :  
*Please assess each urination you record and assign a “Urgency score” to be placed in the 
“urgency” column of the above table based on the following: 
 
        Score Definition  
 
1. No Urgency,  I felt I had no need to empty my bladder, but did so for 
other reasons 
 
2. Mild Urgency, I could wait to void as long as necessary without fear of 
wetting myself. 
 
3. Moderate Urgency, I could wait to void for a short time without fear of 
wetting myself. 
 
4. Severe Urgency, I could not wait to void – I had to rush to the 
restroom/toilet in order not to wet myself. 
 
5. Urge Incontinence, I leaked either a small or large amount before 
reaching the restroom/toilet.   
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APPENDIX F: PATIENT GLOBAL ASSESSMENT 
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 Subject Initials__________________                            Subject #_________________ 
 
Date of Visit_____________________                 
Labs Reviewed?                                                                                Yes                  No 
 
Any clinically significant finding by P.I.?                                        Yes                  No 
 
(If yes, P.I. to explain below reason for continuing or termination) 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
___________________________________________ 
Patient Global Assessment: 
1.   Evaluate the overall change in your condition since your enrollment in the study that you 
believe is due to the study: 
A. Worse         B. No change         C. Improved 
If overall condition improved indicate change as: 
A. Moderately                 B. Greatly                  C. Completely (no symptoms) 
 
2.   Evaluate any change in urgency since your enrollment in the study: 
A. Worse         B. No change         C. Improved 
If urgency improved indicate change as: 
A. Moderately                 B. Greatly                  C. Completely (no symptoms) 
 
3.   Evaluate any change in frequency since your enrollment in the study: 
A. Worse         B. No change         C. Improved 
If frequency improved indicate change as: 
A. Moderately                 B. Greatly                  C. Completely (no symptoms) 
 
4.   Evaluate nocturia. How many times are you up at night to void? _______________ 
 
 
5.   Evaluate oral medication (Elmiron) taking on schedule? Any problems? 
 
 
6. Adverse event reviewed?                                                                 Yes                  No 
7. Con-meds reviewed?                                                                        Yes                  No 
8. Inclusion, exclusion reviewed?                                                        Yes                  No 
9. Pain reviewed?                                                                                 Yes                  No 
Subject completed study per protocol?                                                Yes                  No 
Overall assessment of health status: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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APPENDIX G: MEDICAL OUTCOME STUDY SHORT FORM-36 (SF-36) 
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APPENDIX H: SEXUAL FUNCTION ASSESSMENT 
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APPENDIX I: STUDY FLOW CHART 
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 Study Flow Chart* 
  Baseline 
Screening 
 
Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 
 
Wk 6 
Follow-up 
    Wk12 
    Wk 18 
Visits  V1 
 
V2 
 
V1 
 
V2 V1 
 
V2 
 
V1 
 
V2 
 
V1 
 
V2 V1 V2 Wk 
12 
Wk 
18 
Informed Consent 
 X              
Medical History 
 X              
Physical 
Examination X             X 
Cystoscopy/ 
Hydrodistentiom X              
Uroflow X            X X 
Cystometrogram 
 X              
Ultrasound to 
measure Post Void 
Residual 
X            X X 
Urinalysis 
 X X X X X X X X X X X X X X X 
Urine Culture 
& Sensitivity X X  X  X  X  X X  X X 
Complete Blood 
Count X            X  
BUN,Serum 
Creatinine 
Electrolytes 
X            X  
Pregnancy Test  (if 
applicable) X             X 
HepaticPanel, 
APTT, Platelet 
count, Prothrombin 
time 
X X X X X X X X X X X X X X  
Urine/Blood 
Biomarker, 
Hormone level 
X            X  
Quality of Life 
Questionnaire (SF-
36) 
X       X      X 
 
Voiding Log X  X  X  X  X  X  X X  
Pain Assessment 
 X X X X X X X X X X X X X X X 
 
Parson’s Patient 
Symptom  Scale 
X X X X X X X X X X X X X X X 
O’Leary –Sant 
Symptom/Problem 
Index 
X X X X X X X X X X X X X X X 
Sexual Function 
Assessment 
 
X       X   X  X X 
Patient Global 
Assessment X X X X X X X X X X X X X X X 
Elmiron/Placebo 
Instillation 
 
 X X X X X X X X X X X X   
Adverse Events 
Assessment  X X X X X X X X X X X X X X 
Concomitant 
Medication 
 
X X X X X X X X X X X X X X X 
* All assessments must be done within time frame allowed in protocol; 
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APPENDIX J: DECLARATION OF HELSINKI 
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APPENDIX K: IRB APPROVAL 
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